UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest
event reported): July 7, 2015 (July 2, 2015) |
|
Aetna Inc. |
(Exact Name of Registrant as Specified in its Charter) |
|
|
|
|
|
Pennsylvania |
1-16095 |
23-2229683 |
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
151
Farmington Avenue
Hartford,
CT 06156 |
(Address of Principal Executive Offices) |
|
Registrant’s telephone number, including area code: (860) 273-0123 |
|
N/A |
(Former Name or Former Address, if Changed Since Last Report) |
|
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
| þ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 1 – Registrant’s Business and Operations
Item 1.01. Entry into a Material Definitive Agreement.
Overview
On July 2, 2015, Aetna Inc. (“Aetna”),
Humana Inc. (“Humana”), Echo Merger Sub, Inc., a wholly-owned subsidiary of Aetna (“Merger Sub 1”),
and Echo Merger Sub, LLC, a wholly-owned subsidiary of Aetna (“Merger Sub 2”), entered into an Agreement and
Plan of Merger (the “Merger Agreement”), pursuant to which, subject to the satisfaction or waiver of certain
conditions, Merger Sub 1 will be merged with and into Humana, with Humana surviving the merger as a wholly-owned subsidiary of
Aetna (the “First Merger”), and immediately following the First Merger, Humana will be merged with and into
Merger Sub 2, with Merger Sub 2 surviving the merger as a wholly-owned subsidiary of Aetna (the “Second Merger”
and together with the First Merger, the “Mergers”). At the effective time of the Second Merger, Merger Sub 2
will be renamed Humana LLC.
At the effective time of the First Merger,
each share of Humana common stock (other than treasury shares held by Humana and any shares of Humana common stock beneficially
owned by Aetna, any of Aetna’s subsidiaries or any person who is entitled to and properly demands statutory appraisal of
his or her shares) will be converted into the right to receive (i) 0.8375 (the “Exchange Ratio”) shares of Aetna
common stock (the “Per Share Stock Consideration”) and (ii) $125.00 in cash, without interest (the “Per
Share Cash Consideration,” and, together with the Per Share Stock Consideration, the “Merger Consideration”).
Treatment of Equity Awards
At the effective time of the First Merger,
each option to purchase shares of Humana common stock outstanding under any employee benefit plan (each, a “Humana Stock
Option”) that is vested or that, pursuant to its terms as in effect as of the date of the Merger Agreement, would become
vested as of the effective time of the First Merger, will be canceled and converted into the right to receive an amount in cash,
without interest, equal to the product of (A) the excess, if any, of (1) the sum of (x) the Per Share Cash Consideration plus
(y) the value equal to the product of the Parent Stock Price (as defined below) multiplied by the Exchange Ratio (the sum
of the amounts in clauses (x) and (y), the “Equity Award Cash Consideration”) over (2) the applicable per share
exercise price of such Humana Stock Option multiplied by (B) the total number of shares of Humana common stock subject
to such Humana Stock Option. For purposes of the Merger Agreement, the “Parent Stock Price” means the average
of the volume weighted averages of the trading prices of Aetna common stock on the New York Stock Exchange (as reported by Bloomberg
L.P. or, if not reported therein, in another authoritative source mutually selected by Aetna and Humana) on each of the five consecutive
trading days ending on the trading day that is two trading days prior to the closing date of the First Merger. Each Humana Stock
Option that is vested or that, pursuant to its terms as in effect as of the date of the Merger Agreement, would become vested as
of the effective time of the First Merger, with a per share exercise price greater than or equal to the Equity Award Cash Consideration,
will be cancelled for no consideration.
Each Humana Stock Option that (i) is not
cancelled pursuant to the provisions described in the preceding paragraph or (ii) is granted after the date of the Merger Agreement
(to the extent permitted by the Merger Agreement), at the effective time of the First Merger will, by virtue of the First Merger
and without further action on the part of any holder thereof, be assumed by Aetna and become, as of the effective time of the First
Merger, an option (an “Assumed Stock Option”) to purchase, on the same terms and conditions (including with
respect to vesting, exercise and expiration provisions) as applied to each such Humana Stock Option immediately prior to the effective
time of the First Merger, shares of Aetna common stock, except that (A) the number of shares of Aetna common stock subject to such
Assumed Stock Option will equal (x) the number of shares of Humana common stock that were subject to such Humana Stock Option immediately
prior to the effective time of the First Merger, multiplied by (y) the Equity Award Exchange Ratio (as defined below), rounded
down to the nearest whole share, and (B) the per-share exercise price will equal the quotient of (1) the exercise price per share
of Humana common stock at which such Humana Stock Option was exercisable immediately prior to the effective time of the First Merger,
divided by (2) the Equity Award Exchange Ratio, rounded up to the nearest whole cent. For purposes of the Merger Agreement, the
“Equity Award Exchange Ratio” means the sum of (i) the Per Share Stock
Consideration, plus (ii) the quotient of (x) the Per Share Cash Consideration, divided by (y) the Parent Stock Price,
rounded to the nearest one thousandth.
Immediately prior to the effective time
of the First Merger, for each restricted stock unit award with respect to shares of Humana common stock outstanding under any employee
benefit plan that (i) either (x) vests solely based on the passage of time (each, a “Humana RSU Award”) or (y)
vests based on the achievement of performance goals (each, a “Humana PSU Award”) and (ii) pursuant to its terms
as in effect on the date of the Merger Agreement, provides for accelerated vesting upon the consummation of the transactions contemplated
by the Merger Agreement: (1) the restrictions and vesting conditions applicable to such Humana RSU Award or Humana PSU Award
will lapse and (2) each such Humana RSU Award or Humana PSU Award will, by virtue of the First Merger and without any action
on the part of the holder thereof, be converted as of the effective time of the First Merger into the right to receive, with respect
to each share of Humana common stock underlying such Humana RSU Award or Humana PSU Award, the Merger Consideration plus a
cash amount equal to the accrued but unpaid dividend equivalent rights relating to such Humana RSU Award or Humana PSU Award (collectively,
the “Award Consideration”). Humana PSU Awards will be converted assuming the achievement of maximum level of
performance to the extent required by their terms.
Each Humana RSU Award and Humana PSU Award
that (i) is not converted into a right to receive the Award Consideration or (ii) is granted after the date of the Merger Agreement
(to the extent permitted by the Merger Agreement), at the effective time of the First Merger will, by virtue of the First Merger
and without further action on the part of any holder thereof, be assumed by Aetna and will be converted into a restricted unit
award corresponding to the Merger Consideration (each, an “Assumed Restricted Unit Award”) that settles in (A)
an amount in cash equal to the sum of an amount equal to the accrued but unpaid dividend equivalent rights relating to such Assumed
Restricted Unit Award plus the product of (x) the Per Share Cash Consideration, multiplied by (y) the number of shares of
Humana common stock underlying the Assumed Restricted Unit Award, and (B) a number of shares of Aetna common stock equal to the
product of (x) the Per Share Stock Consideration, multiplied by (y) the number of shares of Humana common stock underlying
the Assumed Restricted Unit Award. Except as provided in the immediately preceding sentence, each Assumed Restricted Unit Award
shall continue to have, and shall be subject to, the same terms and conditions as applied to the corresponding Humana RSU Award
or Humana PSU Award immediately prior to the effective time of the First Merger (including any terms and conditions relating to
accelerated vesting upon a termination of the holder’s employment in connection with or following the First Merger).
Covenants
The Merger Agreement provides that, upon
the closing of the Mergers, the board of directors of Aetna will be expanded to include four Humana directors who are independent
with respect to Aetna and jointly designated by Humana and Aetna. The Merger Agreement also provides that after the closing, Aetna
will maintain the corporate headquarters of its Medicare and Medicaid businesses in Louisville, Kentucky, and Humana LLC will maintain
a significant corporate presence in Louisville, Kentucky.
Aetna and Humana each made customary representations, warranties
and covenants in the Merger Agreement, including, among others, covenants by each of Humana and Aetna to, subject to certain exceptions,
conduct its business in the ordinary course during the interim period between the execution of the Merger Agreement and the consummation
of the First Merger. Under the Merger Agreement, Aetna has agreed that its quarterly dividend will not exceed $0.25 per share and
Humana has agreed that its quarterly dividend will not exceed $0.29 per share, in each case prior to the effective time of the
First Merger. Declaration and payment of future Aetna dividends is at the discretion of Aetna’s board of directors and may
be adjusted as business needs or market conditions change.
Under the
Merger Agreement, each of Aetna and Humana has agreed to use its reasonable best efforts to consummate the Mergers so long as
such actions would not have and would not reasonably be expected to have, individually or in the aggregate, a Regulatory Material
Adverse Effect on Aetna or Humana. “Regulatory Material Adverse Effect” means, with respect to Aetna or Humana,
a material adverse effect on the financial 3 #87371772v13 condition, business, revenue or
earnings before interest, taxes, depreciation and amortization (“EBITDA”) of such person and its subsidiaries,
taken as a whole. For purposes of determining whether any action has had or would reasonably be expected to have a Regulatory
Material Adverse Effect on Humana, Humana and its subsidiaries will collectively be deemed to be a company the size of (and with
revenue and EBITDA equal to those of) Aetna and its subsidiaries, taken as a whole (excluding, for the avoidance of doubt, Humana
and its subsidiaries). In addition, for purposes of
determining whether any action would have or would reasonably be expected to have a Regulatory Material Adverse
Effect on Aetna or on Humana, impacts on Aetna, Humana or any of their respective subsidiaries will be aggregated.
Closing Conditions
The obligation of the parties to
consummate the Mergers is subject to the approval and adoption of the Merger Agreement by Humana’s stockholders (which
will require the approval of stockholders owning at least 75% of the outstanding shares of Humana common stock, unless Humana
and Aetna agree that a lower approval threshold is permitted by Humana’s Certificate of Incorporation) and approval by
Aetna’s shareholders (which will require the approval of a majority of the votes cast at the relevant meeting of Aetna
shareholders at which a quorum is present) of the issuance of Aetna common stock to Humana’s stockholders (the
“Stock Issuance”). The obligation of the parties to consummate the Mergers is further subject to customary
closing conditions, including, among others, the absence of legal impediments in the United States or any of its territories
to the consummation of the Mergers, the receipt of specified governmental consents and approvals, the early termination or
expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, compliance by
Humana and Aetna in all material respects with their respective obligations under the Merger Agreement and, subject in most
cases to exceptions that do not rise to the level of a “Company Material Adverse Effect” or “Parent
Material Adverse Effect” (each as defined in the Merger Agreement), as applicable, the accuracy of representations and
warranties made by Humana and Aetna, respectively. The obligation of Aetna and Humana to consummate the Mergers is also
subject to there not having occurred an event that has had or would reasonably be expected to have, individually or in the
aggregate, a “Company Material Adverse Effect” or “Parent Material Adverse Effect”, respectively. The
obligation of the parties to consummate the Mergers is not subject to any financing condition.
In addition, Aetna’s obligation to
consummate the Mergers is subject to (i) the Centers for Medicare & Medicaid Services (“CMS”) not having
imposed any sanction involving suspension of marketing, enrollment and/or payment (other than civil monetary penalties that do
not involve the suspension of payment) under any Medicare Advantage contract or Medicare Part D contract to which Humana or any
of its subsidiaries is a party, (ii) CMS not having terminated any Medicare Advantage contract or Medicare Part D contract to which
Humana or any of its subsidiaries is a party and (iii) Humana or any of its subsidiaries not having suspended enrollment or marketing
under any Medicare Advantage contract or Medicare Part D contract to which Humana or any of its subsidiaries is a party (each of
the items in clauses (i) through (iii), a “CMS Sanction”), in each case which CMS Sanction, individually or
in the aggregate, is, or would reasonably be expected to be, material and adverse to Humana and its subsidiaries, taken as a whole
(it being understood and agreed that, among other things, the impact (and the reasonably expected impact) on current or future
stars rating, membership, revenue, stars bonus payments, open enrollment and earnings, as well as the impact (both positive and
negative) (and the reasonably expected impact) of any remediation or other offsetting actions taken by Humana or any of its subsidiaries,
shall be taken into account in determining if such CMS Sanction, individually or in the aggregate with any and all other CMS Sanctions,
is, or would reasonably be expected to be, material and adverse to Humana and its subsidiaries, taken as a whole) (a “Material
CMS Sanction”).
Shareholder Meetings; Non-Solicitation; Intervening Events
The Merger Agreement requires Humana and
Aetna to convene a stockholders meeting and shareholders meeting, respectively, for purposes of obtaining the necessary Humana
stockholder approval and Aetna shareholder approval, and, subject to certain exceptions, each of Humana and Aetna have agreed (i)
not to solicit alternative transactions or enter into discussions concerning, or provide information in connection with, any alternative
transaction and (ii) that its board of directors will recommend that its stockholders or shareholders, as applicable, approve and
adopt the Merger Agreement or the Stock Issuance, as applicable.
Prior to the approval of the Stock Issuance by Aetna’s
shareholders or the approval and adoption of the Merger Agreement by Humana’s stockholders, as applicable, the Aetna board
of directors or the Humana board of directors, as applicable, may, in connection with the receipt of a Parent Superior Proposal
or Company Superior Proposal (each as defined on the Merger Agreement), respectively, or an Intervening Event (as defined in the
Merger Agreement), change its recommendation in favor of the Stock Issuance or the Merger Agreement, respectively, subject to complying
with notice and other specified conditions, including giving the other party the opportunity to propose changes to the Merger Agreement
in response to such Parent Superior Proposal or Company Superior Proposal, as applicable, or Intervening Event, if the failure
to make such change in recommendation would be reasonably likely to be inconsistent with its fiduciary duties.
Termination; Termination Fees
If either party’s board of directors
changes its recommendation that its stockholders or shareholders, as applicable, approve and adopt the Merger Agreement or approve
the Stock Issuance, as applicable, the other party may terminate the Merger Agreement. However, the party whose board of directors
changes its recommendation does not have the right to terminate the Merger Agreement in connection with the receipt of a Parent
Superior Proposal or Company Superior Proposal, as applicable, or an Intervening Event.
Aetna may terminate the Merger Agreement
if any Material CMS Sanctions have been imposed, the impact of which is incapable of being or has not been cured or abated by the
“end date” (as it may be extended pursuant to clause (1) of the following sentence). The Merger Agreement contains
certain other termination rights, including the right of each party to terminate the Merger Agreement (1) if the Merger has not
been consummated by the “end date” of June 30, 2016, subject to each party’s right to extend the end date for
an additional six months if all closing conditions (other than (x) receipt of antitrust and other specified regulatory approvals
or (y) the absence of Material CMS Sanctions) have been satisfied by June 30, 2016, (2) if a governmental authority in the United
States or any of its territories has issued a law, injunction, judgment, order or decree which prohibits or enjoins the Mergers
and which, in the case of a judgment, order or decree, has become permanent, final and nonappealable, (3) if the required vote
of Humana stockholders is not obtained, (4) if the required vote of the Aetna shareholders is not obtained or (5) due to the other
party’s breach in any material respect of the provisions of the Merger Agreement relating to non-solicitation of alternative
transactions.
In the event of a termination of the Merger
Agreement under certain circumstances, Aetna or Humana may be required to pay a termination fee to the other. Aetna would be required
to pay to Humana a termination fee of $1.691 billion if the Merger Agreement is terminated by Humana (i) as a result of a change
in the recommendation of Aetna’s board of directors to its shareholders to approve the Stock Issuance or (ii) due to Aetna’s
breach in any material respect of the provisions of the Merger Agreement relating to non-solicitation of alternative transactions.
In addition, Aetna would be required to pay to Humana a termination fee of $1.691 billion if (w) the required vote of Aetna’s
shareholders is not obtained, (x) an acquisition of Aetna was publicly proposed or disclosed prior to such vote, (y) the Merger
Agreement is terminated by either party and (z) within twelve months after such termination, Aetna enters into a definitive agreement
providing for, or consummates, an alternative transaction with a third party. Humana would be required to pay to Aetna a termination
fee of $1.314 billion if the Merger Agreement is terminated by Aetna (i) as a result of a change in the recommendation of Humana’s
board of directors to its stockholders to approve and adopt the Merger Agreement or (ii) due to Humana’s breach in any material
respect of the provisions of the Merger Agreement relating to non-solicitation of alternative transactions. In addition, Humana
would be required to pay to Aetna a termination fee of $1.314 billion if (w) the required vote of Humana’s stockholders is
not obtained, (x) an alternative acquisition of Humana was publicly proposed or disclosed prior to such vote, (y) the Merger Agreement
is terminated by either party and (z) within twelve months after such termination, Humana enters into a definitive agreement providing
for, or consummates, an alternative transaction with a third party.
In the event the Merger Agreement is terminated
(i) as a result of the failure of the Mergers to occur on or before the end date (as it may be extended) due to the failure to
achieve antitrust or other specified regulatory approvals, (ii) as a result of a final and non-appealable order or injunction relating
to antitrust or other specified regulatory approvals or (iii) as a result of Aetna’s failure to take appropriate proceedings
to contest an order or injunction in respect of antitrust or other specified regulatory matters within certain specified time periods,
then Aetna would be required to pay Humana a termination fee of $1 billion.
Description of Merger Agreement Not Complete
The foregoing description of the Merger
Agreement does not purport to be complete, and is qualified in its entirety by reference to the full text of the Merger Agreement,
which is attached hereto as Exhibit 2.1 and is incorporated herein by reference. A copy of the Merger Agreement has been included
to provide Aetna shareholders, Humana stockholders and other security holders with information regarding its terms and is not intended
to provide any factual information about Aetna or Humana. The representations,
warranties and covenants contained in the Merger Agreement have been made solely for the purposes of the Merger Agreement and as
of specific dates; were solely for the benefit of the parties to the Merger Agreement; are not intended as statements of fact to
be relied upon by Aetna’s shareholders, Humana’s stockholders or other security holders, but rather as a way of allocating
the risk between the parties in the event the statements therein prove to be inaccurate; have been modified or qualified by certain
confidential disclosures that were made between the parties in connection with the negotiation of the Merger Agreement, which disclosures
are not reflected in the Merger Agreement itself; may no longer be true as of a given date; and may apply standards of materiality
in a way that is different from what may be viewed as material by Aetna shareholders or Humana stockholders or other security holders.
Aetna shareholders, Humana stockholders and other security holders are not third-party beneficiaries under the Merger Agreement
(except with respect to Humana stockholders’ right to receive the Merger Consideration following the effective time of the
First Merger) and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations
of the actual state of facts or condition of Humana, Aetna, Merger Sub 1 or Merger Sub 2. Moreover, information concerning the
subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information
may or may not be fully reflected in Aetna’s or Humana’s public disclosures. Aetna acknowledges that, notwithstanding
the inclusion of the foregoing cautionary statements, it is responsible for considering whether additional specific disclosures
of material information regarding material contractual provisions are required to make the statements in this Form 8-K not misleading.
Bridge Facility Commitment Letter
On July 2, 2015, Aetna entered into a bridge
facility commitment letter (the “Commitment Letter”) pursuant to which Citigroup Global Markets Inc., UBS AG,
Stamford Branch, and UBS Securities LLC have committed to provide up to $16.2 billion under a 364-day senior unsecured bridge loan
facility to finance the Mergers in the event that Aetna has not received any combination of (i) senior notes, (ii) senior unsecured
term loans and/or (iii) commercial paper in an aggregate principal amount of at least $16.2 billion prior to the consummation of
the Mergers. The commitment is subject to various conditions. The foregoing description of the Commitment Letter does not purport
to be complete, and is qualified in its entirety by reference to the full text of the Commitment Letter, which is attached hereto
as Exhibit 2.2 and is incorporated herein by reference.
Important Information For Investors And Stockholders
This Current Report on Form 8-K does not constitute an offer
to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with
the proposed transaction between Aetna and Humana, Aetna and Humana will file relevant materials with the Securities and Exchange
Commission (the “SEC”), including an Aetna registration statement on Form S-4 that will include a joint proxy
statement of Aetna and Humana that also constitutes a prospectus of Aetna, and a definitive joint proxy statement/prospectus will
be mailed to stockholders of Aetna and Humana. INVESTORS AND SECURITY HOLDERS OF AETNA AND HUMANA ARE URGED TO READ THE JOINT
PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies
of the registration statement and the joint proxy statement/prospectus (when available) and other documents filed with the SEC
by Aetna or Humana through the website maintained by the SEC at http://www.sec.gov.
Copies of the documents filed with the SEC by Aetna will be available free of charge on Aetna’s internet website at http://www.Aetna.com
or by contacting Aetna’s Investor Relations Department at 860-273-8204. Copies of the documents filed with
the SEC by Humana will be available free of charge on Humana’s internet website at http://www.Humana.com
or by contacting Humana’s Investor Relations Department at 502-580-3644.
Aetna, Humana, their respective directors and certain of their
respective executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction.
Information about the directors and executive officers of Humana is set forth in its Annual Report on Form 10-K for the year ended
December 31, 2014, which was filed with the SEC on February 18, 2015, its proxy statement for its 2015 annual meeting of stockholders,
which was filed with the SEC on March 6, 2015, and its Current Report on Form 8-K, which was filed with the SEC on April 17, 2015.
Information about the directors and executive officers of Aetna is set forth in its Annual Report on Form 10-K for the year ended
December 31, 2014, which was filed with the SEC on February 27, 2015, its proxy statement for its 2015 annual meeting of shareholders, which
was filed with the SEC on April 3, 2015 and its Current Reports on Form 8-K, which were filed with the SEC on May 19, 2015 and
May 26, 2015. Other information regarding the participants in the proxy solicitations and a description of their direct and
indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant
materials to be filed with the SEC when they become available.
Section 9 – Financial Statements
and Exhibits
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits
| 2.1 | Agreement and Plan of Merger dated as of July 2, 2015 among Aetna Inc., Echo Merger Sub, Inc., Echo Merger Sub, LLC and Humana
Inc.* |
| 2.2 | Bridge Facility Commitment Letter among Aetna Inc., Citigroup Global Markets Inc., UBS AG, Stamford Branch, and UBS Securities
LLC, dated July 2, 2015. |
* The schedules and exhibits have been omitted pursuant to Item
601(b)(2) of Regulation S-K. Aetna agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof,
to the SEC upon request.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
AETNA INC. |
|
|
|
|
|
|
Date: |
July 7, 2015 |
|
By: |
/s/ Sharon A. Virag |
|
|
|
|
Name: |
Sharon A. Virag |
|
|
|
|
Title: |
Vice President, Controller and Chief Accounting Officer |
INDEX TO EXHIBITS
Exhibit Number |
Description |
2.1 |
Agreement and Plan of Merger dated as of July 2, 2015 among
Aetna Inc., Echo Merger Sub, Inc., Echo Merger Sub, LLC and Humana Inc.*
|
2.2 |
Bridge Facility Commitment Letter among Aetna Inc., Citigroup
Global Markets Inc., UBS AG, Stamford Branch, and UBS Securities LLC, dated July 2, 2015.
|
* The schedules and exhibits have been omitted pursuant to Item
601(b)(2) of Regulation S-K. Aetna agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof,
to the SEC upon request.
|
Exhibit 2.1
EXECUTION VERSION
AGREEMENT AND PLAN OF MERGER
dated as of
July 2, 2015
among
AETNA INC.,
ECHO MERGER SUB, INC.,
ECHO MERGER SUB, LLC
and
HUMANA INC.
TABLE OF CONTENTS
Page
Article 1 |
Definitions |
2 |
Section 1.01. |
Definitions. |
2 |
Section 1.02. |
Other Definitional and Interpretative Provisions. |
15 |
|
|
|
Article 2 |
Closing; Mergers |
16 |
Section 2.01. |
Closing. |
16 |
Section 2.02. |
First Merger. |
16 |
Section 2.03. |
Second Merger. |
16 |
Section 2.04. |
Conversion of Shares. |
17 |
Section 2.05. |
Surrender and Payment. |
18 |
Section 2.06. |
Dissenting Shares. |
20 |
Section 2.07. |
Company Equity Awards. |
20 |
Section 2.08. |
Adjustments. |
23 |
Section 2.09. |
Fractional Shares. |
23 |
Section 2.10. |
Withholding Rights. |
23 |
Section 2.11. |
Lost Certificates. |
24 |
Section 2.12. |
Further Assurances. |
24 |
|
|
|
Article 3 |
Organizational Documents; Directors and Officers |
24 |
Section 3.01. |
Certificate of Incorporation and Bylaws of the Initial Surviving Corporation. |
24 |
Section 3.02. |
Certificate of Formation and Limited Liability Company Agreement of the Surviving Company. |
25 |
Section 3.03. |
Directors and Officers of the Initial Surviving Corporation. |
25 |
Section 3.04. |
Managers and Officers of the Surviving Company. |
25 |
|
|
|
Article 4 |
Representations and Warranties of the Company |
25 |
Section 4.01. |
Corporate Existence and Power. |
25 |
Section 4.02. |
Corporate Authorization. |
25 |
Section 4.03. |
Governmental Authorization. |
26 |
Section 4.04. |
Non-contravention. |
26 |
Section 4.05. |
Capitalization. |
27 |
Section 4.06. |
Subsidiaries. |
28 |
Section 4.07. |
SEC Filings and the Sarbanes-Oxley Act. |
28 |
Section 4.08. |
Financial Statements and Financial Matters. |
30 |
Section 4.09. |
Disclosure Documents. |
30 |
Section 4.10. |
Statutory Financial Statements. |
30 |
Section 4.11. |
Reserves. |
30 |
Section 4.12. |
Capital or Surplus Maintenance. |
31 |
Section 4.13. |
Absence of Certain Changes. |
31 |
Section 4.14. |
No Undisclosed Material Liabilities. |
31 |
Section 4.15. |
Litigation. |
31 |
Section 4.16. |
Permits. |
32 |
Section 4.17. |
Compliance with Applicable Laws. |
32 |
Section 4.18. |
Material Contracts. |
33 |
Section 4.19. |
Taxes. |
35 |
Section 4.20. |
Employees and Employee Benefit Plans. |
37 |
Section 4.21. |
Labor Matters. |
39 |
Section 4.22. |
Intellectual Property. |
39 |
Section 4.23. |
Properties. |
40 |
Section 4.24. |
Environmental Matters. |
41 |
Section 4.25. |
Insurance. |
41 |
Section 4.26. |
Transactions with Affiliates. |
41 |
Section 4.27. |
Antitakeover Statutes. |
42 |
Section 4.28. |
Opinion of Financial Advisor. |
42 |
Section 4.29. |
Finders’ Fees. |
42 |
Section 4.30. |
No Ownership of Parent Common Stock. |
42 |
Section 4.31. |
No Other Company Representations and Warranties. |
42 |
|
|
|
Article 5 |
Representations and Warranties of Parent |
43 |
Section 5.01. |
Corporate Existence and Power. |
43 |
Section 5.02. |
Corporate Authorization. |
44 |
Section 5.03. |
Governmental Authorization. |
44 |
Section 5.04. |
Non-contravention. |
45 |
Section 5.05. |
Capitalization. |
45 |
Section 5.06. |
Subsidiaries. |
46 |
Section 5.07. |
SEC Filings and the Sarbanes-Oxley Act. |
47 |
Section 5.08. |
Financial Statements and Financial Matters. |
48 |
Section 5.09. |
Disclosure Documents. |
48 |
Section 5.10. |
Statutory Financial Statements. |
48 |
Section 5.11. |
Reserves. |
49 |
Section 5.12. |
Capital or Surplus Maintenance. |
49 |
Section 5.13. |
Absence of Certain Changes. |
49 |
Section 5.14. |
No Undisclosed Material Liabilities. |
49 |
Section 5.15. |
Litigation. |
49 |
Section 5.16. |
Permits. |
50 |
Section 5.17. |
Compliance with Applicable Laws. |
50 |
Section 5.18. |
Taxes. |
51 |
Section 5.19. |
Employees and Employee Benefit Plans. |
52 |
Section 5.20. |
Labor Matters. |
53 |
Section 5.21. |
Intellectual Property. |
54 |
Section 5.22. |
Environmental Matters. |
55 |
Section 5.23. |
Antitakeover Statutes. |
55 |
Section 5.24. |
Opinion of Financial Advisor. |
55 |
Section 5.25. |
Finders’ Fees. |
55 |
Section 5.26. |
No Ownership of Company Common Stock. |
55 |
Section 5.27. |
Financing. |
56 |
Section 5.28. |
No Other Parent Representations and Warranties. |
57 |
|
|
|
Article 6 |
Covenants of the Company |
58 |
Section 6.01. |
Conduct of the Company. |
58 |
Section 6.02. |
No Solicitation by the Company. |
62 |
Section 6.03. |
Financing Assistance. |
66 |
Section 6.04. |
Transition. |
67 |
Section 6.05. |
Indenture. |
68 |
Section 6.06. |
280G Calculation. |
68 |
|
|
|
Article 7 |
Covenants of Parent |
68 |
Section 7.01. |
Conduct of Parent. |
68 |
Section 7.02. |
No Solicitation by Parent. |
70 |
Section 7.03. |
Obligations of Merger Sub 1 and Merger Sub 2. |
73 |
Section 7.04. |
Director and Officer Liability. |
73 |
Section 7.05. |
Employee Matters. |
76 |
Section 7.06. |
Financing. |
77 |
Article 8 |
Covenants of Parent and the Company |
79 |
Section 8.01. |
Access to Information; Confidentiality. |
79 |
Section 8.02. |
Reasonable Best Efforts. |
79 |
Section 8.03. |
Certain Filings; SEC Matters. |
83 |
Section 8.04. |
Stockholder Meetings. |
84 |
Section 8.05. |
Public Announcements. |
85 |
Section 8.06. |
Notices of Certain Events. |
86 |
Section 8.07. |
Section 16 Matters. |
86 |
Section 8.08. |
Transaction Litigation. |
86 |
Section 8.09. |
Stock Exchange Delisting. |
87 |
Section 8.10. |
Dividends. |
87 |
Section 8.11. |
Governance Matters. |
87 |
Section 8.12. |
State Takeover Statutes. |
87 |
Section 8.13. |
Tax Matters. |
88 |
|
|
|
Article 9 |
Conditions to the Mergers |
88 |
Section 9.01. |
Conditions to the Obligations of Each Party. |
88 |
Section 9.02. |
Conditions to the Obligations of Parent, Merger Sub 1 and Merger Sub 2. |
88 |
Section 9.03. |
Conditions to the Obligations of the Company. |
90 |
|
|
|
Article 10 |
Termination |
91 |
Section 10.01. |
Termination. |
91 |
Section 10.02. |
Effect of Termination. |
93 |
Section 10.03. |
Termination Fees. |
94 |
|
|
|
Article 11 |
Miscellaneous |
96 |
Section 11.01. |
Notices. |
96 |
Section 11.02. |
Survival. |
97 |
Section 11.03. |
Amendments and Waivers. |
97 |
Section 11.04. |
Expenses. |
97 |
Section 11.05. |
Disclosure Schedule References and SEC Document References. |
97 |
Section 11.06. |
Binding Effect; Benefit; Assignment. |
98 |
Section 11.07. |
Governing Law. |
98 |
Section 11.08. |
Jurisdiction/Venue. |
98 |
Section 11.09. |
WAIVER OF JURY TRIAL. |
99 |
Section 11.10. |
Counterparts; Effectiveness. |
99 |
Section 11.11. |
Entire Agreement. |
100 |
Section 11.12. |
Severability. |
100 |
Section 11.13. |
Specific Performance. |
100 |
EXHIBITS
Exhibit A - Certificate of Incorporation of Initial Surviving
Corporation
AGREEMENT AND PLAN OF MERGER
AGREEMENT AND PLAN OF MERGER (this “Agreement”),
dated as of July 2, 2015, among Aetna Inc., a Pennsylvania corporation (“Parent”), Echo Merger Sub, Inc., a
Delaware corporation and a direct, wholly owned Subsidiary of Parent (“Merger Sub 1”), Echo Merger Sub, LLC,
a Delaware limited liability company and a direct, wholly owned Subsidiary of Parent (“Merger Sub 2”), and Humana
Inc., a Delaware corporation (the “Company”).
WHEREAS, the Board of Directors of the Company
has unanimously (i) determined that this Agreement and the transactions contemplated hereby (including the Mergers) are fair to
and in the best interests of the Company’s stockholders, (ii) approved, adopted and declared advisable this Agreement and
the transactions contemplated hereby (including the Mergers), (iii) directed that the approval and adoption of this Agreement (including
the Mergers) be submitted to a vote at a meeting of the Company’s stockholders, and (iv) recommended the approval and adoption
of this Agreement (including the Mergers) by the Company’s stockholders;
WHEREAS, the Board of Directors of Parent
has unanimously (i) determined that this Agreement and the transactions contemplated hereby (including the Parent Share Issuance)
are fair to and in the best interests of Parent’s stockholders, (ii) approved, adopted and declared advisable this Agreement
and the transactions contemplated hereby (including the Parent Share Issuance), (iii) directed that the Parent Share Issuance be
submitted to a vote at a meeting of Parent’s stockholders, and (iv) recommended the approval of the Parent Share Issuance
by Parent’s stockholders;
WHEREAS, the Board of Directors of Merger
Sub 1 has unanimously (i) approved, adopted and declared advisable this Agreement and the transactions contemplated hereby (including
the First Merger), and (ii) directed that this Agreement be submitted to Parent for its approval and adoption in its capacity as
the sole stockholder of Merger Sub 1;
WHEREAS, the Board of Managers of Merger
Sub 2 has unanimously (i) approved, adopted and declared advisable this Agreement and the transactions contemplated hereby (including
the Second Merger), and (ii) directed that this Agreement be submitted to Parent for its approval and adoption in its capacity
as the sole member of Merger Sub 2;
WHEREAS, the parties intend that the Mergers,
taken together, will qualify as a reorganization within the meaning of Section 368(a) of the Code and the Treasury regulations
promulgated thereunder (the “Treasury Regulations”) and that this Agreement be, and hereby is, adopted as a
“plan of reorganization” for purposes of Section 368 of the Code and the Treasury Regulations thereunder; and
WHEREAS, the Company, Parent, Merger Sub
1 and Merger Sub 2 desire to make certain representations, warranties, covenants and agreements specified in this Agreement in
connection with the Merger and to prescribe certain conditions to the Mergers.
NOW, THEREFORE, in consideration of the
foregoing and the representations, warranties, covenants and agreements contained in this Agreement, the parties agree as follows:
Article
1
Definitions
Section 1.01. Definitions. (a)
As used in this Agreement, the following terms have the following meanings:
“1933 Act” means the
Securities Act of 1933.
“1934 Act” means the
Securities Exchange Act of 1934.
“Affiliate” means, with
respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common control with such Person.
“Antitrust Laws” shall
mean the Sherman Act of 1890, the Clayton Act of 1914, the Federal Trade Commission Act of 1914, the HSR Act and all other federal,
state and foreign Applicable Laws in effect from time to time that are designed or intended to prohibit, restrict or regulate actions
having the purpose or effect of monopolization or restraint of trade.
“Applicable Law(s)” means,
with respect to any Person, any federal, state or local law (statutory, common or otherwise), constitution, treaty, convention,
ordinance, code, rule, regulation, Order or other similar requirement (including any federal, state or local directive or other
requirement that relates to Medicare or Medicaid) enacted, adopted, promulgated or applied by a Governmental Authority that is
binding upon or applicable to such Person, as the same may be amended from time to time unless expressly specified otherwise in
this Agreement. References to “Applicable Law” or “Applicable Laws” shall be deemed to include Health Care
Laws, any applicable insurance law and Antitrust Law.
“ASOPs” means actuarial
standards of practice promulgated by the Actuarial Standards Board for use by actuaries when providing professional services in
the United States.
“Business Day” means
a day, other than Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by Applicable
Law to close.
“CMS” means the Centers
for Medicare & Medicaid Services.
“Code” means the Internal
Revenue Code of 1986.
“Company Acquisition Proposal”
means any indication of interest, proposal or offer from any Person or Group, other than Parent and its Subsidiaries, relating
to any (i) direct or indirect acquisition (whether in a single transaction or a series of related transactions) of assets of the
Company or its Subsidiaries (including securities of Subsidiaries) equal to 20% or more of the consolidated assets of the Company,
or to which 20% or more of the revenues or earnings of the Company on a consolidated basis are attributable, (ii) direct or indirect
acquisition or issuance (whether in a single transaction or a series of related transactions) of 20% or more of any class of equity
or voting securities of the Company, (iii) tender offer or exchange offer that, if consummated, would result in such Person or
Group beneficially owning 20% or more of any class of equity or voting securities of the Company, or (iv) merger, consolidation,
share exchange, business combination, joint venture, reorganization, recapitalization, liquidation, dissolution or similar transaction
involving the Company, under which such Person or Group would acquire, directly or indirectly, (A) assets equal to 20% or more
of the consolidated assets
of the Company, or to which 20% or more
of the revenues or earnings of the Company on a consolidated basis are attributable, or (B) beneficial ownership of 20% or more
of any class of equity or voting securities of the Company.
“Company Balance Sheet”
means the consolidated balance sheet of the Company and its Subsidiaries as of December 31, 2014, and the footnotes to such consolidated
balance sheet, in each case set forth in the Company’s annual report on Form 10-K for the fiscal year ended December 31,
2014.
“Company Balance Sheet Date”
means December 31, 2014.
“Company Common Stock”
means the common stock, $0.16 2/3 par value, of the Company.
“Company Disclosure Schedule”
means the Company Disclosure Schedule delivered to Parent on the date of this Agreement.
“Company Employee Plan”
means any (i) “employee benefit plan” as defined in Section 3(3) of ERISA, (ii) compensation, employment, consulting,
severance, termination protection, change in control, transaction bonus, retention or similar plan, agreement, arrangement, program
or policy, or (iii) other plan, agreement, arrangement, program or policy providing for compensation, bonuses, profit-sharing,
equity or equity-based compensation or other forms of incentive or deferred compensation, vacation benefits, insurance (including
any self-insured arrangement), medical, dental, vision, prescription or fringe benefits, life insurance, relocation or expatriate
benefits, perquisites, disability or sick leave benefits, employee assistance program, workers’ compensation, supplemental
unemployment benefits or post-employment or retirement benefits (including compensation, pension, health, medical or insurance
benefits), in each case whether or not written (x) that is sponsored, maintained, administered, contributed to or entered into
by the Company or any of its Subsidiaries for the current or future benefit of any director, officer, employee or individual independent
contractor (including any former director, officer, employee or individual independent contractor) of the Company or any of its
Subsidiaries, or (y) for which the Company or any of its Subsidiaries has any direct or indirect liability.
“Company Equity Awards”
means Company Stock Options, Company RSU Awards and Company PSU Awards.
“Company Intellectual Property”
means the Owned Intellectual Property and the Licensed Intellectual Property, in each case, of the Company and its Subsidiaries.
“Company
Material Adverse Effect” means a material adverse effect on the financial condition, business
or results of operations of the Company and its Subsidiaries, taken as a whole; provided that no event, change, effect,
development or occurrence to the extent resulting from, arising out of, or relating to any of the following shall be deemed to
constitute, or shall be taken into account in determining whether there has been, a Company Material Adverse Effect, or whether
a Company Material Adverse Effect would reasonably be expected to occur: (i) any changes
in general United States or global economic conditions, (ii) any changes in conditions generally affecting the health care, health
insurance or managed care industry, or any other industry in which the Company or any of its Subsidiaries operate (other than the
Medicare Advantage managed care industry), (iii) any changes in conditions generally affecting the Medicare Advantage managed care
industry, (iv) any decline, in and of itself, in the market price or trading volume of the Company Common Stock (it being understood
and agreed that the foregoing shall not preclude Parent from asserting that any facts or occurrences giving rise to or contributing
to such decline that are not otherwise excluded from the definition of Company
Material
Adverse Effect should be deemed to constitute, or be taken into account in determining whether there has been, or would reasonably
be expected to be, a Company Material Adverse Effect), (v) any changes in regulatory, legislative or political conditions or in
securities, credit, financial, debt or other capital markets, in each case in the United States or any foreign jurisdiction, (vi)
any failure, in and of itself, by the Company or any of its Subsidiaries to meet any internal or published projections, forecasts,
estimates or predictions in respect of enrollments, revenues, earnings or other financial or operating metrics for any period (it
being understood and agreed that the foregoing shall not preclude Parent from asserting that any facts or occurrences giving rise
to or contributing to such failure that are not otherwise excluded from the definition of Company Material Adverse Effect should
be deemed to constitute, or be taken into account in determining whether there has been, or would reasonably be expected to be,
a Company Material Adverse Effect), (vii) the execution and delivery of this Agreement, the public announcement or the pendency
of this Agreement or the Mergers, the taking of any action required or expressly contemplated by this Agreement or the identity
of, or any facts or circumstances relating to Parent or its Subsidiaries, including the impact of any of the foregoing on the relationships,
contractual or otherwise, of the Company or any of its Subsidiaries with Governmental Authorities, customers, Providers, suppliers,
partners, officers or employees (it being understood and agreed that the foregoing shall not apply with respect to any representation
or warranty that is intended to address the consequences of the execution, delivery or performance of this Agreement or the consummation
of the transactions contemplated hereby), (viii) any adoption, implementation, promulgation, repeal, modification, amendment, authoritative
interpretation, change or proposal of any Applicable Law of or by any Governmental Authority, (ix) any changes in GAAP, SAP or
ASOPs (or authoritative interpretations thereof), (x) any changes in geopolitical conditions, the outbreak or escalation of hostilities,
any acts of war, sabotage or terrorism, or any escalation or worsening of any such acts of war, sabotage or terrorism threatened
or underway as of the date of this Agreement, (xi) any taking of any action at the written request of or with the consent of Parent
(it being understood and agreed that, with respect to any action taken with such consent, the foregoing shall not preclude Parent
from asserting that any facts or occurrences resulting from such action that are not otherwise excluded from the definition of
Company Material Adverse Effect should be deemed to constitute, or be taken into account in determining whether there has been,
or would reasonably be expected to be, a Company Material Adverse Effect), (xii) any reduction in the credit rating of the Company
or any of its Subsidiaries (it being understood and agreed that the foregoing shall not preclude Parent from asserting that any
facts or occurrences giving rise to or contributing to such reduction that are not otherwise excluded from the definition of Company
Material Adverse Effect should be deemed to constitute, or be taken into account in determining whether there has been, or would
reasonably be expected to be, a Company Material Adverse Effect), (xiii) any hurricane, earthquake, flood or other natural disasters,
acts of God or any change resulting from weather conditions, (xiv) any changes to reimbursement rates or in methods or procedures
for determining such rates, any changes to eligibility requirements or any other programmatic changes by any Governmental Authority,
in each case, whether such changes are applicable nationally or to only certain geographic areas, (xv) the matters set forth in
Section 1.01 of the Company Disclosure Schedule, or (xvi) any claims, actions, suits or proceedings arising from allegations of
a breach of fiduciary duty or violation of Applicable Law relating to this Agreement or the Mergers, except in the case of each
of clauses (i), (ii), (iii), (v), (viii), (ix) or (xiv), to the extent that any such event, change, effect, development or occurrence
has a materially disproportionate adverse effect on the Company and its Subsidiaries, taken as a whole, relative to the adverse
effect such event, change, effect, development or occurrence has on other companies operating in the managed care industry (it
being understood and agreed that any such disproportionate effect on the Company and its Subsidiaries to the extent resulting from
the greater concentration of the businesses of the Company and its Subsidiaries in any particular industry or geography relative
to other companies operating in the managed care industry
shall
not be taken into account in determining whether there has been, or would reasonably be expected to be, a Company Material Adverse
Effect).
“Company Stock Plans”
means the Amended and Restated 2003 Stock Incentive Plan and the 2011 Stock Incentive Plan, in each case, as amended from time
to time.
“Consent” means any consent,
approval, waiver, license, permit, variance, exemption, franchise, clearances, authorization, acknowledgment, Order or other confirmation.
“Contract” means any
contract, agreement, obligation, understanding or instrument, lease or license.
“Credit Agreement” means
the Second Amended and Restated Credit Agreement, dated as of July 9, 2013, among the Company, the several banks and other financial
institutions from time to time parties thereto, JPMorgan Chase Bank, N.A., as Agent and CAF Loan Agent, Bank of America, N.A.,
as Syndication Agent, Citibank, N.A., PNC Bank, National Association, U.S. Bank National Association and Wells Fargo Bank, National
Association, as Documentation Agents, J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup
Global Markets, Inc., PNC Capital Markets LLC, U.S. Bank National Association, and Wells Fargo Securities, LLC as Joint-Lead Arrangers
and Joint Bookrunners.
“Environmental Law” means
any Applicable Law relating to (i) the protection, preservation or restoration of the environment (including air, surface water,
groundwater, drinking water supply, surface land, subsurface land, plant and animal life or any other natural resource), or (ii)
the exposure to, or the use, storage, recycling, treatment, generation, transportation, processing, handling, labeling, production,
release or disposal of Hazardous Substances.
“Environmental Permits”
means all permits, licenses, franchises, consents (including consents required by Contract), variances, exemptions, orders, certificates,
approvals and other similar authorizations of Governmental Authorities required by Environmental Law and affecting, or relating
to, the business of the Company or any of its Subsidiaries, or the business of Parent or any of its Subsidiaries, as applicable.
“Equity Award Exchange Ratio”
means the sum of (i) the Share Consideration, plus (ii) the quotient of (x) the Cash Consideration, divided by (y)
the Parent Stock Price, rounded to the nearest one thousandth.
“ERISA” means the Employee
Retirement Income Security Act of 1974.
“ERISA Affiliate” means,
with respect to any entity, any other entity that, together with such entity, would be treated as a single employer under Section
414 of the Code.
“Filing” means any registration,
petition, statement, application, schedule, form, declaration, notice, notification, report, submission or other filing.
“Financing Sources” means
the Persons that have entered or will enter into commitment letters or agreements with Parent in connection with the Debt Financing
(including any Persons providing Alternative Financing) and any joinder agreements, indentures or credit agreements entered into
pursuant thereto, including the agents, arrangers, lenders and other entities that have committed to
provide or arrange all or part of the Debt
Financing, and their respective general or limited partners, direct or indirect shareholders, managers, members, Affiliates, Representatives,
successors and assigns.
“GAAP” means United States
generally accepted accounting principles.
“Government Sponsored Health Care
Programs” means (i) the Medicare program established under and governed by the applicable provisions of Title XVIII of
the Social Security Act, the regulations promulgated thereunder and any sub-regulatory guidance issued, (ii) the Medicaid program
governed by the applicable provisions of Title XIX of the Social Security Act, the regulations promulgated thereunder, as well
as any state’s Applicable Laws implementing the Medicaid program, and (iii) any other state or federal health care program
or plan.
“Governmental Authority”
means any transnational, domestic or foreign federal, state or local governmental, regulatory or administrative authority, department,
court, agency, commission or official, including any political subdivision thereof, or any non-governmental self-regulatory agency,
commission or authority.
“Group” means a “group”
as defined in Section 13(d) of the 1934 Act.
“Hazardous Substance”
means any substance, material or waste that is listed, defined, designated or classified as hazardous, toxic, radioactive, dangerous
or a “pollutant” or “contaminant” or words of similar meaning under any Environmental Law or are otherwise
regulated by any Governmental Authority with jurisdiction over the environment or natural resources, including petroleum or any
derivative or byproduct thereof, radon, radioactive material, asbestos or asbestos containing material, urea formaldehyde, foam
insulation or polychlorinated biphenyls.
“Health Care Laws” means
all Applicable Laws relating to: (i) the licensure, certification, qualification or authority to transact business in connection
with the provision of, payment for, or arrangement of, health care services, health benefits or health insurance, including Applicable
Laws that regulate Providers, managed care, third-party payors and Persons bearing the financial risk for, or providing administrative
or other functions in connection with, the provision of, payment for or arrangement of health care services and, including all
Applicable Laws relating to Health Care Programs pursuant to which any Regulated Subsidiary of the Company or Parent, as applicable,
is required to be licensed or authorized to transact business; (ii) health care or insurance fraud or abuse, including the solicitation
or acceptance of improper incentives involving persons operating in the health care industry, patient referrals or Provider incentives
generally, including the following statutes: the Federal anti-kickback law (42 U.S.C. § 1320a-7b), the Stark laws (42 U.S.C.
§ 1395nn), the Federal False Claims Act (31 U.S.C. §§ 3729, et seq.), the Federal Civil Monetary Penalties Law (42
U.S.C. § 1320a-7a), the Federal Program Fraud Civil Remedies Act (31 U.S.C. § 3801 et seq.) and the Federal Health Care
Fraud Law (18 U.S.C. § 1347); (iii) the provision of administrative, management or other services related to any Health Care
Programs, including the administration of health care claims or benefits or processing or payment for health care services, treatment
or supplies furnished by Providers, including the provision of the services of third party administrators, utilization review agents
and Persons performing quality assurance, credentialing or coordination of benefits; (iv) the licensure, certification, qualification
or authority to transact business in connection with the provision of, or payment for, pharmacy services, along with the requirements
of the U.S. Drug Enforcement Administration in connection therewith; (v) the Consolidated Omnibus Budget Reconciliation Act of
1985; (vi) ERISA; (vii) the Medicare Prescription Drug, Improvement, and Modernization Act of 2003; (viii) the Medicare Improvements
for Patients and Providers Act of 2008; (ix) privacy, security, integrity, accuracy,
transmission, storage or other protection
of information about or belonging to actual or prospective participants in the Company’s Health Care Programs or other lines
of business, including the Health Insurance Portability and Accountability Act of 1996 (Pub. L. No. 104-191), as amended by the
Health Information Technology for Economic and Clinical Health Act (Pub. L. No. 111-5), including any other Applicable Laws relating
to medical information; and (x) the Patient Protection and Affordable Care Act (Pub. L. 111-148) as amended by the Health Care
and Education Reconciliation Act of 2010 (Pub. L. 111-152).
“Health Care Programs”
means all lines of business, programs and types of services offered by the Company or any of its Subsidiaries or Parent or any
of its Subsidiaries, as applicable, including Government Sponsored Health Care Programs, commercial risk (individual, small group,
large group), workers compensation, the Federal Employees Health Benefits Program (FEHBP), TRICARE, administrative services only
(ASO) and network rental.
“HSR Act” means the Hart-Scott-Rodino
Antitrust Improvements Act of 1976.
“Intellectual Property”
means any and all of the following, whether or not registered, and all rights therein, arising in the United States or any other
jurisdiction throughout the world: (i) trademarks, service marks, trade names, Internet domain names, Internet account names (including
social networking and media names) and other indicia of origin, together with all goodwill associated therewith or symbolized thereby,
and all registrations and applications relating to the foregoing; (ii) patents and pending patent applications and all divisions,
continuations, continuations-in-part, reissues, reexaminations, and any extensions thereof; (iii) registered and unregistered copyrights
(including those in Software), all registrations and applications to register the same, and all renewals, extensions, reversions
and restorations thereof; (iv) trade secrets and rights in confidential technology and information, know-how, inventions, processes,
formulae, algorithms, models and methodologies; (v) rights in Software; and (vi) other similar types of proprietary or intellectual
property.
“IT Assets” means any
and all computers, Software, firmware, middleware, servers, workstations, routers, hubs, switches, data communications lines and
other information technology equipment, and all associated documentation, owned by, or licensed or leased to, the Company or any
of its Subsidiaries or Parent or any of its Subsidiaries, as applicable.
“knowledge” of any Person
that is not an individual means the actual knowledge of those executive officers of the Company or Parent, as the case may be,
set forth in Section 1.01 of the Company Disclosure Schedule or Section 1.01 of the Parent Disclosure Schedule, as applicable.
“Licensed Intellectual Property”
means any and all Intellectual Property owned by a Third Party and licensed or sublicensed to the Company or any of its Subsidiaries,
or Parent or any of its Subsidiaries, as applicable.
“Lien” means, with respect
to any property or asset, any mortgage, lien, license, pledge, charge, security interest, encumbrance or other adverse claim of
any kind in respect of such property or asset.
“Major Subsidiary” means,
with respect to any Person, each Subsidiary of such Person that is a “significant subsidiary” (as defined in Regulation
S-X) of such Person or a Regulated Subsidiary of such Person.
“Order” means any order,
writ, decree, judgment, award, injunction, ruling, settlement or stipulation issued, promulgated, made, rendered or entered into
by or with any Governmental Authority or arbitrator (in each case, whether temporary, preliminary or permanent).
“Owned Intellectual Property”
means any and all Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries or Parent or any
of its Subsidiaries, as applicable.
“Parent Acquisition Proposal”
means any indication of interest, proposal or offer from any Person or Group, other than the Company and its Subsidiaries, relating
to any (i) direct or indirect acquisition (whether in a single transaction or a series of related transactions) of assets of Parent
or its Subsidiaries (including securities of Subsidiaries) equal to 20% or more of the consolidated assets of Parent, or to which
20% or more of the revenues or earnings of Parent on a consolidated basis are attributable, (ii) direct or indirect acquisition
or issuance (whether in a single transaction or a series of related transactions) of 20% or more of any class of equity or voting
securities of Parent, (iii) tender offer or exchange offer that, if consummated, would result in such Person or Group beneficially
owning 20% or more of any class of equity or voting securities of Parent, or (iv) merger, consolidation, share exchange, business
combination, joint venture, reorganization, recapitalization, liquidation, dissolution or similar transaction involving Parent,
under which such Person or Group would acquire, directly or indirectly, (A) assets equal to 20% or more of the consolidated assets
of Parent, or to which 20% or more of the revenues or earnings of Parent on a consolidated basis are attributable, or (B) beneficial
ownership of 20% or more of any class of equity or voting securities of Parent.
“Parent Balance Sheet”
means the consolidated balance sheet of Parent and its Subsidiaries as of December 31, 2014, and the footnotes to such consolidated
balance sheet, in each case set forth in Parent’s annual report on Form 10-K for the fiscal year ended December 31, 2014.
“Parent Balance Sheet Date”
means December 31, 2014.
“Parent Common Stock”
means the common stock, $0.01 par value, of Parent.
“Parent Disclosure Schedule”
means the Parent Disclosure Schedule delivered to the Company on the date of this Agreement.
“Parent Employee Plan”
means any (i) “employee benefit plan” as defined in Section 3(3) of ERISA, (ii) compensation, employment, consulting,
severance, termination protection, change in control, transaction bonus, retention or similar plan, agreement, arrangement, program
or policy or (iii) other plan, agreement, arrangement, program or policy providing for compensation, bonuses, profit-sharing, equity
or equity-based compensation or other forms of incentive or deferred compensation, vacation benefits, insurance (including any
self-insured arrangement), medical, dental, vision, prescription or fringe benefits, life insurance, relocation or expatriate benefits,
perquisites, disability or sick leave benefits, employee assistance program, workers’ compensation, supplemental unemployment
benefits or post-employment or retirement benefits (including compensation, pension, health, medical or insurance benefits), in
each case whether or not written (x) that is sponsored, maintained, administered, contributed to or entered into by Parent or any
of its Subsidiaries for the current or future benefit of any director, officer, employee or individual independent contractor (including
any former director, officer, employee or individual independent contractor) of Parent or any of its Subsidiaries, or (y) for which
Parent or any of its Subsidiaries has any direct or indirect liability.
“Parent Intellectual Property”
means the Owned Intellectual Property and the Licensed Intellectual Property, in each case, of Parent and its Subsidiaries.
“Parent
Material Adverse Effect” means a material adverse effect on the financial condition, business
or results of operations of Parent and its Subsidiaries, taken as a whole; provided that no event, change, effect, development
or occurrence to the extent resulting from, arising out of, or relating to any of the following shall be deemed to constitute,
or shall be taken into account in determining whether there has been, a Parent Material Adverse Effect, or whether a Parent Material
Adverse Effect would reasonably be expected to occur: (i) any changes in general United
States or global economic conditions, (ii) any changes in conditions generally affecting the health care, health insurance or managed
care industry, or any other industry in which Parent or any of its Subsidiaries operate (other than the Medicare Advantage managed
care industry), (iii) any changes in conditions generally affecting the Medicare Advantage managed care industry, (iv) any decline,
in and of itself, in the market price or trading volume of Parent Common Stock (it being understood and agreed that the foregoing
shall not preclude the Company from asserting that any facts or occurrences giving rise to or contributing to such decline that
are not otherwise excluded from the definition of Parent Material Adverse Effect should be deemed to constitute, or be taken into
account in determining whether there has been, or would reasonably be expected to be, a Parent Material Adverse Effect), (v) any
changes in regulatory, legislative or political conditions or in securities, credit, financial, debt or other capital markets,
in each case in the United States or any foreign jurisdiction, (vi) any failure, in and of itself, by Parent or any of its Subsidiaries
to meet any internal or published projections, forecasts, estimates or predictions in respect of enrollments, revenues, earnings
or other financial or operating metrics for any period (it being understood and agreed that the foregoing shall not preclude the
Company from asserting that any facts or occurrences giving rise to or contributing to such failure that are not otherwise excluded
from the definition of Parent Material Adverse Effect should be deemed to constitute, or be taken into account in determining whether
there has been, or would reasonably be expected to be, a Parent Material Adverse Effect), (vii) the execution and delivery of this
Agreement, the public announcement or the pendency of this Agreement or the Mergers, the taking of any action required or expressly
contemplated by this Agreement or the identity of, or any facts or circumstances relating to the Company or its Subsidiaries, including
the impact of any of the foregoing on the relationships, contractual or otherwise, of Parent or any of its Subsidiaries with Governmental
Authorities, customers, Providers, suppliers, partners, officers or employees (it being understood and agreed that the foregoing
shall not apply with respect to any representation or warranty that is intended to address the consequences of the execution, delivery
or performance of this Agreement or the consummation of the transactions contemplated hereby), (viii) any adoption, implementation,
promulgation, repeal, modification, amendment, authoritative interpretation, change or proposal of any Applicable Law of or by
any Governmental Authority, (ix) any changes in GAAP, SAP or ASOPs (or authoritative interpretations thereof), (x) any changes
in geopolitical conditions, the outbreak or escalation of hostilities, any acts of war, sabotage or terrorism, or any escalation
or worsening of any such acts of war, sabotage or terrorism threatened or underway as of the date of this Agreement, (xi) any taking
of any action at the written request of or with the consent of the Company (it being understood and agreed that, with respect to
any action taken with such consent, the foregoing shall not preclude the Company from asserting that any facts or occurrences resulting
from such action that are not otherwise excluded from the definition of Parent Material Adverse Effect should be deemed to constitute,
or be taken into account in determining whether there has been, or would reasonably be expected to be, a Parent Material Adverse
Effect), (xii) any reduction in the credit rating of Parent or any of its Subsidiaries (it being understood and agreed that the
foregoing shall not preclude the Company from asserting that any facts or occurrences giving rise to or contributing to such reduction
that are not otherwise excluded from the definition of Parent Material Adverse Effect should be deemed
to constitute,
or be taken into account in determining whether there has been, or would reasonably be expected to be, a Parent Material Adverse
Effect), (xiii) any hurricane, earthquake, flood or other natural disasters, acts of God or any change resulting from weather conditions,
(xiv) any changes to reimbursement rates or in methods or procedures for determining such rates, any changes to eligibility requirements
or any other programmatic changes by any Governmental Authority, in each case, whether such changes are applicable nationally or
to only certain geographic areas, or (xv) any claims, actions, suits or proceedings arising from allegations of a breach of fiduciary
duty or violation of Applicable Law relating to this Agreement or the Mergers, except in the case of each of clauses (i), (ii),
(iii), (v), (viii), (ix) or (xiv), to the extent that any such event, change, effect, development or occurrence has a materially
disproportionate adverse effect on Parent and its Subsidiaries, taken as a whole, relative to the adverse effect such event, change,
effect, development or occurrence has on other companies operating in the managed care industry (it being understood and agreed
that any such disproportionate effect on Parent and its Subsidiaries to the extent resulting from the greater concentration of
the businesses of Parent and its Subsidiaries in any particular industry or geography relative to other companies operating in
the managed care industry shall not be taken into account in determining whether there has been, or would reasonably be expected
to be, a Parent Material Adverse Effect).
“Parent Stock Price”
means the average of the volume weighted averages of the trading prices of Parent Common Stock on the NYSE (as reported by Bloomberg
L.P. or, if not reported therein, in another authoritative source mutually selected by Parent and the Company in good faith) on
each of the five (5) consecutive trading days ending on the trading day that is two (2) trading days prior to the Closing Date.
“PBGC” means the Pension
Benefit Guaranty Corporation.
“Pennsylvania Law” the
Pennsylvania Business Corporation Law of 1988.
“Permitted Lien” means
(i) any Liens for Taxes not yet due and payable or which are being contested in good faith by appropriate proceedings and with
respect to which adequate reserves have been established in accordance with GAAP or SAP, as applicable, (ii) carriers’, warehousemen’s,
mechanics’, materialmen’s, repairmen’s or other similar liens, (iii) pledges or deposits in connection with workers’
compensation, unemployment insurance and other social security legislation, (iv) gaps in the chain of title evident from the records
of the applicable Government Authority maintaining such records, easements, rights-of-way, covenants, restrictions and other encumbrances
of record as of the date of this Agreement, (v) easements, rights-of-way, covenants, restrictions and other encumbrances incurred
in the ordinary course of business that do not, in any case, materially detract from the value or the use of the property subject
thereto, (vi) statutory landlords’ liens and liens granted to landlords under any lease, (vii) non-exclusive licenses to
Intellectual Property granted in the ordinary course of business, (viii) any purchase money security interests, equipment leases
or similar financing arrangements, (ix) any Liens which are disclosed on the Company Balance Sheet (in the case of Liens applicable
to the Company or any of its Subsidiaries) or the Parent Balance Sheet (in the case of Liens applicable to Parent and its Subsidiaries),
or the notes thereto, or (x) any Liens that are not material to the Company and its Subsidiaries or Parent and its Subsidiaries,
as applicable, taken as a whole.
“Person” means any individual,
corporation, partnership, limited liability company, association, trust or other entity or organization, including a government
or political subdivision or an agency or instrumentality of such government or political subdivision.
“Providers” means all
primary care physicians and physician groups, medical groups, independent practice associations, specialist physicians, dentists,
optometrists, pharmacies and pharmacists, radiologists and radiology centers, laboratories, mental health professionals, community
health centers, clinics, surgicenters, accountable care organizations, chiropractors, physical therapists, nurses, nurse practitioners,
physician’s assistants, hospitals, skilled nursing facilities, extended care facilities, other health care or services facilities,
durable medical equipment suppliers, home health agencies, alcoholism or drug abuse centers and any other specialty, ancillary
or allied health professional or facility.
“Regulated Subsidiary”
means any Subsidiary of the Company or Parent, as applicable, that is licensed in one or more jurisdictions as an insurance company,
health maintenance organization (including a single healthcare service plan), managed care organization, healthcare service plan,
specialized healthcare service plan, healthcare service corporation, pharmacy, dental maintenance organization, dental plan organization,
prepaid dental plan, third party administrator and/or utilization review agent, broker or agency, including, with respect to the
Company, Humana Government Business, Inc.
“SAP” means, as to any
insurance company or health maintenance organization conducting an insurance business, the statutory accounting practices prescribed
or permitted by Applicable Law or Governmental Authorities seated in the jurisdiction where such insurance company or health maintenance
organization is domiciled and responsible for the regulation thereof.
“Sarbanes-Oxley Act”
means the Sarbanes-Oxley Act of 2002.
“SEC” means the United
States Securities and Exchange Commission.
“Severance Pay Plans”
means the severance plans set forth on Section 7.05(a) of the Company Disclosure Schedule.
“Social Security Act”
means the Social Security Act of 1935.
“Software” means all
(i) computer programs and other software including any and all software implementations of algorithms, models and, methodologies,
assemblers, applets, compilers, development tools, design tools and user interfaces, whether in source code or object code form,
(ii) databases and compilations, including all data and collections of data, whether machine readable or otherwise, and (iii) updates,
upgrades, modifications, improvements, enhancements, derivative works, new versions, new releases and corrections to or based on
any of the foregoing.
“Subsidiary” means, with
respect to any Person, any entity of which securities or other ownership interests having ordinary voting power to elect a majority
of the board of directors or other persons performing similar functions are directly or indirectly owned by such Person. For purposes
of this Agreement, a Subsidiary shall be considered a “wholly owned Subsidiary” of a Person as long as such Person
directly or indirectly owns all of the securities or other ownership interests (excluding any securities or other ownership interests
held by an individual director or officer required to hold such securities or other ownership interests pursuant to Applicable
Law) of such Subsidiary.
“Tax” means any income,
gross receipts, franchise, sales, use, ad valorem, property, payroll, withholding, excise, severance, transfer, employment, estimated,
alternative or add-on minimum, value added, stamp, occupation, premium, environmental or windfall profits taxes, and any other
taxes,
charges, fees, levies, imposts, customs,
duties, licenses or other assessments, together with any interest, penalties and additions to tax (including penalties for failure
to file or late filing of any tax return, report or other filing, and any interest in respect of such penalties, additions to tax
or additional amounts imposed by any federal, state, local, non-U.S. or other Taxing Authority).
“Tax Return” means any
report, return, document, statement, declaration or other information or filing required to be supplied to any Taxing Authority
with respect to Taxes, including information returns, claims for refunds, any documents with respect to or accompanying payments
of estimated Taxes or with respect to or accompanying requests for the extension of time in which to file any such report, return,
document, declaration or other information.
“Tax Sharing Agreement”
means any existing agreement binding any Person or any of its Subsidiaries that provides for the allocation, apportionment, sharing
or assignment of any Tax liability or benefit, or the transfer or assignment of income, revenues, receipts, or gains for the purpose
of determining any Person’s Tax liability, other than (i) agreements entered into in the ordinary course of business that
do not have as a principal purpose addressing Tax matters, (ii) financing agreements that do not have as a principal purpose addressing
Tax matters and (iii) leases.
“Taxing Authority” means
any Governmental Authority responsible for the imposition or collection of any tax.
“Third Party” means any
Person or Group, other than the Company or any of its Affiliates, in the case of Parent, or Parent or any of its Affiliates, in
the case of the Company, and the Representatives of such Persons, in each case, acting in such capacity.
“Willful Breach” means
a material breach of this Agreement that is the consequence of an act or omission by a party with the actual knowledge that the
taking of such act or failure to take such action would be a material breach of this Agreement or as otherwise contemplated by
the last sentence of Section 7.06(b).
(b) Each of the following terms is defined
in the Section set forth opposite such term:
Term |
Section |
Affected Employees |
7.05 |
Agreement |
Preamble |
Alternative Financing |
7.06 |
Annual Incentive Plan |
7.05 |
Assumed Performance Unit Award |
2.07 |
Assumed Restricted Unit Award |
2.07 |
Assumed Stock Option |
2.07 |
Award Consideration |
2.07 |
Bankruptcy and Equity Exceptions |
4.02 |
Benefits Continuation Period |
7.05 |
Cash Consideration |
2.04 |
Certificate |
2.04 |
Change in Control Agreements |
7.05 |
Claim Expenses |
7.04 |
Closing |
2.01 |
Closing Date |
2.01 |
CMS Sanction |
9.02 |
Company |
Preamble |
Company Adverse Recommendation Change |
6.02 |
Company Approval Time |
6.02 |
Company Board Recommendation |
4.02 |
Company Insurance Policies |
4.25 |
Company Intervening Event |
6.02 |
Company Material Contract |
4.18 |
Company Organizational Documents |
4.01 |
Company Permits |
4.16 |
Company Preferred Stock |
4.05 |
Company PSU Award |
2.07 |
Company Record Date |
8.04 |
Company Registered IP |
4.22 |
Company Required Governmental Authorizations |
4.03 |
Company RSU Award |
2.07 |
Company SEC Documents |
4.07 |
Company Securities |
4.05 |
Company Statutory Filings |
4.10 |
Company Stock Option |
2.07 |
Company Stockholder Approval |
4.02 |
Company Stockholder Meeting |
8.04 |
Company Superior Proposal |
6.02 |
Company Termination Fee |
10.03 |
Confidentiality Agreement |
8.01 |
Davis Polk |
8.13 |
Debt Commitment Letter(s) |
5.27 |
Debt Financing |
5.27 |
Delaware Law |
2.02 |
Delaware LLC Law |
2.03 |
Dissenting Shares |
2.06 |
Dissenting Stockholders |
2.06 |
D&O Claim |
7.04 |
D&O Indemnified Parties |
7.04 |
D&O Indemnifying Parties |
7.04 |
EBITDA |
8.02 |
End Date |
10.01 |
Equity Award Cash Consideration |
2.07 |
Exchange Agent |
2.05 |
Exchange Agent Agreement |
2.05 |
Exchange Fund |
2.05 |
Exchange Ratio |
2.04 |
Excluded Shares |
2.04 |
First Certificate of Merger |
2.02 |
First Merger |
2.02 |
First Merger Effective Time |
2.02 |
Fried Frank |
2.01 |
Incentive Plan Participant |
7.05 |
Indenture |
6.05 |
Initial Surviving Corporation |
2.02 |
Initial Surviving Corporation Common Stock |
2.04 |
internal controls |
4.07 |
Joint Proxy Statement/Prospectus |
8.03 |
Lease |
4.23 |
Maximum Premium |
7.04 |
Merger Consideration |
2.04 |
Merger Sub 1 |
Preamble |
Merger Sub 2 |
Preamble |
Mergers |
2.03 |
New Company Plans |
7.05 |
NYSE |
4.03 |
Parent |
Preamble |
Parent Adverse Recommendation Change |
7.02 |
Parent Approval Time |
7.02 |
Parent Board Recommendation |
5.02 |
Parent Equity Award |
5.05 |
Parent Intervening Event |
7.02 |
Parent Organizational Documents |
5.01 |
Parent Permits |
5.16 |
Parent Registered IP |
5.21 |
Parent Required Governmental Authorizations |
5.03 |
Parent SEC Documents |
5.07 |
Parent Securities |
5.05 |
Parent Share Issuance |
5.02 |
Parent Statutory Filings |
5.10 |
Parent Stock Right |
5.05 |
Parent Stock Unit |
5.05 |
Parent Stockholder Approval |
5.02 |
Parent Stockholder Meeting |
8.04 |
Parent Superior Proposal |
7.02 |
Parent Termination Fee |
10.03 |
principal executive officer |
4.07 |
principal financial officer |
4.07 |
Registration Statement |
8.03 |
Regulation S-K |
4.14 |
Regulation S-X |
6.01 |
Regulatory Material Adverse Effect |
8.02 |
Regulatory Termination Fee |
10.03 |
Relevant Factors |
9.02 |
Representatives |
6.02 |
Second Certificate of Merger |
2.03 |
Second Merger |
2.03 |
Second Merger Effective Time |
2.03 |
Share Consideration |
2.04 |
Surviving Company |
2.03 |
Tax Representation Letter |
8.13 |
Transaction Litigation |
8.08 |
Transition Team |
6.04 |
Treasury Regulations |
Recitals |
Uncertificated Share |
2.04 |
Section 1.02. Other Definitional and
Interpretative Provisions. The following rules of interpretation shall apply to this Agreement: (i) the words “hereof”,
“hereby”, “herein” and “hereunder” and words of like import used in this Agreement shall refer
to this Agreement as a whole and not to any particular provision of this Agreement; (ii) the table of contents and captions in
this Agreement are included for convenience of reference only and shall be ignored in the construction or interpretation hereof;
(iii) references to Articles, Sections and Exhibits are to Articles, Sections and Exhibits of this Agreement unless otherwise specified;
(iv) all Exhibits and schedules annexed to this Agreement or referred to in this Agreement, including the Company Disclosure Schedule
and the Parent Disclosure Schedule, are incorporated in and made a part of this Agreement as if set forth in full in this Agreement;
(v) any capitalized term used in any Exhibit, the Company Disclosure Schedule or the Parent Disclosure Schedule but not otherwise
defined therein shall have the meaning set forth in this Agreement; (vi) any singular term in this Agreement shall be deemed to
include the plural, and any plural term the singular, and references to any gender shall include all genders; (vii) whenever the
words “include”, “includes” or “including” are used in this Agreement, they shall be deemed
to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words
of like import; (viii) “writing”, “written” and comparable terms refer to printing, typing and other means
of reproducing words (including electronic media) in a visible form; (ix) references to any Applicable Law shall be deemed to refer
to such Applicable Law as amended from time to time and to any rules or regulations promulgated thereunder; (x) references to any
Contract are to that Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof;
provided that with respect to any Contract listed on any schedule hereto, all such amendments, modifications or supplements
(other than such amendments, modifications or supplements that are immaterial) must also be listed in the appropriate schedule;
(xi) references to any Person include the successors and permitted assigns of that Person; (xii) references “from”
or “through” any date mean, unless otherwise specified, “from and including” or “through and including”,
respectively; (xiii) references to “dollars” and “$” means U.S. dollars; (xiv) the term “made available”
and words of similar import mean that the relevant documents, instruments or materials were (A) posted and made available to the
other party on the Merrill Datasite/Project Hugo due diligence data site, with respect to the Company, or on the Merrill Datasite/Project
Element 2015 due diligence data site, with respect to Parent, as applicable, maintained by such party in connection with the transactions
contemplated hereby, in each case, prior to the date hereof; (B) provided via electronic mail or in person prior to the date hereof;
or (C) filed or furnished to the SEC prior to the date hereof; (xv) the word “extent” in the phrase “to the extent”
shall mean the degree to which a subject or other theory extends and such phrase shall not mean “if”; and (xvi) the
parties hereto have participated jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question
of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the parties hereto and no presumption
or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.
Article
2
Closing; Mergers
Section 2.01. Closing. The closing
of the Mergers (the “Closing”) shall take place in New York City at the offices of Fried, Frank, Harris, Shriver
& Jacobson LLP (“Fried Frank”), One New York Plaza, New York, New York, 10004 at 10:00 a.m., Eastern time,
on the third (3rd) Business Day after the date the conditions set forth in Article 9 (other than conditions that by their nature
are to be satisfied at the Closing, but subject to the satisfaction or, to the extent permitted by Applicable Law, waiver of such
conditions by the party or parties entitled to the benefit thereof at the Closing) have been satisfied or, to the extent permitted
by Applicable Law, waived by the party or parties entitled to the benefit thereof, or at such other place, at such other time or
on such other date as Parent and the Company may mutually agree (the date on which the Closing occurs, the “Closing Date”).
Section 2.02. First Merger.
(a) At the Closing, the Company shall file a certificate of merger (the “First Certificate of Merger”) with
the Delaware Secretary of State and make all other filings or recordings required by the General Corporation Law of the State of
Delaware (the “Delaware Law”) in connection with the First Merger. The First Merger shall become effective at
such time (the “First Merger Effective Time”) as the First Certificate of Merger is duly filed with the Delaware
Secretary of State (or at such later time as Parent and the Company shall agree and is specified in the First Certificate of Merger).
(b) At the First Merger Effective Time,
Merger Sub 1 shall be merged (the “First Merger”) with and into the Company in accordance with the Delaware
Law, whereupon the separate existence of Merger Sub 1 shall cease, and the Company shall be the surviving corporation (the “Initial
Surviving Corporation”).
(c) From and after the First Merger
Effective Time, the Initial Surviving Corporation shall possess all the rights, powers, privileges and franchises and be subject
to all of the obligations, liabilities, restrictions and disabilities of the Company and Merger Sub 1, all as provided under the
Delaware Law.
Section 2.03. Second Merger. (a)
At the Closing and immediately following the First Merger Effective Time, the Initial Surviving Corporation shall file a certificate
of merger (the “Second Certificate of Merger”) with the Delaware Secretary of State and make all other filings
or recordings required by the Delaware Law and the Limited Liability Company Act of the State of Delaware (the “Delaware
LLC Law”) in connection with the Second Merger. The Second Merger shall become effective at such time (the “Second
Merger Effective Time”) as the Second Certificate of Merger is duly filed with the Delaware Secretary of State (or at
such later time as Parent and the Company shall agree and is specified in the Second Certificate of Merger).
(b) At the Second Merger Effective Time,
the Initial Surviving Corporation shall be merged (the “Second Merger”, and together with the First Merger,
the “Mergers”) with and into Merger Sub 2 in accordance with the Delaware Law and the Delaware LLC Law, whereupon
the separate existence of the Initial Surviving Corporation shall cease, and Merger Sub 2 shall be the surviving limited liability
company (the “Surviving Company”).
(c) From and after the Second Merger
Effective Time, the Surviving Company shall possess all the rights, powers, privileges and franchises and be subject to all of
the obligations, liabilities,
restrictions and disabilities of
the Initial Surviving Corporation and Merger Sub 2, all as provided under the Delaware Law and the Delaware LLC Law.
Section 2.04. Conversion of Shares.
(a) At the First Merger Effective Time:
(i) other than (x) shares of
Company Common Stock to be cancelled pursuant to Section 2.04(a)(ii) and (y) Dissenting Shares (such shares together with the shares
of Company Common Stock to be cancelled pursuant to Section 2.04(a)(ii), collectively, the “Excluded Shares”),
each share of Company Common Stock outstanding immediately prior to the First Merger Effective Time shall be converted into the
right to receive (i) 0.8375 (the “Exchange Ratio”) shares of Parent Common Stock (the “Share Consideration”)
and (ii) $125.00 in cash without interest (the “Cash Consideration,” and together with the Share Consideration,
the “Merger Consideration”);
(ii) each share of Company Common
Stock held by the Company as treasury stock or owned by Parent or any of its Subsidiaries immediately prior to the First Merger
Effective Time (other than any such shares owned by Parent or any of its Subsidiaries in a fiduciary, representative or other capacity
on behalf of other Persons, whether or not held in a separate account) shall be cancelled, and no consideration shall be paid with
respect thereto;
(iii) each share of common stock
of Merger Sub 1 outstanding immediately prior to the First Merger Effective Time shall be converted into and become one share of
common stock, par value $0.01 per share, of the Initial Surviving Corporation with the same rights, powers and privileges as the
shares so converted and shall constitute the only outstanding shares of capital stock of the Initial Surviving Corporation (the
“Initial Surviving Corporation Common Stock”); and
(iv) all outstanding shares
of Company Common Stock shall no longer be outstanding and shall automatically be cancelled and retired and shall cease to exist,
and (x) each certificate which immediately prior to the Effective Time represented any such shares of Company Common Stock (each,
a “Certificate”) and (y) each uncertificated share of Company Common Stock (an “Uncertificated Share”)
which immediately prior to the First Merger Effective Time was registered to a holder on the stock transfer books of the Company
shall (other than with respect to Excluded Shares) thereafter represent only the right to receive the Merger Consideration and
the right to receive any dividends or other distributions pursuant to Section 2.05(f) and any cash in lieu of any fractional shares
of Parent Common Stock pursuant to Section 2.09, in each case to be issued or paid in accordance with Section 2.05, without interest.
(b) At the Second Merger Effective Time:
(i) each share of Initial Surviving
Corporation Common Stock outstanding immediately prior to the Second Merger Effective Time shall be cancelled, and no consideration
shall be paid with respect thereto; and
(ii) the limited liability company
interests of Merger Sub 2 outstanding immediately prior to the Second Merger Effective Time shall remain outstanding and shall
constitute the only outstanding limited liability company interests of the Surviving Company.
Section 2.05. Surrender and Payment.
(a) Prior to the First Merger Effective Time, Parent shall appoint a commercial bank or trust company reasonably acceptable to the
Company (the “Exchange Agent”) and enter into an exchange agent agreement with the Exchange Agent reasonable
acceptable to the Company (the “Exchange Agent Agreement”) for the purpose of exchanging (i) Certificates or
(ii) Uncertificated Shares for the Merger Consideration payable in respect of the shares of Company Common Stock. As of the First
Merger Effective Time, Parent shall deposit with the Exchange Agent, for the benefit of the holders of shares of Company Common
Stock, for exchange in accordance with this Section 2.05 through the Exchange Agent, (x) certificates (or evidence of shares in
book-entry form) representing the shares of Parent Common Stock issuable pursuant to Section 2.04(a)(i) in exchange for outstanding
shares of Company Common Stock and (y) cash sufficient to pay the aggregate Cash Consideration payable pursuant to Section 2.04(a)(i).
Parent agrees to make available, directly or indirectly, to the Exchange Agent from time to time as needed additional cash sufficient
to pay any dividends or other distributions to which such holders are entitled pursuant to Section 2.05(f) and cash in lieu of
any fractional share of Parent Common Stock to which such holder is entitled pursuant to Section 2.09. Promptly after the First
Merger Effective Time (and in no event more than two (2) Business Days following the Closing Date), Parent shall send, or shall
cause the Exchange Agent to send, to each holder of shares of Company Common Stock at the First Merger Effective Time a letter
of transmittal and instructions (which shall be in a form reasonably acceptable to the Company and substantially finalized prior
to the First Merger Effective Time and which shall specify that delivery shall be effected, and risk of loss and title shall pass,
only upon proper delivery of the Certificates or transfer of the Uncertificated Shares to the Exchange Agent) for use in such exchange.
All certificates (or evidence of shares in book-entry form) and cash deposited with the Exchange Agent pursuant to this Section
2.05 shall be referred to in this Agreement as the “Exchange Fund.” Parent shall cause the Exchange Agent to
deliver the Merger Consideration contemplated to be issued or paid pursuant to this Article 2 out of the Exchange Fund. The Exchange
Fund shall not be used for any other purpose. The Exchange Agent shall invest any cash included in the Exchange Fund as directed
by Parent; provided that such cash shall only be invested in the manner provided in the Exchange Agent Agreement; and provided,
further, that no such investment or losses thereon shall affect the Merger Consideration payable to holders of Company Common
Stock entitled to receive such consideration or cash in lieu of fractional interests; provided, further, that to the extent
necessary to pay the Merger Consideration, Parent shall promptly cause to be provided additional funds to the Exchange Agent for
the benefit of holders of Company Common Stock entitled to receive such consideration in the amount of any such losses. Any interest
and other income resulting from such investments shall be the property of, and paid to, Parent upon termination of the Exchange
Fund.
(b) Each holder of shares of Company
Common Stock that have been converted into the right to receive the Merger Consideration shall be entitled to receive, upon (i)
surrender to the Exchange Agent of a Certificate, together with a properly completed letter of transmittal, or (ii) receipt of
an “agent’s message” by the Exchange Agent (or such other evidence, if any, of transfer as the Exchange Agent
may reasonably request) in the case of a book-entry transfer of Uncertificated Shares, the Merger Consideration in respect of the
Company Common Stock represented by such Certificate or Uncertificated Share (and cash in lieu of any fractional shares of Parent
Common Stock and any dividends and distributions with respect thereto as contemplated by Section 2.09 and Section 2.05(f)). The
shares of Parent Common Stock constituting part of such Merger Consideration, at Parent’s option, shall be in uncertificated
book-entry form, unless a physical certificate is requested by a holder of shares of Company Common Stock or is otherwise required
under Applicable Law.
(c) If any portion of the Merger Consideration
(and cash in lieu of any fractional shares of Parent Common Stock and any dividends and distributions with respect thereto as contemplated
by Section 2.09 and Section 2.05(f)) is to be paid to a Person other than the Person in whose name the surrendered Certificate
or the transferred Uncertificated Share is registered, it shall be a condition to such payment that (i) either such Certificate
shall be properly endorsed or shall otherwise be in proper form for transfer or such Uncertificated Share shall be properly transferred
and (ii) the Person requesting such payment shall pay to the Exchange Agent any transfer or similar Taxes required as a result
of such payment to a Person other than the registered holder of such Certificate or Uncertificated Share or establish to the satisfaction
of the Exchange Agent that such transfer or similar Taxes has been paid or is not payable.
(d) Upon the First Merger Effective
Time, there shall be no further registration of transfers of shares of Company Common Stock thereafter on the records of the Company.
If, after the First Merger Effective Time, Certificates or Uncertificated Shares are presented to Parent, the Initial Surviving
Corporation, the Surviving Company or the Exchange Agent for any reason, they shall be cancelled and exchanged for the Merger Consideration
(and cash in lieu of any fractional shares of Parent Common Stock and any dividends and distributions) with respect thereto in
accordance with the procedures set forth in, or as otherwise contemplated by, this Article 2.
(e) Any portion of the Exchange Fund
that remains unclaimed by the holders of shares of Company Common Stock twelve (12) months following the Closing Date shall be
delivered to Parent or as otherwise instructed by Parent, and any such holder who has not exchanged shares of Company Common Stock
for the Merger Consideration in accordance with this Section 2.05 prior to that time shall thereafter look only to Parent for payment
of the Merger Consideration and any dividends and distributions (and cash in lieu of any fractional shares of Parent Common Stock)
with respect thereto, without any interest thereon. Notwithstanding the foregoing, Parent and its Subsidiaries (including the Initial
Surviving Corporation and its Subsidiaries and the Surviving Company and its Subsidiaries) shall not be liable to any holder of
shares of Company Common Stock for any amounts properly paid to a public official in compliance with applicable abandoned property,
escheat or similar laws. Any amounts remaining unclaimed by holders of shares of Company Common Stock immediately prior to such
time when the amounts would otherwise escheat to or become property of any Governmental Authority shall become, to the extent permitted
by Applicable Law, the property of Parent free and clear of any claims or interest of any Person previously entitled thereto.
(f) Following the surrender of any Certificates
or the transfer of any Uncertificated Shares as provided in this Section 2.05, Parent shall pay, or cause to be paid, without interest,
to the Person in whose name the shares of Parent Common Stock constituting the Share Consideration have been registered, (i) in
connection with the payment of the Share Consideration, (x) the amount of any cash payable in lieu of fractional shares to which
such Person is entitled pursuant to Section 2.09, and (y) the aggregate amount of all dividends or other distributions payable
with respect to such shares of Parent Common Stock with a record date on or after the First Merger Effective Time that were paid
prior to the time of such surrender or transfer, and (ii) at the appropriate payment date after the payment of the Merger Consideration,
the amount of all dividends or other distributions payable with respect to whole shares of Parent Common Stock constituting the
Share Consideration with a record date on or after the First Merger Effective Time and prior to the time of such surrender or transfer
and with a payment date subsequent to the time of such surrender or transfer. No dividends or other distributions with respect
to shares of Parent Common Stock constituting the Share Consideration, and no cash payment in lieu of fractional shares pursuant
to Section 2.09, shall be paid to the holder of any Certificates not surrendered
or of any Uncertificated Shares
not transferred until such Certificates or Uncertificated Shares are surrendered or transferred, as the case may be, as provided
in this Section 2.05.
(g) The payment of any transfer, documentary,
sales, use, stamp, registration, value added and other Taxes and fees (including any penalties and interest) incurred solely by
a holder of Company Common Stock in connection with the Mergers, and the filing of any related Tax Returns and other documentation
with respect to such Taxes and fees, shall be the sole responsibility of such holder.
Section 2.06. Dissenting Shares. Notwithstanding
anything in this Agreement to the contrary, shares of Company Common Stock that are issued and outstanding immediately prior to
the First Merger Effective Time and that are held by a stockholder who is entitled to demand and properly demands appraisal of
such shares pursuant to, and who complies in all respects with, the provisions of Section 262 of the Delaware Law (such stockholders,
the “Dissenting Stockholders” and such shares of Company Common Stock, the “Dissenting Shares”),
shall not be converted into or be exchangeable for the right to receive the Merger Consideration, but instead such holder shall
be entitled to payment of the fair value of such Dissenting Shares in accordance with the provisions of Section 262 of the Delaware
Law (and, at the First Merger Effective Time, such Dissenting Shares shall no longer be outstanding and shall automatically be
cancelled and shall cease to exist, and such holder shall cease to have any rights with respect thereto, except the right to receive
the fair value of such Dissenting Shares in accordance with the provisions of Section 262 of the Delaware Law), unless and until
such holder shall have failed to perfect or shall have effectively waived, withdrawn or lost rights to appraisal under the Delaware
Law. If any Dissenting Stockholders shall have failed to perfect or shall have effectively waived, withdrawn or lost such rights,
the Dissenting Shares held by such Dissenting Stockholder shall thereupon be deemed to have been converted, as of the First Merger
Effective Time, into the right to receive the Merger Consideration as provided in Section 2.04(a)(i) (and cash in lieu of any fractional
shares of Parent Common Stock and any dividends and distributions with respect thereto as contemplated by Section 2.09 and Section
2.05(f)), without interest. The Company shall give Parent prompt notice of any written demands for appraisal of any shares of Company
Common Stock, attempted withdrawals of such demands and any other instruments served pursuant to the Delaware Law and received
by the Company relating to stockholders’ rights of appraisal in accordance with the provisions of Section 262 of the Delaware
Law, and Parent shall have the right to direct all negotiations and proceedings with respect to all such demands. The Company shall
not, except with the prior written consent of Parent, make any payment with respect to, settle or offer or agree to settle any
such demands. Any portion of the Merger Consideration made available to the Exchange Agent pursuant to Section 2.05 to pay for
shares of Company Common Stock for which appraisal rights have been perfected shall be returned to Parent upon demand.
Section 2.07. Company Equity Awards.
(a) Company Stock Options
(i) At the First Merger Effective
Time, each option to purchase shares of Company Common Stock under any Company Stock Plan that is outstanding and unexercised immediately
prior to the First Merger Effective Time (each, a “Company Stock Option”) that is vested or that, pursuant to
its terms as in effect as of the date hereof, would become vested as of the First Merger Effective Time, with a per share exercise
price less than the Equity Award Cash Consideration, shall be cancelled and converted into the right to receive an amount in cash,
without interest, equal to the product of (A) the excess, if any, of (1) the sum of (x) the Cash Consideration plus (y) the value
equal to the product of the Parent Stock Price multiplied by the
Exchange Ratio (the sum of the
amounts in clauses (x) and (y), the “Equity Award Cash Consideration”) over (2) the applicable per share exercise
price of such Company Stock Option multiplied by (B) the total number of shares of Company Common Stock subject to such Company
Stock Option. At the First Merger Effective Time, each Company Stock Option that is vested or that, pursuant to its terms as in
effect as of the date hereof, would become vested as of the First Merger Effective Time, with a per share exercise price greater
than or equal to the Equity Award Cash Consideration, shall be cancelled for no consideration.
(ii) Each Company Stock Option
that (x) is not cancelled in accordance with Section 2.07(a)(i) or (y) is granted after the date hereof to the extent permitted
under Section 6.01(d), at the First Merger Effective Time shall, by virtue of the First Merger and without further action on the
part of the holder thereof, be assumed by Parent and become, as of the First Merger Effective Time, an option (an “Assumed
Stock Option”) to purchase, on the same terms and conditions (including applicable vesting, exercise and expiration provisions)
as applied to each such Company Stock Option immediately prior to the First Merger Effective Time, shares of Parent Common Stock,
except that (A) the number of shares of Parent Common Stock, rounded down to the nearest whole share, subject to such Assumed Stock
Option shall equal the product of (x) the number of shares of Company Common Stock that were subject to such Company Stock Option
immediately prior to the First Merger Effective Time, multiplied by (y) the Equity Award Exchange Ratio, and (B) the per-share
exercise price, rounded up to the nearest whole cent, shall equal the quotient of (1) the exercise price per share of Company Common
Stock at which such Company Stock Option was exercisable immediately prior to the First Merger Effective Time, divided by (2) the
Equity Award Exchange Ratio; provided that each Company Stock Option (A) which is an “incentive stock option”
(as defined in Section 422 of the Code) shall be adjusted in accordance with the requirements of Section 424 of the Code and (B)
shall be adjusted in a manner that complies with Section 409A of the Code.
(b) Company Restricted Stock Units
(i) Immediately prior to the
First Merger Effective Time, with respect to each restricted stock unit award with respect to shares of Company Common Stock outstanding
under any Company Stock Plan that (x) vests solely based on the passage of time (each, a “Company RSU Award”)
and (y) pursuant to its terms as in effect as of the date hereof, provides for automatic accelerated vesting upon the consummation
of the transactions contemplated by this Agreement, the restrictions and vesting conditions applicable to such Company RSU Award
shall lapse and each such Company RSU Award shall, by virtue of the First Merger and without any action on the part of the holder
thereof, be converted as of the First Merger Effective Time into the right to receive, with respect to each share of Company Common
Stock underlying such Company RSU Award, the Merger Consideration plus a cash amount equal to the accrued but unpaid dividend
equivalent rights relating to such Company RSU Award (with the aggregate amount of Merger Consideration and the applicable dividend
equivalent right amounts in respect of all shares of Company Common Stock underlying a Company RSU Award or a Company PSU Award
(as defined below), as applicable, the “Award Consideration”). The Award Consideration, less applicable Tax
withholdings, shall be paid or provided by Parent as soon as practicable following the Closing Date, but in no event later than
five (5) Business Days following the Closing Date. Applicable Tax withholdings with respect to the Award Consideration first shall
reduce the cash portion of the Award Consideration and then shall reduce the Parent Common Stock portion of the Award Consideration,
with the value of any Tax
withholdings that reduce the number
of shares of Parent Common Stock deliverable pursuant to this Section 2.07(b)(i) to be based on the Parent Stock Price.
(ii) With respect to each Company
RSU Award that (x) is not converted into a right to receive Award Consideration in accordance with Section 2.07(b)(i) or (y) is
granted after the date hereof to the extent permitted under Section 6.01(d), at the First Merger Effective Time, such Company RSU
Award shall, by virtue of the First Merger and without further action on the part of the holder thereof, be assumed by Parent and
shall be converted into a restricted unit award corresponding to the Merger Consideration (each, an “Assumed Restricted
Unit Award”) that settles in (A) an amount in cash equal to the sum of an amount equal to the accrued but unpaid dividend
equivalent rights relating to such Assumed Restricted Unit Award plus the product of (x) the Cash Consideration, multiplied
by (y) the number of shares of Company Common Stock underlying the Company RSU Award, and (B) a number of shares of Parent
Common Stock equal to the product of (x) the Share Consideration, multiplied by (y) the number of shares of Company Common
Stock underlying the Company RSU Award. Except as provided in this Section 2.07(b)(ii), each Assumed Restricted Unit Award shall
continue to have, and shall be subject to, the same terms and conditions as applied to the corresponding Company RSU Award immediately
prior to the First Merger Effective Time (including any terms and conditions relating to accelerated vesting upon a termination
of the holder’s employment in connection with or following the First Merger).
(c) Company Performance-Based Restricted
Stock Units.
(i) Immediately prior to the
First Merger Effective Time, with respect to each restricted stock unit award with respect to shares of Company Common Stock outstanding
under any Company Stock Plan that (x) vests based on the achievement of performance goals (each, a “Company PSU Award”)
and (y) pursuant to its terms as in effect as of the date hereof, provides for automatic accelerated vesting upon the consummation
of the transactions contemplated by this Agreement, the restrictions and vesting conditions applicable to such Company PSU Award
shall lapse and each such Company PSU Award shall, by virtue of the First Merger and without any action on the part of the holder
thereof, be converted as of the First Merger Effective Time into the right to receive, with respect to each share of Company Common
Stock underlying such Company PSU Award (determined assuming the achievement of maximum level of performance to the extent required
by its terms as of the date of this Agreement), the Merger Consideration plus a cash amount equal to the accrued but unpaid
dividend equivalent rights relating to such Company PSU Award. The Award Consideration, less applicable Tax withholdings, shall
be paid or provided by Parent as soon as practicable following the Closing Date, but in no event later than five (5) Business Days
following the Closing Date. Applicable Tax withholdings with respect to the Award Consideration first shall reduce the cash portion
of the Award Consideration and then shall reduce the Parent Common Stock portion of the Award Consideration, with the value of
any Tax withholdings that reduce the number of shares of Parent Common Stock deliverable pursuant to this Section 2.07(c)(i) to
be based on the Parent Stock Price.
(ii) With respect to each Company
PSU Award that (x) is not converted into a right to receive Award Consideration in accordance with Section 2.07(c)(i) or (y) is
granted after the date hereof to the extent permitted under Section 6.01(d), at the First Merger Effective Time, such Company PSU
Award shall, by virtue of the Merger and without further action on the part of the holder thereof, be assumed by Parent and shall
be converted into a restricted unit award
corresponding to the Merger Consideration
(each, an “Assumed Performance Unit Award”) that settles in (A) an amount in cash equal to the sum of an amount
equal to the accrued but unpaid dividend equivalent rights relating to such Assumed Restricted Unit Award plus the product
of (x) the Cash Consideration and (y) the number of shares of Company Common Stock underlying the Company PSU Award (with performance
to be determined in accordance with the applicable agreement) and (B) a number of shares of Parent Common Stock equal to the product
of (x) the Share Consideration and (y) the number of shares of Company Common Stock underlying the Company PSU Award. Except as
provided in this Section 2.07(c)(ii), each Assumed Performance Unit Award shall continue to have, and shall be subject to, the
same terms and conditions as applied to the corresponding Company PSU Award (with performance to be determined in accordance with
the applicable agreement) immediately prior to the First Merger Effective Time (including any terms and conditions relating to
accelerated vesting upon a termination of the holder’s employment in connection with or following the Merger).
(d) Reservation of Shares. As
soon as practicable following the Closing Date (but in no event more than five (5) Business Days following the Closing Date), Parent
shall file a registration statement on Form S-8 (or any successor form) with respect to the issuance of the shares of Parent Common
Stock subject to the Assumed Stock Options, the Assumed Restricted Unit Awards and the Assumed Performance Unit Awards and shall
use its reasonable best efforts to maintain the effectiveness of such registration statement or registration statements (and maintain
the current status of the prospectus or prospectuses contained therein) for so long as the Assumed Stock Options, Assumed Restricted
Units and Assumed Performance Units remain outstanding.
(e) Board Actions. Prior to the
First Merger Effective Time, the Board of Directors of the Company (and/or the Organization and Compensation Committee of the Board
of Directors of the Company) and the Board of Directors of Parent (and/or the compensation committee (or equivalent committee)
of the Board of Directors of Parent) shall adopt such resolutions as are necessary to give effect to the transactions contemplated
by this Section 2.07.
Section 2.08. Adjustments. Without
limiting or affecting any of the provisions of Section 6.01 or Section 7.01, if, during the period between the date of this Agreement
and the First Merger Effective Time, any change in the outstanding shares of capital stock of the Company or Parent shall occur
as a result of any reclassification, recapitalization, stock split (including reverse stock split), merger, combination, exchange
or readjustment of shares, subdivision or other similar transaction, or any stock dividend thereon with a record date during such
period, the Merger Consideration and any other amounts payable pursuant to this Agreement shall be appropriately adjusted to eliminate
the effect of such event on the Merger Consideration or any such other amounts payable pursuant to this Agreement.
Section 2.09. Fractional Shares.
Notwithstanding anything in this Agreement to the contrary, no fractional shares of Parent Common Stock shall be issued in the
First Merger. All fractional shares of Parent Common Stock that a holder of shares of Company Common Stock would otherwise be entitled
to receive as a result of the First Merger shall be aggregated and, if a fractional share results from such aggregation, such holder
shall be entitled to receive, in lieu thereof, an amount in cash, without interest, determined by multiplying the Parent Stock
Price by the fraction of a share of Parent Common Stock to which such holder would otherwise have been entitled.
Section 2.10. Withholding Rights.
Each of the Exchange Agent, Parent, the Initial Surviving Corporation and the Surviving Company shall be entitled to deduct and
withhold from the consideration otherwise payable pursuant to this Agreement such amounts as it is required to deduct and withhold
with
respect to the making of such payment under
any provision of any Applicable Law, including federal, state, local or non-U.S. Tax law. If the Exchange Agent, Parent, the Initial
Surviving Corporation or the Surviving Company, as the case may be, so withholds and pays over all amounts so withheld to the appropriate
Taxing Authority within the period required under Applicable Law, such amounts shall be treated for all purposes of this Agreement
as having been paid to the Person in respect of which the Exchange Agent, Parent, the Initial Surviving Corporation or the Surviving
Company, as the case may be, made such deduction and withholding. Parent shall pay, or shall cause to be paid, all amounts so deducted
or withheld to the appropriate Taxing Authority within the period required under Applicable Law.
Section 2.11. Lost Certificates.
If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming
such Certificate to be lost, stolen or destroyed and, if reasonably required by the Initial Surviving Corporation or the Surviving
Company, the posting by such Person of a customary bond issued for lost, stolen or destroyed stock certificates, in such reasonable
amount as the Initial Surviving Corporation or the Surviving Company may direct, as indemnity against any claim that may be made
against the Initial Surviving Corporation or the Surviving Company, as applicable, with respect to such Certificate, the Exchange
Agent will issue, in exchange for such lost, stolen or destroyed Certificate, the Merger Consideration to be paid in respect of
the shares of Company Common Stock represented by such Certificate, as contemplated by this Article 2.
Section 2.12. Further Assurances.
At and after the First Merger Effective Time, the officers and directors of the Initial Surviving Corporation shall be authorized
to execute and deliver, in the name and on behalf of the Company, any of its Subsidiaries or Merger Sub 1, any deeds, bills of
sale, assignments or assurances and to take and do, in the name and on behalf of the Company, any of its Subsidiaries or Merger
Sub 1, any other actions and things to vest, perfect or confirm of record or otherwise in the Initial Surviving Corporation any
and all right, title and interest in, to and under any of the rights, properties or assets of the Company acquired or to be acquired
by the Initial Surviving Corporation as a result of, or in connection with, the First Merger. At and after the Second Merger Effective
Time, the officers and directors of the Surviving Company shall be authorized to execute and deliver, in the name and on behalf
of the Company, any of its Subsidiaries, Merger Sub 1 or Merger Sub 2, any deeds, bills of sale, assignments or assurances and
to take and do, in the name and on behalf of the Company, any of its Subsidiaries, Merger Sub 1 or Merger Sub 2, any other actions
and things to vest, perfect or confirm of record or otherwise in the Surviving Company any and all right, title and interest in,
to and under any of the rights, properties or assets of the Initial Surviving Corporation acquired or to be acquired by the Surviving
Company as a result of, or in connection with, the Second Merger.
Article
3
Organizational Documents; Directors and Officers
Section 3.01. Certificate of Incorporation
and Bylaws of the Initial Surviving Corporation. At the First Merger Effective Time, the certificate of incorporation of the
Company shall be amended so that it reads in its entirety as set forth on Exhibit A. From and after the First Merger Effective
Time, the certificate of incorporation of the Company as so amended shall be the certificate of incorporation of the Initial Surviving
Corporation until thereafter amended as provided therein or by Applicable Law. The bylaws of Merger Sub 1, as in effect immediately
prior to the First Merger Effective Time, shall be the bylaws of the Initial Surviving Corporation from and after the First Merger
Effective Time until thereafter amended as provided therein, in the certificate of incorporation of the Initial Surviving
Corporation or by Applicable Law, except that
the name of the corporation reflected therein shall be “Humana Inc.”.
Section 3.02. Certificate of Formation
and Limited Liability Company Agreement of the Surviving Company. The certificate of formation and limited liability company
agreement of Merger Sub 2 in effect immediately prior to the Second Merger Effective Time shall be the certificate of formation
and limited liability company agreement of the Surviving Company from and after the Second Merger Effective Time until thereafter
amended as provided therein or by Applicable Law (subject to Section 7.04), except that the name of the limited liability company
reflected therein shall be “Humana LLC”.
Section 3.03. Directors and Officers
of the Initial Surviving Corporation. From and after the First Merger Effective Time, until their respective successors are
duly elected or appointed and qualified in accordance with Applicable Law, (i) the directors of Merger Sub 1 immediately prior
to the First Merger Effective Time shall be the directors of the Initial Surviving Corporation and (ii) the officers of the Company
immediately prior to the First Merger Effective Time shall be the officers of the Initial Surviving Corporation.
Section 3.04. Managers and Officers
of the Surviving Company. From and after the Second Merger Effective Time, until their respective successors are duly elected
or appointed and qualified in accordance with Applicable Law, (i) the managers of Merger Sub 2 immediately prior to the Second
Merger Effective Time shall be the managers of the Surviving Company and (ii) the officers of the Initial Surviving Corporation
immediately prior to the Second Merger Effective Time shall be the officers of the Surviving Company.
Article
4
Representations and Warranties of the Company
Subject to Section 11.05, except (i) other
than with respect to the representations and warranties in Section 4.01, Section 4.02, Section 4.05, Section
4.06, Section 4.27, Section 4.28 and Section 4.29, as disclosed in any publicly available Company SEC Document filed
after December 31, 2014 and before the date of this Agreement or in the Company’s annual report on Form 10-K for the fiscal
year ended December 31, 2013 or in the Company’s proxy statement for the 2014 annual meeting of the Company’s stockholders
or (ii) as set forth in the Company Disclosure Schedule, the Company represents and warrants to Parent that:
Section 4.01. Corporate Existence
and Power. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State
of Delaware. The Company has all corporate powers required to own or lease all of its properties or assets and to carry on its
business as now conducted. The Company is duly qualified to do business and is in good standing in each jurisdiction where such
qualification is necessary, except for those jurisdictions where failure to be so qualified has not had and would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect. Prior to the date of this Agreement,
the Company has made available to Parent true and complete copies of the certificate of incorporation and bylaws of the Company
as in effect on the date of this Agreement (the “Company Organizational Documents”).
Section 4.02. Corporate Authorization.
(a) The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the transactions
contemplated by this Agreement are within the corporate powers of the Company and, except for the Company
Stockholder Approval, have been duly authorized
by all necessary corporate action on the part of the Company. Unless the Company and Parent shall mutually agree otherwise, the
affirmative vote of the holders of at least seventy-five percent (75%) of the outstanding shares of Company Common Stock approving
and adopting this Agreement is the only vote of the holders of any of the Company’s capital stock necessary in connection
with the consummation of the Mergers (the “Company Stockholder Approval”). This Agreement has been duly executed
and delivered by the Company and (assuming due authorization, execution and delivery by Parent, Merger Sub 1 and Merger Sub 2)
constitutes a valid and binding agreement of the Company enforceable against the Company in accordance with its terms (subject
to applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditors’ rights and remedies
generally, and subject, as to enforceability, to general principles of equity (regardless of whether enforcement is sought in a
proceeding at law or in equity) (the “Bankruptcy and Equity Exceptions”)).
(b) At a meeting duly called and held,
the Board of Directors of the Company unanimously adopted resolutions (i) determining that this Agreement and the transactions
contemplated hereby (including the Mergers) are fair to and in the best interests of the Company’s stockholders, (ii) approving,
adopting and declaring advisable this Agreement and the transactions contemplated hereby (including the Mergers), (iii) directing
that the approval and adoption of this Agreement be submitted to a vote at a meeting of the Company’s stockholders, and (iv)
recommending approval and adoption of this Agreement (including the Mergers) by the Company’s stockholders (such recommendation,
the “Company Board Recommendation”). Except as permitted by Section 6.02, the Board of Directors of the Company
has not subsequently rescinded, modified or withdrawn any of the foregoing resolutions.
Section 4.03. Governmental Authorization.
The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the transactions
contemplated hereby require no action by or in respect of Consents of, or Filing with, any Governmental Authority other than (i)
the filing of the First Certificate of Merger and the Second Certificate of Merger with the Delaware Secretary of State and appropriate
documents with the relevant authorities of other states in which the Company is qualified to do business, (ii) compliance with
any applicable requirements of the HSR Act, (iii) compliance with any applicable requirements of the 1933 Act, the 1934 Act and
any other applicable U.S. state or federal securities laws or pursuant to the rules of the New York Stock Exchange (the “NYSE”),
(iv) Consents of, and Filings with, the state insurance departments, federal and state departments of health and other Consents
and Filings required under the Health Care Laws or insurance laws that are listed on Section 4.03 of the Company Disclosure Schedule
(the Consents and Filings required under or in connection with this clause (iv), the “Company Required Governmental Authorizations”),
and (v) any other actions, Consents or Filings the absence of which has not had and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect.
Section 4.04. Non-contravention.
The execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated
hereby do not and will not (i) contravene, conflict with, or result in any violation or breach of any provision of the Company
Organizational Documents, (ii) assuming compliance with the matters referred to in Section 4.03 and receipt of the Company Stockholder
Approval, contravene, conflict with or result in any violation or breach of any provision of any Applicable Law, (iii) assuming
compliance with the matters referred to in Section 4.03 and receipt of the Company Stockholder Approval, require any Consent or
other action by any Person under, constitute a default, or an event that, with or without notice or lapse of time or both, would
constitute a default, under, or cause or permit the termination, cancellation, acceleration or other
change of any right or obligation or the loss
of any benefit to which the Company or any of its Subsidiaries is entitled under, any provision of any Contract binding upon the
Company or any of its Subsidiaries or any governmental Consents (including Consents required by Contract) affecting, or relating
in any way to, the assets or business of the Company and its Subsidiaries, or (iv) result in the creation or imposition of any
Lien on any asset of the Company or any of its Subsidiaries, with such exceptions, in the case of each of clauses (ii) through
(iv), as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse
Effect.
Section 4.05. Capitalization.
(a) The authorized capital stock of the Company consists of (i) 300,000,000 shares of Company Common Stock and (ii) 10,000,000
shares of Preferred Stock, par value $1.00 per share (“Company Preferred Stock”). As of July 1, 2015, there
were outstanding (i) 148,135,932 shares of Company Common Stock (none of which is subject to vesting conditions), (ii) no shares
of Company Preferred Stock, (iii) Company Stock Options to purchase an aggregate of 853,717 shares of Company Common Stock (of
which options to purchase an aggregate of 199,377 shares of Company Common Stock were exercisable and 54,921 were incentive stock
options), (iv) 2,527,536 shares of Company Common Stock were subject to outstanding Company RSU Awards, (v) 1,067,867 shares of
Company Common Stock were subject to outstanding Company PSU Awards, determined assuming maximum performance levels were achieved,
and (vi) 8,668,256 additional shares of Company Common Stock were reserved for issuance pursuant to the Company Stock Plans. Except
as set forth in this Section 4.05(a) and for changes since July 1, 2015 resulting from (x) the exercise of Company Stock Options
outstanding on such date or issued after such date, (y) the vesting and settlement of any Company RSU Awards and Company PSU Awards,
(z) the issuance of Company Equity Awards, in each case as and to the extent permitted by Section 6.01 hereof, there are no issued,
reserved for issuance or outstanding (i) shares of capital stock or other voting securities of, or other ownership interest in,
the Company, (ii) securities of the Company convertible into or exchangeable for shares of capital stock or other voting securities
of, or other ownership interests in, the Company, (iii) warrants, calls, options or other rights to acquire from the Company,
or other obligations of the Company to issue, any capital stock or other voting securities of, or other ownership interests in,
or securities convertible into or exchangeable for capital stock or other voting securities of, or other ownership interests in,
the Company, or (iv) restricted shares, stock appreciation rights, performance units, contingent value rights, “phantom”
stock or similar securities or rights issued by or with the approval of the Company that are derivative of, or provide economic
benefits based, directly or indirectly, on the value or price of, any capital stock or other voting securities of, or other ownership
interests in, the Company (the items in clauses (i) through (iv) being referred to collectively as the “Company Securities”).
(b) All outstanding shares of capital
stock of the Company have been, and all shares that may be issued pursuant to any employee stock option or other compensation plan
or arrangement will be, when issued in accordance with the respective terms thereof, duly authorized and validly issued, fully
paid and nonassessable and free of preemptive rights. No Subsidiary of the Company owns any shares of capital stock of the Company
(other than any such shares owned by Subsidiaries of the Company in a fiduciary, representative or other capacity on behalf of
other Persons, whether or not held in a separate account). Section 4.05(b) of the Company Disclosure Schedule sets forth a true
and complete list, as of July 1, 2015, of all outstanding Company Equity Awards, including with respect to each such equity award,
the holder, date of grant, vesting schedule, whether the award provides for accelerated vesting upon the consummation of the transactions
contemplated by this Agreement, whether subject to performance conditions, number of shares of Company Common Stock subject to
such award, the amount of any accrued but unpaid dividend equivalent rights relating to such award and, for Company
Stock Options, the applicable exercise
price, expiration date and whether it is an incentive stock option. There are no outstanding bonds, debentures, notes or other
indebtedness of the Company having the right to vote (or convertible into, or exchangeable for, securities having the right to
vote) on any matters on which stockholders of the Company may vote. There are no outstanding obligations of the Company or any
of its Subsidiaries to repurchase, redeem or otherwise acquire any Company Securities. Neither the Company nor any of its Subsidiaries
is a party to any agreement with respect to the voting of any Company Securities.
Section 4.06. Subsidiaries. (a)
Each Major Subsidiary of the Company is a corporation or other entity duly incorporated or organized, validly existing and in good
standing under the laws of its jurisdiction of incorporation or organization and has all corporate or other organizational powers,
as applicable, required to carry on its business as now conducted, except for those jurisdictions where failure to be so organized,
validly existing and in good standing or to have such power has not had and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect. Each such Major Subsidiary is duly qualified to do business and is in good
standing in each jurisdiction where such qualification is necessary, except for those jurisdictions where failure to be so qualified
has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect.
Section 4.06(a) of the Company Disclosure Schedule sets forth a true and complete list of each Major Subsidiary of the Company
as of the date of this Agreement, its jurisdiction of incorporation or organization, and, if a Regulated Subsidiary of the Company,
each jurisdiction where it is licensed by the state department of insurance, state department of health or other applicable state
agency.
(b) All of the outstanding capital stock
or other voting securities of, or ownership interests in, each Subsidiary of the Company are owned by the Company, directly or
indirectly, free and clear of any Lien. There are no issued, reserved for issuance or outstanding (i) securities of the Company
or any of its Subsidiaries convertible into or exchangeable for shares of capital stock or other voting securities of, or other
ownership interests in, any Subsidiary of the Company, (ii) warrants, calls, options or other rights to acquire from the Company
or any of its Subsidiaries, or other obligations of the Company or any of its Subsidiaries to issue, any capital stock or other
voting securities of, or other ownership interests in, or any securities convertible into or exchangeable for any capital stock
or other voting securities of, or other ownership interests in, any Subsidiary of the Company, or (iii) restricted shares, stock
appreciation rights, performance units, contingent value rights, “phantom” stock or similar securities or rights issued
by or with the approval of the Company or any of its Subsidiaries that are derivative of, or provide economic benefits based, directly
or indirectly, on the value or price of, any capital stock or other voting securities of, or other ownership interests in, any
Subsidiary of the Company. There are no outstanding obligations of the Company or any of its Subsidiaries to repurchase, redeem
or otherwise acquire any securities described in the foregoing clauses (i) through (iii) of this Section 4.06(b). Except for the
capital stock or other voting securities of, or other ownership interests in, its Subsidiaries and publicly traded securities held
for investment which do not exceed 5% of the outstanding securities of any entity, the Company does not own, directly or indirectly,
any capital stock or other voting securities of, or other ownership interests in, any Person.
Section 4.07. SEC Filings and the
Sarbanes-Oxley Act. (a) The Company has timely filed with or furnished to the SEC all reports, schedules, forms, statements,
prospectuses, registration statements and other documents required to be filed with or furnished to the SEC by the Company since
January 1, 2013. No Subsidiary of the Company is required to file any report, schedule, form, statement, prospectus, registration
statement or other document with the SEC.
(b) As of its filing date, each report,
schedule, form, statement, prospectus, registration statement and other document filed with or furnished to the SEC by the Company
since January 1, 2013 (collectively, together with any exhibits and schedules thereto and other information incorporated therein,
the “Company SEC Documents”) filed prior to the date of this Agreement complied, and each Company SEC Document
filed subsequent to the date of this Agreement (assuming, in the case of the Joint Proxy Statement/Prospectus, that the representation
and warranty set forth in Section 5.09 is true and correct) will comply, in all material respects with the applicable requirements
of the NYSE, the 1933 Act, the 1934 Act and the Sarbanes-Oxley Act, as the case may be.
(c) As of its filing date (or, if amended
or superseded by a filing prior to the date of this Agreement, on the date of such amended or superseding filing), each Company
SEC Document filed prior to the date of this Agreement did not, and each Company SEC Document filed subsequent to the date of this
Agreement (assuming, in the case of the Joint Proxy Statement/Prospectus, that the representation and warranty set forth in Section
5.09 is true and correct) will not, contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.
(d) The Company is, and since January
1, 2013 has been, in compliance in all material respects with (i) the applicable provisions of the Sarbanes-Oxley Act and (ii)
the applicable listing and corporate governance rules and regulations of the NYSE.
(e) The Company and its Subsidiaries
have established and maintain disclosure controls and procedures (as defined in Rule 13a-15 under the 1934 Act). Such disclosure
controls and procedures are designed to ensure that material information relating to the Company, including its consolidated Subsidiaries,
is made known to the Company’s principal executive officer and its principal financial officer by others within those entities,
particularly during the periods in which the periodic reports required under the 1934 Act are being prepared. Such disclosure controls
and procedures are effective in timely alerting the Company’s principal executive officer and principal financial officer
to material information required to be included in the Company’s periodic and current reports required under the 1934 Act.
For purposes of this Agreement, “principal executive officer” and “principal financial officer”
shall have the meanings given to such terms in the Sarbanes-Oxley Act.
(f) The Company and its Subsidiaries
have established and maintain a system of internal controls over financial reporting (as defined in Rule 13a-15 under the 1934
Act) (“internal controls”). Such internal controls are sufficient to provide reasonable assurance regarding
the reliability of the Company’s financial reporting and the preparation of the Company’s financial statements for
external purposes in accordance with GAAP. The Company’s principal executive officer and principal financial officer have
disclosed, based on their most recent evaluation of such internal controls prior to the date of this Agreement, to the Company’s
auditors and the audit committee of the Board of Directors of the Company (x) all significant deficiencies and material weaknesses
in the design or operation of internal controls which are reasonably likely to adversely affect the Company’s ability to
record, process, summarize and report financial information and (y) any fraud, whether or not material, that involves management
or other employees who have a significant role in internal controls. The Company has made available to Parent prior to the date
of this Agreement a true and complete summary of any disclosure of the type described in the preceding sentence made by management
to the Company’s auditors and audit committee since January 1, 2013.
(g) Since January 1, 2013, each of the
principal executive officer and principal financial officer of the Company (or each former principal executive officer and principal
financial officer of the
Company, as applicable) has made
all certifications required by Rule 13a-14 and 15d-14 under the 1934 Act and Sections 302 and 906 of the Sarbanes-Oxley Act and
any related rules and regulations promulgated by the SEC and the NYSE, and the statements contained in any such certifications
are true and complete.
Section 4.08. Financial Statements
and Financial Matters.
(a) The audited consolidated financial
statements and unaudited consolidated interim financial statements of the Company included or incorporated by reference in the
Company SEC Documents present fairly in all material respects, in conformity with GAAP applied on a consistent basis during the
periods involved (except as may be indicated in the notes thereto), the consolidated financial position of the Company and its
Subsidiaries as of the dates thereof and their consolidated results of operations and cash flows for the periods then ended (subject
to normal and recurring year-end audit adjustments in the case of any unaudited interim financial statements). Such consolidated
financial statements have been prepared from, and are in accordance with, the books and records of the Company and its Subsidiaries.
(b) From January 1, 2013 to the date
of this Agreement, the Company has not received written notice from the SEC or any other Governmental Authority indicating that
any of its accounting policies or practices are or may be the subject of any review, inquiry, investigation or challenge by the
SEC or any other Governmental Authority.
Section 4.09. Disclosure Documents.
The information relating to the Company and its Subsidiaries that is provided by the Company, any of its Subsidiaries or any of
their respective Representatives for inclusion or incorporation by reference in the Registration Statement or the Joint Proxy Statement/Prospectus
will not (i) in the case of the Registration Statement, at the time the Registration Statement or any amendment or supplement thereto
becomes effective and at the time of the Company Stockholder Meeting and the Parent Stockholder Meeting, and (ii) in the case of
the Joint Proxy Statement/Prospectus, at the time the Joint Proxy Statement/Prospectus or any amendment or supplement thereto is
first mailed to the stockholders of the Company and Parent and at the time of the Company Stockholder Meeting and the Parent Stockholder
Meeting, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in light of the circumstances under which they were made, not misleading.
Section 4.10. Statutory Financial
Statements. The audited statutory financial statements for the year ended December 31, 2014 and the unaudited statutory financial
statements for the quarter ended March 31, 2015 filed by the Company’s Regulated Subsidiaries that are licensed as insurance
companies or health maintenance organizations prior to the date hereof with the applicable Governmental Authorities (the “Company
Statutory Filings”) and the respective statements of assets, liabilities, capital and surplus, revenues and expenses
and cash flows included or incorporated therein (i) were prepared from the books and records of the applicable Regulated Subsidiary,
(ii) present fairly in all material respects the statutory financial condition and results of operations of the applicable Regulated
Subsidiary as of the date and for the periods then ended (subject to normal and recurring year- end adjustments in the case of
any interim statements), and (iii) were prepared in all material respects in accordance with SAP applied on a consistent basis
(except as may be indicated in the notes thereto).
Section 4.11. Reserves. The loss
reserves and other actuarial amounts of the Regulated Subsidiaries of the Company as of December 31, 2014 recorded in the Company
Statutory Filings: (i) were determined in all material respects in accordance with ASOPs in effect on that date (except as may
be indicated in the notes thereto), (ii) were computed on the basis of methodologies consistent in all
material respects with those used in computing
the corresponding reserves in the prior fiscal year (except as may be indicated in the notes thereto) and (iii) include provisions
for all actuarial reserves that were required at that time to be established in accordance with Applicable Laws based on facts
known to the Company as of such date; provided that, notwithstanding the foregoing, it is acknowledged and agreed by Parent,
Merger Sub 1 and Merger Sub 2 that the Company is not making any representation or warranty in this Agreement and nothing contained
in this Agreement or any other agreement, document or instrument to be delivered in connection with this Agreement is intended
or shall be construed to be a representation or warranty of the Company in respect of the adequacy or sufficiency of the reserves
of the Company or the Company’s Regulated Subsidiaries.
Section 4.12. Capital or Surplus Maintenance.
As of the date of this Agreement, no Regulated Subsidiary of the Company is subject to any requirement imposed by a Governmental
Authority to maintain capital or surplus amounts or levels or is subject to any restriction on the payment of dividends or other
distributions on its shares of capital stock, except for any such requirements or restrictions under Applicable Laws, including
insurance laws and regulations, of general application.
Section 4.13. Absence of Certain Changes.
(a) Since the Company Balance Sheet Date through the date of this Agreement, (i) the business of the Company and its Subsidiaries
has been conducted in all material respects in the ordinary course of business consistent with past practice and (ii) there
has not been any event, change, effect, development or occurrence that has had or would reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect.
(b) Since the Company Balance Sheet
Date through the date of this Agreement, there has not been any action taken by the Company or any of its Subsidiaries that, if
taken during the period from the date of this Agreement through the First Merger Effective Time without Parent’s consent,
would constitute a breach of Section 6.01.
Section 4.14. No Undisclosed Material
Liabilities. There are no liabilities or obligations of the Company or any of its Subsidiaries of any kind whatsoever, whether
accrued, contingent, absolute, determined, determinable or otherwise, other than (i) liabilities or obligations disclosed and provided
for in the Company Balance Sheet or in the notes thereto, (ii) liabilities or obligations incurred in the ordinary course of business
consistent with past practice since the Company Balance Sheet Date, (iii) liabilities arising in connection with the transaction
contemplated hereby, and (iv) other liabilities or obligations that have not had and would not reasonably be expected to have,
individually or in the aggregate, a Company Material Adverse Effect. There are no off-balance sheet arrangements of any type pursuant
to any off-balance sheet arrangement required to be disclosed pursuant to Item 303(a)(4) of Regulation S-K promulgated under the
1933 Act (“Regulation S-K”) that have not been so described in the Company SEC Documents.
Section 4.15. Litigation. There
is no claim, action, suit, investigation or proceeding pending or, to the knowledge of the Company, threatened against or affecting
the Company, any of its Subsidiaries, any present or former officers, directors or employees of the Company or any of its Subsidiaries
in their respective capacities as such, or any of the respective properties of the Company or any of its Subsidiaries, before (or,
in the case of threatened claims, actions, suits, investigations or proceedings, that would be before) any arbitrator or Governmental
Authority, that has had or would reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect
or that in any manner challenges or seeks to prevent, enjoin, alter or materially delay the Mergers or any of the other transactions
contemplated hereby. There is no Order outstanding or threatened against or affecting the Company, any of its Subsidiaries, any
present or former officers, directors or employees of the Company
or any of its Subsidiaries in their respective
capacities as such, or any of the respective properties of any of the Company or any of its Subsidiaries, that has had or would
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect or that would prevent, enjoin,
alter or materially delay the Mergers or any of the other transactions contemplated hereby.
Section 4.16. Permits. Except
as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
the Company and each of its Subsidiaries hold all governmental licenses and Consents necessary for the operation of its respective
businesses (the “Company Permits”). The Company and each of its Subsidiaries is and since January 1, 2013, has
been in compliance with the terms of the Company Permits, except for failures to comply that have not had and would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect. There is no claim, action, suit, investigation
or proceeding pending, or, to the knowledge of the Company, threatened that seeks, or, to the knowledge of the Company, any existing
condition, situation or set of circumstances that would reasonably be expected to result in, the revocation, cancellation, termination,
non-renewal or adverse modification of any Company Permit except where such revocation, cancellation, termination, non-renewal
or adverse modification has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material
Adverse Effect.
Section 4.17. Compliance with Applicable
Laws. (a) The Company and each of its Subsidiaries is, and since January 1, 2013 has been, in compliance with all Applicable
Laws, except for failures to comply that have not had and would not reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect.
(b) Since January 1, 2013, neither the
Company nor any of its Subsidiaries has entered into any agreement or settlement with any Governmental Authority with respect to
any actual or alleged violation of any Applicable Law, except for agreements and settlements that have not had and would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect.
(c) Since January 1, 2013, each Regulated
Subsidiary of the Company has filed all Company Statutory Filings and all other material Filings (including Filings with respect
to premium rates, rating plans, policy terms and other terms established or used by any Subsidiaries of the Company), together
with any amendments required to be made with respect thereto, that it was required to file with any Governmental Authority, including
CMS, state insurance departments, state departments of health, other applicable state Medicaid authorities, and any other agencies
with jurisdiction over the Health Care Programs and including Filings that it was required to file under the Patient Protection
and Affordable Care Act (Pub. L. 111-148) as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152),
except where the failure to make such Company Statutory Filings and other Filings has not had and would not reasonably be expected
to have, individually or in the aggregate, a Company Material Adverse Effect.
(d) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Company and its Subsidiaries
have adopted and implemented policies, procedures or programs reasonably designed to assure that their respective directors, officers,
employees, agents, brokers, producers, contractors, vendors, field marketing organizations, Third Party marketing organizations
and similar entities with which they do business are in compliance with all Applicable Laws.
(e) With respect to participation in
Government Sponsored Health Care Programs, except as has not had and would not reasonably be expected to have, individually or
in the aggregate, a Company Material Adverse Effect, each of the Regulated Subsidiaries of the Company that participates in such
a Government Sponsored Health Care Program (i) meets the requirements for participation in, and receipt of payment from, the Government
Sponsored Health Care Programs in which such Regulated Subsidiary currently participates, and (ii) is a party to one or more valid
agreements with the appropriate Governmental Authority, including CMS or applicable state entities.
(f) Since January 1, 2013, except as
has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
none of the Company, any of its Subsidiaries or any director, officer or employee of the Company or any of its Subsidiaries has
been or is currently suspended, excluded or debarred from contracting with the federal or any state government or from participating
in any Government Sponsored Health Care Program or subject to an investigation or proceeding by any Governmental Authority that
could result in such suspension, exclusion or debarment.
(g) Since January 1, 2013, except as
has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
none of the Company or any of its Subsidiaries (i) has been assessed a civil monetary penalty under Section 1128A of the Social
Security Act, (ii) has been excluded from participation in any federal health care program or state health care program (as such
terms are defined by the Social Security Act), (iii) has been convicted of any criminal offense relating to the delivery of any
item or service under a federal health care program, or (iv) has been or is a party to or subject to any action or proceeding concerning
any of the matters described in the foregoing clauses (i) through (iii) of this Section 4.17(g).
Section 4.18. Material Contracts.
(a) Section 4.18(a) of the Company Disclosure Schedule sets forth a list as of the date of this Agreement of each of the
following Contracts to which the Company or any of its Subsidiaries is a party or by which it is bound (each such Contract listed
or required to be so listed, and each of the following Contracts to which the Company or any of its Subsidiaries becomes a party
or by which it becomes bound after the date of this Agreement, a “Company Material Contract”):
(i) (A) the 25 largest Contracts
of the Company and its Subsidiaries, taken as a whole, with Providers, (B) the 25 largest service vendor Contracts of the Company
and its Subsidiaries, taken as a whole, and (C) the 15 largest commercial customer Contracts of the Company and its Subsidiaries,
in each of (A) through (C) measured in terms of payments made or received (as applicable) by the Company and its Subsidiaries,
taken as a whole, during the twelve (12)-month period ended December 31, 2014;
(ii) any Medicaid, Medicare
or TRICARE Contract or any national Office of Personnel Management Contract with a Governmental Authority;
(iii) any Contracts of the Company
and its Subsidiaries with brokers for which payments made by the Company and its Subsidiaries during the twelve (12)-month period
ended December 31, 2014 exceeded $5,000,000;
(iv) any Contract or policy
for reinsurance ceded to or assumed from a Third Party involving payments in excess of $7,500,000 in any fiscal year;
(v) pharmacy benefit management
agreement or material patient assistance program agreement;
(vi) any Contract that (A) limits
or purports to limit, in any material respect, the freedom of the Company or any of its Subsidiaries to engage or compete in any
line of business or with any Person or in any area or that would so limit or purport to limit, in any material respect, the freedom
of Parent, the Company or any of their respective Affiliates after the First Merger Effective Time or (B) contains exclusivity
or “most favored nation” obligations or restrictions or other provisions restricting or purporting to restrict the
ability of the Company or any of its Subsidiaries to contract or establish prices for health care or other services, to sell products
directly or indirectly through third parties or to solicit any potential employee, Provider or customer that would so restrict
or purport to restrict Parent or any of its Affiliates after the First Merger Effective Time in any material respect;
(vii) any Contract reasonably
expected to result in payments made or received by the Company and its Subsidiaries in excess of $25,000,000 in any year and for
which the execution, delivery and performance by the Company of this Agreement or the consummation of the transactions contemplated
hereby would require any consent or other action by any Person (including notice by the Company) thereunder, constitute a default,
or an event that, with or without notice or lapse of time or both, would constitute a default, thereunder, or cause or permit the
termination, cancellation, acceleration or other change of any right or obligation (including triggering of a price adjustment,
right of renegotiation or other remedy) or the loss of any benefit to which the Company or any of its Subsidiaries is entitled
thereunder;
(viii) promissory notes, loan
agreements, indentures, evidences of indebtedness or other instruments providing for or relating to the lending of money, (A) if
as borrower or guarantor, in excess of $25,000,000, and (B) if as lender, in excess of $5,000,000 (in each case, other than (1)
any such Contract, as lender, with any Provider, as borrower, so long as such Contract was entered into in the ordinary course
of business consistent with past practice, or (2) any such Contracts among the Company and its wholly owned Subsidiaries or among
the Company’s wholly owned Subsidiaries);
(ix) any Contract restricting
the payment of dividends or the making of distributions to stockholders or the repurchase of stock or other equity;
(x) any collective bargaining
agreements;
(xi) any material joint venture,
profit-sharing, partnership or other similar agreements;
(xii) other than with respect
to any transactions involving investments in securities under the Company’s investment portfolio consistent with the Company’s
investment policy in effect as of the date hereof, any Contracts or series of related Contracts relating to the pending acquisition
or disposition of the assets or securities of any Person or any business for a price in excess of $10,000,000 (in each case, whether
by merger, sale of stock, sale of assets or otherwise);
(xiii) any lease or sublease
for real or personal property for which annual rental payments made by the Company and its Subsidiaries during the twelve (12)
month period ended
December 31, 2014 or expected to
be made by the Company and its Subsidiaries during the twelve (12) month period ending December 31, 2015 are greater than $1,000,000;
(xiv) all material Contracts
pursuant to which the Company or any of its Subsidiaries (A) receives or is granted any license or sublicense to, or covenant not
to be sued under, any Intellectual Property (other than licenses to Software that is commercially available on non-discriminatory
pricing terms) or (B) grants any license or sublicense to, or covenant not to be sued under, any Intellectual Property (other than
immaterial, non-exclusive licenses granted in the ordinary course of business);
(xv) any Contracts or other
transactions with any (A) executive officer or director of the Company, (B) record or, to the knowledge of the Company, beneficial
owner of five percent (5%) or more of the voting securities of the Company, or (C) affiliate (as such term is defined in Rule 12b-2
promulgated under the 1934 Act) or “associates” (or members of any of their “immediate family”) (as such
terms are respectively defined in Rule 12b-2 and Rule 16a-1 of the 1934 Act) of any such executive officer, director or beneficial
owner; and
(xvi) any other Contract required
to be filed by the Company pursuant to Item 601(b)(10) of Regulation S-K.
(b) All of the Company Material Contracts
are, subject to the Bankruptcy and Equity Exceptions, valid and binding obligations of the Company or a Subsidiary of the Company
(as the case may be) and, to the knowledge of the Company, each of the other parties thereto, and in full force and effect and
enforceable in accordance with their respective terms against the Company or its Subsidiaries (as the case may be) and, to the
knowledge of the Company, each of the other parties thereto (except for such Company Material Contracts that are terminated after
the date of this Agreement in accordance with their respective terms), except where the failure to be valid and binding obligations
and in full force and effect and enforceable has not had and would not reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect. To the knowledge of the Company, no Person is seeking to terminate or challenging the validity
or enforceability of any Company Material Contract, except such terminations or challenges which have not had and would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect. Neither the Company nor any of its Subsidiaries,
nor to the knowledge of the Company, any of the other parties thereto has violated any provision of, or committed or failed to
perform any act which (with or without notice, lapse of time or both) would constitute a default under any provision of, and neither
the Company nor any of its Subsidiaries has received written notice that it has violated or defaulted under, any Company Material
Contract, except for those violations and defaults (or potential defaults) which have not had and would not reasonably be expected
to have, individually or in the aggregate, a Company Material Adverse Effect.
(c) Section
4.18(c) of the Company Disclosure Schedule sets forth a true and complete list as of the date of this Agreement of each executory
contract, offer or other undertaking that is outside of the ordinary course of business consistent with past practice executed
by the Company or any of its Subsidiaries that, if accepted or executed and delivered by the applicable Third Party would constitute
a Company Material Contract.
Section 4.19. Taxes. Except as
has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect:
(a) All Tax Returns required by Applicable
Law to be filed with any Taxing Authority by, or on behalf of, the Company or any of its Subsidiaries have been filed when due
(giving effect to all extensions) in accordance with all Applicable Law, and all such Tax Returns are true and complete.
(b) The Company and each of its Subsidiaries
has paid (or has had paid on its behalf) or has withheld and remitted to the appropriate Taxing Authority all Taxes due and payable,
or (i) where payment is not yet due, has established (or has had established on its behalf and for its sole benefit and recourse)
in accordance with GAAP or SAP, as applicable, an adequate accrual or (ii) where payment is being contested in good faith pursuant
to appropriate procedures, has established (or has had established on its behalf and for its sole benefit and recourse) in accordance
with GAAP or SAP, as applicable, an adequate reserve, in each case for all Taxes through the end of the last period for which the
Company and its Subsidiaries ordinarily record items on their respective books and records.
(c) (i) All federal income Tax Returns
of the affiliated group of which the Company is the common parent through the Tax year ended December 31, 2013 have been examined
and closed or are Tax Returns with respect to which the applicable period for assessment under Applicable Law, after giving effect
to extensions or waivers, has expired, and (ii) neither the Company nor any of its Subsidiaries (or any member of any affiliated,
consolidated, combined or unitary group of which the Company or any of its Subsidiaries is or has been a member) has granted any
extension or waiver of the limitation period applicable to the assessment or collection of any federal income Tax.
(d) There is no claim, action, suit,
proceeding or investigation (including an audit) pending or, to the Company’s knowledge, threatened in writing against or
with respect to the Company or its Subsidiaries in respect of any Tax or Tax asset.
(e) There are no requests for rulings
or determinations in respect of any Tax or Tax asset pending between the Company or any of its Subsidiaries and any Taxing Authority.
(f) During the two (2)-year period ending
on the date of this Agreement, the Company was not a distributing corporation or a controlled corporation in a transaction intended
to be governed by Section 355 of the Code.
(g) There are no Liens for Taxes (other
than Permitted Liens) upon any of the assets of the Company or any of its Subsidiaries.
(h) No claim has been made in writing
by any Taxing Authority in a jurisdiction where the Company and/or the Company’s Subsidiaries do not file Tax Returns that
the Company or any of its Subsidiaries is or may be subject to taxation by, or required to file any Tax Return in, that jurisdiction.
(i) Neither the Company nor any of its
Subsidiaries (i) has been a member of an affiliated, consolidated, combined or unitary group other than one of which the Company
or any of its Subsidiaries was the common parent, (ii) is party to any Tax Sharing Agreement (other than any such agreement solely
between the Company and its Subsidiaries), or (iii) has any liability for the Taxes of any Person (other than the Company or any
of its Subsidiaries) under Treasury Regulation Section 1.1502-6 (or any similar provision of state, local or non-U.S. law) or any
Tax Sharing Agreement or as a transferee or successor.
(j) Neither the Company nor any of its
Subsidiaries has taken or agreed to take any action or has knowledge of any fact or circumstance that could reasonably be expected
to prevent the Mergers, taken together, from qualifying as a reorganization within the meaning of Section 368(a) of the Code.
Section 4.20. Employees and Employee
Benefit Plans. (a) Section 4.20 of the Company Disclosure Schedule sets forth a true and complete list as of the date
of this Agreement of each material Company Employee Plan and each Company Employee Plan that is subject to ERISA. For each material
Company Employee Plan and each Company Employee Plan that is subject to ERISA, the Company has made available to Parent a copy
of such plan (or a description, if such plan is not written) and all amendments thereto and material written interpretations thereof,
together with a copy of (if applicable) (i) each trust, insurance or other funding arrangement, (ii) each summary plan description
and summary of material modifications, (iii) the most recently filed Internal Revenue Service Forms 5500, (iv) the most recent
favorable determination or opinion letter from the Internal Revenue Service, (v) the most recently prepared actuarial reports and
financial statements in connection with each such Company Employee Plan, (vi) all documents and correspondence relating thereto
received from or provided to the Department of Labor, the PBGC, the Internal Revenue Service or any other Governmental Authority
during the past year, and (vii) all current employee handbooks, manuals and policies.
(b) Neither the Company nor any of its
ERISA Affiliates (nor any predecessor of any such entity) sponsors, maintains, administers or contributes to (or has any obligation
to contribute to), or has since January 1, 2009, sponsored, maintained, administered or contributed to (or had any obligation to
contribute to), any plan subject to Title IV of ERISA, including any multiemployer plan, as defined in Section 3(37) of ERISA.
(c) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, each Company Employee
Plan that is intended to be qualified under Section 401(a) of the Code has received a favorable determination or opinion letter
from the Internal Revenue Service or has applied to the Internal Revenue Service for such a letter within the applicable remedial
amendment period or such period has not expired and, to the knowledge of the Company, no circumstances exist that would reasonably
be expected to result in any such letter being revoked or not being reissued or a penalty under the Internal Revenue Service Closing
Agreement Program if discovered during an Internal Revenue Service audit or investigation. Except as has not had and would not
reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, each trust created under any
such Company Employee Plan is exempt from tax under Section 501(a) of the Code and has been so exempt since its creation.
(d) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, since January 1, 2013,
each Company Employee Plan has been maintained in compliance with its terms and all Applicable Law, including ERISA and the Code.
Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse
Effect, no claim (other than routine claims for benefits), action, suit, investigation or proceeding (including an audit) is pending
against or involves or, to the Company’s knowledge, is threatened against or reasonably expected to involve, any Company
Employee Plan before any court or arbitrator or any Governmental Authority, including the Internal Revenue Service, the Department
of Labor or the PBGC. To the knowledge of the Company, since January 1, 2013, no events have occurred with respect to any Company
Employee Plan that would reasonably be expected to result in the assessment of any excise taxes or penalties against the Company
or any of its Subsidiaries,
except for events that have not
had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect.
(e) With respect to each director, officer,
employee or independent contractor (including each former director, officer, employee or independent contractor) of the Company
or any of its Subsidiaries, the consummation of the transactions contemplated by this Agreement will not, either alone or together
with any other event: (i) entitle any such individual to any payment or benefit, including any bonus, retention, severance, retirement
or job security payment or benefit, (ii) accelerate the time of payment or vesting or trigger any payment or funding (through a
grantor trust or otherwise) of compensation or benefits under, or increase the amount payable or trigger any other obligation under,
any Company Employee Plan or (iii) limit or restrict the right of the Company or any of its Subsidiaries or, after the Closing,
Parent to merge, amend or terminate any Company Employee Plan.
(f) Neither the Company nor any of its
Subsidiaries has any current or projected liability for, and no Company Employee Plan provides or promises, any post-employment
or post-retirement medical, dental, disability, hospitalization, life or similar benefits (whether insured or self-insured) to
any director, officer, employee or individual independent contractor (including any former director, officer, employee or individual
independent contractor) of the Company or any of its Subsidiaries (other than coverage mandated by Applicable Law).
(g) There has been no amendment to,
written interpretation of or announcement (whether or not written) by the Company or any of its Affiliates relating to, or making
a change in employee participation or coverage under, any Company Employee Plan that would materially increase the expense of maintaining
such plan above the level of expense incurred in respect thereof for the fiscal year ended on the Company Balance Sheet Date, except
as required in order to comply with Applicable Law.
(h) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, no Company Employee Plan
or other compensation benefit or arrangement, individually or collectively, would reasonably be expected to result in the payment
of any amount that would not be deductible under Section 280G of the Code. Neither the Company nor any of its Subsidiaries has
any obligation to gross-up, indemnify or otherwise reimburse any director, officer, employee or individual independent contractor
(including any former director, officer, employee or individual independent contractor) of the Company or any of its Subsidiaries
for any tax incurred by such individual, including under Section 409A or 4999 of the Code.
(i) Each Company Employee Plan, and
any award thereunder, that is or forms part of a “nonqualified deferred compensation plan” within the meaning of Section
409A of the Code has been timely amended (if applicable) to comply and has been operated in compliance with, and the Company and
its Subsidiaries have complied in practice and operation with, all applicable requirements of Section 409A of the Code in all material
respects.
(j) With respect to any Company Employee
Plan covered by Subtitle B, Part 4 of Title I of ERISA or Section 4975 of the Code, no non-exempt prohibited transaction has occurred
that has caused or would reasonably be expected to cause the Company or any of its Subsidiaries to incur any material liability
under ERISA or the Code.
(k) No employee of the Company or any
of its Subsidiaries is employed by the Company or any of its Subsidiaries outside of the United States.
Section 4.21. Labor Matters. (a) Except
as has not had or would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
the Company and its Subsidiaries are, and since January 1, 2013 have been, in compliance with all Applicable Laws relating to labor
and employment, including those relating to labor management relations, wages, hours, overtime, employee classification, discrimination,
sexual harassment, civil rights, affirmative action, work authorization, immigration, safety and health, information privacy and
security, workers compensation, continuation coverage under group health plans, wage payment and the payment and withholding of
taxes.
(b) Neither the Company nor any of its
Subsidiaries is, or since January 1, 2013 has been, a party to or subject to, or is currently negotiating in connection with entering
into, any collective bargaining agreement, and, to the Company’s knowledge, there has not been any organizational campaign,
card solicitation, petition or other unionization activity seeking recognition of a collective bargaining unit relating to any
director, officer, employee or individual independent contractor of the Company or any of its Subsidiaries. Except as has not had
and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, there are no
unfair labor practice complaints pending or, to the Company’s knowledge, threatened against the Company or any of its Subsidiaries
before the National Labor Relations Board or any other Governmental Authority or any current union representation questions involving
any director, officer, employee or individual independent contractor (including any former director, officer, employee or individual
independent contractor) of the Company or any of its Subsidiaries with respect to the Company or its Subsidiaries. There is no
labor strike, slowdown, stoppage, picketing, interruption of work or lockout pending or, to the Company’s knowledge, threatened
against or affecting the Company or any of its Subsidiaries.
Section 4.22. Intellectual Property.
(a) Section 4.22(a) of the Company Disclosure Schedule sets forth a list as of the date of this Agreement of all registrations
(including patents and domain name registrations) and applications for registration for Owned Intellectual Property that is Company
Intellectual Property (the “Company Registered IP”). Except as has not had and would not reasonably be expected
to have, individually or in the aggregate, a Company Material Adverse Effect, none of the Company Registered IP has lapsed, expired,
been abandoned or been adjudged invalid or unenforceable, and, to the knowledge of the Company, all Company Registered IP is valid,
enforceable and subsisting.
(b) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (i) the Company and its
Subsidiaries are the sole and exclusive owners of all Owned Intellectual Property included in the Company Intellectual Property
and hold all of their right, title and interest in and to all Company Intellectual Property free and clear of all Liens (other
than non-exclusive licenses granted by the Company or one of its Subsidiaries in the ordinary course of business), (ii) to the knowledge
of the Company, the Company’s Owned Intellectual Property and the Company’s Licensed Intellectual Property constitutes
all of the Intellectual Property necessary to, or used or held for use in, the conduct of the respective businesses of the Company
and its Subsidiaries as currently conducted, and (iii) to the knowledge of the Company, there exist no material restrictions
on the use of any of the Company’s Owned Intellectual Property.
(c) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (i) to the knowledge of
the Company, neither the Company nor any of its Subsidiaries nor the conduct of their respective businesses has infringed, misappropriated,
diluted or otherwise violated any Intellectual Property rights of any Third Party, (ii) there is no claim, action, suit, investigation
or proceeding pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries
(A) alleging that the
Company or any of its Subsidiaries
has infringed, misappropriated, diluted or otherwise violated any Intellectual Property rights of any Third Party or (B) based
upon, or challenging or seeking to deny or restrict, the rights of the Company or any Subsidiary in any of the Company Intellectual
Property, and (iii) to the knowledge of the Company, no Third Party has infringed, misappropriated, diluted or otherwise violated
any Company Intellectual Property.
(d) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (i) the Company and its
Subsidiaries have provided reasonable notice of its privacy and personal data collection and use policies on its websites and other
customer and public communications and the Company and its Subsidiaries have complied with such policies and all Applicable Law
relating to (A) the privacy of the users of the Company’s and its Subsidiaries’ respective products, services and websites
and (B) the collection, use, storage and disclosure of any personally-identifiable information (including personal health information)
and other data or information collected or stored by the Company or any of its Subsidiaries, (ii) there is no claim, action, suit,
investigation or proceeding pending or, to the knowledge of the Company, threatened against the Company or any of its Subsidiaries
alleging any violation of such policies or Applicable Law, (iii) neither this Agreement nor the consummation of the transactions
contemplated hereby will violate any such policy, and (iv) the Company and its Subsidiaries have taken commercially reasonable steps
consistent with normal industry practice to protect the types of information referred to in this Section 4.22(d) against loss and
unauthorized access, use, modification, disclosure or other misuse, and, to the knowledge of the Company, there has been no unauthorized
access, use, modification, disclosure or other misuse of such data or information.
(e) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect, (i) the Company’s
IT Assets operate in accordance with their specifications and related documentation and perform in a manner that permits the Company
and its Subsidiaries to conduct their respective businesses as currently conducted, (ii) the Company and its Subsidiaries take
commercially reasonable actions, consistent with current industry standards, to protect the confidentiality, integrity and security
of the Company’s IT Assets (and all information and transactions stored or contained therein or transmitted thereby) against
any unauthorized use, access, interruption, modification or corruption, including the implementation of commercially reasonable
data backup, disaster avoidance and recovery procedures and business continuity procedures, and (iii) there has been no unauthorized
use, access, interruption, modification or corruption of the Company’s IT Assets (or any information or transactions stored
or contained therein or transmitted thereby).
Section 4.23. Properties. Except
as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect,
(i) the Company and each of its Subsidiaries has good, valid and marketable fee simple title to, or valid leasehold interests in,
as the case may be, each parcel of real property of the Company or any of its Subsidiaries, free and clear of all Liens, except
for Permitted Liens, (ii) each lease, sublease or license (each, a “Lease”) under which the Company or any of
its Subsidiaries leases, subleases or licenses any real property is, subject to the Bankruptcy and Equity Exceptions, a valid and
binding obligation of the Company or a Subsidiary of the Company (as the case may be) and, to the knowledge of the Company, each
of the other parties thereto, and in full force and effect and enforceable in accordance with its terms against the Company or
its Subsidiaries (as the case may be) and, to the knowledge of the Company, each of the other parties thereto (except for such
Leases that are terminated after the date of this Agreement in accordance with their respective terms), (iii) neither the Company
nor any of its Subsidiaries, nor, to the knowledge of the Company, any of the other parties thereto has violated or committed or
failed to perform any act
which (with or without notice, lapse of time
or both) would constitute a default under any provision of any Lease, and (iv) neither the Company nor any of its Subsidiaries
has received written notice that it has violated or defaulted under any Lease.
Section 4.24. Environmental Matters.
(a) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse
Effect:
(i) no notice, notification,
demand, request for information, citation, summons or order has been received, no complaint has been filed, no penalty has been
assessed, and no claim, action, suit, proceeding or investigation (including a review) is pending or, to the knowledge of the Company,
threatened by any Governmental Authority or other Person relating to the Company or any of its Subsidiaries that relates to, or
arises under, any Environmental Law, Environmental Permit or Hazardous Substance;
(ii) the Company and its Subsidiaries
are, and since January 1, 2013 have been, in compliance with all Environmental Laws and all Environmental Permits and hold all
applicable Environmental Permits; and
(iii) there are no liabilities
or obligations of the Company or any of its Subsidiaries of any kind whatsoever, whether accrued, contingent, absolute, determined,
determinable or otherwise arising under or relating to any Environmental Law, Environmental Permit or Hazardous Substance and there
is no existing condition, situation or set of circumstances that could reasonably be expected to result in any such liability or
obligation.
(b) Except as set forth on Section 4.24(b)
of the Company Disclosure Schedule, neither the Company nor any of its Subsidiaries owns, leases or operates any real property,
or conducts any operations, in New Jersey or Connecticut.
Section 4.25. Insurance. The Company
has made available to Parent, prior to the date of this Agreement, a list and summaries of all material insurance policies and
fidelity bonds for which the Company or any of its Subsidiaries is a policyholder or which covers the business, operations, employees,
officers, directors or assets of the Company or any of its Subsidiaries (the “Company Insurance Policies”).
The Company and its Subsidiaries maintain insurance coverage with reputable insurers in such amounts and covering such risks as
the Company reasonably believes, based on past experience, is adequate for the businesses and operations of the Company and its
Subsidiaries (taking into account the cost and availability of such insurance). Except as has not had and would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect, the Company Insurance Policies (i) are
sufficient for compliance by the Company and its Subsidiaries with all Company Material Contracts and (ii) will not terminate or
lapse by their terms by reason of the consummation of the transactions contemplated by this Agreement. Section 4.25 of the
Company Disclosure Schedule sets forth the amount per annum the Company paid in its last full fiscal year ending prior to the date
of this Agreement for the Company’s existing directors’ and officers’ insurance policies.
Section 4.26. Transactions with Affiliates.
To the knowledge of the Company and as of the date of this Agreement, since January 1, 2013, there have been no transactions, or
series of related transactions, agreements, arrangements or understandings in effect, nor are there any currently proposed transactions,
or series of related transactions, agreements, arrangements or understandings, that would be
required to be disclosed under Item 404 of
Regulation S-K that have not been otherwise disclosed in the Company SEC Documents filed prior to the date hereof.
Section 4.27. Antitakeover Statutes.
Assuming the representation and warranty set forth in Section 5.26 is true and correct, neither the restrictions set forth in Section
203 of the Delaware Law nor any other “control share acquisition,” “fair price,” “moratorium”
or other antitakeover laws enacted under U.S. state or federal laws apply to this Agreement or any of the transactions contemplated
hereby.
Section 4.28. Opinion of Financial
Advisor. The Board of Directors of the Company has received the oral opinion (to be confirmed by delivery of a written opinion
promptly after the date hereof) of Goldman, Sachs & Co., financial advisor to the Company, to the effect that, as of the date
of this Agreement, the Merger Consideration to be paid to the Company’s stockholders pursuant to this Agreement is fair from
a financial point of view to such stockholders.
Section 4.29. Finders’ Fees.
Except for Goldman, Sachs & Co., a copy of whose engagement agreement has been provided to Parent prior to the date of this
Agreement, there is no investment banker, broker, finder or other intermediary that has been retained by or is authorized to act
on behalf of the Company or any of its Subsidiaries who might be entitled to any fee or commission from the Company or any of its
Affiliates in connection with the transactions contemplated by this Agreement.
Section 4.30. No Ownership of Parent
Common Stock. Neither the Company nor any of its Subsidiaries beneficially owns, directly or indirectly, any shares of Parent
Common Stock or other securities convertible into, exchangeable for or exercisable for shares of Parent Common Stock and neither
the Company nor any of its Subsidiaries has any rights to acquire any shares of Parent Common Stock (other than any such securities
owned by the Company or any of its Subsidiaries in a fiduciary, representative or other capacity on behalf of other Persons, whether
or not held in a separate account). There are no voting trusts or other agreements or understandings to which the Company or any
of its Subsidiaries is a party with respect to the voting of the capital stock or other equity interest of Parent or any of its
Subsidiaries.
Section 4.31. No Other Company Representations
and Warranties. Except for the representations and warranties made by the Company in this Article 4 (as qualified by the applicable
items disclosed in the Company Disclosure Schedule in accordance with Section 11.05 and the introduction to this Article 4), neither
the Company nor any other Person makes or has made any representation or warranty, expressed or implied, at law or in equity, with
respect to or on behalf of the Company or its Subsidiaries, their businesses, operations, assets, liabilities, financial condition,
results of operations, future operating or financial results, estimates, projections, forecasts, plans or prospects (including
the reasonableness of the assumptions underlying such estimates, projections, forecasts, plans or prospects) or the accuracy or
completeness of any information regarding the Company or its Subsidiaries or any other matter furnished or provided to Parent or
made available to Parent in any “data rooms”, “virtual data rooms”, management presentations or in any
other form in expectation of, or in connection with, this Agreement or the transactions contemplated hereby. The Company and its
Subsidiaries disclaim any other representations or warranties, whether made by the Company or any of its Subsidiaries or any of
their respective Affiliates or Representatives. Without limiting the generality of the foregoing, except for the representations
and warranties made by Company in this Article 4 (as qualified by the applicable items disclosed in the Company Disclosure Schedule
in accordance with Section 11.05 and the introduction to this Article 4), neither the Company nor any other Person makes or has
made any representation or warranty, expressed or implied, at law or in equity, with respect to or on behalf of the Company or
its Subsidiaries with respect to (a) the adequacy or sufficiency of reserves, (b)
the effect of the adequacy or sufficiency
of reserves on any line item, asset, liability or equity amount on any financial or other document, (c) whether or not reserves
were determined in accordance with any actuarial, statutory, regulatory or other standard, or (d) the collectability of any amounts
under any reinsurance Contract. The Company acknowledges and agrees that, except for the representations and warranties made by
Parent in Article 5 (as qualified by the applicable items disclosed in the Parent Disclosure Schedule in accordance with Section
11.05 and the introduction to Article 5), neither Parent nor any other Person is making or has made any representations or warranty,
expressed or implied, at law or in equity, with respect to or on behalf of Parent or its Subsidiaries, their businesses, operations,
assets, liabilities, financial condition, results of operations, future operating or financial results, estimates, projections,
forecasts, plans or prospects (including the reasonableness of the assumptions underlying such estimates, projections, forecasts,
plans or prospects) or the accuracy or completeness of any information regarding Parent or its Subsidiaries or any other matter
furnished or provided to Parent or made available to the Company in any “data rooms,” “virtual data rooms,”
management presentations or in any other form in expectation of, or in connection with, this Agreement, or the transactions contemplated
hereby or thereby. The Company specifically disclaims that it is relying upon or has relied upon any such other representations
or warranties that may have been made by any Person, and acknowledges and agrees that Parent and its Affiliates have specifically
disclaimed and do hereby specifically disclaim any such other representations and warranties. Notwithstanding the foregoing, this
Section 4.31 shall not limit Parent’s, Merger Sub 1’s, Merger Sub 2’s or the Company’s remedies in
the case of fraud.
Article
5
Representations and Warranties of Parent
Subject to Section 11.05, except (i) other
than with respect to the representations and warranties in Section 5.01, Section 5.02, Section 5.05, Section
5.06, Section 5.23, Section 5.24 and Section 5.25, as disclosed in any publicly available Parent SEC Document filed after
December 31, 2014 and before the date of this Agreement or in Parent’s annual report on Form 10-K for the fiscal year ended
December 31, 2013 or in Parent’s proxy statement for the 2014 annual meeting of Parent’s stockholders or (ii) as set
forth in the Parent Disclosure Schedule, Parent represents and warrants to the Company that:
Section 5.01. Corporate Existence
and Power. Parent is a corporation duly incorporated, validly existing and in good standing under the laws of the Commonwealth
of Pennsylvania, Merger Sub 1 is a corporation duly incorporated, validly existing and in good standing under the laws of the State
of Delaware and Merger Sub 2 is a limited liability company duly formed, validly existing and in good standing under the laws of
the State of Delaware. Each of Parent and Merger Sub 1 has all corporate powers required to own or lease all of its properties
or assets and to carry on its business as now conducted, and Merger Sub 2 has all limited liability company powers required to
own or lease all of its properties or assets and to carry on its business as now conducted. Each of Parent, Merger Sub 1 and Merger
Sub 2 is duly qualified to do business and is in good standing in each jurisdiction where such qualification is necessary, except
for those jurisdictions where failure to be so qualified has not had and would not reasonably be expected to have, individually
or in the aggregate, a Parent Material Adverse Effect. As of the date hereof, Parent directly owns all of the outstanding shares
of capital stock of Merger Sub 1 and all of the outstanding limited liability company interests of Merger Sub 2. Prior to the date
of this Agreement, Parent has made available to the Company true and complete copies of the certificate of incorporation and bylaws
of each of Parent, Merger Sub 1, and the certificate of formation and limited liability company agreement of Merger Sub 2, as in
effect on the date of this Agreement (the “Parent Organizational Documents”). Since the date of its formation,
neither Merger Sub 1 nor
Merger Sub 2 has engaged in any activities
other than in connection with or as contemplated by this Agreement.
Section 5.02. Corporate Authorization.
(a) The execution, delivery and performance by each of Parent, Merger Sub 1 and Merger Sub 2 of this Agreement and the consummation
by Parent, Merger Sub 1 and Merger Sub 2 of the transactions contemplated by this Agreement are within the corporate powers of
each of Parent and Merger Sub 1 and the sole member of Merger Sub 2 and, except for the Parent Stockholder Approval and the required
approval of the stockholders of Merger Sub 1 and the members of Merger Sub 2 in connection with the consummation of the Mergers,
have been duly authorized by all necessary corporate action on the part of Parent, Merger Sub 1 and Merger Sub 2. The affirmative
vote of a majority of all votes cast by holders of outstanding shares of Parent Common Stock at a duly called and held meeting
of Parent’s stockholders at which a quorum is present approving the issuance of shares of Parent Common Stock in connection
with the First Merger (the “Parent Share Issuance”) is the only vote of the holders of Parent’s capital
stock necessary in connection with the consummation of the Mergers (the “Parent Stockholder Approval”). This
Agreement has been duly executed and delivered by each of Parent, Merger Sub 1 and Merger Sub 2 and (assuming due authorization,
execution and delivery by the Company) constitutes a valid and binding agreement of each of Parent, Merger Sub 1 and Merger Sub
2 enforceable against Parent, Merger Sub 1 and Merger Sub 2 in accordance with its terms (subject to the Bankruptcy and Equity
Exceptions).
(b) At a meeting duly called and held,
the Board of Directors of Parent unanimously adopted resolutions (i) determining that this Agreement and the transactions contemplated
hereby (including the Parent Share Issuance) are fair to and in the best interests of Parent’s stockholders, (ii) approving,
adopting and declaring advisable this Agreement and the transactions contemplated hereby (including the Parent Share Issuance),
(iii) directing that the approval of the Parent Share Issuance be submitted to a vote at a meeting of Parent’s stockholders
and (iv) recommending approval of the Parent Share Issuance by Parent’s stockholders (such recommendation, the “Parent
Board Recommendation”). The Board of Directors of Merger Sub 1 has unanimously adopted resolutions (i) determining that
this Agreement and the transactions contemplated hereby (including the First Merger) are fair to and in the best interests of Merger
Sub 1’s stockholder, (ii) approving, adopting and declaring advisable this Agreement and the transactions contemplated hereby
(including the First Merger), (iii) directing that the approval and adoption of this Agreement be submitted to a vote of Merger
Sub 1’s stockholder, and (iv) recommending approval and adoption of this Agreement by Merger Sub 1’s stockholder. The
Board of Managers of Merger Sub 2 has unanimously adopted resolutions (i) determining that this Agreement and the transactions
contemplated hereby (including the Second Merger) are fair to and in the best interests of Merger Sub 2’s member, (ii) approving,
adopting and declaring advisable this Agreement and the transactions contemplated hereby (including the Second Merger), (iii) directing
that the approval and adoption of this Agreement be submitted to a vote of Merger Sub 2’s member and (iv) recommending approval
and adoption of this Agreement by Merger Sub 2’s member. Except as permitted by Section 7.02, the Board of Directors of each
of Parent, Merger Sub 1 and Merger Sub 2 has not subsequently rescinded, modified or withdrawn any of the foregoing resolutions.
Section 5.03. Governmental Authorization.
(a) The execution, delivery and performance by each of Parent, Merger Sub 1 and Merger Sub 2 of this Agreement and the consummation
by each of Parent, Merger Sub 1 and Merger Sub 2 of the transactions contemplated hereby require no action by or in respect of
Consents of, or Filing with, any Governmental Authority other than (i) the filing of the First Certificate of Merger and the Second
Certificate of Merger with the Delaware Secretary of State and appropriate documents with the relevant authorities of other states
in which Parent, Merger Sub 1 or
Merger Sub 2 is qualified to do business,
(ii) compliance with any applicable requirements of the HSR Act, (iii) compliance with any applicable requirements of the 1933
Act, the 1934 Act and any other applicable U.S. state or federal securities laws or pursuant to the rules of the NYSE, (iv) Consents
of, and Filings with, the state insurance departments, federal and state departments of health and other Consents and Filings required
under the Health Care Laws or insurance laws that are listed on Section 5.03 of the Parent Disclosure Schedule (the Consents and
Filings required under or in connection with this clause (iv), the “Parent Required Governmental Authorizations”),
and (v) any other actions, Consents or Filings the absence of which has not had and would not reasonably be expected to have, individually
or in the aggregate, a Parent Material Adverse Effect.
Section 5.04. Non-contravention.
The execution, delivery and performance by each of Parent, Merger Sub 1 and Merger Sub 2 of this Agreement and the consummation
of the transactions contemplated hereby do not and will not (i) contravene, conflict with, or result in any violation or breach
of any provision of the Parent Organizational Documents, (ii) assuming compliance with the matters referred to in Section 5.03
and receipt of the Parent Stockholder Approval, contravene, conflict with or result in any violation or breach of any provision
of any Applicable Law, (iii) assuming compliance with the matters referred to in Section 5.03 and receipt of the Parent Stockholder
Approval, require any Consent or other action by any Person under, constitute a default, or an event that, with or without notice
or lapse of time or both, would constitute a default, under, or cause or permit the termination, cancellation, acceleration or
other change of any right or obligation or the loss of any benefit to which Parent or any of its Subsidiaries is entitled under,
any provision of any Contract binding upon Parent or any of its Subsidiaries or any governmental Consents (including Consents required
by Contract) affecting, or relating in any way to, the assets or business of Parent and its Subsidiaries, or (iv) result in the
creation or imposition of any Lien on any asset of Parent or any of its Subsidiaries, with such exceptions, in the case of each
of clauses (ii) through (iv), as has not had and would not reasonably be expected to have, individually or in the aggregate, a
Parent Material Adverse Effect.
Section 5.05. Capitalization.
(a) The authorized capital stock of Parent consists of 2,996,654,333 shares of Parent Common Stock, of which (x) 2,538,741,937
shares are designated shares of Parent Common Stock as of the date of this Agreement and 2,538,741,937 shares (less any shares
purchased by, redeemed by, surrendered to or otherwise acquired by Parent after the date of this Agreement and prior to the Closing
Date, which shares will become undesignated) will be designated shares of Parent Common Stock as of the Closing Date, and (y) 7,625,000
shares are designated Class A Voting Preferred Shares. As of July 1, 2015, there were outstanding (i) 348,598,141 shares of Parent
Common Stock, (ii) no shares of Class A Voting Preferred Shares, and (iii) stock appreciation rights and performance stock appreciation
rights that settle into Parent Common Stock (such stock appreciation rights and performance stock appreciation rights collectively,
“Parent Stock Rights”) with respect to an aggregate of 7,825,475 shares of Parent Common Stock (of which, Parent
Stock Rights with respect to 4,544,426 shares of Parent Common Stock were exercisable) and (iv) 6,564,198 performance share units,
market share units and restricted stock units under Parent’s equity compensation plans (collectively, “Parent Stock
Units” and together with Parent Stock Rights and any other equity or equity-linked awards granted after July 1, 2015,
“Parent Equity Awards”). The shares of Parent Common Stock to be issued as part of the Merger Consideration
have been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will have been validly
issued and will be fully paid and nonassessable and the issuance thereof will be free of preemptive right. Parent owns all of the
issued and outstanding capital stock of Merger Sub 1 and all of the issued and outstanding limited liability company interests
of Merger Sub 2. Except as set forth in this Section 5.05(a) and for changes since July 1, 2015 resulting from (x) the exercise
or vesting and settlement of
Parent Equity Awards outstanding on such date
or issued after such date, or (y) the issuance of Parent Equity Awards after such date, there are no issued, reserved for
issuance or outstanding (i) shares of capital stock or other voting securities of, or other ownership interest in, Parent,
(ii) securities of Parent convertible into or exchangeable for shares of capital stock or other voting securities of, or other
ownership interests in, Parent, (iii) warrants, calls, options or other rights to acquire from Parent, or other obligations of
Parent to issue, any capital stock or other voting securities of, or other ownership interests in, or securities convertible into
or exchangeable for capital stock or other voting securities of, or other ownership interests in, Parent, or (iv) restricted
shares, stock appreciation rights, performance units, contingent value rights, “phantom” stock or similar securities
or rights issued by or with the approval of Parent that are derivative of, or provide economic benefits based, directly or indirectly,
on the value or price of, any capital stock or other voting securities of, or other ownership interests in, Parent (the items in
clauses (i) through (iv) being referred to collectively as the “Parent Securities”).
(b) All outstanding shares of capital
stock of Parent have been, and all shares that may be issued pursuant to any employee stock option or other compensation plan or
arrangement will be, when issued in accordance with the respective terms thereof, duly authorized and validly issued, fully paid
and nonassessable and free of preemptive rights. No Subsidiary of Parent owns any shares of capital stock of Parent (other than
any such shares owned by Subsidiaries of Parent in a fiduciary, representative or other capacity on behalf of other Persons, whether
or not held in a separate account). There are no outstanding bonds, debentures, notes or other indebtedness of Parent having the
right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which stockholders
of Parent may vote. There are no outstanding obligations of Parent or any of its Subsidiaries to repurchase, redeem or otherwise
acquire any Parent Securities. Neither Parent nor any of its Subsidiaries is a party to any agreement with respect to the voting
of any Parent Securities.
Section 5.06. Subsidiaries. (a) Each
Major Subsidiary of Parent is a corporation or other entity duly incorporated or organized, validly existing and in good standing
under the laws of its jurisdiction of incorporation or organization and has all corporate or other organizational powers, as applicable,
required to carry on its business as now conducted, except for those jurisdictions where failure to be so organized, validly existing
and in good standing or to have such power has not had and would not reasonably be expected to have, individually or in the aggregate,
a Parent Material Adverse Effect. Each such Major Subsidiary is duly qualified to do business and is in good standing in each jurisdiction
where such qualification is necessary, except for those jurisdictions where failure to be so qualified has not had and would not
reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect.
(b) All of the outstanding capital stock
or other voting securities of, or ownership interests in, each Subsidiary of Parent are owned by Parent, directly or indirectly,
free and clear of any Lien. There are no issued, reserved for issuance or outstanding (i) securities of Parent or any of its Subsidiaries
convertible into or exchangeable for shares of capital stock or other voting securities of, or other ownership interests in, any
Subsidiary of Parent, (ii) warrants, calls, options or other rights to acquire from Parent or any of its Subsidiaries, or other
obligations of Parent or any of its Subsidiaries to issue, any capital stock or other voting securities of, or other ownership
interests in, or any securities convertible into or exchangeable for any capital stock or other voting securities of, or other
ownership interests in, any Subsidiary of Parent or (iii) restricted shares, stock appreciation rights, performance units, contingent
value rights, “phantom” stock or similar securities or rights issued by or with the approval of Parent or any of its
Subsidiaries that are derivative of, or provide economic benefits based, directly or indirectly, on the value or price of, any
capital stock or other voting securities of, or other
ownership interests in, any Subsidiary
of Parent. There are no outstanding obligations of Parent or any of its Subsidiaries to repurchase, redeem or otherwise acquire
any securities described in the foregoing clauses (i) through (iii) of this Section 5.06(b).
Section 5.07. SEC Filings and the
Sarbanes-Oxley Act. (a) Parent has timely filed with or furnished to the SEC all reports, schedules, forms, statements,
prospectuses, registration statements and other documents required to be filed with or furnished to the SEC by Parent since January
1, 2013. No Subsidiary of Parent is required to file any report, schedule, form, statement, prospectus, registration statement
or other document with the SEC.
(b) As of its filing date, each report,
schedule, form, statement, prospectus, registration statement and other document filed with or furnished to the SEC by Parent since
January 1, 2013 (collectively, together with any exhibits and schedules thereto and other information incorporated therein, the
“Parent SEC Documents”) filed prior to the date of this Agreement complied, and each Parent SEC Document filed
subsequent to the date of this Agreement (assuming, in the case of each of the Registration Statement and the Joint Proxy Statement/Prospectus,
that the representation and warranty set forth in Section 4.09 is true and correct) will comply, in all material respects with
the applicable requirements of the NYSE, the 1933 Act, the 1934 Act and the Sarbanes-Oxley Act, as the case may be.
(c) As of its filing date (or, if amended
or superseded by a filing prior to the date of this Agreement, on the date of such amended or superseding filing), each Parent
SEC Document filed prior to the date of this Agreement did not, and each Parent SEC Document filed subsequent to the date of this
Agreement (assuming, in the case of each of the Registration Statement and the Joint Proxy Statement/Prospectus, that the representation
and warranty set forth in Section 4.09 is true and correct) will not, contain any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they
were made, not misleading.
(d) Parent is, and since January 1,
2013 has been, in compliance in all material respects with (i) the applicable provisions of the Sarbanes-Oxley Act and (ii) the
applicable listing and corporate governance rules and regulations of the NYSE.
(e) Parent and its Subsidiaries have
established and maintain disclosure controls and procedures (as defined in Rule 13a-15 under the 1934 Act). Such disclosure controls
and procedures are designed to ensure that material information relating to Parent, including its consolidated Subsidiaries, is
made known to Parent’s principal executive officer and its principal financial officer by others within those entities, particularly
during the periods in which the periodic reports required under the 1934 Act are being prepared. Such disclosure controls and procedures
are effective in timely alerting Parent’s principal executive officer and principal financial officer to material information
required to be included in Parent’s periodic and current reports required under the 1934 Act.
(f) Parent and its Subsidiaries have
established and maintain a system of internal controls. Such internal controls are sufficient to provide reasonable assurance regarding
the reliability of Parent’s financial reporting and the preparation of Parent’s financial statements for external purposes
in accordance with GAAP. Parent’s principal executive officer and principal financial officer have disclosed, based on their
most recent evaluation of internal controls prior to the date of this Agreement, to Parent’s auditors and the audit committee
of the Board of Directors of Parent (x) all significant deficiencies and material weaknesses in the design or operation of internal
controls which are reasonably
likely to adversely affect Parent’s
ability to record, process, summarize and report financial information and (y) any fraud, whether or not material, that involves
management or other employees who have a significant role in internal controls. Parent has made available to the Company prior
to the date of this Agreement a true and complete summary of any disclosure of the type described in the preceding sentence made
by management to Parent’s auditors and audit committee since January 1, 2013.
(g) Since January 1, 2013, each of the
principal executive officer and principal financial officer of Parent (or each former principal executive officer and principal
financial officer of Parent, as applicable) has made all certifications required by Rule 13a-14 and 15d-14 under the 1934 Act and
Sections 302 and 906 of the Sarbanes-Oxley Act and any related rules and regulations promulgated by the SEC and the NYSE, and the
statements contained in any such certifications are true and complete.
Section 5.08. Financial Statements
and Financial Matters. (a) The audited consolidated financial statements and unaudited consolidated interim financial statements
of Parent included or incorporated by reference in the Parent SEC Documents present fairly in all material respects, in conformity
with GAAP applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto), the consolidated
financial position of Parent and its Subsidiaries as of the dates thereof and their consolidated results of operations and cash
flows for the periods then ended (subject to normal and recurring year-end audit adjustments in the case of any unaudited interim
financial statements). Such consolidated financial statements have been prepared from, and are in accordance with, the books and
records of Parent and its Subsidiaries.
(b) From January 1, 2013 to the date
of this Agreement, Parent has not received written notice from the SEC or any other Governmental Authority indicating that any
of its accounting policies or practices are or may be the subject of any review, inquiry, investigation or challenge by the SEC
or any other Governmental Authority.
Section 5.09. Disclosure Documents.
The information relating to Parent and its Subsidiaries that is provided by Parent, any of its Subsidiaries or any of their respective
Representatives for inclusion or incorporation by reference in the Registration Statement or the Joint Proxy Statement/Prospectus
will not (i) in the case of the Registration Statement, at the time the Registration Statement or any amendment or supplement thereto
becomes effective and at the time of the Company Stockholder Meeting and the Parent Stockholder Meeting, and (ii) in the case of
the Joint Proxy Statement/Prospectus, at the time the Joint Proxy Statement/Prospectus or any amendment or supplement thereto is
first mailed to the stockholders of the Company and Parent and at the time of the Company Stockholder Meeting and Parent Stockholder
Meeting, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in light of the circumstances under which they were made, not misleading.
Section 5.10. Statutory Financial
Statements. The audited statutory financial statements for the year ended December 31, 2014 and the unaudited statutory financial
statements for the quarter ended March 31, 2015 filed by Parent’s Regulated Subsidiaries that are licensed as insurance companies
or health maintenance organizations prior to the date hereof with the applicable Governmental Authorities (the “Parent
Statutory Filings”) and the respective statements of assets, liabilities, capital and surplus, revenues and expenses
and cash flows included or incorporated by reference therein (i) were prepared from the books and records of the applicable Regulated
Subsidiary, (ii) present fairly in all material respects the statutory financial condition and results of operations of the applicable
Regulated Subsidiary as of the date and for the periods then ended (subject to normal and recurring year- end
adjustments in the case of any interim statements),
and (iii) were prepared in all material respects in accordance with SAP applied on a consistent basis (except as may be indicated
in the notes thereto).
Section 5.11. Reserves. The loss
reserves and other actuarial amounts of the Regulated Subsidiaries of Parent as of December 31, 2014 recorded in the Parent Statutory
Filings: (i) were determined in all material respects in accordance with ASOPs in effect on that date (except as may be indicated
in the notes thereto) based on facts known to Parent as of such date, (ii) were computed on the basis of methodologies consistent
in all material respects with those used in computing the corresponding reserves in the prior fiscal year (except as may be indicated
in the notes thereto) and (iii) include provisions for all actuarial reserves that were required at that time to be established
in accordance with Applicable Laws based on facts known to Parent as of such date; provided that, notwithstanding the foregoing,
it is acknowledged and agreed by the Company that Parent is not making any representation or warranty in this Agreement and nothing
contained in this Agreement, or any other agreement, document or instrument to be delivered in connection with this Agreement is
intended or shall be construed to be a representation or warranty of Parent in respect of the adequacy or sufficiency of the reserves
of Parent or Parent’s Regulated Subsidiaries.
Section 5.12. Capital or Surplus Maintenance.
As of the date of this Agreement, no Regulated Subsidiary of Parent is subject to any requirement imposed by a Governmental Authority
to maintain capital or surplus amounts or levels or is subject to any restriction on the payment of dividends or other distributions
on its shares of capital stock, except for any such requirements or restrictions under Applicable Laws, including insurance laws
and regulations, of general application.
Section 5.13. Absence of Certain Changes.
(a) Since the Parent Balance Sheet Date through the date of this Agreement, (i) the business of Parent and its Subsidiaries
has been conducted in all material respects in the ordinary course of business consistent with past practice and (ii) there has
not been any event, change, effect, development or occurrence that has had or would reasonably be expected to have, individually
or in the aggregate, a Parent Material Adverse Effect.
(b) Since the Parent Balance Sheet Date
through the date of this Agreement, there has not been any action taken by Parent or any of its Subsidiaries that, if taken during
the period from the date of this Agreement through the First Merger Effective Time without the Company’s consent, would constitute
a breach of Section 7.01.
Section 5.14. No Undisclosed Material
Liabilities. There are no liabilities or obligations of Parent or any of its Subsidiaries of any kind whatsoever, whether accrued,
contingent, absolute, determined, determinable or otherwise, other than (i) liabilities or obligations disclosed and provided for
in the Parent Balance Sheet or in the notes thereto, (ii) liabilities or obligations incurred in the ordinary course of business
consistent with past practice since the Parent Balance Sheet Date, (iii) liabilities arising in connection with the transaction
contemplated hereby, and (iv) other liabilities or obligations that have not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect. There are no off-balance sheet arrangements of any type pursuant
to any off-balance sheet arrangement required to be disclosed pursuant to Item 303(a)(4) of Regulation S-K that have not been so
described in the Parent SEC Documents.
Section 5.15. Litigation. There
is no claim, action, suit, investigation or proceeding pending or, to the knowledge of Parent, threatened against or affecting
Parent, any of its Subsidiaries, any present or former officers, directors or employees of Parent or any of its Subsidiaries in
their respective capacities as such or any of the respective properties of Parent or any of its Subsidiaries, before (or, in the
case of
threatened claims, actions, suits, investigations
or proceedings, that would be before) any arbitrator or Governmental Authority, that has had or would reasonably be expected to
have, individually or in the aggregate, a Parent Material Adverse Effect or that in any manner challenges or seeks to prevent,
enjoin, alter or materially delay the Mergers or any of the other transactions contemplated hereby. There is no Order outstanding
against Parent, any of its Subsidiaries, any present or former officers, directors or employees of Parent or any of its Subsidiaries
in their respective capacities as such or any of the respective properties of any of Parent or any of its Subsidiaries, that has
had or would reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect or that would prevent,
enjoin, alter or materially delay the Mergers or any of the other transactions contemplated hereby.
Section 5.16. Permits. Except
as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect,
Parent and each of its Subsidiaries hold all governmental licenses and Consents necessary for the operation of its respective businesses
(the “Parent Permits”). Parent and each of its Subsidiaries is and since January 1, 2013, has been in compliance
with the terms of Parent Permits, except for failures to comply that have not had and would not reasonably be expected to have,
individually or in the aggregate, a Parent Material Adverse Effect. There is no claim, action, suit, investigation or proceeding
pending, or, to the knowledge of Parent, threatened that seeks, or, to the knowledge of Parent, any existing condition, situation
or set of circumstances that would reasonably be expected to result in, the revocation, cancellation, termination, non-renewal
or adverse modification of any Parent Permit except where such revocation, cancellation, termination, non-renewal or adverse modification
has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect.
Section 5.17. Compliance with Applicable
Laws. (a) Parent and each of its Subsidiaries is, and since January 1, 2013 has been, in compliance with all Applicable Laws,
except for failures to comply that have not had and would not reasonably be expected to have, individually or in the aggregate,
a Parent Material Adverse Effect.
(b) Since January 1, 2013, neither Parent
nor any of its Subsidiaries has entered into any agreement or settlement with any Governmental Authority with respect to any actual
or alleged violation of any Applicable Law, except for agreements and settlements that have not had and would not reasonably be
expected to have, individually or in the aggregate, a Parent Material Adverse Effect.
(c) Since January 1, 2013, each Regulated
Subsidiary of Parent has filed all Parent Statutory Filings and all other material Filings (including Filings with respect to premium
rates, rating plans, policy terms and other terms established or used by any Subsidiaries of Parent), together with any amendments
required to be made with respect thereto, that it was required to file with any Governmental Authority, including CMS, state insurance
departments, state departments of health, other applicable state Medicaid authorities, and any other agencies with jurisdiction
over the Health Care Programs and including Filings that it was required to file under the Patient Protection and Affordable Care
Act (Pub. L. 111-148) as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152), except where the
failure to make such Parent Statutory Filings and other Filings has not had and would not reasonably be expected to have, individually
or in the aggregate, a Parent Material Adverse Effect.
(d) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, Parent and its Subsidiaries
have adopted and implemented policies, procedures or programs reasonably designed to assure that their respective directors, officers,
employees, agents, brokers, producers,
contractors, vendors, field marketing organizations, Third Party marketing organizations and similar entities with which they do
business are in compliance with all Applicable Laws.
(e) With respect to participation in
Government Sponsored Health Care Programs, except as has not had and would not reasonably be expected to have, individually or
in the aggregate, a Parent Material Adverse Effect, each of the Regulated Subsidiaries of Parent that participates in such a Government
Sponsored Health Care Program (i) meets the requirements for participation in, and receipt of payment from, the Government Sponsored
Health Care Programs in which such Regulated Subsidiary currently participates and (ii) is a party to one or more valid agreements
with the appropriate Governmental Authority, including CMS or applicable state entities.
(f) Since January 1, 2013, except as
has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, none
of Parent, any of its Subsidiaries, or any director, officer or employee of Parent or any of its Subsidiaries has been or is currently
suspended, excluded or debarred from contracting with the federal or any state government or from participating in any Government
Sponsored Health Care Program or subject to an investigation or proceeding by any Governmental Authority that could result in such
suspension, exclusion or debarment.
(g) Since January 1, 2013, except as
has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, none
of Parent or any of its Subsidiaries (i) has been assessed a civil monetary penalty under Section 1128A of the Social Security
Act, (ii) has been excluded from participation in any federal health care program or state health care program (as such terms are
defined by the Social Security Act), (iii) has been convicted of any criminal offense relating to the delivery of any item or service
under a federal health care program or (iv) has been or is a party to or subject to any action or proceeding concerning any of
the matters described in the foregoing clauses (i) through (iii) of this Section 5.17(g).
Section 5.18. Taxes. Except as
has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect:
(a) All Tax Returns required by Applicable
Law to be filed with any Taxing Authority by, or on behalf of, Parent or any of its Subsidiaries have been filed when due (giving
effect to all extensions) in accordance with all Applicable Law, and all such Tax Returns are true and complete.
(b) Parent and each of its Subsidiaries
has paid (or has had paid on its behalf) or has withheld and remitted to the appropriate Taxing Authority all Taxes due and payable,
or (i) where payment is not yet due, has established (or has had established on its behalf and for its sole benefit and recourse)
in accordance with GAAP or SAP, as applicable, an adequate accrual or (ii) where payment is being contested in good faith pursuant
to appropriate procedures, has established (or has had established on its behalf and for its sole benefit and recourse) in accordance
with GAAP or SAP, as applicable, an adequate reserve, in each case for all Taxes through the end of the last period for which Parent
and its Subsidiaries ordinarily record items on their respective books and records.
(c) (i) All federal income Tax Returns
of the affiliated group of which Parent is the common parent through the Tax year ended December 31, 2013 have been examined and
closed or are Tax Returns with respect to which the applicable period for assessment under Applicable Law, after giving effect
to extensions or waivers, has expired, and (ii) neither Parent nor any of its Subsidiaries (or any
member of any affiliated, consolidated,
combined or unitary group of which Parent or any of its Subsidiaries is or has been a member) has granted any extension or waiver
of the limitation period applicable to the assessment or collection of any federal income Tax.
(d) There is no claim, action, suit,
proceeding or investigation (including an audit) pending or, to Parent’s knowledge, threatened in writing against or with
respect to Parent or its Subsidiaries in respect of any Tax or Tax asset.
(e) There are no requests for rulings
or determinations in respect of any Tax or Tax asset pending between Parent or any of its Subsidiaries and any Taxing Authority.
(f) During the two (2)-year period ending
on the date of this Agreement, Parent was not a distributing corporation or a controlled corporation in a transaction intended
to be governed by Section 355 of the Code.
(g) There are no Liens for Taxes (other
than Permitted Liens) upon any of the assets of Parent or any of its Subsidiaries.
(h) No claim has been made in writing
by any Taxing Authority in a jurisdiction where Parent and/or Parent’s Subsidiaries do not file Tax Returns that Parent or
any of its Subsidiaries is or may be subject to taxation by, or required to file any Tax Return in, that jurisdiction.
(i) Neither Parent nor any of its Subsidiaries
(i) has been a member of an affiliated, consolidated, combined or unitary group other than one of which Parent or any of its Subsidiaries
was the common parent, (ii) is party to any Tax Sharing Agreement (other than any such agreement solely between Parent and its
Subsidiaries), or (iii) has any liability for the Taxes of any Person (other than Parent or any of its Subsidiaries) under Treasury
Regulation Section 1.1502-6 (or any similar provision of state, local or non-U.S. law) or any Tax Sharing Agreement or as a transferee
or successor.
(j) Neither Parent nor any of its Subsidiaries
has taken or agreed to take any action or has knowledge of any fact or circumstance that could reasonably be expected to prevent
the Mergers, taken together, from qualifying as a reorganization within the meaning of Section 368(a) of the Code.
Section 5.19. Employees and Employee
Benefit Plans. (a) Neither Parent nor any of its ERISA Affiliates (nor any predecessor of any such entity) sponsors, maintains,
administers or contributes to (or has any obligation to contribute to), or has since January 1, 2009, sponsored, maintained, administered
or contributed to (or had any obligation to contribute to), any plan subject to Title IV of ERISA, including any multiemployer
plan, as defined in Section 3(37) of ERISA.
(b) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, each Parent Employee Plan
that is intended to be qualified under Section 401(a) of the Code has received a favorable determination or opinion letter from
the Internal Revenue Service or has applied to the Internal Revenue Service for such a letter within the applicable remedial amendment
period or such period has not expired and, to the knowledge of Parent, no circumstances exist that would reasonably be expected
to result in any such letter being revoked or not being reissued or a penalty under the Internal Revenue Service Closing Agreement
Program if discovered during an Internal Revenue Service audit or investigation. Except as has not had and would not reasonably
be expected to have, individually or in the aggregate, a Parent Material Adverse Effect,
each trust created under any such Parent Employee Plan is exempt from tax under Section 501(a) of the Code and has been so exempt
since its creation.
(c) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, since January 1, 2013,
each Parent Employee Plan has been maintained in compliance with its terms and all Applicable Law, including ERISA and the Code.
Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse
Effect, no claim (other than routine claims for benefits), action, suit, investigation or proceeding (including an audit) is pending
against or involves or, to Parent’s knowledge, is threatened against or reasonably expected to involve, any Parent Employee
Plan before any court or arbitrator or any Governmental Authority, including the Internal Revenue Service, the Department of Labor
or the PBGC. To the knowledge of Parent, since January 1, 2013, no events have occurred with respect to any Parent Employee Plan
that would reasonably be expected to result in the assessment of any excise taxes or penalties against Parent or any of its Subsidiaries,
except for events that have not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material
Adverse Effect.
(d) Neither Parent nor any of its Subsidiaries
has any current or projected liability for, and no Parent Employee Plan provides or promises, any post-employment or post-retirement
medical, dental, disability, hospitalization, life or similar benefits (whether insured or self-insured) to any director, officer,
employee or individual independent contractor (including any former director, officer, employee or individual independent contractor)
of Parent or any of its Subsidiaries (other than coverage mandated by Applicable Law).
(e) There has been no amendment to,
written interpretation of or announcement (whether or not written) by Parent or any of its Affiliates relating to, or making a
change in employee participation or coverage under, any Parent Employee Plan that would materially increase the expense of maintaining
such plan above the level of expense incurred in respect thereof for the fiscal year ended on the Parent Balance Sheet Date, except
as required in order to comply with Applicable Law.
Section 5.20. Labor Matters. (a)
Except as has not had or would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse
Effect, Parent and its Subsidiaries are, and since January 1, 2013 have been, in compliance with all Applicable Laws relating to
labor and employment, including those relating to labor management relations, wages, hours, overtime, employee classification,
discrimination, sexual harassment, civil rights, affirmative action, work authorization, immigration, safety and health, information
privacy and security, workers compensation, continuation coverage under group health plans, wage payment and the payment and withholding
of taxes.
(b) Neither Parent nor any of its Subsidiaries
is, or since January 1, 2013 has been, a party to or subject to, or is currently negotiating in connection with entering into,
any collective bargaining agreement, and, to Parent’s knowledge, there has not been any organizational campaign, card solicitation,
petition or other unionization activity seeking recognition of a collective bargaining unit relating to any director, officer,
employee or individual independent contractor of Parent of any of its Subsidiaries. Except as has not had and would not reasonably
be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, there are no unfair labor practice complaints
pending or, to Parent’s knowledge, threatened against Parent or any of its Subsidiaries before the National Labor Relations
Board or any other Governmental Authority or any current union representation questions involving any director, officer, employee
or individual independent contractor (including any former director, officer, employee or individual independent contractor) of
Parent or any of its Subsidiaries with respect to Parent or its Subsidiaries. There is no labor strike, slowdown, stoppage, picketing,
interruption
of work or lockout pending or,
to Parent’s knowledge, threatened against or affecting Parent or any of its Subsidiaries.
Section 5.21. Intellectual Property.
(a) Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material
Adverse Effect, none of the registrations (including patents and domain name registrations) and applications for registration for
registration for Owned Intellectual Property that is Parent Intellectual Property (the “Parent Registered IP”)
has lapsed, expired, been abandoned or been adjudged invalid or unenforceable, and, to the knowledge of Parent, all Parent Registered
IP is valid, enforceable and subsisting.
(b) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a (i) Parent Material Adverse Effect, Parent and its Subsidiaries
are the sole and exclusive owners of all Owned Intellectual Property included in Parent Intellectual Property and hold all of their
right, title and interest in and to all of the Parent Intellectual Property free and clear of all Liens (other than non-exclusive
licenses granted by Parent or one of its Subsidiaries in the ordinary course of business), (ii) to the knowledge of Parent, Parent’s
Owned Intellectual Property and Parent’s Licensed Intellectual Property constitutes all of the Intellectual Property necessary
to, or used or held for use in, the conduct of the respective businesses of Parent and its Subsidiaries as currently conducted,
and (iii) to the knowledge of Parent, there exist no material restrictions on the use of any of Parent’s Owned Intellectual
Property.
(c) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, (i) to the knowledge of
Parent, neither Parent nor any of its Subsidiaries nor the conduct of their respective businesses has infringed, misappropriated,
diluted or otherwise violated any Intellectual Property rights of any Third Party, (ii) there is no claim, action, suit, investigation
or proceeding pending or, to the knowledge of Parent, threatened against or affecting Parent or any of its Subsidiaries (A) alleging
that Parent or any of its Subsidiaries has infringed, misappropriated, diluted or otherwise violated any Intellectual Property
rights of any Third Party or (B) based upon, or challenging or seeking to deny or restrict, the rights of Parent or any Subsidiary
in any of Parent Intellectual Property, and (iii) to the knowledge of Parent, no Third Party has infringed, misappropriated, diluted
or otherwise violated any Parent Intellectual Property.
(d) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, (i) Parent and its Subsidiaries
have provided reasonable notice of its privacy and personal data collection and use policies on its websites and other customer
and public communications and Parent and its Subsidiaries have complied with such policies and all Applicable Law relating to (A)
the privacy of the users of Parent’s and its Subsidiaries’ respective products, services and websites and (B) the collection,
use, storage and disclosure of any personally-identifiable information (including personal health information) and other data or
information collected or stored by Parent or any of its Subsidiaries, (ii) there is no claim, action, suit, investigation or
proceeding pending or, to the knowledge of Parent, threatened against Parent or any of its Subsidiaries alleging any violation
of such policies (iii) neither this Agreement nor the consummation of the transactions contemplated hereby will violate any such
policy, and (iv) Parent and its Subsidiaries have taken commercially reasonable steps consistent with normal industry practice
to protect the types of information referred to in this Section 5.21(d) against loss and unauthorized access, use, modification,
disclosure or other misuse and, to the knowledge of Parent, there has been no unauthorized access, use, modification, disclosure
or other misuse of such data or information.
(e) Except as has not had and would
not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect, (i) Parent’s IT
Assets operate in accordance with their specifications and related documentation and perform in a manner that permits Parent and
its Subsidiaries to conduct their respective businesses as currently conducted, (ii) Parent and its Subsidiaries take commercially
reasonable actions, consistent with current industry standards, to protect the confidentiality, integrity and security of Parent’s
IT Assets (and all information and transactions stored or contained therein or transmitted thereby) against any unauthorized use,
access, interruption, modification or corruption, including the implementation of commercially reasonable data backup, disaster
avoidance and recovery procedures and business continuity procedures, and (iii) there has been no unauthorized use, access, interruption,
modification or corruption of Parent’s IT Assets (or any information or transactions stored or contained therein or transmitted
thereby).
Section 5.22. Environmental Matters.
Except as has not had and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse
Effect:
(a) no notice, notification, demand,
request for information, citation, summons or order has been received, no complaint has been filed, no penalty has been assessed,
and no claim, action, suit, proceeding or investigation (including a review) is pending or, to the knowledge of Parent, threatened
by any Governmental Authority or other Person relating to Parent or any of its Subsidiaries that relates to, or arises under, of
any Environmental Law, Environmental Permit or Hazardous Substance;
(b) Parent and its Subsidiaries are,
and since January 1, 2013 have been, in compliance with all Environmental Laws and all Environmental Permits and hold all applicable
Environmental Permits; and
(c) there are no liabilities or obligations
of Parent or any of its Subsidiaries of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or
otherwise arising under or relating to any Environmental Law, Environmental Permit or Hazardous Substance and there is no existing
condition, situation or set of circumstances that could reasonably be expected to result in any such liability or obligation.
Section 5.23. Antitakeover Statutes.
Assuming the representations and warranties set forth in Sections 4.27 and 4.30 are true and correct, no “control share acquisition,”
“fair price,” “moratorium” or other antitakeover laws enacted under U.S. state or federal laws apply to
this Agreement or any of the transactions contemplated hereby.
Section 5.24. Opinion of Financial
Advisor. The Board of Directors of Parent has received separate opinions of each of Citigroup Global Markets Inc. and Lazard
Frères & Co. LLC, financial advisors to Parent, to the effect that, as of the date of this Agreement, the Merger Consideration
to be paid by Parent pursuant to this Agreement is fair from a financial point of view to Parent.
Section 5.25. Finders’ Fees.
Except for Citigroup Global Markets Inc. and Lazard Frères & Co. LLC, there is no investment banker, broker, finder
or other intermediary that has been retained by or is authorized to act on behalf of Parent or any of its Subsidiaries who might
be entitled to any fee or commission from Parent or any of its Affiliates in connection with the transactions contemplated by this
Agreement.
Section 5.26. No Ownership of Company
Common Stock. Neither Parent nor any of its Subsidiaries beneficially owns, directly or indirectly, any shares of Company Common
Stock or other
securities convertible into, exchangeable
for or exercisable for shares of Company Common Stock and neither Parent nor any of its Subsidiaries has any rights to acquire
any shares of Company Common Stock (other than any such securities owned by Parent or any of its Subsidiaries in a fiduciary, representative
or other capacity on behalf of other Persons, whether or not held in a separate account). There are no voting trusts or other agreements
or understandings to which Parent or any of its Subsidiaries is a party with respect to the voting of the capital stock or other
equity interest of the Company or any of its Subsidiaries.
Section 5.27. Financing. (a) Parent
has delivered to the Company a complete and correct copy of a fully executed commitment letter from the Financing Sources (including
all exhibits, schedules, and annexes to such letters as and to the extent delivered to the Company on or prior to the date of this
Agreement, the “Debt Commitment Letter”), pursuant to which the Financing Sources have committed, upon the terms
and subject to the conditions set forth therein, to provide the debt financing described therein in connection with the transactions
contemplated hereby. The Debt Commitment Letter and any other debt commitment letter (including any replacement of the Debt Commitment
Letter in connection with any Alternative Financing) executed in accordance with Section 7.06, as replaced, amended, supplemented,
modified or waived in accordance with Section 7.06, including all exhibits, schedules, and annexes to such letters, are hereinafter
referred to together as the “Debt Commitment Letters.” The financing contemplated pursuant to the Debt Commitment
Letters is hereinafter referred to as the “Debt Financing.”
(b) As of the date of this Agreement,
the Debt Commitment Letters are in full force and effect and are legal, valid and binding obligations of Parent, and to the knowledge
of Parent, the other parties thereto, and enforceable in accordance with their respective terms against Parent, and to the knowledge
of Parent, each of the other parties thereto. All commitment fees required to be paid under the Debt Commitment Letters have been
paid in full or will be duly paid in full as and when due, and Parent, Merger Sub 1 and Merger Sub 2 have otherwise satisfied all
of the other items and conditions required to be satisfied by them pursuant to the terms of the Debt Commitment Letters on or prior
to the date of this Agreement. None of the Debt Commitment Letters have been amended, modified or terminated on or prior to the
date of this Agreement, no such amendment, modification or termination is contemplated as of the date of this Agreement and no
Debt Commitment Letter will be amended, modified or terminated by Parent, Merger Sub 1 or Merger Sub 2 except as consistent with
Section 7.06. As of the date of this Agreement, no event has occurred which, with or without notice, lapse of time or both, would
constitute a breach or default by Parent, Merger Sub 1 or Merger Sub 2 under any Debt Commitment Letter. None of Parent, Merger
Sub 1 or Merger Sub 2 is, as of the date of this Agreement, aware of any fact, occurrence or condition that makes any of the assumptions
or statements set forth in any Debt Commitment Letter inaccurate (assuming the accuracy of the Company’s representations
and warranties set forth in this Agreement) in any material respect, that would cause the commitments provided in the Debt Commitment
Letter to be terminated or ineffective or any of the conditions contained therein not to be met. The consummation of the Debt Financing
is subject to no conditions precedent other than those expressly set forth in the copies of the Debt Commitment Letters delivered
to the Company, and there are no contingencies that would permit the Financing Sources to reduce the total amount of the Debt Financing
other than those expressly set forth in the copies of the Debt Commitment Letters delivered to the Company. Except for fee letters
relating to fees with respect to the Debt Financing (redacted copies of which, removing only fee amounts, market “flex”
provisions and certain other terms (none of which concern or would adversely affect the amounts, availability, timing or conditionality
of the Debt Financing), have been provided to the Company on or prior to the date of this Agreement), there are no side letters
or other agreements, contracts or arrangements related
to the funding of the Debt Financing,
other than as expressly set forth in the Debt Commitment Letters delivered to the Company on or prior to the date of this Agreement.
As of the date of this Agreement, assuming no breach by the Company of its representations and warranties under this Agreement
(and cooperation and assistance by the Company as required by the terms of this Agreement) and no breach or default by the Company
of its obligations under this Agreement (in either case such that the conditions set forth in Section 9.01 or Section 9.02 would
fail to be satisfied), and based upon facts and events known by Parent as of the date of this Agreement, none of Parent, Merger
Sub 1 or Merger Sub 2 have any reason to believe that any of the conditions to the Debt Financing will not be satisfied or the
Debt Financing will not be consummated as contemplated in the Debt Commitment Letters on or prior to the Closing Date. The aggregate
proceeds of the Debt Financing, together with cash or cash equivalents held by Parent and the other sources of funds referenced
in the copies of the Debt Commitment Letters delivered to the Company on or prior to the date of this Agreement, as of the First
Merger Effective Time, will be sufficient to enable Parent to pay in cash all amounts required to be paid by them in cash in connection
with the transactions contemplated hereby, including the Merger Consideration and all payments, fees and expenses payable by them
related to or arising out of the consummation of the transactions contemplated by this Agreement.
Section 5.28. No Other Parent Representations
and Warranties. Except for the representations and warranties made by Parent in this Article 5 (as qualified by the applicable
items disclosed in the Parent Disclosure Schedule in accordance with Section 11.05 and the introduction to this Article 5), neither
Parent nor any other Person makes or has made any representation or warranty, expressed or implied, at law or in equity, with respect
to or on behalf of Parent or its Subsidiaries, their businesses, operations, assets, liabilities, financial condition, results
of operations, future operating or financial results, estimates, projections, forecasts, plans or prospects (including the reasonableness
of the assumptions underlying such estimates, projections, forecasts, plans or prospects) or the accuracy or completeness of any
information regarding Parent or its Subsidiaries or any other matter furnished or provided to the Company or made available to
the Company in any “data rooms”, “virtual data rooms”, management presentations or in any other form in
expectation of, or in connection with, this Agreement or the transactions contemplated hereby. Parent and its Subsidiaries disclaim
any other representations or warranties, whether made by Parent or any of its Subsidiaries or any of their respective Affiliates
or Representatives. Without limiting the generality of the foregoing, except for the representations and warranties made by Parent
in this Article 5 (as qualified by the applicable items disclosed in the Parent Disclosure Schedule in accordance with Section
11.05 and the introduction to this Article 5), neither Parent nor any other Person makes or has made any representation or warranty,
expressed or implied, at law or in equity, with respect to or on behalf of Parent or its Subsidiaries with respect to (a) the adequacy
or sufficiency of reserves, (b) the effect of the adequacy or sufficiency of reserves on any line item, asset, liability or equity
amount on any financial or other document, (c) whether or not reserves were determined in accordance with any actuarial, statutory,
regulatory or other standard, or (d) the collectability of any amounts under any reinsurance Contract. Parent acknowledges and
agrees that, except for the representations and warranties made by the Company in Article 4 (as qualified by the applicable items
disclosed in the Company Disclosure Schedule in accordance with Section 11.05 and the introduction to Article 4), neither the Company
nor any other Person is making or has made any representations or warranty, expressed or implied, at law or in equity, with respect
to or on behalf of the Company or its Subsidiaries, their businesses, operations, assets, liabilities, financial condition, results
of operations, future operating or financial results, estimates, projections, forecasts, plans or prospects (including the reasonableness
of the assumptions underlying such estimates, projections, forecasts, plans or prospects) or the accuracy or completeness of any
information regarding the Company or its Subsidiaries or any other matter furnished or provided to Parent or made available to
Parent in any “data
rooms,” “virtual data rooms,”
management presentations or in any other form in expectation of, or in connection with, this Agreement, or the transactions contemplated
hereby or thereby. Parent specifically disclaims that it is relying upon or has relied upon any such other representations or warranties
that may have been made by any Person, and acknowledges and agrees that the Company and its Affiliates have specifically disclaimed
and do hereby specifically disclaim any such other representations and warranties. Notwithstanding the foregoing, this Section
5.28 shall not limit Parent’s, Merger Sub 1’s, Merger Sub 2’s or the Company’s remedies in the case of
fraud.
Article
6
Covenants of the Company
The Company agrees that:
Section 6.01. Conduct of the Company.
From the date of this Agreement until the earlier of the First Merger Effective Time or the termination of this Agreement, except
(x) as prohibited or required by Applicable Law, (y) as set forth in Section 6.01 of the Company Disclosure Schedule, or (z) as
otherwise required or expressly contemplated by this Agreement, unless Parent shall otherwise consent (which consent shall not
be unreasonably withheld, conditioned or delayed), the Company shall, and shall cause each of its Subsidiaries to, conduct its
business in the ordinary course of business consistent with past practice and in compliance in all material respects with all Applicable
Laws and use its commercially reasonable efforts to preserve intact its business organization and relationships with customers,
members, suppliers, Providers, licensors, licensees and other Third Parties and keep available the services of its present officers
and employees; provided that no action or failure to take action by the Company or any of its Subsidiaries with respect
to matters specifically addressed by any provision of Section 6.01(a) through (s) shall constitute a breach under this sentence
unless such action or failure to take action would constitute a breach of such provision of Section 6.01(a) through (s), as applicable.
Without limiting the generality of the foregoing, except (x) as prohibited or required by Applicable Law, (y) as set forth in Section
6.01 of the Company Disclosure Schedule, or (z) as otherwise required or expressly contemplated by this Agreement, without Parent’s
prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed (other than with respect to Section
6.01(a), Section 6.01(c) or Section 6.01(d)), the Company shall not, and shall cause each of its Subsidiaries not to:
(a) adopt or propose any change to its
certificate of incorporation, bylaws or other organizational documents (whether by merger, consolidation or otherwise) (including
the Company Organizational Documents);
(b) (i) merge or consolidate with any
other Person, (ii) acquire (including by merger, consolidation, or acquisition of stock or assets) any interest in any corporation,
partnership, other business organization or any division thereof or any assets, securities or property, other than (A) acquisitions
of assets, securities or property in the ordinary course of business consistent with past practice in an amount not to exceed $125,000,000
in the aggregate for all such acquisitions, together with all capital contributions permitted by Section 6.01(h)(i)(B), (B) acquisitions
of securities under the Company’s investment portfolio consistent with the Company’s investment policy in effect as
of the date hereof and (C) transactions (1) solely among the Company and one or more of its wholly owned Subsidiaries or (2) solely
among the Company’s wholly owned Subsidiaries, or (iii) adopt a plan of complete or partial liquidation, dissolution, recapitalization
or restructuring;
(c) (i) split, combine or reclassify
any shares of its capital stock (other than transactions (1) solely among the Company and one or more of its wholly owned
Subsidiaries or (2) solely among the Company’s wholly owned Subsidiaries), (ii) amend any term or alter any rights of any
of its outstanding equity securities, (iii) declare, set aside or pay any dividend or make any other distribution (whether in cash,
stock, property or any combination thereof) in respect of any shares of its capital stock or other securities, other than (A) in
the case of the Company, regular cash dividends in the ordinary course of business consistent with past practice in an amount not
to exceed $0.29 per share of Company Common Stock per quarter (appropriately adjusted to reflect any stock dividends, subdivisions,
splits, combinations or other similar events relating to Company Common Stock), or (B) dividends or distributions by a Subsidiary
of the Company to the Company or a wholly owned Subsidiary of the Company, or (iv) redeem, repurchase, cancel or otherwise
acquire or offer to redeem, repurchase, or otherwise acquire any of its securities or any securities of any Subsidiary of the Company,
other than repurchases of shares of Company Common Stock in connection with the exercise of Company Stock Options or the vesting
or settlement of Company RSU Awards or Company PSU Awards (including in satisfaction of any amounts required to be deducted or
withheld under Applicable Law), in each case outstanding as of the date of this Agreement in accordance with the present terms
of such Company Stock Options, Company RSU Awards and Company PSU Awards or granted after the date of this Agreement to the extent
permitted by this Agreement;
(d) issue, deliver or sell, or authorize
the issuance, delivery or sale of, any shares of its capital stock or any securities convertible into or exercisable for, or any
rights, warrants or options to acquire, any such capital stock or any such convertible securities, other than (i) the issuance
of any shares of Company Common Stock upon the exercise of Company Stock Options, the vesting or settlement of shares of Company
RSU Awards or Company PSU Awards that are outstanding on the date of this Agreement in accordance with the present terms of such
Company Stock Options, Company RSU Awards and Company PSU Awards or are granted after the date of this Agreement to the extent
permitted by this Agreement, (ii) with respect to capital stock or securities of any Subsidiary of the Company, in connection with
transactions (A) solely among the Company and one or more of its wholly owned Subsidiaries or (B) solely among the Company’s
wholly owned Subsidiaries, (iii) the grant of Company Equity Awards to employees of the Company or any of its Subsidiaries in connection
with the Company’s annual equity award grant procedures or in connection with promotions or new hires, in each case, conducted
in the ordinary course of business and consistent with past practice, including with respect to timing; provided that any
such grants issued under this clause (iii) shall be subject to the limitations set forth in Section 6.01(d)(iii) of the Company
Disclosure Schedule, or (iv) the grant of Company Equity Awards to non-employee directors in the ordinary course of business, consistent
with past practice;
(e) authorize, make or incur any capital
expenditures or obligations or liabilities in connection therewith, except (i) for any capital expenditures pursuant to projects
contemplated (A) in the capital expenditure budget of the Company and its Subsidiaries for the 2015 Fiscal Year as made available
to Parent prior to the date hereof, or (B) in any subsequent annual capital expenditure budget of the Company that is prepared
in the ordinary course of business consistent with past practice by the Company and approved by the Company’s Board of Directors,
provided that the aggregate amount of capital expenditures authorized to be made under any such subsequent budget may not
be any more than 5% higher than the amount thereof authorized under the capital expenditure budget for the 2015 Fiscal Year, and
(ii) for any other capital expenditures that are less than $625,000 individually or $10,000,000 in the aggregate;
(f) sell, lease, license or otherwise
dispose of any Subsidiary or any division thereof or of the Company or any assets, securities or property, other than (i) in the
ordinary course of business consistent with past practice for fair market value in an amount not to exceed $30,000,000 in the aggregate,
(ii) dispositions of securities under the Company’s investment portfolio consistent with the Company’s investment policy
in effect as of the date hereof, or (iii) transactions (A) solely among the Company and one or more of its wholly owned Subsidiaries
or (B) solely among the Company’s wholly owned Subsidiaries;
(g) sell, assign, license, sublicense,
abandon, allow to lapse, transfer or otherwise dispose of, or create or incur any Lien (other than a Permitted Lien) on, any Owned
Intellectual Property or Licensed Intellectual Property, other than in the ordinary course of business consistent with past practice
(i) pursuant to non-exclusive licenses or (ii) for the purpose of disposing of obsolete or worthless assets;
(h) (i) make any material loans, advances
or capital contributions to any other Person, other than (A) loans, advances or capital contributions (1) by the Company to one
or more of its wholly owned Subsidiaries or (2) by any Subsidiary of the Company to the Company or any wholly owned Subsidiary
of the Company, (B) capital contributions required under the terms of Contracts in effect as of the date hereof in an amount not
to exceed $125,000,000 in the aggregate for all such capital contributions, together with all acquisitions permitted by Section
6.01(b)(ii)(A), (C) extensions of loans or advances to Providers in the ordinary course of business consistent with past practice
or (D) extensions of loans or advances to business associates other than Providers in the ordinary course of business consistent
with past practice, so long as the amount of such loans and advances outstanding at any time does not exceed $20,000,000 in the
aggregate (it being understood and agreed that upon repayment of any loan or advance permitted by this clause (D), the amount of
such repayment shall be available for future loans or advances pursuant to this clause (D), subject to the foregoing restriction
on the aggregate amount of all such loans or advances that may be outstanding at any time) or (ii) incur, assume, guarantee or
repurchase any indebtedness for borrowed money, other than additional borrowings under the Credit Agreement in accordance with
the terms thereof and Section 6.01(h) of the Company Disclosure Schedule (provided that all such indebtedness for borrowed
money permitted to be incurred in this clause (ii) must be prepayable at any time by the Company without penalty);
(i) create or incur any Lien (except
for a Permitted Lien) on any material asset;
(j) (i) enter into any Company Material
Contract (including by amendment of any Contract that is not a Company Material Contract such that such Contract becomes a Company
Material Contract), other than in the ordinary course of business consistent with past practice (except that no Company Material
Contract pursuant to clause (vi) of Section
4.18(a) shall be entered into), or (ii) terminate, renew, extend or amend in any material respect any Company Material Contract
or waive any material right thereunder, other than in the ordinary course of business consistent with past practice;
(k) terminate, suspend, abrogate, amend
or modify (i) any certificate of authority to conduct business as an insurance company or health maintenance organization issued
by the applicable insurance or health regulatory Governmental Authority or (ii) any other material Company Permit, in each case
of (i) and (ii) in a manner material and adverse to the Company and its Subsidiaries, taken as a whole;
(l) except as required by Applicable
Law or Company Employee Plans or other contracts as in effect as of the date hereof, (i) grant any change in control, severance
or termination pay to (or amend any existing arrangement with) any of their respective directors, officers, employees or individual
independent contractors (including former directors, officers, employees or individual independent
contractors) other than severance
or termination pay in the ordinary course of business consistent with past practice for terminated employees in exchange for a
general release of claims or other customary covenants, (ii) enter into any employment, deferred compensation or other similar
agreement (or any amendment to any such existing agreement) with any of their respective current or former directors, executive
officers (as defined in the 1934 Act), employees or individual independent contractors, other than offers letters (and related
compensation arrangements set forth in such offer letters) with any newly hired directors, employees or individual independent
contractors of the Company who are not considered to be executive officers (as defined in the 1934 Act) that are entered into in
the ordinary course of business consistent with past practice, (iii) establish, adopt or amend any Company Employee Plan or labor
agreement, other than in the ordinary course of business consistent with past practice (provided, for the avoidance of doubt,
that this clause (iii) shall not prohibit the Company from issuing 2016 cash incentive awards under its existing incentive plans
and arrangements in the ordinary course of business consistent with past practice, subject to the limitations set forth in clause
(iv) below) or any immaterial amendment that would not increase the cost to the Company or any of its Subsidiaries of maintaining
such Company Employee Plan, or (iv) increase the compensation, bonus or other benefits payable to any of their respective directors,
officers, employees or individual independent contractors (including former directors, officers, employees or individual independent
contractors), other than increases in base compensation and bonus to current directors, individual independent contractors or employees
who are not considered to be executive officers (as defined in the 1934 Act) in the ordinary course of business consistent with
past practice (it being understood that the amount of bonus actually paid may be higher or lower than prior years based on actual
performance and such payment shall not be considered an increase) and increases in employee welfare benefits in the ordinary course
of business consistent with past practice for employees generally; provided that any such base compensation increases shall
not in the aggregate exceed 3.5% of the aggregate base compensation levels as of the date hereof of the Company’s directors
and employees who are not considered to be executive officers (as defined in the 1934 Act) (with those base salary increases previously
disclosed to Parent, which were approved in the ordinary course of business consistent with past practice prior to the date hereof
but are not yet effective as of the date hereof, to be excluded from being counted against such limitation);
(m) make any material change in any
method of financial or statutory accounting or financial or statutory accounting principles or practice, except for any such change
required by reason of (or, in the reasonable good-faith judgment of the Company, advisable under) a change in GAAP, SAP, ASOP or
Regulation S-X under the 1934 Act (“Regulation S-X”), as approved by its independent public accountants;
(n) make any material change in investment,
hedging, underwriting or claims administration principles or practices or in methodologies for estimating and providing for medical
costs and other liabilities, in each case with respect to the Company or any of its “significant subsidiaries” (as
defined in Rule 102(w) of Regulation S-X), except, to the extent applicable, for any such changes required by reason of a change
in GAAP, SAP, ASOP or Regulation S-X, as approved by its independent public accountants;
(o) (i) make or change any material
Tax election; (ii) change any annual Tax accounting period; (iii) adopt or change any material method of Tax accounting; (iv) enter
into any material closing agreement with respect to Taxes; or (v) settle or surrender any material Tax claim, audit or assessment;
(p) settle or compromise, or propose
to settle or compromise, any claim, action, suit, investigation or proceeding involving or against the Company or any of its Subsidiaries,
other than (i) in the ordinary course of business consistent with past practice, including in connection with the processing
and paying of claims to members
or Providers or risk sharing arrangements with Providers (provided that any individual settlement or compromise or any series
of related settlements or compromises involving payments by the Company and its Subsidiaries in excess of $15,000,000, other than
any such settlements or compromises with Providers that do not relate to sequestration matters, shall not be deemed to be in the
ordinary course of business), or (ii) involving only a monetary payment by the Company or any of its Subsidiaries in an amount
not to exceed $5,000,000 individually or $20,000,000 in the aggregate;
(q) reduce in any material respect the
budget or scope of the Company’s and its Subsidiaries’ program for, or otherwise reduce in any material respect the
resources or efforts specifically dedicated by the Company and its Subsidiaries to, (i) the maintenance and improvement of their
respective Medicare star ratings, or (ii) retrospective chart review, coding audits or the collection of prospective home assessments
or patient assessment forms;
(r) (i) commence doing business outside
of the U.S. and its territories, or (ii) offshore any material service to a jurisdiction other than the U.S. and its territories;
or
(s) agree, commit or propose to do any
of the foregoing.
Section 6.02. No Solicitation by the
Company. (a) From the date of this Agreement until the earlier of the First Merger Effective Time or the termination
of this Agreement, except as otherwise set forth in this Section 6.02, the Company shall not, and shall cause its Subsidiaries
not to, and shall use its reasonable best efforts to cause its and its Subsidiaries’ officers, directors, employees, investment
bankers, attorneys, accountants, consultants and other agents, advisors and representatives (collectively, “Representatives”)
not to, directly or indirectly, (i) solicit, initiate or take any action to knowingly facilitate or knowingly encourage the submission
of any Company Acquisition Proposal, (ii) enter into or participate in any discussions or negotiations with, furnish any information
relating to the Company or any of its Subsidiaries or afford access to the business, properties, assets, books or records of the
Company or any of its Subsidiaries to, otherwise cooperate in any way with, or knowingly assist, participate in, knowingly facilitate
or knowingly encourage any effort by, any Third Party that the Company knows is seeking to make, or has made, a Company Acquisition
Proposal, (iii) (A) fail to make or withdraw or qualify, amend or modify in any manner adverse to Parent, the Company Board Recommendation,
(B) fail to include the Company Board Recommendation in the Joint Proxy Statement/Prospectus or (C) recommend, adopt or approve
or publicly propose to recommend, adopt or approve any Company Acquisition Proposal (any of the foregoing in this clause (iii),
a “Company Adverse Recommendation Change”), (iv) take any action to make any “moratorium,” “control
share acquisition,” “fair price,” “supermajority,” “affiliate transactions” or “business
combination statute or regulation” or other similar anti-takeover laws and regulations of the State of Delaware, including
Section 203 of the Delaware Law, inapplicable to any Third Party or Company Acquisition Proposal, (v) approve any transaction
(other than the transactions contemplated by this Agreement) under, or any Person becoming a “related company” under,
the Eleventh Article of the Restated Certificate of Incorporation of the Company as in effect on the date hereof, or take any other
action to make any other antitakeover provision in the Restated Certificate of Incorporation of the Company inapplicable to any
Third Party or Company Acquisition Proposal or (vi) fail to enforce or grant any waiver or release under any standstill or
similar agreement with respect to any class of equity securities of the Company or any of its Subsidiaries unless the Board of
Directors of the Company determines after consulting with its outside legal counsel that the failure to waive such provision would
be inconsistent with its fiduciary duties under Applicable Law (provided that the obligation not to fail to enforce any
such standstill or
similar agreement under this Section 6.02(a)(vi)
shall apply with respect to known breaches of such agreements only).
(b) Notwithstanding the foregoing, if
at any time prior to the receipt of the Company Stockholder Approval (the “Company Approval Time”) (and in no
event after the Company Approval Time), the Board of Directors of the Company receives a bona fide written Company Acquisition
Proposal made after the date hereof which has not resulted from a violation of this Section 6.02, the Board of Directors of the
Company, directly or indirectly through its Representatives, may (x) contact the Third Party that has made such Company Acquisition
Proposal in order to ascertain facts or clarify terms for the sole purpose of the Board of Directors of the Company informing itself
about such Company Acquisition Proposal and such Third Party and (y) subject to compliance with this Section 6.02(b), Section 6.02(c)
and Section 6.02(e), (i) engage in negotiations or discussions with any Third Party that, subject to the Company’s compliance
with Section 6.02(a), has made after the date of this Agreement a Company Superior Proposal or an unsolicited bona fide
written Company Acquisition Proposal that the Board of Directors of the Company determines in good faith, after consultation with
its financial advisor and outside legal counsel, is reasonably likely to lead to a Company Superior Proposal, (ii) furnish to such
Third Party and its Representatives and financing sources nonpublic information relating to the Company or any of its Subsidiaries
pursuant to (x) a confidentiality agreement between the Company and such Third Party in existence on or prior to the date hereof
or (y) a confidentiality agreement with confidentiality terms in the aggregate no less favorable to the Company than those contained
in the Confidentiality Agreement, a copy of which shall be provided, promptly after its execution, to Parent for informational
purposes; provided that all such non-public information (to the extent that such information has not been previously provided
or made available to Parent) is provided or made available to Parent, as the case may be, substantially concurrently with the time
it is provided or made available to such Third Party, and (iii) following receipt of a Company Superior Proposal after the date
of this Agreement, make a Company Adverse Recommendation Change, but in each case referred to in the foregoing clauses (i) through
(iii) only if the Board of Directors of the Company determines in good faith, after consultation with the Company’s outside
legal counsel and financial advisor, that the failure to take such action would be reasonably likely to be inconsistent with its
fiduciary duties under Applicable Law. Nothing contained herein shall prevent the Board of Directors of the Company from (x) complying
with Rule 14e-2(a) under the 1934 Act with regard to a Company Acquisition Proposal, so long as any action taken or statement made
to so comply is consistent with this Section 6.02; or (y) making any required disclosure to the stockholders of the Company if
the Board of Directors of the Company determines in good faith, after consultation with outside legal counsel, that the failure
to take such action would be reasonably likely to be inconsistent with Applicable Law, provided that any Company Adverse
Recommendation Change involving or relating to a Company Acquisition Proposal may only be made in accordance with the provisions
of Section 6.02(b), Section 6.02(c) and Section 6.02(e). For the avoidance of doubt, a “stop, look and listen” disclosure
or similar communication of the type contemplated by Rule 14d-9(f) under the 1934 Act shall not be a Company Adverse Recommendation
Change.
(c) In addition to the requirements
set forth in Section 6.02(b), the Board of Directors of the Company shall not
take any of the actions referred to in clauses (i) through (iii)
of Section 6.02(b) unless the Company shall have first delivered to Parent written
notice advising Parent that it intends to take such action, and the Company shall continue to advise Parent, on a current basis,
after taking such action of the status and material terms of any discussions and negotiations with the applicable Third Party.
In addition, the Company shall notify Parent promptly (but in no event later than twenty-four (24) hours) after receipt by the
Company (or any of its Representatives) of any Company Acquisition Proposal, any
indication that a Third Party is
considering making a Company Acquisition Proposal or any request for information relating to the Company or any of its Subsidiaries
or for access to the business, properties, assets, books or records of the Company or any of its Subsidiaries by any Third Party
that, to the knowledge of the Company or any member of its Board of Directors, is considering making, is reasonably likely to make
or has made, a Company Acquisition Proposal, which notice shall be provided in writing and shall identify the Third Party making,
and the material terms and conditions of, any such Company Acquisition Proposal, indication or request (including any material
changes thereto). The Company shall keep Parent fully informed, on a current basis, of the status and details of any such Company
Acquisition Proposal, indication or request (including any changes thereto) and shall promptly (but in no event later than twenty-four
(24) hours after receipt) provide to Parent copies of all material correspondence and written materials sent or provided to the
Company or any of its Subsidiaries that describes any terms or conditions of any Company Acquisition Proposal (as well as written
summaries of any material oral communications addressing such matters).
(d) Notwithstanding anything in this
Agreement to the contrary, at any time prior to the Company Approval Time (and in no event after the Company Approval Time), the
Board of Directors of the Company may effect a Company Adverse Recommendation Change involving or relating to a Company Intervening
Event if the Board of Directors of the Company determines in good faith, after consultation with its outside legal counsel, that
the failure to take such action would be reasonably likely to be inconsistent with its fiduciary duties under Applicable Law; provided
that (i) the Company shall (A) promptly notify Parent in writing of its intention to take such action and (B) negotiate in
good faith with Parent for three (3) Business Days following such notice regarding revisions to the terms of this Agreement proposed
by Parent, and (ii) the Board of Directors of the Company shall not effect any Company Adverse Recommendation Change involving
or relating to a Company Intervening Event unless, after the three (3) Business Day period described in the foregoing clause (B),
the Board of Directors of the Company determines in good faith, after consultation with its outside legal counsel, that the failure
to take such action would be reasonably likely to be inconsistent with its fiduciary duties under Applicable Law.
(e) Without limiting or affecting Section
6.02(a), Section 6.02(b) or Section 6.02(c), the Board of Directors of the Company shall not make a Company Adverse Recommendation
Change involving or relating to a Company Superior Proposal unless (i) the Company promptly notifies Parent, in writing at least
three (3) Business Days before taking such action, that it intends to take such action, which notice attaches the most current
version of any proposed agreement or a detailed summary of all material terms of such Company Superior Proposal and the identity
of the offeror, (ii) if requested by Parent, during such three (3) Business Day period, the Company and its Representatives have
discussed and negotiated in good faith with Parent regarding any proposal by Parent to amend the terms of this Agreement in response
to such Company Superior Proposal and (iii) after such three (3) Business Day period, the Board of Directors of the Company determines
in good faith, taking into account any proposal by Parent to amend the terms of this Agreement, that such Company Acquisition Proposal
continues to constitute a Company Superior Proposal (it being understood and agreed that in the event of any amendment to the financial
terms or other material terms of any such Company Superior Proposal, a new written notification from the Company consistent with
that described in clause (i) of this Section 6.02(e) shall be required and a new notice period under clause (i) of this Section
6.02(e) shall commence, during which notice period the Company shall be required to comply with the requirements of this Section
6.02(e) anew, except that such new notice period shall be for two (2) Business Days (as opposed to three (3) Business Days)). After
delivery of such written notice pursuant to the immediately preceding sentence, the Company shall promptly keep Parent informed
of all material developments affecting the material
terms of any such Company Superior
Proposal (and the Company shall provide Parent with copies of any additional written materials received that relate to such Company
Superior Proposal).
(f) “Company Superior Proposal”
means any bona fide, written Company Acquisition Proposal (other than a Company Acquisition Proposal which has resulted
from a violation of this Section 6.02) (with all references to “20%” in the definition of Company Acquisition
Proposal being deemed to be references to “50%”) on terms that the Board of Directors of the Company determines in
good faith, after consultation with its financial advisor and outside legal counsel, and taking into account all the terms and
conditions of the Company Acquisition Proposal that the Board of Directors of the Company considers to be appropriate (including
the identity of the Person making the Company Acquisition Proposal and the expected timing and likelihood of consummation, any
governmental or other approval requirements (including divestitures and entry into other commitments and limitations), break-up
fees, expense reimbursement provisions, conditions to consummation and availability of necessary financing), would result in a
transaction (i) that if consummated, is more favorable to the Company’s stockholders from a financial point of view (taking
into account, among other items, the tax attributes of such transaction) than the Mergers (taking into account any proposal by
Parent to amend the terms of this Agreement), (ii) that is reasonably capable of being completed on the terms proposed, taking
into account the identity of the Person making the Company Acquisition Proposal, any approval requirements and all other financial,
regulatory, legal and other aspects of such Company Acquisition Proposal and (iii) for which financing, if a cash transaction (whether
in whole or in part), is then fully committed in a manner comparable to Parent’s, Merger Sub 1’s and Merger Sub 2’s
financing (or which is reasonably determined to be available by the Board of Directors of the Company).
(g) “Company Intervening Event”
means any material event, change, effect, development or occurrence occurring or arising after the date of this Agreement that
(i) was not known or reasonably foreseeable, or the material consequences of which were not known or reasonably foreseeable, in
each case to the Board of Directors or executive officers of the Company as of or prior to the date of this Agreement, and (ii)
does not relate to or involve any Company Acquisition Proposal; provided that (A) in no event shall any action taken by
either party pursuant to the affirmative covenants set forth in Section 8.02, or the consequences of any such action, constitute,
be deemed to contribute to or otherwise be taken into account in determining whether there has been a Company Intervening Event,
and (B) in no event shall any event, change, effect, development or occurrence that would fall within any of the exceptions to
the definition of “Parent Material Adverse Effect” constitute, be deemed to contribute to or otherwise be taken into
account in determining whether there has been a Company Intervening Event.
(h) The Company shall, and shall cause
its Subsidiaries to, and shall use its reasonable best efforts to cause its and its Subsidiaries’ respective Representatives
to, cease immediately and cause to be terminated any and all existing activities, discussions or negotiations, if any, with any
Third Party conducted prior to the date of this Agreement with respect to any Company Acquisition Proposal and shall use its reasonable
best efforts to cause any such Party (or its agents or advisors) in possession of confidential information about the Company that
was furnished by or on behalf of the Company to return or destroy all such information.
(i) Notwithstanding (i) any Company
Adverse Recommendation Change, (ii) the making of any Company Acquisition Proposal or (iii) anything in this Agreement to the contrary,
until termination of this Agreement (x) in no event may the Company or any of its Subsidiaries (A) enter into any agreement in
principle, letter of intent, term sheet, merger agreement, acquisition agreement, option agreement, joint venture agreement, partnership
agreement or other similar instrument constituting or relating to a Company Acquisition Proposal, (B) except as required by Applicable
Law, make, facilitate
or provide information in connection
with any SEC or other Filings in connection with the transactions contemplated by any Company Acquisition Proposal or (C) seek
any Consents in connection with the transactions contemplated by any Company Acquisition Proposal and (y) the Company shall otherwise
remain subject to all of its obligations under this Agreement.
Section 6.03. Financing Assistance.
Prior to the Closing, the Company shall, and shall cause its Subsidiaries to, at the sole expense of Parent, use its and their
commercially reasonable efforts to provide such cooperation as may be reasonably requested by Parent in connection with the arrangement
of the Debt Financing (provided that such requested cooperation does not unreasonably interfere with the ongoing operations
of the Company and its Subsidiaries). Without limiting the generality of the foregoing sentence, prior to the Closing, the Company
shall, and shall cause its Subsidiaries to, at the sole expense of Parent, use its and their commercially reasonable efforts to:
(i) as promptly as reasonably practicable provide information (financial or otherwise) relating to Company to the Financing Sources
(including information to be used in the preparation of an information package regarding the business, operations, financial projections
and prospects of Parent and the Company customary or reasonably necessary for the completion of such financing) to the extent reasonably
requested by Parent to prepare customary offering or information documents to be used for the completion of the Debt Financing,
(ii) cooperate with the marketing efforts of Parent and the Financing Sources, including participating in a reasonable number of
meetings, due diligence sessions and road shows, at times and at locations reasonably acceptable to the Company, (iii) reasonably
assist in preparing customary offering memoranda, rating agency presentations, lender presentations, financial statements (including
pro forma financial statements, all of which unaudited financial statements shall have been reviewed by the Company’s independent
accountants as provided in Statement on Accounting Standards No. 100), private placement memoranda, prospectuses and other similar
documents, including delivery of (A) audited consolidated balance sheets and related audited statements of operations, stockholders’
equity and cash flows of the Company for each of the three fiscal years most recently ended at least 60 days prior to the Closing
Date (and audit reports for such financial statements shall not be subject to any “going concern” qualifications) and
(B) unaudited consolidated balance sheets and related unaudited statements of operations, stockholders’ equity and cash flows
of the Company for each subsequent fiscal quarter ended at least 40 days prior to the Closing Date, (iv) make available, on a customary
and reasonable basis and upon reasonable notice, appropriate personnel, documents and information relating to the Company and its
Subsidiaries, in each case, as may be reasonably requested by Parent, or as may be requested by the SEC in connection with the
completion of the financing, (v) obtain any necessary consents from the Company’s independent public accounting firm
in connection with any filings with the SEC, (vi) obtain customary financing accountants’ comfort letters and consents of
accountants for use of their reports in any materials relating to the financing and in connection with any filings required to
be made by Parent pursuant to the 1933 Act or the 1934 Act (including the Registration Statement), (vii) subject to customary confidentiality
provisions, provide customary authorization letters to the Financing Sources authorizing the distribution of information to prospective
lenders or investors and (viii) obtain customary payoff letters and instruments of discharge to be delivered at Closing to allow
for the payoff, discharge and termination in full on the Closing Date of the Credit Agreement. Notwithstanding the foregoing, (1)
neither the Company nor any of its Subsidiaries shall be required to pay any commitment or other similar fee or incur prior to
the Closing any other liability or obligation in connection with the Debt Financing, (2) none of the Company, its Subsidiaries
or their respective officers, directors or employees shall be required to execute or enter into or perform any agreement with respect
to the Debt Financing that is not contingent upon the Closing occurring or that would be effective prior to the Closing (other
than authorization letters contemplated by clause (vii) of this Section 6.03 and for the avoidance of doubt, the boards of directors
or other
equivalent governing bodies of Parent, Merger
Sub 1, Merger Sub 2, the Initial Surviving Corporation and/or the Surviving Company shall enter into or provide any resolutions,
consents, approvals or other closing arrangements on behalf of the Company and its Subsidiaries as may be required by the Financing
Sources pursuant to the Debt Commitment Letter at, or as of, the Closing), and (3) nothing shall obligate the Company or any of
its Subsidiaries to provide, or cause to be provided, any legal opinion by its counsel, or to provide, or cause to be provided,
any information or take, or cause to be taken, any action to the extent it would result in a violation of Applicable Law or loss
of any privilege. Parent shall, promptly upon request by the Company, reimburse the Company for all reasonable and documented out-of-pocket
costs and expenses (including reasonable attorneys’ fees) incurred by the Company or any of its Subsidiaries in satisfying
its obligations under this Section 6.03. Parent, Merger Sub 1 and Merger Sub 2 shall, on a joint and several basis, indemnify and
hold harmless the Company and its Subsidiaries and their respective Representatives from and against any and all losses, claims,
damages, liabilities, costs, reasonable attorneys’ fees, judgments, fines, penalties and amounts paid in settlement (including
all interest, assessments and other charges paid or payable in connection with or in respect of any thereof) suffered or incurred
in connection with any financing or other securities offering of Parent and/or its Subsidiaries or any assistance or activities
provided in connection therewith.
Section 6.04. Transition. (a)
In order to facilitate the integration and the operations of the Company and Parent and their respective Subsidiaries and to permit
the coordination of their related operations on a timely basis after the First Merger Effective Time, and in an effort to accelerate
to the earliest time possible after the First Merger Effective Time the realization of synergies, operating efficiencies and other
benefits expected to be realized as a result of the Mergers, upon Parent’s request, the parties shall establish a transition
planning team of at least six members (the “Transition Team”) comprised of an equal number of representatives
of Parent and the Company, which shall be responsible for facilitating a transition and integration planning process to ensure
the successful combination of the operations of Parent and the Company. Upon Parent’s request, subject to Applicable Law,
the Transition Team shall be responsible for developing and implementing a detailed action plan for the combination of the businesses
from and after the First Merger Effective Time and shall (i) confer on a regular and continued basis regarding the status of the
transition and integration planning process, (ii) communicate and consult with its members with respect to (x) the manner in which
the respective businesses will be conducted from and after the First Merger Effective Time and (y) the manner in which the Company’s
accounting, investment, hedging, underwriting and claims administration policies and practices will be conformed to those of Parent
from and after the First Merger Effective Time and (iii) coordinate human resources integration.
(b) Between the date of this Agreement
and the Closing Date, (i) (A) Parent intends to implement retention and/or incentive programs for employees of Parent and of Company
(which programs, for the avoidance of doubt, may be implemented in Parent’s sole discretion), under which programs employees
of the Company will be considered for participation based on substantially the same factors and in substantially the same manner
as similarly situated employees of Parent and (B) at the reasonable request of Parent, the Company shall cooperate in good faith
with Parent to establish and implement Company-sponsored employee retention and transition incentive programs designed to encourage
the retention and performance of employees and groups of employees of the Company and its Subsidiaries who are mutually identified
by the Company and Parent, and (ii) the Company shall, and shall cause its Subsidiaries to, coordinate with Parent with respect
to the formulation and dissemination of internal and external communications and announcements relating to the impact on employees
of the Company and its Subsidiaries of the Mergers and the integration of the operations of the Company with those of Parent. Notwithstanding
anything to the contrary in this Agreement, the adoption of a retention
and transition incentive program
described above in this Section 6.04(b) pursuant to the mutual written agreement of the Company and Parent, and the obligations
and liabilities relating to such agreed program, shall be disregarded for purposes of determining the completeness, truthfulness
and accuracy of the representations of the Company set forth in Article 4 and for purposes of determining the Company’s compliance
with its covenants under Section 6.01.
Section 6.05. Indenture. The Company
shall use its reasonable best efforts to timely provide or cause to be provided, in accordance with the provisions of the indenture
relating to the Company’s 6.30% Senior Notes due 2018, 7.20% Senior Notes due 2018, 8.15% Senior Notes due 2038, 3.150% Senior
Notes due 2022, 4.625% Senior Notes due 2042, 2.625% Senior Notes due 2019, 3.850% Senior Notes due 2024 and 4.950% Senior Notes
due 2044 (the “Indenture”), to the trustee under the Indenture, any notices, announcements, certificates or
legal opinions required by the Indenture to be provided in connection with the Mergers prior to the First Merger Effective Time.
Parent and its counsel shall be given a reasonable opportunity to review and comment on any such notice, announcement, certificate
or legal opinion, in each case before such document is provided to such trustee, and the Company shall give reasonable and good
faith consideration to any comments made by Parent and its counsel.
Section 6.06. 280G Calculation.
As soon as practicable, but in no event later than thirty (30) Business Days after the date hereof, the Company will make available
to Parent true and correct copies of preliminary Section 280G calculations (based on the assumptions set forth in the applicable
calculations) with respect to each “disqualified individual” (within the meaning of Section 280G of the Code)
who is reasonably likely to receive payments or benefits in connection with the transactions contemplated by this Agreement that
would not be deductible under Section 280G of the Code.
Article
7
Covenants of Parent
Parent agrees that:
Section 7.01. Conduct of Parent.
From the date of this Agreement until the earlier of the First Merger Effective Time or the termination of this Agreement, except
(x) as prohibited or required by Applicable Law, (y) as set forth in Section 7.01 of the Parent Disclosure Schedule, or (z) as
otherwise required or expressly contemplated by this Agreement, unless the Company shall otherwise consent (which consent shall
not be unreasonably withheld, conditioned or delayed), Parent shall, and shall cause each of its Subsidiaries to, conduct its business
in the ordinary course of business consistent with past practice and in compliance in all material respects with all Applicable
Laws and use its commercially reasonable efforts to preserve intact its business organization and relationships with customers,
members, suppliers, Providers, licensors, licensees and other Third Parties and keep available the services of its present officers
and employees; provided that no action or failure to take action by Parent or any of its Subsidiaries with respect to matters
specifically addressed by any provision of Section 7.01(a) through (f) shall constitute a breach under this sentence unless such
action or failure to take action would constitute a breach of such provision of Section 7.01(a) through (f), as applicable. Without
limiting the generality of the foregoing, except (x) as prohibited or required by Applicable Law, (y) as set forth in Section 7.01
of the Parent Disclosure Schedule, or (z) as otherwise required or expressly contemplated by this Agreement, without the Company’s
prior written consent (which consent
shall not be unreasonably withheld, conditioned
or delayed), Parent shall not, and shall cause each of its Subsidiaries not to:
(a) adopt or propose any change to the
Parent Organizational Documents in a manner that would be materially adverse to the Company’s stockholders (whether by merger,
consolidation or otherwise);
(b) acquire (including by merger, consolidation,
or acquisition of stock or assets) any interest in any corporation, partnership, other business organization or any division thereof
or any assets, securities or property, other than (A) acquisitions of any of the foregoing in an amount not to exceed $1,000,000,000
individually or $5,000,000,000 in the aggregate, (B) acquisitions of securities under Parent’s investment portfolio consistent
with Parent’s investment policy and (C) transactions (1) solely among Parent and one or more of its wholly owned Subsidiaries
or (2) solely among Parent’s wholly owned Subsidiaries, or (iii) adopt a plan of complete or partial liquidation or dissolution
with respect to Parent, Merger Sub 1 or Merger Sub 2;
(c) (i) split, combine or reclassify
any shares of its capital stock (other than transactions (1) solely among Parent and one or more of its wholly owned Subsidiaries
or (2) solely among Parent’s wholly owned Subsidiaries), (ii) amend any term or alter any rights of any of its outstanding
equity securities, (iii) declare, set aside or pay any dividend or make any other distribution (whether in cash, stock, property
or any combination thereof) in respect of any shares of its capital stock or other securities, other than (A) in the case of Parent,
regular cash dividends in the ordinary course of business consistent with past practice in an amount not to exceed $0.25 per share
of Parent Common Stock per quarter (appropriately adjusted to reflect any stock dividends, subdivisions, splits, combinations or
other similar events relating to Parent Common Stock), or (B) dividends or distributions by a Subsidiary of Parent to Parent or
another wholly owned Subsidiary of Parent, or (iv) redeem, repurchase, cancel or otherwise acquire or offer to redeem, repurchase,
or otherwise acquire any of its securities or any securities of any Subsidiary of Parent, other than in the ordinary course of
business consistent with past practice, including repurchases of shares of Parent Common Stock (A) pursuant to accelerated
share repurchase programs or agreements in the ordinary course of business consistent with past practice and (B) in connection
with the exercise or the vesting and settlement of Parent Equity Awards (including in satisfaction of any amounts required to be
deducted or withheld under Applicable Law), in each case in this clause (B) outstanding as of the date of this Agreement in accordance
with the present terms of such Parent Equity Awards or granted after the date of this Agreement;
(d) issue, deliver or sell,
or authorize the issuance, delivery or sale of, any shares of its capital stock or any securities convertible into or exercisable
for, or any rights, warrants or options to acquire, any such capital stock or any such convertible securities, other than (i) the
issuance of any shares of Parent Common Stock upon the exercise of Parent Equity Awards or other equity and equity-linked awards
that are outstanding on the date of this Agreement or are granted after the date of this Agreement, (ii) with respect to capital
stock or securities of any Subsidiary of Parent, in connection with transactions (A) solely among Parent and one or more of its
wholly owned Subsidiaries or (B) solely among the Parent’s wholly owned Subsidiaries, (iii) the grant of Parent Equity Awards
or other equity and equity-linked awards to employees, directors or individual independent contractors of Parent or any of its
Subsidiaries pursuant to Parent’s equity compensation plans, or (iv) in connection with the Parent Share Issuance;
(e) sell, lease, license or
otherwise dispose of any Subsidiary or any division thereof or of Parent or any assets, securities or property, other than (i)
dispositions of any of the foregoing in an
amount not to exceed $3,000,000,000
individually or $6,000,000,000 in the aggregate, (ii) dispositions of securities under Parent’s investment portfolio consistent
with Parent’s investment policy, or (iii) transactions (A) solely among Parent and one or more of its Subsidiaries or (B)
solely among Parent’s Subsidiaries; or
(f) agree, commit or propose to do any
of the foregoing.
Section 7.02. No Solicitation by Parent.
(a) From the date of this Agreement until the earlier of the First Merger Effective Time or the termination of this Agreement,
except as otherwise set forth in this Section 7.02, Parent shall not, and shall cause its Subsidiaries not to, and shall use its
reasonable best efforts to cause its and its Subsidiaries’ Representatives not to, directly or indirectly, (i) solicit, initiate
or take any action to knowingly facilitate or knowingly encourage the submission of any Parent Acquisition Proposal, (ii) enter
into or participate in any discussions or negotiations with, furnish any information relating to Parent or any of its Subsidiaries
or afford access to the business, properties, assets, books or records of Parent or any of its Subsidiaries to, otherwise cooperate
in any way with, or knowingly assist, participate in, knowingly facilitate or knowingly encourage any effort by, any Third Party
that Parent knows is seeking to make, or has made, a Parent Acquisition Proposal, (iii) (A) fail to make or withdraw or qualify,
amend or modify in any manner adverse to the Company, Parent Board Recommendation, (B) fail to include Parent Board Recommendation
in the Joint Proxy Statement/Prospectus or (C) recommend, adopt or approve or publicly propose to recommend, adopt or approve
any Parent Acquisition Proposal (any of the foregoing in this clause (iii), a “Parent Adverse Recommendation Change”),
(iv) take any action to make any “moratorium,” “control share acquisition,” “fair price,” “supermajority,”
“affiliate transactions” or “business combination statute or regulation” or other similar anti-takeover
laws and regulations of the State of Pennsylvania, including Section 2555 of the Pennsylvania Law, inapplicable to any Third Party
or Parent Acquisition Proposal, (v) take any action to make any other antitakeover provision in the articles of incorporation of
Parent inapplicable to any Third Party or Parent Acquisition Proposal or (vi) fail to enforce or grant any waiver or release
under any standstill or similar agreement with respect to any class of equity securities of Parent or any of its Subsidiaries unless
the Board of Directors of Parent determines after consulting with its outside legal counsel that the failure to waive such provision
would be inconsistent with its fiduciary duties under Applicable Law (provided that the obligation not to fail to enforce
any such standstill or similar agreement under this Section 7.02(a)(vi) shall apply with respect to known breaches of such agreements
only).
(b) Notwithstanding the foregoing, if
at any time prior to the receipt of the Parent Stockholder Approval (the “Parent Approval Time”) (and in no
event after the Parent Approval Time), the Board of Directors of Parent receives a bona fide written Parent Acquisition
Proposal made after the date hereof which has not resulted from a violation of this Section 7.02, the Board of Directors of Parent,
directly or indirectly through its Representatives, may (x) contact the Third Party that has made such Parent Acquisition Proposal
in order to ascertain facts or clarify terms for the sole purpose of the Board of Directors of Parent informing itself about such
Parent Acquisition Proposal and such Third Party and (y) subject to compliance with this Section 7.02(b), Section 7.02(c) and Section
7.02(e), (i) engage in negotiations or discussions with any Third Party that, subject to Parent’s compliance with Section
7.02(a), has made after the date of this Agreement a Parent Superior Proposal or an unsolicited bona fide written Parent
Acquisition Proposal that the Board of Directors of Parent determines in good faith, after consultation with its financial advisor
and outside legal counsel, is reasonably likely to lead to a Parent Superior Proposal, (ii) furnish to such Third Party and its
Representatives and financing sources nonpublic information relating to Parent or any of its Subsidiaries pursuant to (x) a confidentiality
agreement between Parent and such
Third Party in existence on or prior to the date hereof or (y) a confidentiality agreement with confidentiality terms in the aggregate
no less favorable to Parent than those contained in the Confidentiality Agreement, a copy of which shall be provided, promptly
after its execution, to the Company for informational purposes; provided that all such non-public information (to the extent
that such information has not been previously provided or made available to the Company) is provided or made available to the Company,
as the case may be, substantially concurrently with the time it is provided or made available to such Third Party, and (iii) following
receipt of a Parent Superior Proposal after the date of this Agreement, make a Parent Adverse Recommendation Change, but in each
case referred to in the foregoing clauses (i) through (iii) only if the Board of Directors of Parent determines in good faith,
after consultation with Parent’s outside legal counsel and financial advisor, that the failure to take such action would
be reasonably likely to be inconsistent with its fiduciary duties under Applicable Law. Nothing contained herein shall prevent
the Board of Directors of Parent from (x) complying with Rule 14e-2(a) under the 1934 Act with regard to a Parent Acquisition Proposal,
so long as any action taken or statement made to so comply is consistent with this Section 7.02; or (y) making any required disclosure
to the stockholders of Parent if the Board of Directors of Parent determines in good faith, after consultation with outside legal
counsel, that the failure to take such action would be reasonably likely to be inconsistent with Applicable Law, provided
that any Parent Adverse Recommendation Change involving or relating to a Parent Acquisition Proposal may only be made in accordance
with the provisions of Section 7.02(b), Section 7.02(c) and Section 7.02(e). For the avoidance of doubt, a “stop, look and
listen” disclosure or similar communication of the type contemplated by Rule 14d-9(f) under the 1934 Act shall not be a Parent
Adverse Recommendation Change.
(c) In addition to the requirements
set forth in Section 7.02(b), the Board of Directors of Parent shall not take
any of the actions referred to in clauses (i) through (iii)
of Section 7.02(b) unless Parent shall have first delivered to the Company written
notice advising the Company that it intends to take such action, and Parent shall continue to advise the Company, on a current
basis, after taking such action of the status and material terms of any discussions and negotiations with the applicable Third
Party. In addition, Parent shall notify the Company promptly (but in no event later than twenty-four (24) hours) after receipt
by Parent (or any of its Representatives) of any Parent Acquisition Proposal, any indication that a Third Party is considering
making a Parent Acquisition Proposal or any request for information relating to Parent or any of its Subsidiaries or for access
to the business, properties, assets, books or records of Parent or any of its Subsidiaries by any Third Party that, to the knowledge
of Parent or any member of its Board of Directors, is considering making, is reasonably likely to make or has made, a Parent Acquisition
Proposal, which notice shall be provided in writing and shall identify the Third Party making, and the material terms and conditions
of, any such Parent Acquisition Proposal, indication or request (including any material changes thereto). Parent shall keep the
Company fully informed, on a current basis, of the status and details of any such Parent Acquisition Proposal, indication or request
(including any changes thereto) and shall promptly (but in no event later than twenty-four (24) hours after receipt) provide to
the Company copies of all material correspondence and written materials sent or provided to Parent or any of its Subsidiaries that
describes any terms or conditions of any Parent Acquisition Proposal (as well as written summaries of any material oral communications
addressing such matters).
(d) Notwithstanding anything in this
Agreement to the contrary, at any time prior to the Parent Approval Time (and in no event after the Parent Approval Time), the
Board of Directors of Parent may effect a Parent Adverse Recommendation Change involving or relating to a Parent Intervening Event
if the Board of Directors of Parent determines in good faith, after consultation with its outside legal
counsel, that the failure to take
such action would be reasonably likely to be inconsistent with its fiduciary duties under Applicable Law; provided that
(i) Parent shall (A) promptly notify the Company in writing of its intention to take such action and (B) negotiate in good
faith with the Company for three (3) Business Days following such notice regarding revisions to the terms of this Agreement proposed
by Parent, and (ii) the Board of Directors of Parent shall not effect any Parent Adverse Recommendation Change involving or relating
to a Parent Intervening Event unless, after the three (3) Business Day period described in the foregoing clause (B), the Board
of Directors of Parent determines in good faith, after consultation with its outside legal counsel, that the failure to take such
action would be reasonably likely to be inconsistent with its fiduciary duties under Applicable Law.
(e) Without limiting or affecting
Section 7.02(a), Section 7.02(b) or Section 7.02(c), the Board of Directors of Parent shall not make a Parent Adverse
Recommendation Change involving or relating to a Parent Superior Proposal unless (i) Parent promptly notifies the Company, in
writing at least three (3) Business Days before taking such action, that it intends to take such action, which notice
attaches the most current version of any proposed agreement or a detailed summary of all material terms of such Parent
Superior Proposal and the identity of the offeror, (ii) if requested by the Company, during such three (3) Business Day
period, Parent and its Representatives have discussed and negotiated in good faith with the Company regarding any proposal by
the Company to amend the terms of this Agreement in response to such Parent Superior Proposal and (iii) after such three (3)
Business Day period, the Board of Directors of Parent determines in good faith, taking into account any proposal by the
Company to amend the terms of this Agreement, that such Parent Acquisition Proposal continues to constitute a Parent Superior
Proposal (it being understood and agreed that in the event of any amendment to the financial terms or other material terms of
any such Parent Superior Proposal, a new written notification from Parent consistent with that described in clause (i) of
this Section 7.02(e) shall be required and a new notice period under clause (i) of this Section 7.02(e) shall commence,
during which notice period Parent shall be required to comply with the requirements of this Section 7.02(e) anew, except that
such new notice period shall be for two (2) Business Days (as opposed to three (3) Business Days)). After delivery of such
written notice pursuant to the immediately preceding sentence, Parent shall promptly keep the Company informed of all
material developments affecting the material terms of any such Parent Superior Proposal (and Parent shall provide the Company
with copies of any additional written materials received that relate to such Parent Superior Proposal).
(f) “Parent Superior Proposal”
means any bona fide, written Parent Acquisition Proposal (other than a Parent Acquisition Proposal which has resulted from
a violation of this Section 7.02) (with all references to “20%” in the definition of Parent Acquisition Proposal being
deemed to be references to “50%”) on terms that the Board of Directors of Parent determines in good faith, after consultation
with its financial advisor and outside legal counsel, and taking into account all the terms and conditions of the Parent Acquisition
Proposal that the Board of Directors of Parent considers to be appropriate (including the identity of the Person making the Parent
Acquisition Proposal and the expected timing and likelihood of consummation, any governmental or other approval requirements (including
divestitures and entry into other commitments and limitations), break-up fees, expense reimbursement provisions, conditions to
consummation and availability of necessary financing), would result in a transaction (i) that if consummated, is more favorable
to Parent’s stockholders from a financial point of view (taking into account, among other items, the tax attributes of such
transaction) than the Mergers (taking into account any proposal by the Company to amend the terms of this Agreement), (ii) that
is reasonably capable of being completed on the terms proposed, taking into account the identity of the Person making the Parent
Acquisition Proposal, any approval requirements and all other financial, regulatory, legal and other aspects of such Parent Acquisition
Proposal and (iii) for which financing, if a cash transaction
(whether in whole or in part),
is then fully committed in a manner comparable to Parent’s, Merger Sub 1’s and Merger Sub 2’s financing (or which
is reasonably determined to be available by the Board of Directors of Parent).
(g) “Parent Intervening Event”
means any material event, change, effect, development or occurrence occurring or arising after the date of this Agreement that
(i) was not known or reasonably foreseeable, or the material consequences of which were not known or reasonably foreseeable, in
each case to the Board of Directors or executive officers of Parent as of or prior to the date of this Agreement, and (ii) does
not relate to or involve any Parent Acquisition Proposal; provided that (A) in no event shall any action taken by either
party pursuant to the affirmative covenants set forth in Section 8.02, or the consequences of any such action, constitute, be deemed
to contribute to or otherwise be taken into account in determining whether there has been a Parent Intervening Event, and (B) in
no event shall any event, change, effect, development or occurrence that would fall within any of the exceptions to the definition
of “Company Material Adverse Effect” constitute, be deemed to contribute to or otherwise be taken into account in determining
whether there has been a Parent Intervening Event.
(h) Parent shall, and shall cause its
Subsidiaries to, and shall use its reasonable best efforts to cause its and its Subsidiaries’ respective Representatives
to, cease immediately and cause to be terminated any and all existing activities, discussions or negotiations, if any, with any
Third Party conducted prior to the date of this Agreement with respect to any Parent Acquisition Proposal and shall use its reasonable
best efforts to cause any such Party (or its agents or advisors) in possession of confidential information about Parent that was
furnished by or on behalf of Parent to return or destroy all such information.
(i) Notwithstanding (i) any Parent Adverse
Recommendation Change, (ii) the making of any Parent Acquisition Proposal or (iii) anything in this Agreement to the contrary,
until termination of this Agreement (x) in no event may Parent or any of its Subsidiaries (A) enter into any agreement in principle,
letter of intent, term sheet, merger agreement, acquisition agreement, option agreement, joint venture agreement, partnership agreement
or other similar instrument constituting or relating to a Parent Acquisition Proposal, (B) except as required by Applicable Law,
make, facilitate or provide information in connection with any SEC or other Filings in connection with the transactions contemplated
by any Parent Acquisition Proposal or (C) seek any Consents in connection with the transactions contemplated by any Parent Acquisition
Proposal and (y) Parent shall otherwise remain subject to all of its obligations under this Agreement.
Section 7.03. Obligations of Merger
Sub 1 and Merger Sub 2. Until the First Merger Effective Time and the Second Merger Effective Time, respectively, Parent shall
at all times be the direct owner of all of the outstanding shares of capital stock of Merger Sub 1 and all of the outstanding limited
liability company interests of Merger Sub 2. Parent shall take all action necessary to cause each of Merger Sub 1 and Merger Sub
2 to perform its obligations under this Agreement and to consummate the Mergers on the terms and conditions set forth in this Agreement.
Promptly following the execution of this Agreement, Parent, as the sole stockholder of Merger Sub 1 and the sole member of Merger
Sub 2, shall execute and deliver written consents adopting this Agreement in accordance with the Delaware Law and the Delaware
LLC Law, as applicable, and provide copies of such written consents to the Company.
Section 7.04. Director and Officer
Liability. (a) Without limiting any additional rights that any director, officer or employee may have under any indemnification
agreement or under the Company Organizational Documents or similar organizational documents of the Company’s Subsidiaries,
from
and after the First Merger Effective Time,
Parent shall, and shall cause the Surviving Company or any applicable Subsidiary thereof (collectively, the “D&O Indemnifying
Parties”), to the fullest extent each such D&O Indemnifying Party is so authorized or permitted by Applicable Law,
as now or hereafter in effect, to: (i) indemnify and hold harmless each person who is at the date hereof, was previously, or during
the period from the date hereof through the date of the First Merger Effective Time will be serving as a director, officer or employee
of the Company or any of its Subsidiaries or, at the request or for the benefit of the Company or any of its Subsidiaries, as a
director, trustee, officer or employee of any other entity or any benefit plan maintained by the Company or any of its Subsidiaries
(collectively, the “D&O Indemnified Parties”), as now or hereafter in effect, in connection with any D&O
Claim and any losses, claims, damages, liabilities, costs, Claim Expenses, judgments, fines, penalties and amounts paid in settlement
(including all interest, assessments and other charges paid or payable in connection with or in respect of any thereof) relating
to or resulting from such D&O Claim; and (ii) promptly pay on behalf of or, within ten (10) Business Days after any request
for advancement by a D&O Indemnified Party, advance to such D&O Indemnified Party, any Claim Expenses incurred in defending,
serving as a witness with respect to or otherwise participating with respect to any D&O Claim in advance of the final disposition
of such D&O Claim, including payment on behalf of or advancement to the D&O Indemnified Party of any Claim Expenses incurred
by such D&O Indemnified Party in connection with enforcing any rights with respect to such indemnification and/or advancement,
in each case without the requirement of any bond or other security, but subject to the D&O Indemnifying Party’s receipt
of a written undertaking by or on behalf of such D&O Indemnified Party to repay such Claim Expenses if it is ultimately determined
under Applicable Law that such D&O Indemnified Party is not entitled to be indemnified. The indemnification and advancement
obligations of the Surviving Company pursuant to this Section 7.04(a) shall extend to acts or omissions occurring at or before
the First Merger Effective Time and the Second Merger Effective Time, as applicable, and any D&O Claim relating thereto (including
with respect to any acts, facts, events or omissions occurring in connection with the approval of this Agreement, the Mergers and
the consummation of the other transactions contemplated by this Agreement, including the consideration and approval thereof and
the process undertaken in connection therewith and any D&O Claim relating thereto), and all rights to indemnification and advancement
conferred hereunder shall continue as to a person who has ceased to be a director, officer or employee of the Company or any of
its Subsidiaries after the date hereof and shall inure to the benefit of such Person’s heirs, successors, executors, and
personal and legal representatives. As used in this Section 7.04: (x) the term “D&O Claim” means any threatened,
asserted, pending or completed claim, action, suit, proceeding, inquiry or investigation, whether instituted by any party hereto,
any Governmental Authority or any other Person, whether civil, criminal, administrative, investigative or other, including any
arbitration or other alternative dispute resolution mechanism, arising out of or pertaining to matters that relate to such D&O
Indemnified Party’s duties or service (A) as a director, officer or employee of the Company or the applicable Subsidiary
thereto at or prior to the First Merger Effective Time (including with respect to any acts, facts, events or omissions occurring
in connection with the approval of this Agreement, the Mergers and the consummation of the other transactions contemplated by this
Agreement, including the consideration and approval thereof and the process undertaken in connection therewith and any D&O
Claim relating thereto) or (B) as a director, trustee, officer or employee of any other entity or any benefit plan maintained by
the Company or any of its Subsidiaries (for which such D&O Indemnified Party is or was serving at the request or for the benefit
of the Company or any of its Subsidiaries) at or prior to the First Merger Effective Time; and (y) the term “Claim Expenses”
means reasonable attorneys’ fees and all other reasonable out-of-pocket costs, expenses and obligations (including experts’
fees, travel expenses, court costs, retainers, transcript fees, duplicating, printing and binding costs, as well as telecommunications,
postage and courier charges) paid or incurred in connection with investigating, defending, being a witness in or participating
in (including on appeal), or preparing to
investigate, defend, be a witness in or participate in, any D&O Claim for which indemnification is authorized pursuant to this
Section 7.04(a), including any action relating to a claim for indemnification or advancement brought by a D&O Indemnified Party.
No D&O Indemnifying Party shall settle, compromise or consent to the entry of any judgment in any actual or threatened D&O
Claim in respect of which indemnification has been sought by such D&O Indemnified Party hereunder unless such settlement, compromise
or judgment includes an unconditional release of such D&O Indemnified Party from all liability arising out of such D&O
Claim, or such D&O Indemnified Party otherwise consents thereto.
(b) Without limiting the foregoing,
Parent agrees that all rights to indemnification and exculpation from liabilities for acts or omissions occurring at or prior to
the First Merger Effective Time now existing in favor of the current or former directors, officers or employees of the Company
or any of its Subsidiaries as provided in the Company Organizational Documents, similar organizational documents of the Company’s
Subsidiaries and indemnification agreements of the Company and its Subsidiaries shall survive the Mergers and shall continue in
full force and effect in accordance with their terms. The organizational documents of the Initial Surviving Corporation and, for
a period of six (6) years from the Second Merger Effective Time, the limited liability company agreement and other organizational
documents of the Surviving Company and its Subsidiaries, shall contain provisions no less favorable with respect to indemnification
and limitations on liability of directors and officers than are set forth in the Company Organizational Documents, which provisions
shall not be amended, repealed or otherwise modified for a period of six (6) years from the Second Merger Effective Time in any
manner that would affect adversely the rights thereunder of individuals who, at or prior to the First Merger Effective Time, were
directors, officers or employees of the Company or any of its Subsidiaries, unless such modification shall be required by Applicable
Law and then only to the minimum extent required by Applicable Law. At the Company’s option and expense, prior to the First
Merger Effective Time, the Company may purchase (and pay in full the aggregate premium for) a six (6)-year prepaid “tail”
insurance policy (which policy by its express terms shall survive the Mergers) of at least the same coverage and amounts and containing
terms and conditions that are no less favorable to the directors, officers, employees, agents or fiduciaries of the Company or
any of its Subsidiaries as the Company’s and its Subsidiaries’ existing directors’ and officers’ insurance
policy or policies with a claims period of six (6) years from the First Merger Effective Time for D&O Claims arising from facts,
acts, events or omission that occurred on or prior to the First Merger Effective Time; provided that the premium for such
tail policy shall not exceed three hundred percent (300%) of the aggregate annual amounts currently paid by the Company and its
Subsidiaries for such insurance (such amount being the “Maximum Premium”). If the Company fails to obtain such
tail policy prior to the First Merger Effective Time, Parent or the Surviving Company shall obtain such a tail policy, provided
that the premium for such tail policy shall not exceed the Maximum Premium; provided, further, that if such tail
policy cannot be obtained or can be obtained only by paying aggregate annual premiums in excess of the Maximum Premium, Parent,
the Company or the Surviving Company shall only be required to obtain as much coverage as can be obtained by paying an annual premium
equal to the Maximum Premium. Parent and the Surviving Company shall cause any such policy (whether obtained by Parent, the Company
or the Surviving Company) to be maintained in full force and effect, for its full term, and Parent shall cause the Surviving Company
to honor all its obligations thereunder.
(c) If any of Parent or the Surviving
Company or any of their respective successors or assigns (i) consolidates with or merges with or into any other Person and shall
not be the continuing or surviving company, partnership or other Person of such consolidation or merger or (ii) liquidates, dissolves
or winds-up, or transfers or conveys all or substantially all of its properties and assets to any Person, then,
and in each such case, proper provision
shall be made so that the successors and assigns of Parent or the Surviving Company, as applicable, assume the obligations set
forth in this Section 7.04.
Section 7.05. Employee Matters.
(a) From the Closing Date through December 31, 2017 (the “Benefits Continuation Period”), the Surviving
Company shall provide, and Parent shall cause the Surviving Company to provide, to the individuals who are employed by the Company
and its Subsidiaries immediately prior to the First Merger Effective Time and to the extent they continue as employees of the Surviving
Company, Parent or any of Parent’s Subsidiaries (including Subsidiaries of the Surviving Company) during all or a portion
of the Benefits Continuation Period (the “Affected Employees”) compensation (including base salary, bonus and
other cash incentive compensation opportunities) and employee benefits no less favorable in the aggregate than the compensation
and employee benefits provided to the Affected Employees under the Company Employee Plans immediately prior to the First Merger
Effective Time; provided that, for purposes of determining that such compensation and employee benefits no less favorable
in the aggregate, equity compensation, defined benefit pension plan benefits, retention or change in control payments or awards
or any similar compensation or benefit, shall not be taken into account; and provided, further, that, Affected Employees
shall be eligible to receive equity compensation from Parent on a basis that is comparable to similarly situated employees of Parent.
During the Benefits Continuation Period, individuals who are employed by the Company and its Subsidiaries immediately prior to
the First Merger Effective Time shall be provided with severance benefits in amounts and on terms and conditions that are no less
favorable than those provided to such individuals immediately prior to the First Merger Effective Time, as set forth in the Company’s
Severance Pay Plans as in effect as of the date hereof.
(b) With respect to any employee benefit
plan in which any Affected Employee first becomes eligible to participate on or after the First Merger Effective Time (the “New
Company Plans”), Parent shall: (i) waive all pre-existing conditions, exclusions and waiting periods with respect to
participation and coverage requirements applicable to such Affected Employee under any New Company Plan that is a health and welfare
plan in which such Affected Employee may be eligible to participate after the First Merger Effective Time, (ii) recognize service
of Affected Employees (to the extent credited by the Company or its Subsidiaries) accrued prior to the First Merger Effective Time
for all purposes under (but not for the purposes of benefit accrual under any defined benefit pension plan) any New Company Plan
in which such Affected Employees may be eligible to participate after the First Merger Effective Time, provided, however,
that in no event shall any credit be given to the extent it would result in the duplication of benefits for the same period of
service, and (iii) if applicable, cause to be credited, in any New Company Plan that is a health plan in which Affected Employees
participate, any deductibles or out-of-pocket expenses incurred by such Affected Employees and their beneficiaries and dependents
during the portion of the calendar year in which the Closing Date occurs prior to their participation in Parent’s health
plans with the objective that there be no double counting during the year in which the First Merger Effective Time occurs of such
deductibles or out-of-pocket expenses.
(c) From and after the First Merger
Effective Time, Parent will or, as applicable, will cause its Subsidiaries to, honor all contractual obligations under all Company
Employee Plans that exist on the date of this Agreement (or as established or amended in accordance with or permitted by this Agreement)
that apply to any current or former employee, or current or former director, of the Company or its Subsidiaries, including the
retention and severance plans or programs adopted after the date hereof to the extent permitted under Section 6.01(l) of the Company
Disclosure Schedule. For the avoidance of doubt, for purposes of any Company Employee Plan containing a definition of “change
in control” or
“change of control”
(or language having a similar meaning), the Closing shall be deemed to constitute a “change in control” or “change
of control” (or language having a similar meaning).
(d) Parent agrees that, with respect
to the annual cash incentive plans set forth on Section 7.05(d) of the Company Disclosure Schedule (the “Annual Incentive
Plans”), it shall, or shall cause the Surviving Company, to provide each participant in an Annual Incentive Plan (each
an “Incentive Plan Participant”) who remains employed with the Surviving Company through the end of the year
during which the Closing occurs, with an annual cash incentive award for the year during which the Closing occurs, the amount of
which shall be determined as the sum of the following: (i) a pro-rated portion of the bonus with respect to the portion of the
year of the Closing that occurs prior to the Closing, which bonus shall be determined based upon actual performance through the
Closing Date, as determined by the Company in accordance with the applicable Annual Incentive Plan plus (ii) a pro-rated
portion of the bonus with respect to the portion of the year of the Closing that occurs after the Closing, which bonus shall be
no less than the bonus payable at the applicable Incentive Plan Participant’s target incentive level under such Annual incentive
Plan; provided that if an Incentive Plan Participant’s employment is terminated by Parent or the Surviving Corporation
for any reason following the Closing Date (other than for “cause” (as defined in Section 7.05(d) of the Company
Disclosure Schedule)), or, for those Incentive Plan Participants who are a party to one of the agreements listed in Section 7.05(d)
of the Company Disclosure Schedule (collectively, the “Change in Control Agreements”), the Incentive Plan Participant
resigns for “good reason” (as defined in the applicable Change in Control Agreement), such Incentive Plan Participant
shall be entitled to the prorated payment set forth in clause (i) as soon as practicable following such termination of employment;
and provided, further, that in no event shall payment of any amounts under the Annual Incentive Plans (or any pro-rated
portion thereof) pursuant to this Section 7.05(d) result in the duplication of payments to any Incentive Plan Participant
under any other incentive, severance or other similar arrangement.
(e) Nothing contained in this Section
7.05 or elsewhere in this Agreement, express or implied (i) shall cause either Parent or any of its Affiliates to be obligated
to continue to employ any Person, including any Affected Employees, for any period of time following the First Merger Effective
Time, (ii) shall prevent Parent or its Affiliates from revising, amending or terminating any Company Employee Plan or any other
employee benefit plan, program or policy in effect from time to time, (iii) shall be construed as an amendment of any Company Employee
Plan, Parent Employee Plan, or (iv) shall create any third-party beneficiary rights in any director, officer, employee or individual
Person, including any present or former employee, officer, director or individual independent contractor of the Company or any
of its Subsidiaries (including any beneficiary or dependent of such individual.
Section 7.06. Financing. (a)
Each of Parent, Merger Sub 1 and Merger Sub 2 shall take, or shall cause to be taken, all actions and to do, or cause to be done,
all things necessary to arrange the Debt Financing on the terms and conditions described in the Debt Commitment Letters, including
(i) to negotiate and enter into the definitive agreements with respect thereto on the terms and conditions contained in the Debt
Commitment Letters (including, as necessary, the “flex” provisions contained in any related fee letter) by the Closing
Date, and (ii) to satisfy (or if determined advisable by Parent, obtain the waiver of) on a timely basis all conditions to obtaining
the Debt Financing within Parent’s control and to comply with all of its obligations pursuant to the Debt Commitment Letters
and the definitive agreements related thereto. In the event that all conditions to funding the commitments contained in the Debt
Commitment Letters have been satisfied, each of Parent, Merger Sub 1 and Merger Sub 2 shall use its reasonable best efforts to
cause the Financing Sources to fund the Debt Financing required to consummate the transactions contemplated by this Agreement and
to pay related
fees and expenses on the Closing Date (including
by taking enforcement action to cause the Financing Sources to provide the Debt Financing). Each of Parent, Merger Sub 1 and Merger
Sub 2 shall use its reasonable best efforts to enforce all of its rights under the Debt Commitment Letters. Parent shall give the
Company prompt notice of any material breach by any party to the Debt Commitment Letters or the definitive agreements related thereto
of which Parent has become aware or any termination of any of the Debt Commitment Letters or such definitive agreements. In the
event that any portion of the Debt Financing becomes unavailable, Parent, Merger Sub 1 and Merger Sub 2 shall (1) use their reasonable
best efforts to obtain, as promptly as practicable following the occurrence of such event, alternative debt financing for any such
portion from alternative debt sources (“Alternative Financing”) in an amount that will still enable Parent,
Merger Sub 1 and Merger Sub 2 to consummate the transactions contemplated by this Agreement, and (2) promptly notify the Company
of such unavailability and the reason therefor. If obtained, Parent shall deliver to the Company true and complete copies of all
agreements (including redacted copies of engagement and fee letters, removing only fee amounts, market “flex” provisions
and certain other terms (none of which concern or would adversely affect the amounts, availability, timing or conditionality of
the Debt Financing)) pursuant to which any such alternative source shall have committed to provide Parent, the Initial Surviving
Corporation or the Surviving Company with Alternative Financing. Parent, Merger Sub 1 and Merger Sub 2 shall not, without the Company’s
prior written consent, permit any amendment or modification to, or any waiver of any provision or remedy under, any Debt Commitment
Letter or any definitive agreements related thereto unless the terms of such Debt Commitment Letter or definitive agreements related
thereto, in each case as so amended, modified or waived, are substantially similar to those in such Debt Commitment Letter or definitive
agreement related thereto, prior to giving effect to such amendment, modification or waiver (other than economic terms, which shall
be as good as or better for Parent, Merger Sub 1 and Merger Sub 2 than those in the Debt Commitment Letter or definitive agreement
relating thereto prior to giving effect to such amendment, modification or waiver); provided that in the case of amendments
or modifications of any Debt Commitment Letter or a definitive agreement relating thereto, the foregoing shall only apply if such
amendment or modification (x) could reasonably be expected to (I) adversely affect the ability or likelihood of Parent, Merger
Sub 1 or Merger Sub 2 timely consummating the transactions contemplated by this Agreement or (II) make the timely funding of the
Debt Financing or the satisfaction of the conditions to obtaining the Debt Financing less likely to occur, (y) reduces the amount
of the Debt Financing or (z) adversely affects the ability of Parent, Merger Sub 1 or Merger Sub 2 to enforce their rights against
other parties to the Debt Commitment Letters or the definitive agreements relating thereto. Parent shall provide the Company with
prompt written notice of the receipt of any notice or other communication from any Financing Source with respect to such Financing
Source’s failure or anticipated failure to fund its commitments under any Debt Commitment Letters or definitive agreement
in connection therewith. Parent shall keep the Company reasonably informed on a current basis of the status of its efforts to consummate
the Debt Financing.
(b) Notwithstanding anything contained
in this Agreement to the contrary, Parent expressly acknowledges and agrees that Parent’s, Merger Sub 1’s and Merger
Sub 2’s obligations hereunder are not conditioned in any manner upon Parent, Merger Sub 1 or Merger Sub 2 obtaining any financing.
The failure, for any reason, other than as a result of any material breach of this Agreement by the Company, of Parent, Merger
Sub 1 and Merger Sub 2 to have sufficient cash available on the date that the Closing is required to occur pursuant to Section
2.01 hereof and/or the failure to pay the aggregate Cash Consideration on the date that the Closing is required to occur pursuant
to Section 2.01 hereof shall constitute a Willful Breach of this Agreement by Parent, Merger Sub 1 and Merger Sub 2.
Article
8
Covenants of Parent and the Company
The parties hereto agree that:
Section 8.01. Access to Information;
Confidentiality. (a) Upon reasonable notice and subject to Applicable Law, each of the Company and Parent shall, and
each shall cause its Subsidiaries to, afford to the other party and its Representatives, reasonable access, during normal business
hours during the period from the date of this Agreement to the earlier of the First Merger Effective Time or the termination of
this Agreement, to all of its properties, books, contracts and records, and, during such period, each of the Company and Parent
shall, and each shall cause its Subsidiaries to, make available to the other party all other information concerning its businesses,
properties and personnel as the other may reasonably request, and instruct its Representatives to reasonably cooperate with the
other party in its investigation. All information furnished pursuant to this Agreement shall be subject to the confidentiality
agreement, dated as of May 24, 2015, between Parent and the Company (the “Confidentiality Agreement”). No information
or knowledge obtained in any investigation pursuant to this Section 8.01 shall affect or be deemed to modify any representation
or warranty made by the Company or Parent pursuant to this Agreement.
(b) Notwithstanding anything to the
contrary in Sections 8.01, 8.02 or 8.03, none of the Company, Parent or any of their respective Subsidiaries shall be required
to provide access to its properties, books, contracts, records or personnel if such access would unreasonably disrupt its operations,
or provide access to or to disclose information where such access or disclosure would jeopardize the attorney-client privilege
of such party or its Subsidiaries or contravene any Applicable Law, fiduciary duty or binding agreement entered into prior to the
date of this Agreement; provided that each of the Company and Parent shall, and each shall cause its Subsidiaries to, use
reasonable best efforts to make appropriate substitute disclosure arrangements under circumstances in which such restrictions apply
(including redacting such information (i) to remove references concerning valuation, (ii) as necessary to comply with contractual
arrangements in effect on or after the date hereof, and (iii) as necessary to address reasonable attorney-client or other privilege
or confidentiality concerns); provided, however, that in no event shall either party have access to individual performance
or evaluation records, medical histories or other similar information that in the reasonable opinion of the applicable party is
sensitive or the disclosure of which would reasonably be expected to subject such party or any of its Subsidiaries to risk of liability.
Each of the Company and Parent may, as each deems advisable and necessary, reasonably designate any competitively sensitive material
provided to the other under Section 8.01 or Section 8.02 as “Outside Counsel Only Material.” Such materials and the
information contained therein shall be given only to the outside counsel of the recipient and, subject to any additional confidentiality
or joint defense agreement the parties may mutually propose and enter into, will not be disclosed by such outside counsel to employees,
officers or directors of the recipient unless express permission is obtained in advance from the source of the materials (the Company
or Parent, as the case may be) or its legal counsel.
Section 8.02. Reasonable Best Efforts.
(a) Subject to the terms and conditions of this Agreement, including Section 8.02(b), each of the Company and Parent shall,
and each shall cause its Subsidiaries to, use their respective reasonable best efforts to take, or cause to be taken, all actions
and to do, or cause to be done, all things necessary, proper or advisable under Applicable Law to consummate the Mergers and other
transactions contemplated hereby, (x) including (i) preparing and filing as promptly as practicable with any Governmental Authority
or other Third Party all
documentation to effect all necessary Filings,
(ii) obtaining as promptly as practicable and thereafter maintaining all Consents required to be obtained from any Governmental
Authority or other Third Party that are necessary, proper or advisable to consummate the Mergers or other transactions contemplated
hereby, and complying with the terms and conditions of each Consent, and (iii) cooperating to the extent reasonable with the other
parties hereto in their efforts to comply with their obligations under this Agreement, including in seeking to obtain as promptly
as practicable any required Consents and (y) which includes contesting (which includes by litigation) any (i) action, suit, investigation
or proceeding brought by any Governmental Authority in a federal, state or administrative court seeking to enjoin, restrain, prevent,
prohibit or make illegal consummation of the Mergers or other transactions contemplated hereby or seeking damages or to impose
any terms or conditions in connection with the Mergers or (ii) Order that has been entered by a federal, state or administrative
court that enjoins, restrains, prevents, prohibits or makes illegal consummation of the Mergers or other transactions contemplated
hereby or imposes any damages, terms or conditions in connection with the Mergers or other transactions contemplated hereby. The
parties understand and agree that Parent’s obligation to use its reasonable best efforts set forth in this Section 8.02(a)
includes taking all actions and doing all things necessary, proper or advisable under Applicable Law (including divestitures, hold
separate arrangements, the termination, assignment, novation or modification of Contracts (or portions thereof) or other business
relationships, the acceptance of restrictions on business operations, and the entry into other commitments and limitations) to
obtain the governmental approvals described in clauses (x), (y) and (z) of the first sentence of Section 8.02(b) to consummate
the Mergers and the other transactions contemplated hereby so long as such actions would not have and would not reasonably be expected
to have, individually or in the aggregate, a Regulatory Material Adverse Effect on Parent or on the Company.
(b) Notwithstanding Section 8.02(a)
or anything else in this Agreement to the contrary, nothing in this Agreement will obligate or require Parent, Merger Sub 1, Merger
Sub 2 or any of their respective Subsidiaries to take or cause to be taken any action (or refrain or cause to refrain from taking
any action) or agree or cause to agree to any term, condition or limitation (including, in each case, any of the actions or items
referred to in the last sentence of Section 8.02(a)) as a condition to, or in connection with, (x) the expiration or termination
of any applicable waiting period relating to the Mergers under the HSR Act, (y) any other Antitrust Law or (z) obtaining any Parent
Required Governmental Authorization or Company Required Governmental Authorization or any other Consent from a Governmental Authority
or otherwise, in each case if such action (or refraining from such action), term, condition or limitation would have or would reasonably
be expected to have, individually or in the aggregate, a Regulatory Material Adverse Effect on Parent or on the Company. “Regulatory
Material Adverse Effect” means, with respect to any Person, a material adverse effect on the financial condition, business,
revenue or EBITDA of such Person and its Subsidiaries, taken as a whole; provided that, for purposes of determining whether
any action, term or condition has had or would reasonably be expected to have a Regulatory Material Adverse Effect on the Company,
the Company and its Subsidiaries will collectively be deemed to be a company the size of (and with revenue and EBITDA equal to
those of) Parent and its Subsidiaries, taken as a whole (excluding, for the avoidance of doubt, the Company and its Subsidiaries);
provided, further, that, for purposes of determining whether any action, term or condition would have or would reasonably
be expected to have a Regulatory Material Adverse Effect on Parent or on the Company, impacts on Parent, the Company or any of
their respective Subsidiaries will be aggregated. “EBITDA” means, with respect to any Person, the sum of (1)
consolidated net income, determined in accordance with GAAP, plus (2) without duplication and to the extent deducted in determining
such consolidated net income, the sum of (I) consolidated interest expense, (II) consolidated
income tax expense and (III) all
amounts attributed to depreciation or amortization, in each case of such Person and its Subsidiaries.
(c) Neither
the Company nor Parent shall, and each shall cause its Subsidiaries not to, directly or indirectly (whether
by merger, consolidation or otherwise), acquire, purchase, lease or license (or agree to acquire,
purchase, lease or license) any business, corporation, partnership, association
or other business organization or division or part thereof,
or any securities or collection of assets, if doing so would reasonably be expected to: (i) impose any material delay in the obtaining
of, or materially increase the risk of not obtaining, any Consent of any Governmental Authority necessary to consummate the Mergers
or the other transactions contemplated hereby or the expiration or termination of any applicable waiting period; (ii) materially
increase the risk of any Governmental Authority entering an Order prohibiting the consummation of the Mergers or the other transactions
contemplated hereby; (iii) materially increase the risk of not being able to remove any such Order on appeal or otherwise; or (iv)
otherwise prevent or materially delay the consummation of the Mergers or the other transactions contemplated hereby.
(d) Parent shall, in consultation
with the Company, be entitled to direct the defense of the transactions contemplated hereby before any Governmental Authority and
to take the lead in the scheduling of, and strategic planning for, any meetings with, and the conducting of negotiations with,
Governmental Authorities regarding the clearances and approvals of the Mergers described in clauses (x), (y) and (z) of the first
sentence of Section 8.02(b), so long as Parent’s actions in connection therewith are otherwise in accordance with Parent’s
obligations under this Section 8.02.
(e) In furtherance and not
in limitation of the foregoing, each of the Company and Parent shall, and each shall cause its Subsidiaries to, as promptly as
practicable following the date of this Agreement, make all Filings with all Governmental Authorities that may be or may become
reasonably necessary, proper or advisable under this Agreement or Applicable Law to consummate and make effective the Mergers and
the other transactions contemplated hereby, including: (i) not later than thirty (30) Business Days following the date of this
Agreement, Parent filing, or causing to be filed, “Form A Statements” or similar change of control applications, with
the insurance commissioners or regulators or departments of health or other Governmental Authorities in each jurisdiction where
required by Applicable Law seeking approval of Parent’s acquisition of control of each of the Regulated Subsidiaries which
results from the Mergers; (ii) as promptly as practicable following the date of this Agreement, Parent filing, or causing to be
filed, any pre-acquisition notifications on “Form E” or similar market share notifications to be filed in each jurisdiction
where required by Applicable Laws with respect to the Mergers and the other transactions contemplated hereby; (iii) not later than
ten (10) Business Days following the date of this Agreement (unless the Parties otherwise agree to another time period), the Company
and Parent each making an appropriate Filing of a notification and report form pursuant to the HSR Act with the Federal Trade Commission
and the Antitrust Division of the United States Department of Justice with respect to the Mergers and the other transactions contemplated
hereby and requesting early termination of the waiting period under the HSR Act; (iv) the Company and Parent each making any other
Filing that may be required under any other Antitrust Laws or by any Governmental Authority having antitrust jurisdiction under
Applicable Law; (v) not later than thirty (30) Business Days following the date of this Agreement, the Company and Parent filing
any required notices to CMS, with a separate notice to the CMS Medicare Drug Benefit Group and Central Office Medicare Advantage
plan manager, if applicable; and (vi) the Company and Parent each promptly following the date hereof making any other Filing that
may be
required under any Health Care
Laws, insurance laws or other Applicable Laws or by any Governmental Authority with jurisdiction over enforcement of any of the
foregoing.
(f) To the extent permitted by Applicable
Law, the Company and Parent shall, as promptly as practicable, (i) upon the reasonable request of the other party, furnish to such
party and upon any reasonable request from a Governmental Authority, furnish to such Governmental Authority, any information or
documentation concerning themselves, their Affiliates, directors, officers and stockholders, information or documentation concerning
the Mergers and the other transactions contemplated hereby and such other matters as may be requested, and (ii) make available
their respective Representatives to each other and, upon reasonable request, any Governmental Authority, in connection with (A)
the preparation of any Filing made by or on their behalf to any Governmental Authority in connection with the Mergers or the other
transactions contemplated hereby or (B) any investigation, review or approval process.
(g) Subject to Applicable Laws
relating to the sharing of information and the terms and conditions of the Confidentiality Agreement and all other agreements entered
into by the parties to this Agreement, each of the Company and Parent shall, and each shall cause its Subsidiaries to: (i) (A)
as far in advance as practicable, notify the other party of any Filing or material or substantive communication or inquiry it or
any of its Affiliates intends to make with any Governmental Authority relating to the matters that are the subject of this Agreement,
(B) prior to submitting any such Filing or making any such communication or inquiry, the submitting or making party shall provide
the other party and its counsel a reasonable opportunity to review, and shall consider in good faith the comments of the other
party in connection with any such Filing, communication or inquiry, and (C) promptly following the submission of such Filing or
making such communication or inquiry, provide the other party with a copy of any such Filing or, if in written form, communication
or inquiry; (ii) as promptly as practicable following receipt, furnish the other party with a copy of any Filing or, if in written
form, material or substantive communication or inquiry, it or any of its Affiliates receives from any Governmental Authority relating
to matters that are the subject of this Agreement; provided that if any such communication or inquiry is not in written
form, the receiving party shall provide the other party with a written summary of such communication or inquiry; (iii) coordinate
and cooperate fully with the other party in exchanging such information and providing such assistance as the other party may reasonably
request in connection with this Section 8.02 (including in seeking early termination of any applicable waiting periods under the
HSR Act); and (iv) consult with each other in connection with any inquiry, hearing, investigation or litigation by, or negotiations
with, any Governmental Authority relating to the transactions contemplated hereby or any Filings with respect thereto under Applicable
Law, including the scheduling of, and strategic planning for, any meetings with any Governmental Authority relating thereto. None
of the Company, Parent or their respective Representatives shall agree to participate in any material or substantive meeting or
conference (including by telephone) with any Governmental Authority, or any member of the staff of any Governmental Authority,
in respect of any Filing, proceeding, investigation (including the settlement of any investigation), litigation, or other inquiry
regarding the Mergers unless it consults with the other party in advance and, to the extent permitted by such Governmental Authority,
allows the other party to participate.
(h) Notwithstanding anything in this
Agreement to the contrary, in no event shall (i) Parent or any of its Affiliates or the Company or its Affiliates be required to
agree to take or enter into any action which is not conditioned upon the Closing, or (ii) the Company or its Affiliates agree to
any obligation, restriction, requirement, limitation, qualification, condition, remedy or other action relating to Consents required
to be obtained by the parties or their respective Subsidiaries in connection with the Mergers
without the prior written consent
of Parent (which consent shall not be withheld, delayed or conditioned if doing so would be inconsistent with Parent’s obligations
under Section 8.02(a)). Each of the Company and Parent further covenant and agree not to voluntarily extend any waiting period
associated with any Consent of any Governmental Authority (including under the HSR Act) or enter into any agreement with any Governmental
Authority or other Third Party not to consummate the Mergers and the other transactions contemplated hereby, except with the prior
written consent of the other party.
Section 8.03. Certain Filings; SEC
Matters. (a) As promptly as practicable following the date of this Agreement, (i) the Company and Parent shall jointly
prepare and file with the SEC a proxy statement relating to the Company Stockholder Meeting and the Parent Stockholder Meeting
(together with all amendments and supplements thereto, the “Joint Proxy Statement/Prospectus”) in preliminary
form, and (ii) Parent shall prepare and file with the SEC a Registration Statement on Form S-4 which shall include the Joint Proxy
Statement/Prospectus (together with all amendments and supplements thereto, the “Registration Statement”) relating
to the registration of the shares of Parent Common Stock to be issued to the stockholders of the Company pursuant to the Parent
Share Issuance. The Joint Proxy Statement/Prospectus and Registration Statement shall comply as to form in all material respects
with the applicable provisions of the 1933 Act and the 1934 Act and other Applicable Law.
(b) Each of the Company and Parent shall
use its reasonable best efforts to have the Joint Proxy Statement/Prospectus cleared by the SEC as promptly as practicable after
its filing, and Parent shall use its reasonable best efforts to have the Registration Statement declared effective under the 1933
Act as promptly as practicable after its filing and keep the Registration Statement effective for so long as necessary to consummate
the Mergers. Each of the Company and Parent shall, as promptly as practicable after the receipt thereof, provide the other party
with copies of any written comments and advise the other party of any oral comments with respect to the Joint Proxy Statement/Prospectus
and the Registration Statement received by such party from the SEC, including any request from the SEC for amendments or supplements
to the Joint Proxy Statement/Prospectus and the Registration Statement, and shall provide the other with copies of all material
or substantive correspondence between it and its Representatives, on the one hand, and the SEC, on the other hand. Notwithstanding
the foregoing, prior to filing the Registration Statement or mailing the Joint Proxy Statement/Prospectus or responding to any
comments of the SEC with respect thereto, each of the Company and Parent shall provide the other party and its counsel a reasonable
opportunity to review such document or response (including the proposed final version of such document or response) and consider
in good faith the comments of the other party in connection with any such document or response. None of the Company, Parent or
their respective Representatives shall agree to participate in any material or substantive meeting or conference (including by
telephone) with the SEC, or any member of the staff thereof, in respect of the Registration Statement or the Joint Proxy Statement/Prospectus
unless it consults with the other party in advance and, to the extent permitted by the SEC, allows the other party to participate.
Parent shall advise the Company, promptly after receipt of notice thereof, of the time of effectiveness of the Registration Statement,
and the issuance of any stop order relating thereto or the suspension of the qualification of shares of Parent Common Stock for
offering or sale in any jurisdiction, and each of the Company and Parent shall use its reasonable best efforts to have any such
stop order or suspension lifted, reversed or otherwise terminated. Each of the Company and Parent shall use its reasonable best
efforts to take any other action required to be taken by it under the 1933 Act, the 1934 Act, Delaware Law, Pennsylvania Law (solely
in the case of Parent) and the rules of the NYSE in connection with the filing and distribution of the Joint Proxy Statement/Prospectus
and the Registration Statement, and the solicitation of proxies from the stockholders of each of the Company and Parent thereunder.
Subject to Section 6.02, the Joint Proxy Statement Prospectus shall include the Company Board Recommendation, and,
subject to Section 7.02, the Joint
Proxy Statement Prospectus shall include the Parent Board Recommendation.
(c) Parent shall use its reasonable
best efforts to take, or cause to be taken, all actions, and to do or cause to be done all things, necessary, proper or advisable
under Applicable Laws and the rules and policies of the NYSE and the SEC to enable the listing of the Parent Common Stock being
registered pursuant to the Registration Statement on the NYSE no later than the First Merger Effective Time, subject to official
notice of issuance. Parent shall also use its reasonable best efforts to obtain all necessary state securities law or “blue
sky” permits and approvals required to carry out the transactions contemplated by this Agreement (provided that in
no event shall Parent be required to qualify to do business in any jurisdiction in which it is not now so qualified or file a general
consent to service of process).
(d) Each of the Company and Parent shall,
upon request, furnish to the other all information concerning itself, its Subsidiaries, directors, officers and (to the extent
reasonably available to the applicable party) stockholders and such other matters as may be reasonably necessary or advisable in
connection with any statement, Filing, notice or application made by or on behalf of the Company, Parent or any of their respective
Subsidiaries, to the SEC or the NYSE in connection with the Mergers and the other transactions contemplated by this Agreement,
including the Registration Statement and the Joint Proxy Statement/Prospectus. In addition, each of the Company and Parent shall
use its reasonable best efforts to provide information concerning it necessary to enable the Company and Parent to prepare required
pro forma financial statements and related footnotes in connection with the preparation of the Registration Statement or the Joint
Proxy Statement/Prospectus.
(e) If at any time prior to the Company
Approval Time and the Parent Approval Time, any information relating to the Company or Parent, or any of their respective Affiliates,
officers or directors, should be discovered by the Company or Parent that should be set forth in an amendment or supplement to
either of the Registration Statement or the Joint Proxy Statement/Prospectus, so that either of such documents would not include
any misstatement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, the party that discovers such information shall promptly notify the other
party hereto and an appropriate amendment or supplement describing such information shall promptly be prepared and filed with the
SEC and, to the extent required under Applicable Law, disseminated to the stockholders of each of the Company and Parent.
Section 8.04. Stockholder Meetings.
(a) As promptly as practicable following the effectiveness of the Registration Statement, the Company shall, in consultation
with Parent, in accordance with Applicable Law and the Company Organizational Documents, (i) establish a record date (the “Company
Record Date”) for, duly call and give notice of a meeting of the stockholders of the Company entitled to vote on the
Mergers (the “Company Stockholder Meeting”) at which meeting the Company shall seek the Company Stockholder
Approval, which record date shall be no later than ten (10) days after the date on which the Registration Statement is declared
effective under the 1933 Act, (ii) cause the Joint Proxy Statement/Prospectus (and all other proxy materials for the Company Stockholder
Meeting) to be mailed to its stockholders and (iii) within forty (40) days after the Company Record Date, duly convene and hold
the Company Stockholder Meeting. Subject to Section 6.02, the Company shall use its reasonable best efforts to take, or cause to
be taken, all actions, and do or cause to be done all things, necessary, proper or advisable on its part to cause the Company Stockholder
Approval to be received at the Company Stockholder Meeting or any adjournment or postponement thereof, and shall comply with all
legal requirements applicable to the Company Stockholder Meeting. The Company shall not, without
the prior written consent of Parent,
adjourn, postpone or otherwise delay the Company Stockholder Meeting; provided that the Company may, without the prior written
consent of Parent, adjourn or postpone the Company Stockholder Meeting, after consultation with Parent, if the Company believes
in good faith that such adjournment or postponement is reasonably necessary to allow reasonable additional time to (x) solicit
additional proxies necessary to obtain the Company Stockholder Approval, or (y) distribute any supplement or amendment to the Joint
Proxy Statement/Prospectus that the Board of Directors of the Company has determined in good faith after consultation with outside
legal counsel is necessary under Applicable Law and for such supplement or amendment to be reviewed by the Company’s stockholders
prior to the Company Stockholder Meeting.
(b) As promptly as practicable following
the effectiveness of the Registration Statement, the Parent shall, in consultation with the Company, in accordance with Applicable
Law and the Parent Organizational Documents, (i) establish a record date (which date shall be the same as the Company Record Date)
for, duly call and give notice of a meeting of the stockholders of Parent entitled to vote on the Parent Share Issuance (the “Parent
Stockholder Meeting”) at which meeting Parent shall seek the Parent Stockholder Approval, (ii) cause the Joint Proxy
Statement/Prospectus (and all other proxy materials for the Parent Stockholder Meeting) to be mailed to its stockholders and (iii)
duly convene and hold the Parent Stockholder Meeting on the same date and time as the Company Stockholder Meeting. Subject to Section
7.02, Parent shall use its reasonable best efforts to take, or cause to be taken, all actions, and do or cause to be done all things,
necessary, proper or advisable on its part to cause the Parent Stockholder Approval to be received at the Parent Stockholder Meeting
or any adjournment or postponement thereof, and shall comply with all legal requirements applicable to the Parent Stockholder Meeting.
Parent shall not, without the prior written consent of the Company, adjourn, postpone or otherwise delay the Parent Stockholder
Meeting; provided that Parent may, without the prior written consent of the Company, adjourn or postpone the Parent Stockholder
Meeting, after consultation with the Company, if Parent believes in good faith that such adjournment or postponement is reasonably
necessary to allow reasonable additional time to (x) solicit additional proxies necessary to obtain the Parent Stockholder Approval,
or (y) distribute any supplement or amendment to the Joint Proxy Statement/Prospectus that the Board of Directors of Parent has
determined in good faith after consultation with outside legal counsel is necessary under Applicable Law and for such supplement
or amendment to be reviewed by Parent’s stockholders prior to the Parent Stockholder Meeting.
(c) Notwithstanding (x) any Company
Adverse Recommendation Change or Parent Adverse Recommendation Change, (y) the public proposal or announcement or other submission
to the Company or any of its Representatives of a Company Acquisition Proposal or the public proposal or announcement or other
submission to Parent or any of its Representatives of a Parent Acquisition Proposal or (z) anything in this Agreement to the contrary,
unless this Agreement is terminated in accordance with its terms, the obligations of the Company and Parent under Section 8.03
and this Section 8.04 shall continue in full force and effect.
Section 8.05. Public Announcements.
The initial press release concerning this Agreement and the transactions contemplated hereby shall be a joint press release to
be reasonably agreed upon by the Company and Parent. Following such initial press release, Parent and the Company shall consult
with each other before issuing any additional press release, making any other public statement or scheduling any press conference,
conference call or meeting with investors or analysts with respect to this Agreement or the transactions contemplated hereby and,
except as may be required by Applicable Law or any listing agreement with or rule of any national securities exchange or association,
shall not issue any such press release, make any such other public statement or schedule any such press conference,
conference call or meeting before such consultation
(and, to the extent applicable, shall provide copies of any such press release, statement or agreement (or any scripts for any
conference calls) to the other party and shall consider in good faith the comments of the other party); provided that the
restrictions set forth in this Section 8.05 shall not apply to any release or public statement (a) made or proposed to be
made by the Company in compliance with Section 6.02 with respect to the matters contemplated by Section 6.02, (b) made or proposed
to be made by Parent in compliance with Section 7.02 with respect to the matters contemplated by Section 7.02, or (c) in connection
with any dispute between the parties regarding this Agreement, the Mergers or the other transactions contemplated hereby.
Section 8.06. Notices of Certain Events.
(a) Each of the Company and Parent shall promptly advise the other of (i) any notice or other material communication from any Person
alleging that the consent of such Person is or may be required in connection with the transactions contemplated by this Agreement;
(ii) any notice or other communication from any Governmental Authority in connection with the transactions contemplated by this
Agreement; (iii) any actions, suits, claims, investigations or proceedings commenced or, to its knowledge, threatened against,
relating to or involving or otherwise affecting the Company or any of its Subsidiaries or Parent and any of its Subsidiaries, as
the case may be, that, if pending on the date of this Agreement, would have been required to have been disclosed pursuant to any
Section of this Agreement or that relate to the consummation of the transactions contemplated by this Agreement; (iv) any change
or event that has had or would be reasonably likely to have, individually or in the aggregate, a Company Material Adverse Effect,
in the case of the Company, or a Parent Material Adverse Effect, in the case of Parent; or (v) any change or event that it believes
would or would be reasonably likely to cause or constitute a material breach of any of its representations, warranties or covenants
contained in this Agreement; and (b) the Company shall notify Parent promptly (but in no event later than one (1) Business Day)
after the imposition or occurrence of any CMS Sanction; provided that no such notification shall affect the representations,
warranties, covenants or agreements of the parties (or remedies with respect thereto) or the conditions to the obligations of the
parties under this Agreement; provided, further, that a failure to comply with this Section 8.06 shall not constitute the
failure of any condition set forth in Article 9 to be satisfied unless the underlying change or event would independently result
in the failure of a condition set forth in Article 9 to be satisfied.
Section 8.07. Section 16 Matters.
Prior to the First Merger Effective Time, Parent and the Company shall take all such steps as may be required (to the extent permitted
under Applicable Law) to cause any dispositions of Company Common Stock (including derivative securities with respect to Company
Common Stock) or acquisitions of Parent Common Stock (including derivative securities with respect to Parent Common Stock) resulting
from the transactions contemplated by this Agreement by each individual who is subject to the reporting requirements of Section
16(a) of the 1934 Act with respect to the Company, or will become subject to such reporting requirements with respect to Parent,
to be exempt under Rule 16b-3 promulgated under the 1934 Act.
Section 8.08. Transaction Litigation.
Each of the Company and Parent shall promptly notify the other of any stockholder demands, litigations, arbitrations or other similar
claims, actions, suits or proceedings (including derivative claims) commenced against it and/or its respective directors or officers
relating to this Agreement or any of the transactions contemplated hereby or any matters relating thereto (collectively, “Transaction
Litigation”) and shall keep the other party informed regarding any Transaction Litigation. Each of the Company and Parent
shall cooperate with the other in the defense or settlement of any Transaction Litigation, and shall give the other party the opportunity
to consult with it regarding the defense or settlement of such Transaction Litigation and shall give the other
party’s advice due consideration with
respect to such Transaction Litigation. Prior to the First Merger Effective Time, none of the Company or any of its Subsidiaries
shall settle or offer to settle any Transaction Litigation without the prior written consent of Parent (which consent shall not
be unreasonably withheld, conditioned or delayed).
Section 8.09. Stock Exchange Delisting.
Each of the Company and Parent agrees to cooperate with the other party in taking, or causing to be taken, all actions necessary
to delist the Company Common Stock from the NYSE and terminate its registration under the 1934 Act, provided that such delisting
and termination shall not be effective until the First Merger Effective Time.
Section 8.10. Dividends. Each
of the Company and Parent shall coordinate with the other regarding the declaration and payment of dividends in respect of Company
Common Stock and Parent Common Stock and the record dates and payment dates relating thereto, it being the intention of the Company
and Parent that no holder of Company Common Stock or Parent Common Stock shall receive two dividends, or fail to receive one dividend,
for any single calendar quarter with respect to its shares of Company Common Stock, on the one hand, and shares of Parent Common
Stock any holder of Company Common Stock receives pursuant to the First Merger, on the other.
Section 8.11. Governance Matters.
(a) Prior to the First Merger Effective
Time, Parent shall take all requisite actions so that, as of the First Merger Effective Time, the size of the Board of Directors
of Parent shall be increased by four (4) members, and individuals who are serving as directors of the Company immediately prior
to the First Merger Effective Time who are independent with respect to Parent and jointly designated by the Company and Parent
prior to the Closing shall be appointed to fill the vacancies on the Board of Directors of Parent created by such increase.
(b) Following the First Merger Effective
Time, Parent and its Subsidiaries shall maintain the corporate headquarters of its Medicare and Medicaid businesses in Louisville,
Kentucky, and Parent shall cause the Surviving Company to maintain a significant corporate presence in Louisville, Kentucky.
(c) Parent acknowledges and agrees that
(i) the audited consolidated financial statements and unaudited consolidated interim financial statements of the Company included
or incorporated by reference in the Company SEC Documents do not include the financial information of The Humana Foundation Inc.,
(ii) the assets and liabilities of The Humana Foundation Inc. shall not be transferred in connection with the Mergers or the other
transactions contemplated hereby, and (iii) after the Closing, The Humana Foundation Inc. shall continue to be independently managed
by its board of directors.
Section 8.12. State Takeover Statutes.
Each of Parent, Merger Sub 1, Merger Sub 2 and the Company shall (a) take all action necessary so that no “moratorium,”
“control share acquisition,” “fair price,” “supermajority,” “affiliate transactions”
or “business combination statute or regulation” or other similar state anti-takeover laws or regulations, or any similar
provision of the Company Organizational Documents or the Parent Organizational Documents, as applicable, is or becomes applicable
to the Mergers or any of the other transactions contemplated hereby, and (b) if any such anti-takeover law, regulation or provision
is or becomes applicable to the Mergers or any other transactions contemplated hereby, cooperate and grant such approvals and take
such actions as are reasonably necessary so that the transactions contemplated hereby may be consummated as promptly as practicable
on the terms contemplated hereby and otherwise act to eliminate or minimize the effects of such statute or regulation on the transactions
contemplated hereby
Section 8.13. Tax Matters.
(a) The Company shall use its reasonable
best efforts to deliver to Fried Frank, counsel to the Company, and Davis Polk & Wardwell LLP (“Davis Polk”),
counsel to Parent, a “Tax Representation Letter,” dated as of the Closing Date (and, if requested, dated as
of the date the Registration Statement shall have been declared effective by the SEC), signed by an executive officer of the Company,
containing representations of the Company, and Parent shall use its reasonable best efforts to deliver to Fried Frank and Davis
Polk a Tax Representation Letter, dated as of the Closing Date (and, if requested, dated as of the date the Registration Statement
shall have been declared effective by the SEC), signed by an executive officer of Parent, containing representations of Parent,
in each case, as shall be reasonably necessary, appropriate or customary to enable Fried Frank and Davis Polk to render the opinions
described in Section 9.03(f) and 9.02(f), respectively, and to enable Fried Frank and Davis Polk to render any opinions required
to be attached to the Registration Statement.
(b) Each of Parent and the Company shall
use its reasonable best efforts (i) to cause the Mergers, taken together, to qualify as a “reorganization” within the
meaning of Section 368(a) of the Code with respect to which Parent and the Company will each be a “party to the reorganization”
within the meaning of Section 368(b) of the Code and (ii) not to, and not permit or cause any of its respective Subsidiaries or
Affiliates to, take or cause to be taken any action reasonably likely to cause the Mergers, taken together, to fail to qualify
as a “reorganization” under Section 368(a) of the Code.
Article
9
Conditions to the Mergers
Section 9.01. Conditions to the Obligations
of Each Party. The obligations of the Company, Parent, Merger Sub 1 and Merger Sub 2 to consummate the Mergers are subject
to the satisfaction (or, to the extent permitted by Applicable Law, waiver) of the following conditions:
(a) the Company Stockholder Approval
shall have been obtained in accordance with the Delaware Law;
(b) the Parent Stockholder Approval
shall have been obtained in accordance with the rules of the NYSE;
(c) no Applicable Law shall be in effect
in the U.S. or any of its territories that enjoins, prevents or prohibits the consummation of either of the Mergers;
(d) the Registration Statement shall
have been declared effective and no stop order suspending the effectiveness of the Registration Statement shall be in effect and
no proceedings for such purpose shall be pending before the SEC; and
(e) the shares of Parent Common Stock
to be issued in the Parent Share Issuance shall have been approved for listing on the NYSE, subject to official notice of issuance.
Section 9.02. Conditions to the Obligations
of Parent, Merger Sub 1 and Merger Sub 2. The obligations of Parent, Merger Sub 1 and Merger Sub 2 to consummate the Mergers
are subject to the satisfaction (or, to the extent permitted by Applicable Law, waiver by Parent) of the following further conditions:
(a) the Company shall have performed
in all material respects all of its obligations hereunder required to be performed by it at or prior to the First Merger Effective
Time;
(b) (i) the representations and warranties
of the Company contained in Section 4.05(a) shall be true and correct, subject only to de minimis exceptions, at and as
of the date of this Agreement and at and as of the Closing as if made at and as of the Closing (or, if such representations and
warranties are given as of another specific date, at and as of such date); (ii) the representations and warranties of the Company
contained in Section 4.01 (other than the third sentence thereof), Section 4.02,
Section 4.04(i), Section 4.06(b)
(solely with respect to Major Subsidiaries of the Company), Section 4.27, Section 4.28
and Section 4.29 shall be true and correct in all material respects at and as
of the date of this Agreement and at and as of the Closing as if made at and as of the Closing (or, if such representations and
warranties are given as of another specific date, at and as of such date); and (iii) the other representations and warranties of
the Company contained in this Agreement, disregarding all qualifications and exceptions contained therein relating to materiality
or Company Material Adverse Effect, shall be true and correct at and as of the date of this Agreement and at and as of the Closing
as if made at and as of the Closing (or, if such representations and warranties are given as of another specific date, at and as
of such date), except, in the case of this clause (iii) only, where the failure of such representations and warranties to be true
and correct has not had and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse
Effect;
(c) since the date of this Agreement,
there shall not have occurred any event, change, effect, development or occurrence that has had or would reasonably be expected
to have, individually or in the aggregate, a Company Material Adverse Effect;
(d) both (i) the early termination or
expiration of the waiting period required under the HSR Act shall have occurred and (ii) the Company Required Governmental Authorizations
and the Parent Required Governmental Authorizations set forth in Section 9.02(d) of the Parent Disclosure Schedule shall have been
made or obtained and shall be in full force and effect and, in each case in this clause (d), shall not impose any term or condition
that would have or would reasonably be expected to have, individually or in the aggregate, a Regulatory Material Adverse Effect
on Parent or the Company;
(e) Parent shall have received a certificate
from an executive officer of the Company confirming the satisfaction of the conditions set forth in Sections 9.02(a), 9.02(b) and
9.02(c);
(f) Parent shall have received an opinion
of Davis Polk (or another nationally recognized law firm) substantially to the effect that (i) for U.S. federal income tax purposes
the Mergers, taken together, will be treated as a reorganization within the meaning of Section 368(a) of the Code and (ii) the
Company and Parent will each be a “party to the reorganization” within the meaning of Section 368(b) of the Code. In
rendering such opinion, Davis Polk shall be entitled to rely upon assumptions, representations, warranties and covenants, including
those contained in this Agreement and in the Tax Representation Letters described in Section 8.13; and
(g) (i) CMS shall not have imposed any
sanction involving suspension of marketing, enrollment and/or payment (it being understood and agreed that the imposition of a
civil monetary penalty that does not involve the suspension of payment will not be included in this clause (i)) under any Medicare
Advantage Contract or Medicare Part D Contract to which the Company or any of its Subsidiaries is a party, (ii) CMS shall not have
terminated any Medicare Advantage Contract or Medicare Part D Contract to which the Company or any of its Subsidiaries is a party
and (iii) the Company or any of its Subsidiaries shall not have suspended enrollment or marketing under any
Medicare Advantage Contract or
Medicare Part D Contract to which the Company or any of its Subsidiaries is a party (each of the items in clauses (i), (ii) and
(iii) of this Section 9.02(g), a “CMS Sanction”), in each case which CMS Sanction, individually or in the aggregate
with any and all other CMS Sanctions, is, or would reasonably be expected to be, material and adverse to the Company and its Subsidiaries,
taken as a whole (it being understood and agreed that, among other things, the impact (and the reasonably expected impact) on current
or future stars rating, membership, revenue, stars bonus payments, open enrollment and earnings, as well as the impact (both positive
and negative) (and the reasonably expected impact) of any remediation or other offsetting actions taken by the Company or any of
its Subsidiaries (collectively, the “Relevant Factors”), shall be taken into account in determining if such
CMS Sanction, individually or in the aggregate with any and all other CMS Sanctions, is, or would reasonably be expected to be,
material and adverse to the Company and its Subsidiaries, taken as a whole).
Section 9.03. Conditions to the Obligations
of the Company. The obligations of the Company to consummate the Mergers are subject to the satisfaction (or, to the extent
permitted by Applicable Law, waiver by the Company) of the following further conditions:
(a) each of Parent, Merger Sub 1 and
Merger Sub 2 shall have performed in all material respects all of its obligations hereunder required to be performed by it at or
prior to the First Merger Effective Time;
(b) (i) the representations and warranties
of Parent contained in Section 5.05(a) shall be true and correct, subject only to de minimis exceptions, at and as of the
date of this Agreement and at and as of the Closing as if made at and as of the Closing (or, if such representations and warranties
are given as of another specific date, at and as of such date); (ii) the representations and warranties of Parent contained in
Section 5.01 (other than the third sentence thereof), Section 5.02, Section
5.04(i), Section 5.06(b) (solely with respect to Major Subsidiaries of Parent),
Section 5.23, Section 5.24 and Section 5.25
shall be true and correct in all material respects at and as of the date of this Agreement and at and as of the Closing as if made
at and as of the Closing (or, if such representations and warranties are given as of another specific date, at and as of such date);
and (iii) the other representations and warranties of Parent contained in this Agreement, disregarding all qualifications and exceptions
contained therein relating to materiality or Parent Material Adverse Effect, shall be true and correct at and as of the date of
this Agreement and at and as of the Closing as if made at and as of the Closing (or, if such representations and warranties are
given as of another specific date, at and as of such date), except, in the case of this clause (iii) only, where the failure of
such representations and warranties to be true and correct has not had and would not reasonably be expected to have, individually
or in the aggregate, a Parent Material Adverse Effect;
(c) since the date of this Agreement,
there shall not have occurred any event, change, effect, development or occurrence that has had or would reasonably be expected
to have, individually or in the aggregate, a Parent Material Adverse Effect;
(d) both (i) the early termination or
expiration of the waiting period required under the HSR Act shall have occurred and (ii) the Company Required Governmental Authorizations
and the Parent Required Governmental Authorizations set forth in Section 9.03(d) of the Company Disclosure Schedule, in each case,
to the extent required under Applicable Law to consummate the transactions contemplated hereby at Closing, shall have been made
or obtained and shall be in full force and effect;
(e) the Company shall have received
a certificate from an executive officer of Parent confirming the satisfaction of the conditions set forth in Section 9.03(a), Section
9.03(b) and Section 9.03(c); and
(f) the Company shall have received
an opinion of Fried Frank (or another nationally recognized law firm) substantially to the effect that (i) for U.S. federal income
tax purposes the Mergers, taken together, will be treated as a reorganization within the meaning of Section 368(a) of the Code
and (ii) the Company and Parent will each be a “party to the reorganization” within the meaning of Section 368(b) of
the Code. In rendering such opinion, Fried Frank shall be entitled to rely upon assumptions, representations, warranties and covenants,
including those contained in this Agreement and in the Tax Representation Letters described in Section 8.13.
Article
10
Termination
Section 10.01. Termination. This
Agreement may be terminated and the Mergers and the other transactions contemplated hereby may be abandoned at any time prior to
the First Merger Effective Time (notwithstanding receipt of the Company Stockholder Approval or the Parent Stockholder Approval):
(a) by mutual written agreement of the
Company and Parent;
(b) by either the Company or Parent,
if:
(i) the Mergers have not been
consummated on or before June 30, 2016 (as such date may be extended pursuant to the following proviso, the “End Date”);
provided that if on such date, the conditions to the Closing set forth in Section 9.02(d), Section 9.03(d), Section 9.01(c)
(if the applicable Order relates to the matters referenced in Section 9.02(d) or Section 9.03(d)) or Section 9.02(g) shall not
have been satisfied, but all other conditions to the Closing shall have been satisfied (or in the case of conditions that by their
terms are to be satisfied at the Closing, shall be capable of being satisfied on such date), then the End Date shall be extended
to and including December 31, 2016, if either the Company or Parent notifies the other party in writing on or prior to June 30,
2016, of its election to extend the End Date to December 31, 2016; provided that (A) the right to terminate this Agreement
or extend the End Date pursuant to this Section 10.01(b)(i) shall not be available to any party whose breach of any provision of
this Agreement results in the failure of the Mergers to be consummated by such time and (B) the right to extend the End Date pursuant
to this Section 10.01(b)(i) shall not be available to the Company if the Company has not, or has not caused its Subsidiaries to,
use their respective reasonable best efforts to cure the impact of the applicable CMS Sanction(s) (taking into account, among other
things, the Relevant Factors) following the imposition or occurrence of such CMS Sanction(s);
(ii) there shall be in effect
any Applicable Law in the U.S. or any of its territories that enjoins, prevents or prohibits the consummation of either of the
Mergers and, if such Applicable Law is an Order, such Order shall have become final and non-appealable; provided that the
right to terminate this Agreement pursuant to this Section 10.01(b)(ii) shall not be available to any party who has failed to perform
fully its obligations under Section 8.02, if such failure results in such Applicable Law being in effect;
(iii) the Company Stockholder
Approval shall not have been obtained upon a vote taken thereon at the Company Stockholder Meeting (including any adjournment or
postponement thereof); or
(iv) the Parent Stockholder
Approval shall not have been obtained upon a vote taken thereon at the Parent Stockholder Meeting (including any adjournment or
postponement thereof); or
(c) by Parent, if:
(i) (A) a Company Adverse Recommendation
Change shall have occurred or (B) the Board of Directors of the Company shall have failed to publicly confirm the Company Board
Recommendation within seven (7) Business Days after a written request by Parent that it do so;
(ii) a breach of any representation
or warranty or failure to perform any covenant or agreement on the part of the Company set forth in this Agreement shall have occurred
that would cause any condition set forth in Section 9.02(a) or Section 9.02(b) not to be satisfied, and such breach or failure
to perform (A) is incapable of being cured by the End Date or (B) has not been cured by the Company within forty-five (45) days
following written notice to the Company from Parent of such breach or failure to perform, but only so long as Parent is not then
in breach of its representations, warranties, covenants or agreements set forth in this Agreement, which breach by Parent would
cause any condition set forth in Section 9.03(a) or Section
9.03(b) not to be satisfied;
(iii) the Company shall have
breached any of its obligations under Section 6.02 or 8.04 in any material respect, other than in the case where (w) such breach
is a result of an isolated action by a Representative of the Company (other than a director or officer of the Company), (x) such
breach was not caused by, or within the knowledge of, the Company, (y) the Company takes appropriate actions to remedy such breach
upon discovery thereof, and (z) Parent is not significantly harmed as a result thereof; provided that in no event shall
Parent be entitled to terminate this Agreement on the basis of any breach of Section 8.04 following the receipt of the Company
Stockholder Approval; or
(iv) any CMS Sanction shall
have been imposed or otherwise occurred, (A) which CMS Sanction, individually or in the aggregate with any and all other CMS Sanctions,
is, or would be reasonably be expected to be, material and adverse to the Company and its Subsidiaries, taken as a whole (taking
into account, among other things, the Relevant Factors), and (B) which CMS Sanction (including the impact (and the reasonably expected
impact) thereof, taking into account, among other things, the Relevant Factors), (1) is incapable of being cured or abated by the
End Date or (2) has not been cured or abated by the End Date (it being understood and agreed that, among other things, the lifting,
termination or other cessation of any CMS Sanction shall not, in and of itself, be deemed to cure or abate the impact (or the reasonably
expected impact) of such CMS Sanction (taking into account, among other things, the Relevant Factors)); or
(d) by the Company, if:
(i) (A) a Parent Adverse Recommendation
Change shall have occurred or (B) the Board of Directors of Parent shall have failed to publicly confirm the Parent Board
Recommendation within seven (7) Business
Days after a written request by the Company that it do so;
(ii) if a breach of any representation
or warranty or failure to perform any covenant or agreement on the part of Parent, Merger Sub 1 or Merger Sub 2 set forth in this
Agreement shall have occurred that would cause any condition set forth in Section 9.03(a) or Section 9.03(b) not to be satisfied,
and such breach or failure to perform (A) is incapable of being cured by the End Date or (B) has not been cured by Parent, Merger
Sub 1 or Merger Sub 2, as applicable, within forty-five (45) days following written notice to Parent from the Company of such breach
or failure to perform, but only so long as the Company is not then in breach of its representations, warranties, covenants or agreements
set forth in this Agreement, which breach by the Company would cause any condition set forth in Section
9.02(a) or Section 9.02(b) not to be satisfied;
(iii) Parent shall have breached
any of its obligations under Section 7.02 or 8.04 in any material respect, other than in the case where (w) such breach is a result
of an isolated action by a Representative of Parent (other than a director or officer of Parent), (x) such breach was not caused
by, or within the knowledge of, Parent, (y) Parent takes appropriate actions to remedy such breach upon discovery thereof, and
(z) the Company is not significantly harmed as a result thereof; provided that in no event shall the Company be entitled
to terminate this Agreement on the basis of any breach of Section 8.04 following the receipt of the Parent Stockholder Approval;
or
(iv) if (A) there shall be in
effect any Order in respect of the matters contemplated by clauses (x), (y) and/or (z) of the first sentence of Section 8.02(b)
that shall not have become final and non-appealable and that enjoins, restrains, prevents, prohibits or makes illegal the consummation
of either of the Mergers, (B) within thirty (30) days after such Order first being in effect, Parent shall not have instituted
appropriate proceedings seeking to have such Order vacated, lifted, reversed, overturned or terminated and (C) such failure to
institute appropriate proceedings shall not have been cured by Parent within ten (10) days following irrevocable written notice
to Parent from the Company of the Company’s intent to terminate this Agreement pursuant to this Section 10.01(d)(iv) in respect
of such failure (which notice may not be given prior to the expiration of such thirty (30)-day period and, for the avoidance of
doubt, shall not be effective if Parent institutes such appropriate proceedings within such ten (10)-day period).
The party desiring to terminate this Agreement
pursuant to this Section 10.01 (other than pursuant to Section 10.01(a)) shall give written notice of such termination to the other
party.
Section 10.02. Effect of Termination.
If this Agreement is terminated pursuant to Section 10.01, this Agreement shall become void and of no effect without liability
of any party (or any stockholder or Representative of such party) to the other party hereto, except as provided in Section 10.03;
provided that, subject to Section 10.03(e), neither Parent nor the Company shall be released from any liabilities or damages
arising out of any (i) fraud by any party, (ii) the Willful Breach by any party of any representation or warranty on the part of
such party set forth in this Agreement or (iii) the Willful Breach of any covenant or agreement set forth in this Agreement. The
provisions of this Section 10.02, Section 10.03 and Article 11 (other than Section 11.13) shall survive any termination hereof
pursuant to Section 10.01. In addition, the termination of this Agreement shall not affect the parties’ respective obligations
under the Confidentiality Agreement.
Section 10.03. Termination Fees.
(a) If this Agreement is terminated: (i) by Parent pursuant to Section 10.01(c)(i) or 10.01(c)(iii); or (ii) by
the Company or Parent pursuant to Section 10.01(b)(iii), and in the case of clause (ii) of this sentence: (I) at or prior to the
Company Stockholder Meeting a Company Acquisition Proposal shall have been publicly disclosed or announced; and (II) on or prior
to the first (1st) anniversary of such termination of this Agreement: (1) a transaction relating to a Company Acquisition
Proposal is consummated; or (2) a definitive agreement relating to a Company Acquisition Proposal is entered into by the Company,
then, in the case of each of the foregoing clauses (i) and (ii), the Company shall pay to Parent, in cash at the time specified
in the following sentence, a fee in the amount of $1,314,000,000 (the “Company Termination Fee”). The Company
Termination Fee shall be paid as follows: (x) in the case of clause (i) of the preceding sentence, within three (3) Business Days
after the date of termination of this Agreement; and (y) in the case of clause (ii) of the preceding sentence, within three (3)
Business Days after the earlier of the consummation of the applicable transaction or the date upon which the definitive agreement
is entered into. “Company Acquisition Proposal” for purposes of the foregoing clause (ii)(II) of this Section 10.03(a)
shall have the meaning assigned thereto in the definition thereof set forth in Section 1.01 except that references in the definition
to “20%” shall be replaced by “50%.”
(b) If this Agreement is terminated:
(i) by the Company pursuant to Section 10.01(d)(i) or 10.01(d)(iii); or (ii) by the Company or Parent pursuant to Section 10.01(b)(iv),
and in the case of clause (ii) of this sentence: (I) at or prior to the Parent Stockholder Meeting a Parent Acquisition Proposal
shall have been publicly disclosed or announced; and (II) on or prior to the first (1st) anniversary of such termination
of this Agreement: (1) a transaction relating to a Parent Acquisition Proposal is consummated; or (2) a definitive agreement relating
to a Parent Acquisition Proposal is entered into by Parent, then, in the case of each of the foregoing clauses (i) and (ii), Parent
shall pay to the Company, in cash at the time specified in the following sentence, a fee in the amount of $1,691,000,000 (the “Parent
Termination Fee”). The Parent Termination Fee shall be paid as follows: (x) in the case of clause (i) of the preceding
sentence, within three (3) Business Days after the date of termination of this Agreement; and (y) in the case of clause (ii) of
the preceding sentence, within three (3) Business Days after the earlier of the consummation of the applicable transaction or the
date upon which the definitive agreement is entered into. “Parent Acquisition Proposal” for purposes of the foregoing
clause (ii)(II) of this Section 10.03(b) shall have the meaning assigned thereto in the definition thereof set forth in Section
1.01 except that references in the definition to “20%” shall be replaced by “50%.”
(c) In the event this Agreement is terminated
pursuant to Section 10.01(b)(i), Section 10.01(b)(ii) (solely in respect of any Applicable Law in respect of the matters contemplated
by clauses (x), (y) and/or (z) of the first sentence of Section 8.02(b)) or Section 10.01(d)(iv) and, at the time of such termination,
(A) the condition set forth in Section 9.02(d) has not been satisfied and (B) the conditions set forth in Section 9.01 (other than
the condition set forth in Section 9.01(c) solely in respect of any Applicable Law in respect of the matters contemplated by clauses
(x), (y) and/or (z) of the first sentence of Section 8.02(b)) and Section 9.02 (other than the condition set forth in Section 9.02(d))
have been satisfied (or in the case of conditions that by their nature are to be satisfied at the Closing, are capable of being
satisfied if the Closing were to occur on the date of such termination), then Parent shall pay or cause to be paid a fee in the
amount of $1,000,000,000 (the “Regulatory Termination Fee”) to the Company as promptly as reasonably practicable
(and in any event within five Business Days following such termination); provided that no Regulatory Termination Fee shall
be payable by Parent pursuant to this Section 10.03(c) if the failure of the condition set forth in Section 9.02(d) to be satisfied
is caused by the Company’s Willful Breach of Section 8.02.
(d) Any payment of the Company Termination
Fee, the Parent Termination Fee or the Regulatory Termination Fee shall be made by wire transfer of immediately available funds
to an account designated in writing by Parent or the Company, as applicable.
(e) The parties agree and understand
that (x) in no event shall the Company be required to pay the Company Termination Fee on more than one occasion and in no event
shall Parent be required to pay either the Parent Termination Fee or the Regulatory Termination Fee on more than one occasion,
or more than one of the Parent Termination Fee or the Regulatory Termination Fee under any circumstances, and (y) in no event shall
Parent be entitled, pursuant to this Section 10.03, to receive an amount greater than the Company Termination Fee and in no event
shall the Company be entitled, pursuant to this Section 10.03, to receive an amount greater than the Parent Termination Fee or
the Regulatory Termination Fee, as applicable. Notwithstanding anything to the contrary in this Agreement, except in the case of
fraud, (i) if Parent receives the Company Termination Fee from the Company pursuant to this Section 10.03 or if the Company receives
the Parent Termination Fee or the Regulatory Termination Fee from Parent pursuant to this Section 10.03, such payment shall be
the sole and exclusive remedy of the receiving party against the paying party and its Subsidiaries and their respective former,
current or future partners, stockholders, managers, members, Affiliates and Representatives and none of the paying party, any of
its Subsidiaries or any of their respective former, current or future partners, stockholders, managers, members, Affiliates or
Representatives shall have any further liability or obligation relating to or arising out of this Agreement or the transactions
contemplated hereby, and (ii) if (A) Parent, Merger Sub 1 or Merger Sub 2 receive any payments from the Company in respect of any
breach of this Agreement and thereafter Parent receives the Company Termination Fee pursuant to this Section 10.03 or (B) the Company
receives any payments from Parent, Merger Sub 1 or Merger Sub 2 in respect of any breach of this Agreement and thereafter the Company
receives the Parent Termination Fee or the Regulatory Termination Fee pursuant to this Section 10.03, the amount of such Company
Termination Fee, Parent Termination Fee or Regulatory Termination Fee, as applicable, shall be reduced by the aggregate amount
of such payments made by the party paying the Company Termination Fee, Parent Termination Fee or Regulatory Termination Fee, as
applicable, in respect of any such breaches. The parties acknowledge that the agreements contained in this Section 10.03 are an
integral part of the transactions contemplated hereby, that, without these agreements, the parties would not enter into this Agreement
and that any amounts payable pursuant to this Section 10.03 do not constitute a penalty. Accordingly, if any party fails to promptly
pay any amount due pursuant to this Section 10.03, such party shall also pay any costs and expenses (including reasonable legal
fees and expenses) incurred by the party entitled to such payment in connection with a legal action to enforce this Agreement that
results in a judgment for such amount against the party failing to promptly pay such amount. Any amount not paid when due pursuant
to this Section 10.03 shall bear interest from the date such amount is due until the date paid at a rate equal to the prime rate
as published in The Wall Street Journal, Eastern Edition in effect on the date of such payment.
(f) None of the Financing Sources shall
have any liability to the Company or any Person that is an Affiliate of the Company prior to giving effect to the Mergers relating
to or arising out of this Agreement, the Debt Financing or otherwise, whether at law, or equity, in contract, in tort or otherwise,
and neither the Company nor any Person that is an Affiliate of the Company prior to giving effect to the Mergers shall have any
rights or claims directly against any of the Financing Sources hereunder or thereunder.
Article
11
Miscellaneous
Section 11.01. Notices. All notices,
requests and other communications to any party hereunder shall be in writing (including facsimile transmission) and shall be given,
If to the Company, to:
Humana Inc.
500 West Main Street
Louisville, KY 40202
Attention: Law Department
Facsimile: (502) 580-2799
with a copy to (which shall not constitute notice):
Fried, Frank, Harris, Shriver & Jacobson LLP
One New York Plaza
New York, NY 10004
Attn: Jeffrey Bagner, Esq.
Brian Mangino, Esq.
Philip Richter, Esq.
Facsimile: (212) 859-4000
If to Parent, Merger Sub 1, Merger Sub 2 and, post-closing,
the Initial Surviving Corporation and the Surviving Company, to:
Aetna Inc.
151 Farmington Avenue, RC6A
Hartford, Connecticut 06156
Attention: General Counsel
Facsimile: (860) 273-8340
with a copy to (which shall not constitute notice):
Davis Polk & Wardwell LLP
450 Lexington Avenue
New York, New York 10017
Attn: David L. Caplan
H. Oliver Smith
Facsimile: (212) 701-5800
or to such other address or facsimile number as such party may
hereafter specify for the purpose by notice to the other parties hereto. All such notices, requests and other communications shall
be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. on a Business Day in the place
of receipt. Otherwise, any such notice, request or communication shall be deemed to have been received on the next succeeding Business
Day in the place of receipt.
Section 11.02. Survival. The representations,
warranties and agreements contained in this Agreement and in any certificate or other writing delivered pursuant hereto shall not
survive the First Merger Effective Time, except for the agreements set forth in Article 2, Section 7.04, Section 7.05 and this
Article 11.
Section 11.03. Amendments and Waivers.
(a) Any provision of this Agreement may be amended or waived prior to the First Merger Effective Time if, but only if, such
amendment or waiver is in writing and is signed, in the case of an amendment, by each party to this Agreement or, in the case of
a waiver, by each party against whom the waiver is to be effective; provided that after the Company Stockholder Approval
or the Parent Stockholder Approval has been obtained there shall be no amendment or waiver that would require the further approval
of the stockholders of the Company or the stockholders of Parent under Applicable Law without such approval having first been obtained.
(b) Notwithstanding anything to the
contrary in this Agreement, the provisions in Section 10.03(f), this Section 11.03(b), Section 11.06(a), Section 11.07, Section
11.08(b) or Section 11.09 may not be amended in a manner that is material and adverse to the Financing Sources without their prior
written consent.
(c) No failure or delay by any party
in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise
thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies
in this Agreement provided shall be cumulative and not exclusive of any rights or remedies provided by Applicable Law.
Section 11.04. Expenses. Except
as otherwise provided in this Agreement, all costs and expenses incurred in connection with this Agreement shall be paid by the
party incurring such cost or expense.
Section 11.05. Disclosure Schedule
References and SEC Document References. (a) The parties hereto agree that each section or subsection of the Company Disclosure
Schedule or the Parent Disclosure Schedule, as applicable, shall be deemed to qualify the corresponding section or subsection of
this Agreement, irrespective of whether or not any particular section or subsection of this Agreement specifically refers to the
Company Disclosure Schedule or the Parent Disclosure Schedule, as applicable. The parties hereto further agree that (other than
with respect to any items disclosed in Section 4.18(a) of the Company Disclosure Schedule, for which an explicit reference in any
other section shall be required in order to apply to such other section) disclosure of any item, matter or event in any particular
section or subsection of either the Company Disclosure Schedule or the Parent Disclosure Schedule shall be deemed disclosure with
respect to any other section or subsection of the Company Disclosure Schedule or the Parent Disclosure Schedule, as applicable,
to which the relevance of such disclosure would be reasonably apparent, notwithstanding the omission of a cross-reference to such
other section or subsections.
(b) The parties hereto agree that in
no event shall any disclosure contained in any part of any Company SEC Document or Parent SEC Document entitled “Risk Factors”,
“Forward-Looking Statements”, “Cautionary Note Regarding Forward-Looking Statements” or “Special
Note Regarding Forward Looking Statements” or containing a description or explanation of “Forward-Looking Statements”
or any other disclosures in any Company SEC Document or Parent SEC Document that are cautionary, predictive or forward-looking
in nature be deemed to be an exception to (or a disclosure for purposes of) any representations and warranties of any party contained
in this Agreement.
Section 11.06. Binding Effect; Benefit;
Assignment. (a) The provisions of this Agreement shall be binding upon and shall inure solely to the benefit of the parties
hereto, except for: (i) only following the First Merger Effective Time, the right of the Company’s stockholders and holders
of Company Equity Awards, as applicable, to receive (x) the Merger Consideration in respect of shares of Company Common Stock
pursuant to Section 2.02, (y) the applicable consideration or Assumed Stock Option in respect of Company Stock Options pursuant
to Section 2.07(a), and (z) the Award Consideration, Assumed Restricted Unit Award or Assumed Performance Unit Award payable in
respect of Company RSU Awards and Company PSU Awards pursuant to Sections 2.07(b) and 2.07(c), (ii) the right of the Company
on behalf of its stockholders to seek equitable relief or to pursue damages suffered by the Company (including claims for damages
based on loss of the economic benefit of the Mergers to the Company’s stockholders (taking into consideration relevant matters,
including other combination opportunities and the time value of money)) in the event of the wrongful termination of this Agreement
or Willful Breach of this Agreement by Parent, Merger Sub 1 or Merger Sub 2 (whether or not this Agreement has been terminated
pursuant to Section 10.01), which right is hereby expressly acknowledged and agreed by Parent, Merger Sub 1 and Merger Sub 2, (iii)
the right of the D&O Indemnified Parties to enforce the provisions of Section 7.04 only, and (iv) the right of each of the
Financing Sources as an express third-party beneficiary of Section 10.03(f), Section 11.03(b), this Section 11.06(a), Section 11.07,
Section 11.08(b) and Section 11.09. The third-party beneficiary rights referenced in clause (ii) of the preceding sentence may
be exercised only by the Company (on behalf of its stockholders as their agent) through actions expressly approved by the Board
of Directors of the Company, and no stockholder of the Company whether purporting to act in its capacity as a stockholder or purporting
to assert any right (derivatively or otherwise) on behalf of the Company, shall have any right or ability to exercise or cause
the exercise of any such right, and (iv) the right of the Company’s stockholders to require Parent to take all actions necessary
to cause the Second Merger to occur.
(b) No party may assign, delegate or
otherwise transfer any of its rights or obligations under this Agreement without the prior written consent of each other party
hereto, except that Parent may transfer or assign its rights and obligations under this Agreement, in whole or from time to time
in part, to any Person after the Closing, and each of Merger Sub 1 and Merger Sub 2 may transfer or assign its rights and obligations
under this Agreement, in whole or from time to time in part, to any other wholly owned Subsidiary of Parent, which Subsidiary shall
be, in the case of Merger Sub 1, a Delaware corporation, or, in the case of Merger Sub 2, a Delaware limited liability company;
provided that such transfer or assignment shall not relieve Parent, Merger Sub 1 or Merger Sub 2 of its obligations hereunder
or enlarge, alter or change any obligation of any other party hereto or due to Parent, Merger Sub 1 or Merger Sub 2.
Section 11.07. Governing Law.
This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts
of law rules of such state.
Section 11.08. Jurisdiction/Venue.
(a) Each of the parties hereto (i) irrevocably consents to the service of the summons and complaint and any other process in
any action or proceeding relating to the transactions contemplated hereby, on behalf of itself or its property, in accordance with
Section 11.01 or in such other manner as may be permitted by Applicable Law, and nothing in this Section 11.08 shall affect the
right of any party to serve legal process in any other manner permitted by Applicable Law, (ii) irrevocably and unconditionally
consents and submits itself and its property in any action or proceeding to the exclusive general jurisdiction of the Delaware
Court of Chancery and any state appellate court therefrom within the State of Delaware (or, only if the Delaware Court of Chancery
declines to accept
jurisdiction over a particular matter, any
federal court within the State of Delaware) in the event any dispute arises out of this Agreement or the transactions contemplated
hereby, or for recognition and enforcement of any judgment in respect thereof, (iii) agrees that it shall not attempt to deny or
defeat such personal jurisdiction by motion or other request for leave from any such court, (iv) agrees that any actions or proceedings
arising in connection with this Agreement or the transactions contemplated hereby shall be brought, tried and determined only in
the Delaware Court of Chancery (or, only if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter,
any federal court within the State of Delaware), (v) waives any objection that it may now or hereafter have to the venue of any
such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not
to plead or claim the same and (vi) agrees that it shall not bring any action relating to this Agreement or the transactions contemplated
hereby in any court other than the aforesaid courts. Each of Parent, Merger Sub 1, Merger Sub 2 and the Company agrees that a final
judgment in any action or proceeding in such court as provided above shall be conclusive and may be enforced in other jurisdictions
by suit on the judgment or in any other manner provided by Applicable Law.
(b) Notwithstanding anything herein
to the contrary, the parties hereto acknowledge and irrevocably agree (i) that any action or proceeding, whether in law or in equity,
whether in contract or tort or otherwise, involving the Financing Sources arising out of or related to the transactions contemplated
hereby, the Debt Financing or the performance of services thereunder or related thereto shall be subject to the exclusive jurisdiction
of any state or federal court sitting in the Borough of Manhattan, New York, New York, and any appellate court thereof and each
party hereto submits for itself and its property with respect to any such action or proceeding to the exclusive jurisdiction of
such court, and (ii) that any such action or proceeding shall be governed by, and construed in accordance with, the laws of the
State of New York, without regard to the conflicts of law rules of such State that would result in the application of the laws
of any other State.
Section 11.09. WAIVER OF JURY TRIAL.
EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND
DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO
A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE MERGERS OR
THE OTHER TRANSACTIONS CONTEMPLATED HEREBY (INCLUDING WITH RESPECT TO THE FINANCING SOURCES). EACH PARTY CERTIFIES AND ACKNOWLEDGES
THAT (i) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY
WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE
IMPLICATIONS OF THIS WAIVER, (iii) EACH PARTY MAKES THIS WAIVER VOLUNTARILY AND (iv) EACH PARTY HAS BEEN INDUCED TO ENTER INTO
THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 11.09.
Section 11.10. Counterparts; Effectiveness.
This Agreement may be signed in any number of counterparts, including by facsimile or by email with .pdf attachments, each of which
shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement
shall become effective when each party hereto shall have received a counterpart hereof signed and delivered (by electronic communication,
facsimile or otherwise) by all of the other parties
hereto. Until and unless each party has received
a counterpart hereof signed by the other party hereto, this Agreement shall have no effect and no party shall have any right or
obligation hereunder (whether by virtue of any other oral or written agreement or other communication).
Section 11.11. Entire Agreement.
This Agreement and the Confidentiality Agreement constitute the entire agreement between the parties with respect to the subject
matter thereof and supersedes all prior agreements and understandings, both oral and written, between the parties with respect
to the subject matter thereof.
Section 11.12. Severability. If
any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other Governmental
Authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement
shall remain in full force and effect and shall in no way be affected, impaired or invalidated so long as the economic or legal
substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such a determination,
the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely
as possible in an acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated
to the fullest extent possible.
Section 11.13. Specific Performance.
The parties acknowledge and agree that irreparable harm would occur and that the parties would not have any adequate remedy at
law (i) for any breach of the provisions of this Agreement or (ii) in the event that any of the provisions of this Agreement were
not performed in accordance with their specific terms. It is accordingly agreed that, except where this Agreement is terminated
in accordance with Section 10.01, the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement
and to specifically enforce the terms and provisions of this Agreement (including Section 7.06), without proof of actual damages,
and each party further agrees to waive any requirement for the securing or posting of any bond in connection with such remedy.
The parties further agree that (x) by seeking the remedies provided for in this Section 11.13, a party shall not in any respect
waive its right to seek any other form of relief that may be available to a party under this Agreement, including, subject to Section
10.03(e), monetary damages in the event that this Agreement has been terminated or in the event that the remedies provided for
in this Section 11.13 are not available or otherwise are not granted and (y) nothing contained in this Section 11.13 shall require
any party to institute any proceeding for (or limit any party’s right to institute any proceeding for) specific performance
under this Section 11.13 before exercising any termination right under Section 10.01 (and pursuing damages after such termination)
nor shall the commencement of any action pursuant to this Section 11.13 or anything contained in this Section 11.13 restrict or
limit any party’s right to terminate this Agreement in accordance with the terms of Section 10.01 or pursue any other remedies
under this Agreement that may be available then or thereafter.
[Remainder of page
intentionally left blank; signature pages follow]
IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.
|
HUMANA INC. |
|
|
|
By: |
/s/ Bruce D. Broussard |
|
|
Name: Bruce D. Broussard Title: President and Chief
Executive Officer |
|
ECHO MERGER SUB, INC. |
|
|
|
By: |
/s/ Bjorn B. Thaler |
|
|
Name: Bjorn B. Thaler Title: President |
|
ECHO MERGER SUB, LLC |
|
|
|
By: |
/s/ Bjorn B. Thaler |
|
|
Name: Bjorn B. Thaler Title: President |
|
AETNA INC. |
|
|
|
By: |
/s/ Mark T. Bertolini |
|
|
Name: Mark T. Bertolini Title: Chairman nad Chief Executive Officer |
[Signature
Page to Agreement and Plan of Merger]
Exhibit 2.2
EXECUTION VERSION
CITIGROUP GLOBAL MARKETS INC.
390 Greenwich Street
New York, New York 10013
|
UBS AG, STAMFORD BRANCH
677 Washington Boulevard
Stamford, Connecticut 06901
|
|
|
|
UBS SECURITIES LLC
1285 Avenue of the Americas
New York, New York 10019
|
|
CONFIDENTIAL
July 2, 2015
Aetna Inc.
151 Farmington Avenue
Hartford, CT 06156
Attention: David Buda
Vice President, Finance and Treasurer
Project Element
Bridge Facility Commitment Letter
Ladies and Gentlemen:
Aetna Inc., a Pennsylvania corporation
(the “Borrower” or “you”), has informed Citi (as defined below), UBS AG, Stamford Branch
(“UBS Bank”) and UBS Securities LLC (“UBS Securities” and, together with UBS Bank, “UBS”)
that the Borrower intends to acquire (the “Acquisition”) all the issued and outstanding equity interests in
an entity previously identified to us and codenamed “Hydrogen” (the “Acquired Company”
and, together with its subsidiaries, the “Acquired Business”) pursuant to the Agreement and Plan of Merger,
dated as of July 2, 2015, among Aetna Inc., Echo Merger Sub, Inc., Echo Merger Sub, LLC and Humana Inc. (together with the exhibits
and schedules thereto, the “Merger Agreement”) for consideration consisting of shares of the Borrower’s
common stock and cash. Capitalized terms used and not defined in this letter (together with Annexes A, B and C hereto, this “Commitment
Letter”) have the meanings assigned to them in Annex B hereto. Citi, UBS and any other Lenders that become parties to
this Commitment Letter as additional “Commitment Parties” as provided in Section 3 hereof are referred to herein,
collectively, as the “Commitment Parties”, “we” or “us”. For purposes
of this Commitment Letter, “Citi” shall mean Citigroup Global Markets Inc. (“CGMI”), Citibank,
N.A., Citicorp USA, Inc., Citicorp North America, Inc. and/or any of their affiliates as CGMI shall determine to be appropriate
to provide the services contemplated herein.
You have informed us that the cash consideration
payable in connection with the Acquisition and amounts required to pay expenses related to the Transactions will be obtained from
the following sources:
| · | available cash of the Borrower and the Acquired Business in the amount of approximately $3,300,000,000; |
| · | the issuance or incurrence by the Borrower of approximately $16,200,000,000 in aggregate principal
amount of any combination of (x) its senior notes (the “Notes”) pursuant to a registered public offering or
Rule 144A or other private placement (the “Notes Offering”), (y) its senior |
unsecured term
loans (the “Term Loans”) and/or (z) its commercial paper issued to finance the Acquisition (the “Commercial
Paper”);
or, in the event $16,200,000,000 in aggregate
principal amount of any combination of the Notes, the Term Loans and/or the Commercial Paper has not been issued on or prior to
the Closing Date, borrowings by the Borrower of term loans under a senior unsecured bridge facility having the terms set forth
on Annex B hereto (the “Facility”) in an aggregate principal amount of $16,200,000,000 less the net cash proceeds
received from the issuance of the Notes, the Term Loans and/or the Commercial Paper on or prior to the Closing Date.
1. Commitments; Titles and Roles.
In connection with the foregoing, (a) Citi
is pleased to commit, severally and not jointly, to provide 50% of the principal amount of the Facility, and UBS Bank is pleased
to commit, severally and not jointly, to provide 50% of the principal amount of the Facility, (b) Citi and UBS Securities are pleased
to confirm their agreement to act, and you hereby appoint Citi and UBS Securities to act, as joint lead arrangers and joint bookrunners
in connection with the Facility (in such capacities, the “Arrangers”), (c) Citibank, N.A. is pleased to confirm
its agreement to act, and you hereby appoint Citibank, N.A. to act, as sole administrative agent for the Facility and (d) UBS Securities
is pleased to confirm its agreement to act, and you hereby appoint UBS Securities to act, as sole syndication agent for the Facility,
in each case on the terms and subject to the conditions set forth in this Commitment Letter and the Fee Letter (as defined below);
provided that, the amount of the Facility shall be automatically reduced as provided under “Optional Commitment Reductions
and Prepayments” and “Mandatory Commitment Reductions and Prepayments” in Annex B hereto, and that any such reduction
will be allocated among the commitments of Citi and UBS Bank and the additional Commitment Parties ratably or, in the event a Successful
Syndication (as defined in the Fee Letter) shall not have been achieved during the Initial Syndication Period (as defined below),
in the manner determined by the Arrangers in consultation with the Borrower (it being agreed that the commitments of Citi and UBS
Bank will in any event be reduced by equal amounts).
It is agreed that, except during the Initial
Syndication Period as provided in the Syndication Plan (as defined below), (a) no other agents, co-agents, arrangers, co-arrangers
or bookrunners will be appointed and no other titles will be awarded unless the Arrangers and the Borrower shall so agree, and
(b) no compensation will be paid in connection with the Facility unless the Arrangers shall so agree.
The fees for, and other amounts to be paid
in connection with, the commitments of Citi and UBS Bank hereunder and the services of Citi and UBS related to the Facility are
set forth in an Arranger Fee Letter (the “Fee Letter”) being entered into by you, Citi and UBS on the date hereof.
2. Conditions Precedent.
Each of the Commitment Parties’ commitments
and agreements hereunder are subject to (a) the execution and delivery of a credit agreement (the “Credit Agreement”)
and other definitive documentation for the Facility prepared by counsel for Citi and UBS reflecting the terms set forth or referred
to in this Commitment Letter and the Fee Letter (modified as provided in the “Market Flex” provisions of the Fee Letter,
if applicable); and (b) the other conditions expressly set forth in Annex C hereto.
Notwithstanding anything herein to the
contrary, the terms of the Credit Agreement will be such that they do not impair the availability of the Facility on the Closing
Date if the conditions set forth in this Section 2 and in Annex C hereto are satisfied.
3. Syndication.
The Arrangers reserve the right, in accordance
with the provisions of this Section 3, prior to or after the Closing Date, to syndicate the Facility to the Lenders. During
the period of 45 days following the date of this Commitment Letter (the “Initial Syndication Period”), the syndication
of the Facility, including determinations as to the timing of offers to prospective Lenders, the selection of Lenders, the acceptance
and final allocation of commitments, the awarding of titles or roles to any Lenders and the amounts offered and the compensation
provided to each Lender from the amounts to be paid to the Arrangers pursuant to the terms of this Commitment Letter and the Fee
Letter, will be conducted jointly by the Arrangers and the Borrower and, except to the extent the Arrangers and the Borrower otherwise
agree, in accordance with the syndication plan heretofore discussed by such parties (the “Syndication Plan”).
Without limiting the foregoing, the Facility will be syndicated during the Initial Syndication Period only to Lenders identified
in the Syndication Plan (“Designated Lenders”). Following the Initial Syndication Period, if and for so long
as a Successful Syndication has not been achieved, the syndication of the Facility shall be conducted by the Arrangers in consultation
with the Borrower, and departures may be made from the Syndication Plan (including in the selection of Lenders) after consultation
with the Borrower and to the extent required in the reasonable judgment of the Arrangers to achieve a Successful Syndication. In
connection with any commitments received from Designated Lenders selected in accordance with this paragraph (or other Lenders approved
in writing by you), whether before or after the Initial Syndication Period (but prior to the execution and delivery of the Credit
Agreement), you agree, at the request of the Arrangers, to enter into one or more customary joinder agreements providing for such
additional Lenders to become additional Commitment Parties under this Commitment Letter and extend commitments in respect of the
Facility directly to you (it being agreed that, subject to the second paragraph of Section 1, such joinder agreements
will contain such provisions relating to titles, the allocation of any reductions in the amount of the Facility and other matters
relating to the relative rights of the Arrangers and such additional Commitment Parties as the Arrangers may reasonably request,
which provisions, in the case of any joinder agreement entered into during the Initial Syndication Period, will be consistent with
the Syndication Plan). The commitments of Citi and UBS Bank hereunder with respect to the Facility shall be reduced on a pro rata
basis dollar-for-dollar by the amount of each commitment for the Facility received from a Designated Lender (or other Lender approved
in writing by you) upon such Lender becoming a party to this Commitment Letter as an additional “Commitment Party”
pursuant to a joinder agreement or a party to the Credit Agreement as a Lender.
You and the Arrangers agree to use commercially
reasonable efforts to negotiate, execute and deliver the Credit Agreement (with the Lenders selected as provided in this Section 3
as parties thereto) as promptly as practicable and in any event within 60 days following the date of this Commitment Letter.
You agree to use your commercially reasonable
efforts to ensure that the Arrangers’ syndication efforts benefit from your and your affiliates’ existing relationships
with banks and other financial institutions. To facilitate an orderly and successful syndication of the Facility, you agree that,
until the earlier of (a) the achievement of a Successful Syndication and (b) 90 days following the date of initial funding
under the Facility (such earlier date being called the “Syndication Date”), you will not, and will not permit
any of your subsidiaries to, and will use commercially reasonable efforts to cause the Acquired Business not to, syndicate or issue,
attempt to syndicate or issue or announce or authorize the announcement of the syndication or issuance (or plans for the syndication
or issuance) of, any debt or credit facility or any debt security of the Borrower or any of its subsidiaries or of the Acquired
Business (other than (i) the Facility, (ii) the Notes, the Term Loans and the Commercial Paper, (iii) prior to the closing of the
Acquisition, any indebtedness of the Acquired Business permitted to be incurred under the Merger Agreement, (iv) Excluded
Debt and (v) one or more commitment increases of up to $1,000,000,000 in the aggregate in respect of the Borrower’s existing
revolving credit facility under the Existing Credit Agreement), without the prior written consent of the Arrangers (such consent
may be
withheld only if, in the reasonable judgment
of the Arrangers, such financing, syndication or placement would be likely to have a materially detrimental effect on the ability
of the Arrangers to syndicate the Facility).
The Arrangers and the Borrower intend to
commence syndication efforts promptly after the execution and delivery of this Commitment Letter. To assist the Arrangers in such
syndication efforts, until the Syndication Date, you agree (a) to prepare and provide, and to use commercially reasonable efforts
to cause the Acquired Business to prepare and provide, customary information with respect to the Borrower and its subsidiaries,
the Acquired Business and the transactions contemplated hereby reasonably requested by the Arrangers in connection with the syndication
of the Facility and (b) to cooperate, and to use commercially reasonable efforts to cause the Acquired Business to cooperate, with
the Arrangers in connection with (i) the preparation of one or more information packages (collectively, the “Confidential
Information Memorandum”) containing such information regarding the business, operations, assets, liabilities, financial
position, pro forma financial statements, projections and prospects of the Borrower and its subsidiaries, the Acquired Business
and the transactions contemplated hereby as shall be reasonably deemed necessary by the Arrangers to complete the syndication of
the Facility, (ii) the presentation of one or more information packages reasonably acceptable in format and content to the Arrangers
(collectively, the “Lender Presentation”) in a reasonable number of meetings and other communications with prospective
Lenders in connection with the syndication of the Facility at times to be mutually agreed and upon reasonable notice (including
through direct contact between senior management and representatives, with appropriate seniority and expertise, of the Borrower
and prospective Lenders and participation of such persons in a reasonable number of meetings with prospective Lenders) and (iii)
the obtaining as promptly as practicable of a public rating of the Borrower’s Index Debt from Moody’s Investor Services,
Inc. (“Moody’s”) and a public rating of the Borrower’s Index Debt from Standard & Poor’s
Ratings Group, a division of The McGraw Hill Corporation (“S&P”), in each case taking into account the Transactions.
You will be solely responsible for the contents of the Confidential Information Memorandum, the Lender Presentation and all other
information, documentation or other materials delivered to the Arrangers in connection therewith, and acknowledge that the Arrangers
will be using and relying upon such information without independent verification thereof.
Notwithstanding anything to the contrary
set forth in this Commitment Letter or the Fee Letter or any other agreement, the commencement or completion of any syndication
of the Facility, obtaining of ratings and compliance with this Commitment Letter shall in no event constitute a condition precedent
to the commitments hereunder or the funding of the Facility on the Closing Date.
You agree that information regarding the
Facility and the Information provided by or on behalf of the Borrower or its affiliates to the Arrangers in connection with the
Facility or the other transactions contemplated hereby (including draft and execution versions of the Credit Agreement, the Confidential
Information Memorandum, the Lender Presentation, publicly filed financial statements, and draft or final offering materials relating
to contemporaneous or prior securities issuances by the Borrower) may be disseminated to prospective Lenders and other persons
through one or more internet sites (including an IntraLinks, SyndTrak or other electronic workspace (the “Platform”))
created for purposes of syndicating the Facility or otherwise, in accordance with the Arrangers’ standard syndication practices,
and you acknowledge that neither the Arrangers nor any of their affiliates will be responsible or liable to you or any other person
or entity for damages arising from the use by others of any Information or other materials obtained on the Platform.
You acknowledge that certain of the Lenders
may be “public side” Lenders that do not wish to receive material non-public information within the meaning of federal,
state or other applicable securities laws with respect to the Borrower, the Acquired Business, their respective affiliates or any
securities of any of
the foregoing (such information being called
“MNPI” and each such Lender being called a “Public Lender”). At the request of the Arrangers,
you agree to prepare, and to use your commercially reasonable efforts to cause the Acquired Business to assist in the preparation
of, an additional version of the Confidential Information Memorandum and the Lender Presentation to be used by Public Lenders that
does not contain MNPI. It is understood that, in connection with your assistance described above, you will provide, and use commercially
reasonable efforts to cause all other applicable persons to provide, authorization letters to the Arrangers authorizing the distribution
of the Information to prospective Lenders and containing a representation to the Arrangers that such versions of the Confidential
Information Memorandum and the Lender Presentation do not contain MNPI. In addition, you agree upon our reasonable request clearly
to designate as such all Information provided to the Arrangers by or on behalf of the Borrower, the Acquired Business or their
respective affiliates that is suitable to make available to Public Lenders (it being agreed that distribution of any Information
that is not so identified may be restricted by the Arrangers to Lenders that are not Public Lenders). You acknowledge and agree
that the following documents may, after you shall have been given a reasonable opportunity to review them, be distributed to Public
Lenders (unless you notify the Arrangers in writing prior to such distribution that any such document contains MNPI): (a) drafts
and final versions of the Credit Agreement, (b) administrative materials prepared by the Arrangers for prospective Lenders (such
as a lender meeting invitation, allocations and funding and closing memoranda) and (c) term sheets and notification of changes
in the terms and conditions of the Facility.
4. Information.
You represent and warrant that (a) all
information (other than financial projections and other forward-looking information and information of a general economic or industry
nature) (the “Information”) provided by or on behalf of the Borrower or its representatives to the Commitment
Parties or the Lenders in written form (including, for the avoidance of doubt, all Information set forth in the Confidential Information
Memorandum) does not and will not, when furnished, contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements contained therein not materially misleading when taken as a whole and in light of the circumstances
under which such statements were made (giving effect to any supplements then or theretofore furnished) and (b) the financial projections
provided by or on behalf of the Borrower or its representatives to the Commitment Parties or the Lenders in connection with the
Facility have been and will be prepared in good faith based upon assumptions that are believed by the Borrower to be reasonable
at the time such financial projections are furnished to the Commitment Parties or the Lenders, it being understood and agreed that
financial projections are not a guarantee of financial performance and are subject to significant uncertainties and contingencies,
many of which are beyond the Borrower’s and/or the Acquired Business’ control, that no assurance can be given that
such financial projections will be realized, that actual results may differ from financial projections and that such differences
may be material; provided that, prior to the consummation of the Acquisition, such representation with respect to any Information
relating to the Acquired Business or its affiliates is made only to the best of your knowledge. You agree that if at any time prior
to the later of (i) the Closing Date and (ii) the Syndication Date, any of the representations in the preceding sentence would
be incorrect if such Information or such financial projections were being furnished, and such representations were being made,
at such time, then you will (or with respect to Information or financial projections relating to the Acquired Business, you will
use commercially reasonable efforts to) promptly supplement, or cause to be supplemented, such Information or such financial projections
so that such representations will be correct under those circumstances. In arranging and syndicating the Facility, the Arrangers
will be entitled to use and rely on the Information and the financial projections without responsibility for independent verification
thereof, and you acknowledge and agree that the Arrangers will have no obligation to conduct any independent evaluation or appraisal
of the assets or liabilities of the Borrower, the Acquired Business or any other person or to advise or opine on any related solvency
issues.
5. Indemnification and Related
Matters.
In connection with arrangements such as
this, it is the policy of the Commitment Parties to receive indemnification. You agree to the provisions with respect to our indemnity
and other matters set forth in Annex A, which is incorporated by reference into this Commitment Letter.
6. Assignments.
This Commitment Letter may not be assigned
by you without the prior written consent of the Arrangers (and any purported assignment without such consent will be null and void)
and, except as set forth in Annex A hereto, is intended to be solely for the benefit of the parties hereto and is not intended
to confer any benefits upon, or create any rights in favor of or be enforceable by or at the request of, any person other than
the parties hereto. Any Commitment Party may assign its commitment and agreements hereunder, in whole or in part, to any of its
affiliates and, in the case of Citi and UBS Bank, as part of the syndication of the Facility, subject to the provisions of Section 3
hereof, to any Lender; provided that, except as contemplated by Section 3 hereof or as otherwise agreed in writing
by the Borrower, in the event that, notwithstanding the satisfaction of all applicable conditions to funding, any Lender (other
than a Designated Lender or another Lender approved in writing by the Borrower) shall default on its obligation to fund its commitment
in respect of the Facility on the Closing Date, each of Citi and UBS Bank shall remain severally obligated to assume its ratable
share of the unfunded commitment of such Lender and to fund such share of such commitment.
7. Confidentiality.
Please note that this Commitment Letter
and the Fee Letter, the terms hereof and thereof and any written communications provided by, or oral discussions with, the Arrangers
in connection with this arrangement are exclusively for your information and may not be disclosed by you to any other person or
circulated or referred to publicly without the prior written consent of the Arrangers; provided that we hereby consent to
your disclosure of (a) this Commitment Letter and the Fee Letter, the terms hereof and thereof and such communications and discussions
(i) to your officers, directors, employees, partners, agents and advisors who are directly involved in the consideration of the
Facility and who have been advised by you of the confidential nature of such information or (ii) pursuant to a subpoena or order
issued by a court or by judicial, administrative or legislative body or committee, or as otherwise required by applicable law or
compulsory legal process (in which case you agree to inform the Arrangers promptly thereof to the extent not prohibited by law)
or required or requested by governmental and/or regulatory authorities, (b) this Commitment Letter and the terms hereof, and a
version of the Fee Letter that shall have been redacted in a manner reasonably acceptable to the Arrangers (but not any of the
other terms of the Fee Letter), to the Acquired Company and to the Acquired Company’s officers, directors, employees, partners,
agents and advisors who are directly involved in the consideration of the Facility and who have been advised of the confidential
nature of such information, (c) information regarding the Facility (but not the Fee Letter or the terms thereof) in any prospectus
or other offering memorandum relating to the offering of the Notes or any filing with the Securities and Exchange Commission or
any other governmental authority in connection with the Acquisition (provided, that the Borrower may include the aggregate
amount payable as fees under the Fee Letter as part of aggregate transaction expenses in a customary sources and uses disclosure
in any such filing) and (d) information regarding the Facility and the related transactions (but not the Fee Letter or the terms
thereof) to Moody’s and S&P on a confidential basis after consultation with the Arrangers. Notwithstanding the foregoing,
following your acceptance hereof, the Commitment Letter (but not the Fee Letter) may be filed with the Securities and Exchange
Commission, and thereafter the foregoing restrictions on the disclosure of the Commitment Letter shall no longer apply.
Each Commitment Party will treat as confidential
all confidential information provided to it by or on behalf of the Borrower or the Acquired Business hereunder; provided,
that nothing herein shall prevent the Commitment Parties from disclosing any such information (i) to any Lenders or participants
or prospective Lenders or participants or to any direct or indirect contractual counterparties to any swap or derivative transaction
relating to the Borrower or its obligations under the Facility (collectively, “Specified Counterparties”), (ii)
to its affiliates and its and their respective officers, directors, members, partners, agents, advisors, employees and representatives
on a confidential and need-to-know basis, (iii) pursuant to a subpoena or order issued by a court or by a judicial, administrative
or legislative body or committee, or as otherwise required by applicable law or compulsory legal process or required or requested
by governmental and/or regulatory authorities, including any self-regulatory organization (in which case such Commitment Party
agrees to inform the Borrower promptly thereof to the extent not prohibited by law, except to the extent in connection with a request
from a regulatory authority having jurisdiction over it or its affiliates), (iv) as requested by any state, federal or foreign
authority or examiner regulating banks or banking or otherwise having jurisdiction over such Commitment Party or its affiliates,
(v) in connection with the exercise of any remedies hereunder or any suit, action or proceeding relating to this Commitment Letter
or the Fee Letter, or enforcement hereof or thereof, or the assertion of any due diligence defense, (vi) to the extent such confidential
information is publicly available or becomes publicly available other than as a result of a breach of this provision, (vii) provided
to it from a source, other than the Borrower, the Acquired Business or their respective affiliates, which is not to such Commitment
Party’s knowledge subject to any confidentiality or fiduciary obligation to the Borrower or the Acquired Business with respect
to such information, (viii) to Moody’s and S&P and other rating agencies or to market data collectors or similar service
providers to the lending industry and service providers to the Arrangers and the Lenders in connection with the administration
and management of the Facility; provided that such information is limited to Annex B and Annex C hereto and is supplied
only on a confidential basis, and (ix) to the extent that such information was already in the Commitment Parties’ possession
(other than as a result of any Commitment Party being provided such information by or on behalf of the Borrower or the Acquired
Business hereunder) or is independently developed by the Commitment Parties; provided, that the disclosure of any such information
to any Lenders or prospective Lenders or participants or prospective participants or Specified Counterparties referred to above
shall be made subject to the acknowledgment and acceptance by such Lender or prospective Lender or participant or prospective participant
or Specified Counterparty that such information is being disseminated on a confidential basis in accordance with the standard syndication
process of the Arrangers or customary market standards for dissemination of such types of information, subject to customary confidentiality
restrictions that are no less restrictive in any material respect than those in this paragraph; and provided, further,
that the foregoing obligations of the Commitment Parties shall remain in effect until the earlier of (i) 18 months from the date
hereof and (ii) the execution and delivery of the Credit Agreement by the parties thereto, at which time any confidentiality undertaking
in the Credit Agreement shall supersede the provisions in this paragraph. Notwithstanding the foregoing, following your filing
of the Commitment Letter with the Securities and Exchange Commission, the foregoing restrictions shall no longer apply insofar
(and only insofar) as they relate to the disclosure of this Commitment Letter and the terms hereof.
Notwithstanding anything herein to the
contrary, the Borrower (and each employee, representative or other agent of the Borrower) may disclose to any and all persons,
without limitation of any kind, the tax treatment and tax structure of the Facility and all materials of any kind (including opinions
or other tax analyses) that are provided to the Borrower relating to such tax treatment and tax structure. However, any information
relating to the tax treatment or tax structure will remain subject to the confidentiality provisions hereof (and the foregoing
sentence will not apply) to the extent reasonably necessary to enable the parties hereto, their respective affiliates and their
respective affiliates’ directors and employees to comply with applicable securities laws. For this purpose, “tax treatment”
means U.S. federal or state income tax treatment, and “tax structure” is limited to any facts relevant to the U.S.
federal income tax
treatment of the transactions contemplated
by this Commitment Letter but does not include information relating to the identity of the parties hereto or any of their respective
affiliates.
8. Absence of Fiduciary Relationship;
Affiliates; Etc.
As you know, each of the Arrangers (together
with their affiliates, the “Arranger Parties”), is a full service financial institution engaged, either directly
or through its affiliates, in a broad array of activities, including commercial and investment banking, financial advisory, market
making and trading, investment management (both public and private investing), investment research, principal investment, financial
planning, benefits counseling, risk management, hedging, financing, brokerage and other financial and non-financial activities
and services globally. In the ordinary course of their various business activities, each of the Arranger Parties and funds or other
entities or persons in which each of the Arranger Parties co-invests may at any time purchase, sell, hold or vote long or short
positions and investments in securities, derivatives, loans, commodities, currencies, credit default swaps and other financial
instruments for their own account and for the accounts of their customers. In addition, each of the Arranger Parties may at any
time communicate independent recommendations and/or publish or express independent research views in respect of such assets, securities
or instruments. Any of the aforementioned activities may involve or relate to assets, securities and/or instruments of the Borrower,
the Acquired Business, their respective affiliates and other entities and persons that may be involved in transactions arising
from or relating to the arrangement contemplated by this Commitment Letter or have other relationships with the Borrower, the Acquired
Business or their respective affiliates. In addition, each of the Arranger Parties may provide investment banking, commercial banking,
underwriting and financial advisory services to such other entities and persons. The arrangement contemplated by this Commitment
Letter may have a direct or indirect impact on the investments, securities or instruments referred to in this paragraph, and employees
working on the financing contemplated hereby may have been involved in originating certain of such investments and those employees
may receive credit internally therefor. Although the Arranger Parties in the course of such other activities and relationships
may acquire information about the transactions contemplated by this Commitment Letter or other entities and persons that may be
the subject of the financing contemplated by this Commitment Letter, none of the Arranger Parties shall have any obligation to
disclose such information, or the fact that such Arranger Party is in possession of such information, to you or any of your affiliates
or to use such information on your or your affiliates’ behalf.
Consistent with the policies of each of
the Arranger Parties to hold in confidence the affairs of its customers, neither of the Arranger Parties will furnish confidential
information obtained from you by virtue of the transactions contemplated by this Commitment Letter to any of its other customers.
Furthermore, you acknowledge that the Arranger Parties and their respective affiliates have no obligation to use in connection
with the transactions contemplated by this Commitment Letter, or to furnish to you, confidential information obtained or that may
be obtained by them from any other person.
Each of the Arranger Parties may have economic
interests that conflict with yours or those of your equityholders or affiliates. You agree that each of the Arranger Parties will
act under this Commitment Letter as an independent contractor and that nothing in this Commitment Letter or the Fee Letter will
be deemed to create an advisory, fiduciary or agency relationship or fiduciary or other implied duty between either Arranger Party,
on the one hand, and you or your equityholders or affiliates, on the other hand with respect to the financing transactions contemplated
hereby. You acknowledge and agree that the financing transactions contemplated by this Commitment Letter and the Fee Letter (including
the exercise of rights and remedies hereunder and thereunder) are arm’s-length commercial transactions between each of the
Arranger Parties, on the one hand, and you, on the other hand, and in connection therewith and with the process leading thereto,
(a) neither of the Arranger Parties has assumed advisory or fiduciary responsibilities in favor of you or your equityholders or
affiliates with respect to the financing
transactions contemplated hereby (or the
exercise of rights or remedies with respect thereto) or the process leading thereto (irrespective of whether any Arranger Party
has advised, is currently advising or will advise you or your equityholders or affiliates on other matters) or any other obligation
to you, except the obligations expressly set forth in this Commitment Letter and the Fee Letter and (b) each of the Arranger Parties
is acting solely as a principal and not as an agent or fiduciary of you or your management, equityholders, affiliates, creditors
or any other person in connection with the financing transactions contemplated by this Commitment Letter and the Fee Letter. You
acknowledge and agree that you have consulted your own legal and financial advisors to the extent you deemed appropriate and that
you are responsible for making your own independent judgment with respect to such financing transactions and the process leading
thereto. You agree that you will not claim that either of the Arranger Parties has rendered advisory services of any nature or
respect, or owes a fiduciary or similar duty to you, in connection with such financing transactions or the process leading thereto.
As you know, Citi has been retained by you as financial advisor, and, prior to the date hereof, UBS had been retained by you as
financial advisor (each, in such capacity, the “Financial Advisors”) in connection with the Acquisition.
You agree not to assert any claim you might allege based on any actual or potential conflicts of interest that might be asserted
to arise or result from, on the one hand, the engagement of the Financial Advisors and, on the other hand, the Arranger Parties
and their affiliates’ relationships with you as described and referred to herein. In addition, the Arranger Parties may employ
the services of their affiliates in providing services and/or performing their obligations hereunder and may exchange with such
affiliates information concerning the Borrower, the Acquired Business and other entities or persons that may be the subject of
this arrangement, and such affiliates will be entitled to the benefits afforded to the Arranger Parties hereunder.
In addition, please note that the Arranger
Parties do not provide accounting, tax or legal advice.
9. Miscellaneous.
The Commitment Parties’ commitments
and agreements hereunder will automatically terminate upon the first to occur of (a) the consummation of the Acquisition, (b) the
termination of the Merger Agreement or the public announcement by you of your intention not to proceed with the Acquisition, (c)
the execution of the Credit Agreement by the parties thereto and (d) the End Date (as defined in the Merger Agreement as in effect
on the date hereof).
The provisions set forth under Sections
5 (including Annex A), 7 and 8 hereof and this Section 9 and the provisions of the Fee Letter will remain in full force and
effect notwithstanding the expiration or termination of this Commitment Letter or the commitments and agreements hereunder; provided
that your and our obligations under this Commitment Letter (other than those under Sections 3, 4, 7 (solely as it relates to
restrictions on your disclosure of the Fee Letter), 8 and, to the extent applicable, this Section 9 and the provisions of
the Fee Letter, all of which shall survive), shall automatically terminate and be of no further force and effect (and, if applicable,
shall be superseded by the Credit Agreement) on the date the Credit Agreement is executed, and you and we shall be automatically
released from all liability hereunder in connection therewith at such time (provided, that Section 5 (including Annex
A) will so terminate and be superseded only to the extent the Credit Agreement contains provisions affording the Commitment Parties
rights to expense reimbursement and indemnity not less comprehensive than those provided for in such Section 5).
Each party hereto agrees, for itself
and its affiliates, that any suit, action or proceeding arising in respect of this Commitment Letter or the Commitment Parties’
commitments or agreements hereunder or the Fee Letter brought by it or any of its affiliates shall be brought, and shall be heard
and determined, exclusively in any Federal court of the United States of America sitting in the Borough of Manhattan or, if that
court does not have subject matter jurisdiction, in any state
court located in the City and County
of New York. Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the jurisdiction
of, and to venue in, such court and irrevocably and unconditionally waives any objection which it may now or hereafter have to
the laying of venue of any suit, action or proceeding arising in respect of this Commitment Letter or the Commitment Parties’
commitments or agreements hereunder or the Fee Letter in any such court and any defense of any inconvenient forum to the maintenance
of any such suit, action or proceeding in any such court. Each of the parties hereto agrees that a final judgment in any such suit,
action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner
provided by law. Service of any process, summons, notice or document by registered mail or overnight courier addressed to any of
the parties hereto at the addresses above (and, in the case of service upon the Borrower, with a copy delivered by registered mail
or overnight courier addressed to Aetna Inc., 151 Farmington Avenue, Hartford, CT 06156, Attention: General Counsel) shall be effective
service of process against such party for any such suit, action or proceeding brought in any court. Any right to trial by jury
with respect to any suit, action or proceeding arising in connection with or as a result of either the Commitment Parties’
commitments or agreements hereunder or the Fee Letter or any matter referred to in this Commitment Letter or the Fee Letter is
hereby irrevocably and unconditionally waived by the parties hereto. This Commitment Letter and the Fee Letter will be governed
by and construed in accordance with the laws of the State of New York without regard to principles of conflicts of laws; provided
that (a) the interpretation of the definition of Company Material Adverse Effect and whether there shall have occurred a Company
Material Adverse Effect, (b) whether the Acquisition has been consummated as contemplated by the Merger Agreement and (c) whether
the representations and warranties made by the Acquired Company in the Merger Agreement are accurate and whether as a result of
any inaccuracy thereof the Borrower has the right to terminate its obligations under the Merger Agreement or not to consummate
the Acquisition, shall be determined in accordance with the laws of the State of Delaware without regard to principles of conflicts
of laws that would result in the application of the laws of another jurisdiction.
The Arrangers hereby notify you that pursuant
to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Patriot
Act”) the Arrangers and each Lender may be required to obtain, verify and record information that identifies the Borrower,
which information includes the name and address of the Borrower and other information that will allow the Arrangers and each Lender
to identify the Borrower in accordance with the Patriot Act. This notice is given in accordance with the requirements of the Patriot
Act and is effective for the Arrangers and each Lender.
This Commitment Letter may be executed
in any number of counterparts, each of which when executed will be an original, and all of which, when taken together, will constitute
one agreement. Delivery of an executed counterpart of a signature page of this Commitment Letter by facsimile transmission or electronic
transmission (in pdf format) will be effective as delivery of a manually executed counterpart hereof. This Commitment Letter and
the Fee Letter are the only agreements that have been entered into among the parties hereto with respect to the Facility and set
forth the entire understanding of the parties hereto with respect thereto and supersede any prior written or oral agreements between
the parties hereto with respect to the Facility. This Commitment Letter may not be amended, and no term or provision hereof may
be waived or modified, except by an instrument in writing signed by each of the parties hereto; provided, that any amendment, waiver
or modification that affects only the rights or obligations of Citi and UBS may be effected by the Borrower and Citi and UBS without
the consent of any other Commitment Party. The Fee Letter may not be amended, and no term or provision thereof may be waived or
modified, except by an instrument in writing signed by each of the parties thereto.
[Remainder of page intentionally left blank]
Please confirm that the foregoing is in
accordance with your understanding by signing and returning to the Arrangers the enclosed copy of this Commitment Letter, together,
if not previously executed and delivered, with the Fee Letter, on or before the close of business on July 3, 2015, whereupon this
Commitment Letter and the Fee Letter will become binding agreements between Citi, UBS and you. If this Commitment Letter and the
Fee Letter have not been signed and returned as described in the preceding sentence by such date, this offer will terminate on
such date. We look forward to working with you on this transaction.
|
Very truly yours, |
|
|
|
CITIGROUP GLOBAL MARKETS INC. |
|
|
|
By: |
/s/ Maureen Maroney |
|
|
Name: Maureen R.
Maroney Title: Authorized Signatory |
|
UBS SECURITIES LLC |
|
|
|
By: |
/s/ Luke Bartolone |
|
|
Name: Luke
Bartolone Title: Director |
|
By: |
/s/ David W. Barth |
|
|
Name: David W.
Barth Title: Managing Director
Leveraged Capital Markets |
|
UBS AG, STAMFORD BRANCH |
|
|
|
By: |
/s/ Luke Bartolone |
|
|
Name: Luke
Bartolone Title: Director |
|
By: |
/s/ David W. Barth |
|
|
Name: David W.
Barth Title: Managing Director
Leveraged Capital Markets |
[Signature Page to Commitment Letter]
ACCEPTED AND AGREED AS OF
THE DATE FIRST SET FORTH ABOVE:
AETNA INC. |
|
By: |
/s/ David Buda |
|
Name: David Buda Title: Vice President, Finance and Treasurer |
[Signature Page to Commitment Letter]
ANNEX A
You agree to indemnify and hold each
Indemnified Person (as defined below) harmless against (and, in the case of expenses, to reimburse each Indemnified Person as the
same are incurred for, promptly following written demand thereof) any and all losses, claims, damages, liabilities and expenses
to any person, including you, the Acquired Business or any of your or its equityholders or affiliates, and any reasonable out-of-pocket
legal and other expenses, in each case arising out of any investigation, litigation, claim or proceeding in connection with or
as a result of the transactions contemplated by this Commitment Letter or the Fee Letter (together the “Letters”
(whether or not such investigation, litigation, claim or proceeding is brought by you, the Acquired Business or any of your or
its equityholders, affiliates or creditors or any Indemnified Person and whether or not any Indemnified Person is otherwise a party
thereto), except to the extent that (and only for so long as) such loss, claim, damage, liability or related expense (a) has been
found by a judgment of the highest court of competent jurisdiction to have considered such matter to have resulted from the bad
faith, gross negligence or willful misconduct of such Indemnified Person (or any of its controlling persons or subsidiaries of
controlling persons or any of their or such Indemnified Person’s partners, members, directors, agents, employees or controlling
persons) in performing the services that are the subject of the Letters, or the material breach of the material agreements of such
Indemnified Person set forth in one or both of the Letters or (b) arises out of or is in connection with any claim, litigation,
loss or proceeding not involving an act or omission of you or any of your affiliates or related parties or the Acquired Business
and that is brought by an Indemnified Person against another Indemnified Person (other than against any of the Arrangers, the Administrative
Agent or other bookrunner in their capacities as such). If for any reason the foregoing indemnification is unavailable to any Indemnified
Person or insufficient to hold it harmless, then you will contribute to the amount paid or payable by such Indemnified Person as
a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect (a) the relative economic interests
of (i) you, the Acquired Business and your and its equityholders and affiliates, on the one hand and (ii) such Indemnified Person
on the other hand, in the matters contemplated by the Letters, and if (but only if and to the extent) the allocation provided for
in the immediately preceding clause (a) is for any reason held to be unenforceable, (b) the relative fault of (1) you, the Acquired
Business and your and its equityholders and affiliates, on the one hand and (2) such Indemnified Person on the other hand, with
respect to such loss, claim, damage or liability and any other relevant equitable considerations. Your reimbursement, indemnity
and contribution obligations under this paragraph shall be in addition to any liability or obligation that you may otherwise have,
shall extend upon the same terms and conditions to each affiliate of each Commitment Party and the partners, members, directors,
agents, employees and controlling persons and subsidiaries of such controlling persons, as the case may be, of such Commitment
Party and each such affiliate (collectively, the “Indemnified Persons”), and will be binding upon and inure
to the benefit of any successors, assigns, heirs and personal representatives of you, such Commitment Party, each such affiliate
and any such person. You will not be required to indemnify the Indemnified Persons for any amount paid or payable by the Indemnified
Persons in the settlement of any action, proceeding or investigation without your written consent (such consent not to be unreasonably
withheld), but you agree to indemnify and hold harmless each Indemnified Person from and against any loss or liability by reason
of the settlement of any claim or action with your consent. You shall not settle any such claim or action without the prior written
consent of the applicable Indemnified Persons (such consent not to be unreasonably withheld) unless such settlement provides for
a full and unconditional release of all liabilities arising out of such claim or action against such Indemnified Persons. You also
agree that none of the Indemnified Persons will have any liability to you or any person asserting claims on behalf of or in right
of you in connection with or as a result of either this arrangement or any matter referred to in the Letters, except, in the case
of any such liability to you, to the extent that (and only for so long as) any losses, claims, damages, liabilities or expenses
incurred by you have been found by a judgment of the highest court of competent jurisdiction to have considered such matter to
have resulted from the bad faith, gross negligence or willful misconduct of such Indemnified Person (or any of its controlling
persons or subsidiaries of controlling persons or any of their or such Indemnified Person’s
partners, members, directors,
agents, employees or controlling persons) in performing the services that are the subject of the Letters, or the material breach
of the material agreements of such Indemnified Person set forth in the Letters; provided, however, that in no event
will you or any Indemnified Person have any liability for any indirect, special, consequential or punitive damages in connection
with or as a result of the transactions contemplated by the Letters (it being agreed, however, that your indemnity and contribution
obligations, as set forth in the preceding provisions of this Annex A, will apply in respect of any indirect, special, consequential
or punitive damages that may be awarded against any Indemnified Person).
Notwithstanding the foregoing, (x) the
Borrower’s obligation to reimburse legal expenses shall be limited to the fees, charges and disbursements of one counsel
for all Indemnified Persons (and, if reasonably necessary, one local counsel plus one specialist counsel in, respectively, any
relevant jurisdiction or applicable specialty), which, if the Arrangers or their affiliates shall be parties or potential parties
to any such action or proceeding, shall be selected by the Arrangers, and, solely in the case of an actual or potential conflict
of interest affecting any Indemnified Person or Indemnified Persons, of one additional counsel (and if reasonably necessary, one
local counsel plus one specialist counsel in, respectively, any relevant jurisdiction or applicable specialty) for the affected
Indemnified Person or Indemnified Persons and (y) to the extent that it is found by a judgment of the highest court of competent
jurisdiction to have considered such matter that an Indemnified Person is not entitled to indemnification because such loss, claim,
damage or liability resulted from the bad faith, gross negligence or willful misconduct of such Indemnified Person (or any of its
controlling persons or subsidiaries of controlling persons or any of their or such Indemnified Person’s partners, members,
directors, agents, employees or controlling persons) in performing the services that are the subject of the Letters, or the material
breach of the material agreements of such Indemnified Person set forth in one or both of the Letters, then such Indemnified Person
will refund to the Borrower any portion of the reimbursed amounts that is attributable to expenses incurred in relation to the
act or omission of such Indemnified Person which is the subject of such finding; provided, that any amount so refunded shall be
returned by the Borrower if such finding is overturned by a higher court.
The provisions of this Annex A will
survive any termination or completion of the arrangement provided by the Letters.
ANNEX B
Project Element
Summary of the Facility
This Summary outlines certain terms
of the Facility referred to in the Commitment Letter, of which this Annex B is a part. Capitalized terms used but not defined
in this Annex B have the meanings given thereto in the Commitment Letter.
Borrower: |
Aetna Inc., a Pennsylvania corporation (the “Borrower”). |
|
|
Joint Lead Arrangers and Joint Bookrunners: |
Citigroup Global Markets, Inc. (“CGMI”) and UBS Securities LLC (“UBS Securities” and, together with CGMI, the “Arrangers”). |
|
|
Sole Administrative Agent: |
Citibank, N.A. (in such capacity, the “Administrative Agent”). |
|
|
Sole Syndication Agent: |
UBS Securities. |
|
|
Lenders: |
Banks and other financial institutions selected by the Arrangers and the Borrower in accordance with the Commitment Letter (each, a “Lender” and, collectively, the “Lenders”). |
|
|
Transactions: |
The Borrower intends to acquire (the “Acquisition”) all the issued and outstanding equity interests in an entity previously identified to us and codenamed “Hydrogen” (the “Acquired Company” and, together with its subsidiaries, the “Acquired Business”) pursuant to the Agreement and Plan of Merger, dated as of July 2, 2015, among Aetna Inc., Echo Merger Sub, Inc., Echo Merger Sub, LLC and Humana Inc. (together with the exhibits and schedules thereto, the “Merger Agreement”) for consideration consisting of shares of the Borrower’s common stock and cash. The cash consideration payable in the Acquisition and expenses incurred in connection with the Transactions (as defined below) will be obtained from (a) available cash of the Borrower and the Acquired Business in the amount of approximately $3,300,000,000 and (b) the issuance or incurrence by the Borrower of $16,200,000,000 in aggregate principal amount of any combination of (x) its senior notes (the “Notes”) pursuant to a registered public offering or Rule 144A or other private placement (the “Notes Offering”), (y) its senior unsecured term loans (the “Term Loans”) and/or (z) its commercial paper issued to finance the Acquisition (the “Commercial Paper”) or, in the event $16,200,000,000 in aggregate principal amount of any combination of the Notes, the Term Loans and/or the Commercial Paper has not been issued on or prior to the Closing Date (as defined below), borrowings by the Borrower under the Facility described herein. The acquisition and the other transactions described in this paragraph are collectively referred to as the “Transactions”. |
|
|
Facility: |
A senior bridge loan facility in an aggregate principal amount of up to $16,200,000,000, less the amount of any reductions of the commitments on or prior to the Closing Date as set forth under “Optional Commitment Reductions and Prepayments” and “Mandatory Commitment Reductions and Prepayments” below (the |
|
“Facility”). |
|
|
Purpose/Use of Proceeds: |
The proceeds of the Loans under the Facility (the “Loans”) will be used on the Closing Date, together with available cash of the Borrower and the Acquired Business and any proceeds from the issuance of the Notes, the Term Loans and/or the Commercial Paper prior to the Closing Date, to pay the cash portion of the consideration under the Merger Agreement and to pay fees and expenses incurred in connection with the Transactions. |
|
|
Closing Date: |
The date on or before the date on which the Acquisition is consummated (the “Closing Date”). |
|
|
Availability: |
Loans will be available in a single drawing on the Closing Date. The Loans will be available in U.S. dollars. |
|
|
Maturity: |
The Loans will mature on the day that is 364 days after the Closing Date. |
|
|
Ranking: |
The Loans will be unsecured and will rank pari passu in right of payment with all other unsecured senior obligations of the Borrower. |
|
|
Pricing: |
As set forth on Schedule I to this Annex B. |
|
|
Optional Commitment Reductions and Prepayments: |
Commitments may be terminated in whole or reduced in part, at the option of the Borrower, at any time without premium or penalty, upon three business days’ written notice, in minimum amounts and multiples to be agreed. |
|
|
|
Loans may be prepaid, in whole or in part, at the option of the Borrower, at any time without premium or penalty (except LIBOR breakage costs), upon two business days’ written notice, in minimum amounts and multiples to be agreed. |
|
|
Mandatory Commitment Reductions and Prepayments: |
Commitments under the Facility will be reduced, and Loans will be required to be prepaid within three business days following the receipt of the applicable proceeds, in an aggregate amount equal to: |
|
|
|
(a) Without duplication of clause (d) below, 100% of the net cash proceeds received by the Borrower or any of its subsidiaries from the issuance of the Notes, the Term Loans and the Commercial Paper or any Debt Incurrence (as defined below) after the date of the Commitment Letter to which this Annex B is attached (the “Commitment Letter”), whether before or after the Closing Date; |
|
|
|
(b) 100% of the net cash proceeds received by the Borrower from any Equity Issuance (as defined below) after the date of the |
|
Commitment Letter, whether before or after the Closing Date; |
|
|
|
(c) 100% of the net cash proceeds in excess of $300,000,000 received by the Borrower or any of its subsidiaries from any sale or other disposition of assets (including proceeds from the sale of equity interests in any subsidiary of the Borrower to a third party) consummated after the date of the Commitment Letter, whether before or after the Closing Date, subject to customary 180-day reinvestment rights and exceptions for (i) dispositions in the ordinary course of business (including ordinary course sales of investments in the investment portfolios of the Borrower and its subsidiaries), (ii) dispositions by regulated insurance subsidiaries to the extent that, notwithstanding the use of commercially reasonable efforts by the Borrower and such subsidiaries, regulatory approvals required for the upstreaming of the proceeds to the Borrower cannot be obtained and (iii) such other exceptions as the Arrangers and the Borrower may agree upon; and |
|
|
|
(d) 100% of the committed amount of any term loan credit facility entered into for the purpose of financing the Transactions (such reduction to occur automatically upon the effectiveness of definitive documentation for such term loan credit facility and receipt by the Arrangers of a notice from the Borrower that such term loan credit facility constitutes a Qualifying Term Loan Facility (as defined below)). |
|
|
|
“Qualifying Term Loan Facility” shall mean a term loan facility entered into by the Borrower for the purpose of financing the Transactions that is subject to conditions precedent to funding and limitations on assignments prior to the Closing Date that are no less favorable to the Borrower than the conditions set forth herein to the funding of the Facility, as determined by the Borrower. |
|
|
|
“Debt Incurrence” means any incurrence of debt for borrowed money by the Borrower or any of its subsidiaries, whether pursuant to a public offering or in a Rule 144A or other private placement of debt securities (including debt securities convertible into equity securities) or incurrence of loans under any loan or credit facility, other than (a) debt under the Existing Credit Agreement (as defined below) in an amount equal to the commitments thereunder in effect on the date hereof plus one or more commitment increases after the date hereof not to exceed $1,000,000,000 in the aggregate (including through an amendment or an amendment and restatement of the Existing Credit Agreement), (b) refinancings of the Borrower’s existing senior notes due at any time during 2017, including its 5.95% Senior Notes due March 15, 2017, its 1.75% Senior Notes due May 15, 2017, and its 1.50% Senior Notes due November 15, 2017, (c) intercompany debt, (d) issuances of commercial paper (other than, for the avoidance of doubt, the Commercial Paper), (e) capital leases, (f) purchase money indebtedness incurred in the ordinary course, (g) working capital facilities of foreign subsidiaries of the Borrower to be agreed upon, |
|
(h) overdraft facilities and (i) a $100,000,000 general basket (collectively, “Excluded Debt”). |
|
|
|
“Equity Issuance” means any issuance of equity or equity-linked securities by the Borrower, whether pursuant to a public offering or in a Rule 144A or other private placement, other than (a) issuances of securities pursuant to employee and/or director stock plans or employee and/or director compensation plans and (b) the issuance of common stock, options, units and/or other equity interests of the Borrower to shareholders and/or employees of the Acquired Company as provided in the Merger Agreement. |
|
|
Documentation: |
The Facility will be documented under a credit agreement (the “Credit Agreement”) based on and substantially similar to the Borrower’s existing Five-Year Credit Agreement dated as of March 27, 2012 as amended though the date hereof (the “Existing Credit Agreement”), modified as appropriate to reflect the terms and conditions set forth herein and in Annex C to the Commitment Letter and as appropriate in view of the structure and intended use of the Facility and the operational requirements of the Administrative Agent, and containing representations and warranties, affirmative and negative covenants, a financial covenant and events of default substantially the same as the Existing Credit Agreement (including, for the avoidance of doubt, as to baskets, materiality thresholds and grace periods). The documentation will include a “most favored nations” provision under which the Credit Agreement will incorporate covenants and events of default agreed to by the Borrower after the date hereof in other syndicated bank credit facilities that are not included in the Credit Agreement or are more restrictive than the corresponding provisions of the Credit Agreement. |
|
|
Representations and Warranties: |
To include (and be limited to) corporate existence and power; corporate and governmental authorization in connection with the Transactions; no contravention by the Transactions of organizational documents, laws or agreements; enforceability; financial statements (including (i) a representation that pro forma financial statements delivered by the Borrower have been prepared in good faith based on assumptions believed to be reasonable and fairly present the Borrower’s pro forma financial condition and results and (ii) a representation that financial projections delivered by the Borrower have been prepared in good faith based on assumptions believed to be reasonable) and absence of material adverse change; absence of material litigation (including in connection with the Transactions); ERISA matters; compliance with laws and agreements; Investment Company Act; Federal Reserve margin regulations; full disclosure; solvency on a consolidated basis as of the Closing Date; taxes; Patriot Act; Anti-Corruption Laws and Sanctions. |
|
|
Affirmative and Negative Covenants: |
To include (and be limited to) delivery of financial statements and other notices and information; conduct of business and maintenance of existence and insurance; limitation on liens; consolidations, |
|
mergers and sales of assets; use of proceeds; compliance with laws (including Federal Reserve margin regulations, Anti-Corruption Laws and Sanctions); inspection of property, books and records; payment of obligations; and a covenant limiting restricted payments, with exceptions for the payment of regular cash dividends, share repurchases pursuant to share repurchase programs announced by the Borrower in an aggregate amount not to exceed $2,500,000,000 and special cash dividends in an aggregate amount not to exceed $1,000,000,000. |
|
|
Financial Covenant: |
Limited to a maximum ratio of consolidated total indebtedness to adjusted consolidated capitalization (defined as the sum of consolidated total indebtedness and adjusted consolidated net worth) at each quarter end not to exceed 0.50 to 1.00. |
|
|
|
Adjusted consolidated net worth will exclude (a) any adjustment recorded to reflect the overfunded or underfunded status of the Borrower’s defined benefit pension and other post retirement plans in accordance with ASC 715, and (b) any net unrealized capital gains and losses, in each case as reflected in the Borrower’s consolidated balance sheets. |
|
|
Events of Default: |
To include (and be limited to) nonpayment of principal when due; nonpayment of interest or fees within five business days of due date; violation of covenants (subject to grace periods in the case of certain affirmative covenants and the limitation on liens); inaccuracy of representations and warranties in any material respect when made or deemed made; payment default or default resulting in or permitting acceleration in respect of indebtedness of $100,000,000 or more; bankruptcy or insolvency events; change in control; undischarged judgments in excess of $50,000,000; and certain ERISA events. |
|
|
Conditions Precedent to Funding: |
The obligations of the Lenders to make the Loans will be subject only to the conditions precedent referred to in Section 2 of the Commitment Letter and in Annex C thereto. |
|
|
Assignments and Participations: |
Lenders may assign all or, in an amount not less than $5,000,000, any part of, their loans and commitments under the Facility to their affiliates (other than the Borrower, its affiliates and natural persons), approved funds or one or more banks, financial institutions or other entities, subject to the consent of the Administrative Agent and the Borrower, in each case not to be unreasonably withheld or delayed; provided that assignments made after the Closing Date to affiliates of Lenders (other than natural persons), approved funds or other Lenders will not be subject to the above described consent or minimum assignment amount requirements. Upon such assignment, the assignee will become a Lender for all purposes under the Credit Agreement. A $3,500 processing fee will be required in connection with any such assignment, with exceptions to be agreed. The Lenders will also have the right to sell participations without restriction, |
|
subject to customary limitations on voting rights, in their loans and commitments under the Facility. |
|
|
|
Notwithstanding the foregoing, prior to the achievement of a Successful Syndication, assignments may be made in accordance with the procedures set forth in the Commitment Letter. |
|
|
Requisite Lenders: |
Lenders holding a majority in interest of the commitments and Loans under the Facility or, where provided in the Existing Credit Agreement, all Lenders or all affected Lenders. |
|
|
Yield Protection: |
The Credit Agreement will contain provisions substantially similar to those in the Existing Credit Agreement (a) protecting the Administrative Agent and the Lenders against increased costs or loss of yield resulting from changes in reserve, capital adequacy and capital or liquidity requirements (or their interpretation), illegality, unavailability and other requirements of law and the imposition of or changes in certain withholding or other taxes and (b) indemnifying the Lenders for “breakage costs” incurred in connection with prepayments of or the failure to borrow Loans bearing interest determined by reference to LIBOR on a day other than the last day of an interest period with respect thereto. For all purposes of the Credit Agreement, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines and directives promulgated thereunder and (ii) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States regulatory authorities, in each case, pursuant to Basel III, shall be deemed introduced or adopted after the Closing Date. |
|
|
Defaulting Lenders: |
The Credit Agreement will contain provisions relating to “Defaulting Lenders” substantially similar (to the extent applicable) as those in the Existing Credit Facility. |
|
|
Indemnity and Expense Reimbursement: |
The Credit Agreement will contain provisions relating to indemnity, expense reimbursement, exculpation and related matters substantially similar to those in the Existing Credit Facility and as otherwise agreed by the Borrower and the Arrangers. |
|
|
Governing Law and Jurisdiction: |
The Credit Agreement and other loan documentation will be governed by New York law (subject to exceptions corresponding to those set forth in the third paragraph of Section 9 of the Commitment Letter). Each of the parties thereto will submit to the exclusive jurisdiction and venue of the federal and state courts of the State of New York and will waive any right to trial by jury. |
Counsel to the Arrangers and the Administrative Agent: |
Shearman & Sterling LLP. |
SCHEDULE I TO ANNEX B
CONFIDENTIAL
Interest Rates: |
The interest rates for borrowings under the Facility will be, at the option of the Borrower, (i) LIBOR or (ii) Base Rate, plus, in each case, the applicable LIBOR Margin or Base Rate Margin depending upon the ratings (the “Ratings”) of the Index Debt by Moody’s Investor Services, Inc. (“Moody’s”), Standard & Poor’s Ratings Group, a division of The McGraw Hill Corporation (“S&P”) and Fitch Ratings Ltd. (“Fitch”), as set forth in the Facility Pricing Grid below; provided that the applicable margins at each Pricing Level in such Facility Pricing Grid will increase by 25 basis points on the 90th day following the Closing Date and by an additional 25 basis points each 90th day thereafter while Loans remain outstanding under the Facility. |
|
|
|
“LIBOR” means the London interbank offered rate (which shall not be less than 0%). |
|
|
|
“Base Rate” means, for any day, a rate per annum equal to the highest of (i) the Prime Rate for such day, (ii) the sum of the Federal Funds Effective Rate on such day plus 1/2 of 1.00% per annum and (iii) the sum of LIBOR on such day for an interest period of one month plus 1.00% per annum; provided that Prime Rate shall not be less than 0.0%. |
|
|
|
“Index Debt” means long-term indebtedness of the Borrower for borrowed money that is not subordinated to any other indebtedness for borrowed money and is not secured or supported by a guarantee, letter of credit or other form of credit enhancement. |
|
|
|
The Borrower may elect interest periods of one, two, three or six months for LIBOR loans. |
|
|
|
Calculation of interest shall be on the basis of actual days elapsed in a year of 360 days (or 365 or 366 days, as the case may be, in the case of Base Rate loans based on the Prime Rate). Interest shall be payable at the end of each applicable interest period (and at three-month intervals in the case of interest periods exceeding three months) on LIBOR loans and quarterly on Base Rate loans. |
|
|
Default Rate: |
With respect to overdue principal, the applicable interest rate plus 2.00% per annum and, with respect to any other overdue amount, the interest rate applicable to Base Rate loans plus 2.00% per annum. |
|
|
Commitment Fees: |
The Borrower will pay to each Lender a Commitment Fee of 0.10% per annum (computed on the basis of the actual number of days elapsed in a year of 360 days) on the amount of its commitment from time to time under the Facility, commencing upon the later to occur of (i) the 90th day following the execution and delivery of the Commitment Letter and (ii) the date of execution and delivery of the Credit Agreement. Commitment Fees will be payable quarterly in arrears and on the Closing Date or any earlier date on which the commitments terminate. |
|
|
Duration Fees: |
The Borrower will pay to each Lender on each of the dates set forth |
|
below a Duration Fee equal to the applicable percentage set forth below of the aggregate principal amount of such Lender’s Loans outstanding on such date: |
|
|
|
Date |
Duration Fee Percentage |
90 days after the Closing Date |
0.50% |
180 days after the Closing Date |
0.75% |
270 days after the Closing Date
|
1.00% |
Facility Pricing Grid
(bps per annum): |
|
Ratings
(Moody’s/S&P/Fitch) |
LIBOR Margin |
Base Rate Margin |
Pricing Level I |
A1/A+/A+ or higher |
75 |
0 |
Pricing Level II |
A2/A/A or higher |
87.5 |
0 |
Pricing Level III |
A3/A-/A- or higher |
100 |
0 |
Pricing Level IV |
Baa1/BBB+/BBB+ or higher |
112.5 |
12.5 |
|
Pricing Level V |
Baa2/BBB/BBB or lower |
125 |
25 |
|
Margins set forth for each Pricing Level
will increase on the 90th day following the Closing Date and on each 90th day thereafter as provided under “Interest
Rates” above. Pricing will be determined by reference to the Pricing Level most favorable to the Borrower that is achieved
by at least two of the three Ratings. If the ratings established by any of Moody’s, S&P and/or Fitch shall be changed
as a result of a change in its rating system, the new rating of such rating agency that most closely corresponds to the level specified
above for such rating agency shall be substituted for such level. Each change in the margins shall apply during the period commencing
on the effective date of such change and ending on the date immediately preceding the effective date of the next such change.
|
ANNEX C
Project Element
Summary of Additional Conditions Precedent to the Facility
This Summary outlines certain of the
conditions precedent to the Facility referred to in the Commitment Letter, of which this Annex C is a part. Capitalized terms
used but not defined in this Annex C have the meanings given thereto in the Commitment Letter.
| 1. | Acquisition. The Acquisition shall have been consummated, or substantially concurrently
with the funding under the Facility shall be consummated, in each case pursuant to and on the terms set forth in the Merger Agreement
and without giving effect to amendments, supplements, waivers or other modifications to the Merger Agreement (other than waivers
by the Acquired Company) that are materially adverse to the Lenders and that have not been approved by the Arrangers (it being
understood and agreed that any change to the definition of “Company Material Adverse Effect” in the Merger Agreement
and any amendment that extends the End Date beyond December 31, 2016 shall be deemed materially adverse to the Lenders). |
| 2. | Financial Statements. The Arrangers shall have received (a) audited consolidated balance
sheets and related audited statements of operations, stockholders’ equity and cash flows of the Borrower and the Acquired
Company for each of the three fiscal years most recently ended at least 60 days prior to the Closing Date (and audit reports
for such financial statements shall not be subject to any qualification or “going concern” disclosures) and (b) unaudited
consolidated balance sheets and related unaudited statements of operations, stockholders’ equity and cash flows of the Borrower
and the Acquired Company for each subsequent fiscal quarter ended at least 45 days prior to the Closing Date; provided that
the filing of financial statements complying with the foregoing requirements on Form 10-K or Form 10-Q, as the case may
be, by the Company or the Acquired Company will satisfy the applicable conditions set forth in this paragraph 2. The Arrangers
acknowledge the receipt of each of the Borrower’s and the Acquired Company’s Form 10-K for the fiscal year ended December 31,
2014, and Form 10-Qs for the quarterly period ended March 31, 2015 (each of which are deemed to have been delivered by
or on behalf of the Borrower). |
| 3. | Performance of Obligations. All fees, reasonable out-of-pocket expenses and other compensation
required by the Commitment Letter and the Fee Letter to be paid to the Arrangers, the Administrative Agent or the Lenders shall
have been paid to the extent due and, in the case of expenses, invoiced at least two business days prior to the Closing Date. |
| 4. | Customary Closing Documents. The Borrower shall have complied with the following conditions:
(a) delivery of customary legal opinions, organizational documents of the Borrower, evidence of authority of the Borrower,
a good standing certificate of the Borrower and customary secretary’s and officer’s certificates; and (b) delivery
of a solvency certificate from the chief financial officer of the Borrower in the form attached hereto as Exhibit I. The Arrangers
shall have received at least three business days prior to the Closing Date all documentation and other information required by
bank regulatory authorities under applicable “know-your-customer” and anti-money laundering rules and regulations,
including the Patriot Act to the extent requested in writing to the Borrower not fewer than eight business days prior to the Closing
Date. |
| 5. | Accuracy of Representations; Absence
of Certain Defaults. The accuracy on and as of the Closing Date in all material respects of (i) the representations and
warranties made by or with respect to the Acquired Business in the Merger Agreement that are material to the interests of the
Lenders, but only to the extent that the Borrower has the right under the Merger Agreement not to consummate the Acquisition,
or to terminate its obligations under the Merger Agreement, as a |
result
of such representations and warranties in the Merger Agreement not being true and correct (the “Merger Agreement Representations”)
and (ii) the Specified Representations (as defined below). As used herein, “Specified Representations”
means representations and warranties with respect to due organization of the Borrower; organizational power and authority of the
Borrower to enter into the Credit Agreement; due authorization, execution, delivery and enforceability of the Credit Agreement;
no conflicts with organizational documents, the Existing Credit Agreement or the Borrower’s existing senior notes; Investment
Company Act; Federal Reserve Regulations; solvency (to be defined in a manner consistent with Exhibit I hereto); Patriot
Act; and compliance with OFAC and the Foreign Corrupt Practices Act. On the Closing Date, there shall not have occurred and be
continuing any payment or bankruptcy default, or default resulting in or permitting acceleration in respect of the Existing Credit
Agreement or the Borrower’s existing senior notes.
| 6. | Acquired Company Credit Agreement. On or prior to the Closing Date, the Acquired Company’s
existing Second Amended and Restated Credit Agreement, dated as of July 9, 2013, among the Acquired Company, the several banks
and other financial institutions from time to time party thereto and JPMorgan Chase Bank, N.A., as Agent and CAF Loan Agent (as
amended, restated, supplemented or otherwise modified on or prior to the Closing Date) shall have been terminated and all amounts
outstanding, accrued or otherwise owing thereunder shall have been paid. |
| 7. | Prior Marketing of Notes. The Borrower shall have used commercially reasonable efforts to
(a) deliver to the financial institutions engaged in the offering of the Notes (the “Financial Institutions”)
a complete printed preliminary prospectus supplement or preliminary offering memorandum or preliminary private placement memorandum
that is suitable for use in a customary road show relating to the Notes that contains (or incorporates by reference) all financial
statements (including all audited financial statements, all unaudited financial statements (which shall have been reviewed by the
independent accountants for the Borrower or the Acquired Business, as applicable, as provided in Statement on Auditing Standards
No. 100) and all pro forma financial statements prepared in accordance with generally accepted accounting principles in the
United States and prepared in accordance with Regulation S-X and all other data (including selected financial data), in each
case that the Securities and Exchange Commission would require in a registration statement on form S-3 for a registered offering
of the Notes or that would be necessary for the Financial Institutions to receive customary “comfort” letters (including
“negative assurance” comfort letters) from the independent auditors of the Borrower and the Acquired Business and such
disclosure as is necessary for outside counsel of the Borrower to render customary opinions and negative assurance letters, in
each case in connection with the offering of the Notes and (b) if reasonably requested by the underwriters of the Notes, cause
the senior management and representatives of the Borrower to participate in a customary road show for any registered offering or
private placement of the Notes. |
| 8. | No Material Adverse Effect. Since the date hereof, there shall not have occurred any event,
change, effect, development or occurrence that has had or would reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect (as defined in the Merger Agreement). |
EXHIBIT I TO ANNEX C
Form of Solvency Certificate
This Solvency Certificate (this “Certificate”)
is delivered pursuant to Section [ ] of the Credit Agreement, dated as of [ ], 20[ ] (as amended, supplemented
or otherwise modified from time to time, the “Credit Agreement”), among Aetna Inc. (the “Borrower”),
Citibank, N.A., as Administrative Agent, UBS Securities LLC, as Syndication Agent, and each lender from time to time party thereto
(collectively, the “Lenders” and individually, a “Lender”). Capitalized terms used herein
without definition have the same meanings as in the Credit Agreement.
I, [ ],
solely in my capacity as the duly appointed and acting Chief Financial Officer of the Borrower, and not individually, DO HEREBY
CERTIFY to the Lenders, as follows:
1. I am knowledgeable
of the financial and accounting matters of the Borrower and its subsidiaries, the Credit Agreement and the covenants and representations
(financial or otherwise) contained therein.
2. Immediately after
giving effect to the Acquisition on the Closing Date:
a. the fair value of the property
of the Borrower and its subsidiaries, on a consolidated basis, will be greater than the total amount of liabilities, including
contingent liabilities, of the Borrower and its subsidiaries, on a consolidated basis;
b. the present fair saleable
value of the assets of the Borrower and its subsidiaries, on a consolidated basis, will be greater than the amount that will be
required to pay the probable liability of the Borrower and its subsidiaries on their debts, on a consolidated basis, as they become
absolute and matured;
c. the capital of the Borrower
and its subsidiaries, on a consolidated basis, is not unreasonably small in relation to their collective businesses, taken as a
whole, as now conducted and as proposed to be conducted immediately following the Closing Date; and
d. the Borrower and its subsidiaries,
on a consolidated basis, do not intend to incur, or believe that they will incur on or immediately following the Closing Date,
debts, including current obligations, beyond their ability to pay such debts as they become absolute and matured.
For the purposes of this
Certificate, the amount of any contingent liability at any time shall be computed as the amount that, in the light of all the facts
and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.
For the purpose of this Certificate, it is assumed that the indebtedness and the other obligations incurred under and in connection
with the Facility will come due at maturity.
IN WITNESS WHEREOF, I
have hereunto set my hand as of the date first written above.
|
AETNA INC. |
|
|
|
By: |
|
|
|
Name: Title: Chief Financial Officer |
Exhibit I to Annex C
Humana (NYSE:HUM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Humana (NYSE:HUM)
Historical Stock Chart
From Jul 2023 to Jul 2024